Clinical Development  
EGF816 (Nazartinib) 
Protocol CEGF816X2101 / [STUDY_ID_REMOVED]
A phase I/II, multicenter, open-label study of EGFRmut –TKI 
EGF816 administered orally in adult patients with EGFRmut 
solid malignancies 
Author(s):  
Document type:  Amended Protocol Version 
EUDRACT number  2013 -004482 -14 
Version number  07 (Clean ) 
Development phase  I/II 
Document status : final 
Release date:  11-Mar-2020
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published or otherwise disclosed  
without the consent of [COMPANY_001]  

[COMPANY_001]  Confidential  Page 2 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Table of contents  
Table of contents  ................................ ................................ ................................ .................  [ADDRESS_928789] of figures  ................................ ................................ ................................ ......................  8 
Amendment 07 (11 -Mar-2020)  ................................ ................................ ...........................  9 
Amendment 06 (07 -Apr-2017)  ................................ ................................ ..........................  [ADDRESS_928790] of abbreviations  ................................ ................................ ................................ ..........  46 
Glossary of terms  ................................ ................................ ................................ ...............  50 
1 Background ................................ ................................ ................................ ........................  51 
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013]  ..............  51 
1.2 Introduction to investigational treatment(s) and other study treatment(s) .............  52 
1.2.1  Overview of  EGF816  ................................ ................................ ............  52 
2 Rationale  ................................ ................................ ................................ ............................  59 
2.1 Study rationale and purpose ................................ ................................ ...................  59 
2.2 Rationale for the study design  ................................ ................................ ...............  60 
2.3 Rationale for dose and regimen selection  ................................ ..............................  62 
2.4 The recommended phase II dose (RP2D) was determined based on the safety 
and efficacy data obtained from the Phase I part (dose -escalation) at 150 
mg/day on capsules and tablets. Rationale for choice of combination drugs  ........  62 
2.5 Rationale for choice of comparators drugs  ................................ ............................  62 
2.6 Risks and benefits  ................................ ................................ ................................ .. 62 
3 Objectives and endpoints  ................................ ................................ ................................ ... 63 
4 Study design  ................................ ................................ ................................ ......................  65 
4.1 Description of study design  ................................ ................................ ...................  65 
4.2 Timing of interim analyses and design adaptations  ................................ ...............  67 
4.3 Definition of end of the study  ................................ ................................ ................  68 
4.4 Early study termination ................................ ................................ ..........................  68 
5 Population  ................................ ................................ ................................ ..........................  69 
5.1 Patient Population  ................................ ................................ ................................ .. 69 
5.2 Inclusion criteria  ................................ ................................ ................................ .... 69 
5.3 Exclusion criteria  ................................ ................................ ................................ ... 71 
6 Treatment  ................................ ................................ ................................ ...........................  74 
[COMPANY_001]  Confidential  Page 3 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 6.1 Study treatment  ................................ ................................ ................................ ...... 74 
6.1.1  Dosing regimen  ................................ ................................ .....................  74 
6.1.2  Treatment duration  ................................ ................................ ................  75 
6.2 Dose -escalation guidelines  ................................ ................................ ....................  76 
6.2.1  Starting dose rationale  ................................ ................................ ...........  76 
6.2.2  Provisional dose levels for Phase I part (dose -escalation)  ....................  77 
6.2.3  Guidance for dose escalation and determination of MTD/ RP2D  .........  78 
6.2.4  Definitions of dose -limiting toxicities (DLTs) for Phase I part 
(dose -escalation)  ................................ ................................ ...................  81 
6.3 Dose modifications for toxicities  ................................ ................................ ...........  81 
6.3.1  Dose modification and dose delay  ................................ ........................  81 
6.3.2  Guidelines for screening, monitoring and management of HBV / 
HCV reactivation  ................................ ................................ ..................  88 
6.3.3  Guidelines for the management and dose modification of skin -
related toxicities  ................................ ................................ ....................  93 
6.3.4  Guidelines for the management and dose modification of non -
infectious pneumonitis/interstitial lung disease  ................................ .... 95 
6.3.5  Follow -up for toxicities  ................................ ................................ .........  97 
6.3.6  Anticipated risks and safety concerns of the study drug  .......................  99 
6.4 Concomitant medications  ................................ ................................ ......................  99 
6.4.1  Permitted concomitant therapy  ................................ .............................  99 
6.4.2  Permitted concomitant therapy requiring caution and/or action  .........  100 
6.4.3  Prohibited concomitant therapy  ................................ ..........................  100 
6.5 Patient numbering, treatment assignment or randomization  ...............................  101 
6.5.1  Patient numbering  ................................ ................................ ...............  101 
6.5.2  Treatment assignment  ................................ ................................ .........  101 
6.6 Study drug preparation and dispensation  ................................ .............................  101 
6.6.1  Study drug packaging and labeling  ................................ .....................  101 
6.6.2  Drug supply and storage ................................ ................................ ...... 102 
6.6.3  Study drug compliance and accountability  ................................ .........  102 
6.6.4  Disposal and destruction  ................................ ................................ ..... 102 
7 Visit schedule and assessments  ................................ ................................ .......................  103 
7.1 Study flow and visit schedule  ................................ ................................ ..............  103 
7.1.1  Molecular pre -screening  ................................ ................................ ...... 117 
7.1.2  Screening  ................................ ................................ .............................  117 
7.1.3  Treatment period  ................................ ................................ .................  120 
7.1.4  Discontinuation of Study Treatment  ................................ ...................  120 
7.1.5  Follow -up period  ................................ ................................ .................  121 
[COMPANY_001]  Confidential  Page 4 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 7.1.[ADDRESS_928791] to follow -up ................................ ................................ .................  122 
7.2 Assessment types  ................................ ................................ ................................ . 123 
7.2.1  Efficacy assessments  ................................ ................................ ...........  123 
7.2.2  Safety and tolerability assessments  ................................ .....................  127 
7.2.3  Pharmacokinetics  ................................ ................................ ................  130 
7.2.4  Biomarkers  ................................ ................................ ..........................  133 
7.2.5  [For Japan only] Radiological examinations  ................................ ....... [ADDRESS_928792]  ................................ .......................  139 
8.2 Serious adverse events  ................................ ................................ .........................  139 
8.2.1  Definitions  ................................ ................................ ...........................  139 
8.2.2  Reporting  ................................ ................................ .............................  140 
8.3 Pregnancies  ................................ ................................ ................................ ..........  141 
8.4 Warnings and precautions ................................ ................................ ....................  141 
8.5 Data Monitoring Committee  ................................ ................................ ................  141 
8.6 Steering Committee  ................................ ................................ .............................  142 
8.7 Blinded Independent Review Committee (BIRC)  ................................ ...............  142 
9 Data collection and management  ................................ ................................ .....................  142 
9.1 Data confidentiality  ................................ ................................ .............................  142 
9.2 Site monitoring  ................................ ................................ ................................ .... 143 
9.3 Data collection  ................................ ................................ ................................ ..... 143 
9.4 Database management and quality control  ................................ ..........................  144 
10 Statistical methods and data analysis  ................................ ................................ ..............  145 
10.1  Analysis sets  ................................ ................................ ................................ ........  145 
10.1.1  Phase I part  ................................ ................................ ..........................  145 
10.1.2  Phase II part ................................ ................................ .........................  146 
10.2  Patient demographics/other baseline characteristics  ................................ ...........  147 
10.3  Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], compliance)  .....................  147 
10.3.1  Study treatment  ................................ ................................ ...................  147 
10.3.2  Concomitant therapi[INVESTIGATOR_014]  ................................ ................................ .........  147 
10.3.3  Compliance  ................................ ................................ .........................  147 
10.4  Primary objective  ................................ ................................ ................................ . 147 
10.4.1  Variable  ................................ ................................ ...............................  147 
[COMPANY_001]  Confidential  Page 5 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 10.4.2  Statistical hypothesis, model and method of analysis  .........................  148 
10.4.3  Handling of missing values/censoring/discontinuations  .....................  150 
10.4.4  Supportive analyses  ................................ ................................ .............  150 
10.5  Secondary objectives  ................................ ................................ ...........................  150 
10.5.1  Safety objectives  ................................ ................................ .................  150 
10.5.2  Efficacy objectives  ................................ ................................ ..............  152 
10.5.3  Pharmacokinetics  ................................ ................................ ................  154 
  155 
  155 
  155 
10.7  Interim analysis  ................................ ................................ ................................ .... 156 
10.8  Sample size calculation ................................ ................................ ........................  157 
10.8.1  Phase I part  ................................ ................................ ..........................  157 
10.8.2  Phase II part ................................ ................................ .........................  157 
10.9  Power for analysis of key secondary variables  ................................ ....................  157 
11 Ethical considerations and administrative procedures  ................................ ....................  158 
11.1  Regulatory and ethical compliance  ................................ ................................ ...... 158 
11.2  Responsibilities of the investigator and IRB/IEC/REB  ................................ ....... [ADDRESS_928793] keepi[INVESTIGATOR_5304]  .....................  160 
11.7  Confidentiality of study documents and patient records  ................................ ..... 160 
11.8  Audits and inspections  ................................ ................................ .........................  160 
11.9  Financial disclosures  ................................ ................................ ............................  161 
12 Protocol adherence  ................................ ................................ ................................ ..........  161 
12.1  Amendments to the protocol  ................................ ................................ ................  161 
13 References (available upon request)  ................................ ................................ ................  162 
14 Appendices  ................................ ................................ ................................ ......................  165 
14.1  Appendix 1 – Guidelines for response, duration of overall response, TTF, 
TTP, progression -free survival and overall survival (based on RECIST 1.1)  ..... 165 
14.1.1  Introduction  ................................ ................................ .........................  167 
14.1.2  Efficacy assessments  ................................ ................................ ...........  167 
14.1.3  Definitions  ................................ ................................ ...........................  167 
14.1.4  Disease measurability ................................ ................................ ..........  167 
14.1.5  Eligibility based on measurable disease  ................................ ..............  168 
14.1.6  Methods of tumor measurement - general guidelines  .........................  168 
14.1.7  Baseline documentation of target and non -target lesions  ...................  170 

[COMPANY_001]  Confidential  Page 6 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 14.1.[ADDRESS_928794] overall response ................................ ................................ ...........  176 
14.1.18  Time to event variables  ................................ ................................ ....... 178 
14.1.19  Progression -free survival  ................................ ................................ .... 178 
14.1.20  Overall survival  ................................ ................................ ...................  179 
14.1.21  Time to progression ................................ ................................ .............  179 
14.1.22  PFS2  ................................ ................................ ................................ .... 179 
14.1.23  Time to treatment failure  ................................ ................................ ..... 179 
14.1.24  Duration of response  ................................ ................................ ...........  180 
14.1.25  Time to response  ................................ ................................ .................  181 
14.1.26  Definition of start and end dates for time to event variables  ..............  181 
14.1.27  Handling of patients with non -measurable disease only at baseline  ... 182 
14.1.28  Sensitivity analyses  ................................ ................................ .............  183 
14.1.29  Data handling and programming rules  ................................ ................  185 
14.1.30  Study/project specific decisions  ................................ ..........................  [ADDRESS_928795] -treatment follow -up (study phase completion)  ................  186 
14.1.33  Medical validation of programmed overall lesion response  ...............  187 
14.1.34  Programming rules  ................................ ................................ ..............  187 
14.1.35  Calculation of ‘time to event’ variables  ................................ ..............  [ADDRESS_928796] known date patient alive or death  ...............  188 
14.1.38  Non-target lesion response  ................................ ................................ .. 188 
14.1.39  Study/project specific programming  ................................ ...................  188 
14.1.40  Censoring reason  ................................ ................................ .................  188 
14.1.41  References (available upon request)  ................................ ...................  190 
14.2  Appendix 2 – Operating characteristics of the Bayesian logistic regression 
mode and hypothetical dose -escalation scenarios  ................................ ...............  191 
14.2.1  Introduction  ................................ ................................ .........................  191 
14.2.2  Model specifications  ................................ ................................ ...........  191 
[COMPANY_001]  Confidential  Page 7 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 14.2.[ADDRESS_928797] of tables  
Table 1 -1 Superiority of EGFR TKIs over chemotherapy in EGFRmut 
NSCLC  ................................ ................................ ................................ .. 51 
Table 3 -1 Objectives and related endpoints (Phase I part)  ................................ .... 63 
Table 3 -2 Objectives and related endpoints (Phase II part)  ................................ ... 64 
Table 6 -1 Dose and treatment schedule  ................................ ................................ . 74 
Table 6 -2 Provisional dose levels for Phase I part (dose -escalation)  ....................  78 
Table 6 -3 Criteria for defining dose -limiting toxicities in the Phase I part  ...........  81 
Table 6 -4 Recommended dose reduction steps for the Phase I and II parts  ..........  82 
Table 6 -5 Criteria for dose reduction/interruption and re -initiation of EGF816 
treatment for adverse drug reactions  ................................ .....................  82 
Table 6 -6 Actions to be taken based on hepatitis B results screening  ...................  89 
Table 6 -7 Guidelines for management of HBV reactivation  ................................ . 90 
Table 6 -8 Guidelines for management of HCV reactivation  ................................ . 92 
Table 6 -9 Guidelines for prevention and symptomatic care of rash/skin 
toxicities  ................................ ................................ ................................  93 
Table 6 -10 Management and dose modification for maculopapular rash1, 2 ...........  93 
Table 6 -11 Management and dose modification for other rashes including 
acneiform rash  ................................ ................................ .......................  94 
Table 6 -12 Management of non -infectious pneumonitis / interstitial lung 
disease  ................................ ................................ ................................ ... 96 
Table 6 -13 Supply and storage of study treatment  ................................ ................  102 
Table 7 -1 Visit evaluation schedule (Phase I Part)  ................................ ..............  104 
Table 7 -2 Visit evaluation schedule (Phase II part)  ................................ ............  109 
Table 7 -3 Imaging collection plan (Phase I part)  ................................ ................  123 
Table 7 -4 Imaging collection plan (Phase II part)  ................................ ...............  124 
Table 7 -5 ECOG performance status ................................ ................................ ... 127 
Table 7 -6 Local clinical laboratory parameters collection plan  ..........................  128 
Table 7 -7 Central ECG collection plan for all patients (for Phase I)  ..................  129 
Table 7 -8 Extensive ECG collection plan (for Phase II)  ................................ ..... 129 
Table 7 -9 Phase I part: schedule of blood sample collections for 
pharmacokinetics ................................ ................................ .................  130 
[COMPANY_001]  Confidential  Page 8 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Table 7 -10 Phase II part: schedule of blood sample collections for 
pharmacokinetics ................................ ................................ .................  132 
  134 
  135 
Table 10 -1 Noncompartmental pharmacokinetic parameters  ................................  154 
Table 10 -2 Probability of success at the primary analysis based on various 
numbers of responders observed at the IA  ................................ ..........  156 
Table 10 -3 Operating characteristics given sample size of 40 patients and 
interim analysis at 20 patients  ................................ .............................  157 
Table 14 -1 Response criteria for target lesions  ................................ .....................  172 
Table 14 -2 Response criteria for non -target lesions  ................................ ..............  174 
Table 14 -3 Overall lesion response at each assessment  ................................ ........  175 
Table 14 -4 Overall lesion response at each assessment: patients with non -
target disease only  ................................ ................................ ...............  182 
Table 14 -5 Options for event dates used in PFS, TTP, duration of response  ........  183 
Table 14 -6 Prior distribution of model parameters  ................................ ...............  192 
Table 14 -7 Summary of prior distribution of DLT rates  ................................ ....... 192 
Table 14 -8 Hypothetical scenarios for capsule on-study decisions (cohort size: 
1-6) ................................ ................................ ................................ ...... 193 
Table 14 -9 Hypothetical scenarios for capsule on-study decisions (cohort size: 
3) ................................ ................................ ................................ .........  [ADDRESS_928798] tablet 
dose-escalation meeting  ................................ ................................ ...... 197 
Table 14 -11 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset 1  ................................ ...................  197 
Table 14 -12 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset 2  ................................ ...................  198 
Table 14 -13 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset [ADDRESS_928799] percentage change from baseline in sum of diameters of target 
lesions as per investigator by [CONTACT_3148] (Capsule) – Full analysis 
set ................................ ................................ ................................ ..........  58 
Figure 4 -1 Study design, Phase II part  ................................ ................................ .... 67 
Figure 4 -2 Study visit flow (Phase I part)  ................................ ...............................  67 
Figure 4 -3 Study visit flow (Phase II part)  ................................ .............................  67 

[COMPANY_001]  Confidential  Page 9 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Amendment 07 (11-Mar-2020 )  
Amendment rationale  
As of the release of this amendment ( 11-Mar-2020 ), the study is closed to enrollment. I n the 
phase I part (dose -escalation) of the study, 180 patients were enrolled; 11 patients are 
ongoing.  Forty -five patients were enrolled in Phase 2 part ( expansion  phase) of this study and 
18 patients  are ongoing.   
Study initiated with capsules and moved to tablets, as it became the Formulated Market Image 
(FMI) strategy. However, based on the shelf -life superiority of the capsules in comparison to 
tablets, [COMPANY_001] has strategically decided to move back to capsules to provide better shelf -life 
for the market.  The main purpose of this amendment is to implement the use of the capsules 
form  again  (25 mg / 50 mg / 100  mg) instead of tablets for the ongoing patients  promptly upon 
availability . The decision to switch back from tablet to capsule is based on the following:  
- The capsule formulation has a superior stability profile compared to the tablets, allowing 
the assignment of longer shelf lives  
- Statistical analysis showed that exposure s between tablet and capsule are comparable 
with geometric mean ratios of 1.04 and 1.03 for AUCtau and Cmax, respectively, 
following single 150 mg dose, and 1.06 and 1.12 for AUCtau and Cmax, respectively, 
following 150 mg QD . 
Therefore, based on this rationale, capsules will be used in a time ly manner following  approval 
of this amendment for the remainder of this study  for all ongoing patients in phase I  and phase 
II parts .  
 
Additionally, the guidelines for some selected  toxicities  (hepatitis B, skin rash, including 
maculo -papular rash and I nterstitial Lung Disease (ILD) /pneumonitis) have been updated to 
optimize the patient’s safety.  These changes are not due to new safety findings but reflects new 
internal/international clinical guidelines.  
Finally, t he list s of permitted and prohibited concomitant medications included in Appendi x [ADDRESS_928800] been revised based on periodic update.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.  
The following sections and tables w ere changed:  
• List of abbreviations  – added and updated abbreviations  
• Section 2.3  – removed the referenc e to the use of tablets in the p hase II part  
• Section 6.1.1  – introduced the implementation of  capsules use based on this amendment 
rationale  
• Section 6.2.1 – clarification added for the change of drug formulation pertaining to protocol 
amendment #03  
• Sections [IP_ADDRESS] and [IP_ADDRESS] – clarification added for the change of drug formulation 
pertaining to protocol amendment #07  
[COMPANY_001]  Confidential  Page 10 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Section [IP_ADDRESS]  – revised since all patients are o n treatment at RP2D with tablets therefore 
the intra -patient dose escalation switch cannot occur  
• Section  6.3.2 , Table  6-6, Table  6-7 and Table 6 -8 – Guidelines for screening, monitoring 
and man agement of HBV/HCV reactivation updated as per new internal/international 
clinical guidelines  
• Table 6 -9 - Guidelines for prevention and symptomatic care of rash/skin toxicities updated 
as per new internal/international clinical guidelines  
• Table 6 -10 – Management and dose modification for maculopapular rash updated as per 
new internal/international clinical guidelines  
• Table 6 -11 - Management and dose modification for other rashes including acneiform rash 
updated as per new internal/international clinical guidelines  
• Section 6.3.4  and Table  6-12 - Guidelines for  the management and dose modifi cation of 
non-infectious  pneumonitis/interstitial lung disease updated as per new 
internal/international clinical guidelines  
• Table 7 -1 and Table 7 -2 – Updated to reflect the change of HBV and HCV monitoring  
• Section 13 – Updated with the addition of  the reference related to the new clinical 
guidelines for hepatitis management  
• Appendix 3 ( Table 14 -14) and Appendix 4 ( Table 14 -15): Permitted concomitant 
medications requiring caution and prohibited concomitant medications lists  revised based 
on periodic update   
In addition, as part of this amendment, minor editorial changes (e.g. typographical mistakes,  
grammatical changes, rewording) to improve flow and consistency, and correction of spelling  
errors or typographical errors have been made throughout the protocol.  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.  
 
[COMPANY_001]  Confidential  Page 11 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Amendment 06 (07-Apr-2017)  
Amendment rationale  
As of 31 -Mar-2017 in the Phase I part (dose -escalation) of the study, [ADDRESS_928801] been 
enrolled with 7 different dose levels at 10 sites in 8 countries; 42 patients were ongoing. During 
a dose -escalation meeting on 30 -Aug-2016, the Investigators and [COMPANY_001] agreed to declare the 
Recommended Phase 2 Dose (RP2D) of EGF816 (Nazartinib) capsules and tablets at the dose 
level of 150 mg QD based on the available safety, pharmacokinetic, efficacy data and on the 
Bayesian Logistic Regression Model recommenda tion. 
The Phase II part (expansion phase) of this study was originally planned to enroll patients in 6 
different groups defined by [CONTACT_685366]. However, the rapid evolving landscape including ongoin g trials in this disease setting 
led to the decision not to start the enrollment of patients who received more than 1 line of prior 
antineoplastic therapy in Groups 2 to 6. Indeed, it is noteworthy that approval has been granted 
in different cou ntries to o simertinib (Tagrisso®) for the treatment of adult patients with locally 
advanced or metastatic epi[INVESTIGATOR_3506] (EGFR) T790M mutation -positive 
non-small cell lung cancer (NSCLC) who have progressed on or after prior systemic therapy, 
including an EGFR -TKI givin g patients in this setting access to 3rd generation EGFR -TKI as 
per FDA and EMA information. Therefore, the Phase II part of the study will continue as a 
single group of patients, all treated at 150 mg QD Nazartinib.  
An Investigator letter dated 07 -Dec-2016 informed the investigators about the opening of the 
Phase II part of the study for enrollment in Group 1 only. This group will now enroll a minimum 
of 40 treatment -naïve patients instead of 60 patients ( Section 10.8.2 ), who have locally 
advanced or metastatic NSCLC with EGFR activating mutation (e.g., L858R and/or ex19del), 
have not received any systemic antineoplastic therapy for advanced NSCLC, and are eligible to 
receive EGFR -TKI treatment. As of [ADDRESS_928802] been enrolled in the Phase II 
part and were ongoing.  
In addition, a previous protocol amendment (#4 released on 05 -May-2015) introduced the 
implementation of central laboratories to evaluate the safety of  EGF816  (Nazartinib ) (e.g., 
hematology, chemistry, urinalysis, coagulation and pregnancy test) for all 6 groups in the Phase 
II part ; given that  only one group will  now be opened, the laboratories for screening and safety 
monitoring will continue to be implemented locally as it is currently being done in the Phase I 
part.  
The main purpose of this amendment is to implement the above -mentioned decisions that were 
already communicated to all Investigators and submitted to all Ethics Committees and Health 
Authorities in participating countries . 
Furthermore, Amendment 6 implements other substantial changes as follows:  
- Provides an update on EGF816 overview based on the most recent version of the 
Investigator ’s Brochure (Ed ition 5, released on 13 -Jul-2016  with a data cut -off date 18 -
Dec-2015 ) 
- Introduces the RP2D that was declared on 30 -Aug-2016 during the Phase I part of the 
study. All patients enrolled in the Phase II will receive the RP2D, i.e. EGF816 150 mg 
QD. The recommended dose reduction steps starting from the RP2D are also introduced i n 
this amendment.  
[COMPANY_001]  Confidential  Page 12 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 - Removes the exclusion criterion on fasting plasma glucose >  175 mg/dL (>  9.8 mmol/L) 
in the absence of evidence of interaction with glucose in light of the most recent available 
clinical data and according to the latest version of EGF816 Investigator ’s Brochure (Ed. 5, 
data cut -off date 18-Dec-2015) 
- Updates the ex clusion criterion on QTcF threshold from 480 to 470 ms as defined by 
[CONTACT_685367] a safety margin of 30 ms for QTc > 
500, a significant liability for TdP, and a [ADDRESS_928803] QTcF 
category of >[ADDRESS_928804]/MRI scans or other imaging data in the Phase I part of the 
study for potential retrospective central review.  
- Update s to clarify criteria for treatment beyond disease progression of patients as per 
Investigator’s judgment  
- Removes in Phase I part for all ongoing patients, the visit on Day [ADDRESS_928805] recent av ailable clinical 
data.  
- Updates the definition of the end of study to detail study continuation conditions after 
completion of the primary analysis until all patients are discontinued, or until another 
clinical trial becomes available for all ongoing patients to be transferred to  that clinical 
study and continue to receive EGF816.  
- Adds  follow -up requirements for potential QTcF prolongation (in case of QTcF >500 ms, 
or QTcF prolongation >60 ms from baseline)  and potential drug -induced liver injury to 
align with other [COMPANY_001] -sponsored study protocols  
- Introduces the modalities and conditions for patient re -screening after screen failure, 
together with screening assessments to be performed again during the new screening 
phase.  
-  
 
 
 
 
 
-  
 
 

[COMPANY_001]  Confidential  Page 13 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 - Updates the exclusion criterion related to women of child -bearing potential and the 
description of imaging efficacy assessments for consistency with other [COMPANY_001] Oncology 
sponsored studies.  
Other non -substantial changes were made to provide more clarity to the protocol:  
- Clarifies the time window for post -dose ECG during the visits with PK sampling.  
- Clarifies that the exclusion criterion on the QTc interval value should be based on the 
Investigator interpretation of the ECG.  
Change to the protocol  
• Protocol summary:  
• Update purpose and rationale, inclusion and exclusion criteria, data analysis 
according to the main changes provided the protocol  
• Section 1.2.1 .2 Clinical experience    
• Updated according to last version of the Investigator ’s Brochure (Ed. 5, data cut -off 
date 18 -Dec-2015)  
• Update efficacy data based on latest data presented in a poster at ASCO 2016  
• Section 2.1: Study rational e and purpose  
• Clarify that the Phase I part will include patients with tumors harboring specific 
EGFR mutations  
• Clarify that in the Phase II part patients to be enrolled will be in first line of 
antineoplastic systemic therapy (EGFR TKI and chemotherapy naïve) and whose 
tumors harbor specific EGFR activating mutations (e.g., L858R and ex19del)  
• Remove the description of the groups 2 to 6 originally planned for the Phase II part  
• Section 2.2: Rational e for study design  
• Remove the description of groups originally planned for the Phase II part  
• Section 2.6: Risk and Benefits  
• Introduce Risk and Benefits section for consistency with other [COMPANY_001] Oncology 
sponsored stud y protocol s  
•  
•  
  
• Section 4.1: Description of study design  
• Update description of patient population and sample size of phase II part  
• Clarify that EGFR mutation status is determined by a local laboratory for patient in 
Phase II part  
• Figure 4 -1: Study design, Phase II part  
• Update the Study design of Phase II part following removal of the groups  2 to 6  
initially planned   
• Table 4 -1: Key features of patient population in each of the 6 groups (Phase II)  
• Remove the table entirely as the 6 groups will no longer be applicable for Phase II 
part 

[COMPANY_001]  Confidential  Page 14 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Section 4.2: Timing for interim analysis and design adaptation  
• Remove all the 6 groups description and clarify the assessment of futility will be 
based on the calculated Bayesian probability of success (PoS).  
• Section 4.3: Definition of end of study  
• Update to clarify that primary analysis will be conducted on Phase I and II patients 
and end of study definition is applicable for Phase I and II patients  
• Remove the description of the 6 groups  
• Section 5: Population  
• Remove the description of the [ADDRESS_928806] received any prior line of systemic antineoplastic therapy in the advanced 
setting (NSCLC stage IIIB or IV). However, patients who have failed  no more than 1 
cycle of antineoplastic therapy  in the advanced setting are allowed . 
• Section 5.2: Inclusion criteria  
• Update Inclusion criterion [ADDRESS_928807] be neurologically stable, having no new 
neurologic deficits on clinical examination, and no new findings on central nervous 
system imaging.  
• Update inclusion criterion 11 to r emove the 6 groups and  define the p atient population 
for Phase II ( NSCLC with locally documented EGFR mutation L858R and/or 
ex19del, and must be naïve from any line of systemic antineoplastic  therapy in the 
advanced setting ) 
• Section 5.3: Exclusion criteria  
• Update exclusion criteri on 7 to clarify that patient with QTcF value above 470ms 
instead of 480ms would be excluded from study provided it was defined as threshold 
for oncology studies by [CONTACT_685368], and  it provides a safety margin of 30 ms for 
QTc>[ADDRESS_928808] QTcF category of >480 ms. In addition it was clarified 
to use  the mean QTcF value from  triplicate screening ECGs according to 
Investigator ’s assessment  
• Update exclusion criterion [ADDRESS_928809] 
been treated with chemotherapy or biologic therapy or other investigational agent from 
≤  1 week to ≤ [ADDRESS_928810] dose of study treatment  
• Update exclusion criterion [ADDRESS_928811] dose of study treatment  
• Update exclusion criteri on 12 to remove Fasting Plasma glucose  in light of IB ed. 5 
data and add editorial updates for ANC, Hemoglobin, Platelets and Creatinine 
Clearance criteria  
• Update exclusion criteri a19 and 20 to provide more clarity on pregnancy / 
contraception and clarify when a condom should be used  
• Section 6.1.1: Dosing Regimen  
[COMPANY_001]  Confidential  Page 15 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Clarify that for patient s in Phase II part, the orally administered film -coated tablet 
formulation will be treated with RP2D and provided with 2 doses strength of 25  mg 
and 50  mg.  
• Clarify  that patients in Phase I part will be continued on capsule or tablets 
formulations  
• Clarify when the dose should be taken on PK days  
• Clarify which fruits must  be avoided during the treatment period of the study  
• Section 6.1.2: Treatment duration  
• Update to remove confirmation of disease progression by [CONTACT_685369]  
• Add that patient may continue treatment until patient experiences unacceptable 
toxicity, disease progression and/or treatment is discontinued at the discretion of the 
investigator or withdrawal of consent.  
• Section [IP_ADDRESS]: new section added to provide details about treatment beyond disease 
progression of patients  
• Section 6.2.1: Starting dose rationale  
• Add details on EGF816 strength and reference to support the formulation change 
from capsules to tablets  
• Table 6 -4: Recommended dose reduction steps for the Phase II part  
• Update the dose reduction steps based on the declared RP2D for Phase I and II 
patients  
• Table 6 -5: Criteria for reduction/interruption and re -initiation of EGF816 treatment for 
adverse drug reactions:  
• Update criteria for Isolated AST/ALT to match with CTCAE and provide guidance 
based on patient’s baseline AST/ALT values and match with new [COMPANY_001] -sponsored 
study protocols  
• Ad criteria for Grade 4 QTcF  
• Update to clarify when the dose modifications/interruptions are recommendations  or 
mandatory and also align with other [COMPANY_001] -sponsored study protocols  
• Table 6 -8: Guidelines for management of HCV reactivation  
• Update to correct the date of viral reactivation from 22Jan to 01Jan2015  
• Table 6 -10: Management and dose modification for maculopapular rash  
• Clarify that Grade ≥3 rash should be re -assessed every week and if more than 1 
epi[INVESTIGATOR_44715] ≥ Grade [ADDRESS_928812] be permanently discontinued  
• Clarify that study drug may be resumed although steroids for rash management are 
still ongoing or being tapered  
• Table 6 -11: Management and dose modification for other rashes including acneiform rash  
• Clarify that re -assessment should be conducted every 2 weeks instead of after 2 weeks  
• Section: 6.3.5: Follow -up for toxicity  
• Add new section [IP_ADDRESS]: follow up on potential QTcF prolongation  to align with 
other [COMPANY_001] -sponsored  study protocols  
[COMPANY_001]  Confidential  Page 16 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Add new section [IP_ADDRESS]: f ollow up on potential drug -induced liver injury (DILI) 
cases  to align with other [COMPANY_001] -sponsored  study protocol s 
• Section 6.4: Concomitant medications  
• Clarify that the use of bisphosph onates is allowe d as no drug -drug interaction is 
expected  with EGF816  
• Editorial changes in Section 6.4.2 and 6.4.3  
• Section 6.5: Patient numbering, treatment assignment or randomization  
• Clarify that this is a non -randomized trial and Integrated Response Technology (IRT) 
will only be used for patient registration and drug supply management in the Phase II 
part 
• Remove the description of treatment assignment of 6 groups originally planned in the 
protocol  
• Section 6.6.1: Study drug packaging and labeling  
• Editorial changes to add more clarity on the packaging difference between Phase I 
and Phase II  
• Table 7 -1: Visit Evaluation Schedule (Phase I part)  
• Greyed out Day 15 for all subsequent cycles after cycle 2 to reduce patient’s visits for 
ongoing Phase I patients after protocol amendment 06  
• Add footnote to clarify that EOT tumor assessment doesn’t need to be repeated if was 
performed ≤ 28 days  
•  
 
 
 
• Remove Body fluid collection/results as no cytology samples will be collected and 
only the cytology form needs to be completed  
• Merge Disposition for  Screening and Treatment for consistency with Table 7 -2 and 
add Disposition for Disease Progression F/U as this information is collected for Phase 
I patients  
• Add row for safety follow -up as this assessment is performed for Phase I patients  
• Table 7 -2: Visit Evaluation Schedule (Phase II part)  
• Greyed out all visits that are no longer applicable for Phase II patients and added the 
corresponding footnote  
• Update to clarify that EGFR mutation status needs to be confirmed by [CONTACT_685370] 
• Remove all the assessments related to Groups 2 to 6  as they are no longer applicable  
• Move Chest X -Ray (for Japanese Patients Only) from the Tumor assessment section 
to the Physical examination section for more clarity  
• Provide more details on the imaging data to be collected for  tumor assessment per 
RECIST 1.1 and as per the imaging collection plan in Table 7 -4  
• Update to clarify that all phase II patients will now have extensive ECG collection   

[COMPANY_001]  Confidential  Page 17 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 •  
  
 
  
• Remove Body fluid collection/results as no cytology samples will be not collected 
and only the cytology form needs to be completed and submitted to central imaging 
CRO  
• Section 7.1.1: Molecular pre -screening  
• Remove all the descriptions related to patients in group s 2 to 6  
• Group [ADDRESS_928813] different groups  
• Clarify that EGFR activ ating  mutation will be confirmed by [CONTACT_22274]  
• Section 7.1.2: Screening  
•  
 
• Clarify that HBV and HCV tests will be performed by a local laboratory for Phase I 
and II patients  
• Section [IP_ADDRESS]: Eligibility Screening  
• Update eligibility text by [CONTACT_685371]/re -screening procedure 
and failures for patients enrolled in Phase II part of the study  
• Section 7.1.4 : Discontinuation of study treatment  
• Add more details on when the patient “should” and not “must” discontinue the study 
treatment  
• Add clarification about when patient is considered to have withdrawn from the study 
and when treatment is continued beyond disease progression  
• Section [IP_ADDRESS]: Post -treatment follow -up 
• Add that antineoplastic therapi[INVESTIGATOR_685322] 7 -1 and 7 -2 
• Section [IP_ADDRESS]: Survival follow -up 
• Add that antineoplastic therapi[INVESTIGATOR_685323]  
• Section 7.1.6: Withdrawal of consent  
• Add reasons when patient can withdraw consent  and clarify that the Investigator 
should make every effort to understand the primary reason of this decision  
• Section 7.2.1: Efficacy Assessment  
• Clarify that central imaging review will be done by [CONTACT_685372] I  
• Editorial changes in Section [IP_ADDRESS] regarding baseline imaging assessment to align 
with other [COMPANY_001] -sponsored study protocols and move the text related to post -
baseline imaging assessment in section [IP_ADDRESS]  

[COMPANY_001]  Confidential  Page 18 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Rename [CONTACT_68979] [IP_ADDRESS] from Subsequent imaging for response assessment to post -
baseline imaging assessment to match with other [COMPANY_001] -sponsored study protocols  
• Section [IP_ADDRESS]: Post -baseline imaging assessment  
• Sub-section renamed to match with other [COMPANY_001] -sponsored study protocols  
• Repetitive statements removed to add some clarity  
•  
•  
 
• Section [IP_ADDRESS]: BIRC confirmation of disease progression  
• Delete sub-section as BIRC PD confirmation is not required and needed provided the 
primary efficacy analysis is based on ORR and not on PFS  
• Section [IP_ADDRESS]: Physical examination  
• Define the complete and targeted physical examination  
• Section [IP_ADDRESS]: Laboratory evaluations  
• Amend to clarify that local lab will be used for patients in Phase I and Phase II and no 
central lab will be used for patients in Phase II  
• Amend to add Phosphorus to match with inclusion criterion  
• Amend to add Amylase and Lipase in the chemistry panel to allow monitoring of 
occurring pancreatic AEs  
• Section [IP_ADDRESS].1: Electrocardiogram (ECG)  
• Update  to clarify that  extensive ECG will be done for all the patients trea ted in Phase 
II part provided groups 2 to 6 were removed  
• Clarify that triplicate ECGs should be performed within 15 minutes prior to the 
collection of PK sample at the matched time -point  
• Update to align wording with other [COMPANY_001] -sponsored study protocols  
• Section 7.2.3: Pharmacokinetics  
• Add dose reference ID prior to PK sampling in Tables 7 -9 and 7 -10 
• Section 7.2.4:  Biomarkers  
• Split  the biomarker section into 2 sub -sections for Phase I and for Phase II part of the 
study  
  
 
• Add reason for biomarker collection and assessments in Phase II part of the study  
• Table 7 -12: Biomarker sample collection plan for Phase II part  
• Update  to remove  description for biomarker collection from  patients in group s 2 to 6  
• Specify that mandatory tumor samples at screening instead of pre -screening should be 
collected and block or a minimum of 11 slides instead of 6 slides are required   
• Specify that m andatory tumor samples (if available ) at C1D1 instead of screening 
should be collected and block or additional 5 slides instead of 10 slides are needed  

[COMPANY_001]  Confidential  Page 19 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Update to clarify that C1D1 o ptional tumor sample now include either n ewly obtained 
tumor biopsy or archival material (3 to 10 slides) if fresh material not available at 
C1D1  
• Add the possibility to provide optional newly acquired biopsy during the treatment 
phase for assessing the study drug effect and mechanisms of resistance to EGF816 
treatment  
•  
•  
 
  
 
• Add optional on treatment blood sample collection to be paired with on treatment 
newly acquired biopsy  
• Remove the tissue requirement needed in the companion protocol for phase II patients  
• Section 8.1 .1: Definitions and reporting  
• Update to clarify  AE reporting  and align with other [COMPANY_001] -sponsored study 
protocols  
• Section 8.1.3: Adverse events of special interest  
• New section added to align with other [COMPANY_001] -sponsored study protocols and define 
the AESIs to be monitored for EGF816  
• Section 8.2.2: Reporting  
• Update the Serious Adverse Event reporting process to allow possible electronic 
reporting to the Sponsor  and name [CONTACT_685461] (CMO&PS)  
• Section 8.3: Pregnancies  
• Replace “Drug Safety and Epi[INVESTIGATOR_066]” by “ Chief Medical Office and 
Patient Safety (DS&ECMO&PS) ” 
• Update: Pregnancy outcomes should  be collected for the female partners  
• Section 8.5: Data Monitoring Committee  
• Update to remove description regarding groups 2 to 6  
• Section 8.7: Blinded Independent Review Committee (BIRC):  
• Reinstate that BIRC review will be performed for patients from Phase I part  
• Remove expedited PD review following local assessment of progression  
• Section 9.4: Database management and quality control  
• Update to align with other [COMPANY_001] -sponsored study protocols  
• Section 10: Statistical methods and analysis:  
• Remove description regarding groups 2 to 6  
• Section 10.1: Analysis sets  
• Update to remove description regarding groups 2 to 6  and description of the 
pharmacokinetic analysis set for phase I and II  

[COMPANY_001]  Confidential  Page 20 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Section 10.2: Patient demographics/other baseline characteristics  
• Update to remove description regarding groups 2 to 6  
• Section 10.3: Treatments  
• Update to remove description regarding groups 2 to 6  
• Section 10.4: Primary objective  
• Remove all the description regarding group s 2 to 6  
• Clarify the interim analysis for futility to  be performed when approximately [ADDRESS_928814] 4 cycles or discontinued treatment prior to that time.  
• Section 10.4.3: Handling of missing values/censoring/discontinuations  
• Add “Patients who have disease progression and continue to receive study drug after 
progression will qualify for PD at the time of progression and will be counted as PD 
in the derivation of efficacy endpoints”  
• Section [IP_ADDRESS]: Adverse events  
• Clarify that Serious adverse events, non -serious adverse events and adverse events of 
special interest during the on -treatment period will be tabulated  
• Section [IP_ADDRESS]: Laboratory abnormalities  
• Clarify that CTCAE grades will be based on observed laboratory values  
• Section 10.5.2: Efficacy analysis  
• Clarify that analyses will be based on the FAS  
• Section [IP_ADDRESS]: Analysis set and the groupi[INVESTIGATOR_685324]  
• Update to confirm phase II part analyses will be summarized for all patients  
• Section [IP_ADDRESS]: Secondary efficacy endpoints  
• Add that Best Overall Response (BOR) will be included in the phase I/II secondary 
efficacy endpoints and  BOR will be summarized by [CONTACT_685373].  
• Section 10.5.3: Pharmacokinetics  
• Update to clarify the planned PK analyses  
• Update Table 10 -1 to remove Cmin as it  could be the concentration at the end of the 
absorption lag phase . 
• Section [IP_ADDRESS]: Data analysis principles  
• Specify which PK plasma concentrations will be included in the analysis   
  
   
  
• Section 10.7: Interim  analysis  
• Remove all group 2 to 6 description  
• Table 10 -2: Update the table to provide the probabilities of success at the primary analysis 
based on different numbers of responders observed at the IA  
• Section 10.8: Sample Size Calculation  
• Update to remove all the groups 2 -6  

[COMPANY_001]  Confidential  Page 21 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Clarify the number  of patients to be enrolled and the number of responders required  
• Table 10 -3 displays the probabilities to stop for futility at the interim analysis and to 
declare preliminary anti -tumor activity of the study treatment at the primary analysis 
(observing at least 22 responses in 40 patients) under different true ORR values  
• Section 11.5: update the section regarding the publication of study protocol and results  to 
align with other [COMPANY_001] -sponsored study protocols  
• Section 14.3 – Appendix 3, Table 14 -14: Permitted Concomitant Medications requiring 
caution  
• Update to include last updates from the Oncology Clinical Pharmacology Drug -Drug 
Interaction Database (release date: May 2016)  
• Section 14.1 – Appendix 1  
• Update to include most recent guidelines for response version 3.[ADDRESS_928815] 1.1  
• Section 14.4 - Appendix 4, Table 14 -15: Prohibited Concomitant Medications  
• Update to include last updates from the Oncology Clinical Pharmacology Drug -Drug 
Interaction Database (release date: May 2016)  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein  affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.   
[COMPANY_001]  Confidential  Page 22 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Amendment [ADDRESS_928816] been enrolled in the Phase I part (dose -escalation) of the 
study at 9 sites in 8 countries  in Asia, Europe and North America . 
As of 08 -July-2015, 2 serious adverse events (SAEs)  of viral hepatitis B (HBV) reactivation 
have been reported in [ADDRESS_928817] and was not on antiviral 
treatment  at study entry. The patient developed  a HBV reactivation  during the study and died 
due to hepatic  failure  despi[INVESTIGATOR_685325] . The second patient  also received EGF816 at 225 mg capsule QD, had a history of  
HBV and was not on antiviral treatment  at the time of joining the study ; however, HBV 
reactivation was detected  approximately 10 weeks on study . Antiviral treatment  was 
immediately initiated , EGF816 was interrupted and the HBV infection was brought under 
control . The p atient later resumed EGF816 at the same dose of 225 mg QD . The viral 
reactivation in these two patients wa s likely due to immuno suppression related to  EGF816. 
Reactivation of HBV and viral hepatitis C  (HCV)  has been reported with other anticancer 
therapi[INVESTIGATOR_685326]. To ensure the safety of all patients participating in 
CEGF816X2101  trial, changes have been made to the protocol to implement the safety 
measures regarding the reactivation of HBV and HCV.  
In addition, early preclinical and clinical findings suggest that EGF816 may have an 
immunomodulatory effect, related to its ability to inhibit the Tec family of kinases (ITK, TEC, 
and TXK). While some preclinical and clinical data suggest that Tec kinase inhibition by 
[CONTACT_32574]816 leads to immunosuppression, other preclinical data indicate that it may lead to a shift 
in differentiation of T cell subtypes that could result in an immunostimulatory effect (Fowell et 
al., 1999, Sagiv -Barfi et al., 2015 ).  Changes have been made to the protocol to allow sample 
acquisition at time points at which the presence of such an effect can be evaluated.  Clinical 
data in the context of immune checkpoint inhibition have demonstrated that several months of 
treatment w ith an immunomodulatory agent may be necessary before changes in tumor immune 
infiltrates can be observed.  Therefore, to assess changes in tumor immune infiltrates during 
EGF816 treatment as compared to baseline, the timing of the on -treatment biopsy ha s been 
moved to a later time point.  In addition, to assess changes in circulating cytokines, additional 
blood collection for plasma has been added at baseline and on the first day of each cycle.  
Based on the rationales for Groups 1 -6 in the Phase II part, the protocol has been amended to 
allow similar patient populations to be enrolled in the Phase I part of the study.  
Changes made to the protocol  are summarized below and  include:  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
• Updated Section [IP_ADDRESS].2 to include preclinical results showing inhibition of Tec family 
kinases by [CONTACT_32574]816 and their potential role in EGF816 effects . 
• Updated Section [IP_ADDRESS] Clinical experience with new clinical data and information on the 
2 SAEs of the HBV reactivation in patients participating in CEGF816X2101.  
[COMPANY_001]  Confidential  Page 23 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 • Protocol Sections 2, 4.1, 5, 7.1.1 and 10 were revised to allow NSCLC patients harboring 
specific EGFR mutations, corresponding to the groups in Phase II part, but with some 
differences in restrictions on prior lines of therapy, to be included in Phase I p art 
• Protocol Sections 3, 4 and 7 were revised to be consistent with Companion Sample 
Collection Protocol languages  
• Protocol Sections 3 and 7 were revised that the assessment of progressive disease (PD) with 
newly obtained tumor samples at screening and C1D15 will be performed up to protocol 
amendment 05. After that, the on -treatment biopsy will be moved from C1D15 to C 4D1, 
C6D1 (optional), C8D1 (optional) and EOT (optional).  
•  
•  
• Protocol Section 4.1, 5, Table 6 -5, Sections 6.3.2, 7.1, 7.2 and Table 7 -6 were revised to 
add assessment and follow up regarding HBV, HCV testing  
• Added exclusion criterion in Section 5.3 to exclude patients who  
• have a history of other malignancies.  
• have undergone a bone marrow or solid organ transplant.  
• have a known history of human immunodeficiency virus (HIV) seropositivity.  
• are receiving concomitant immunosuppressive agents or chronic corticosteroids use at 
the time of study entry.  
• have a history of Torsade de Pointes  
• Protocol Section 6.1.2, [IP_ADDRESS], [IP_ADDRESS], [IP_ADDRESS], 8.7 and 10.5.2  were revised to change the 
imaging assessment from BIRC to investigator assessment for the phase I part  
• Updated Section 6.4.2 to include additional p ermitted concomitant therap ies requiring 
caution and/or action . 
• Updated Table 6 -10 to recommend consideration of skin biopsy in the event of a 
maculopapular rash.  
• Study phase completion part was removed in Section [IP_ADDRESS]  
• Pregnancy assessments were clarified in Section [IP_ADDRESS].6  
• Updated Table 14 -14 and Table 14 -15 in Section 14.3 Appendix 3.  
IRB/IEC/REB Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol (other than the Urgent Safety Measure) require 
IRB/IEC approval prior to implementation. In addition, if the changes herein affect the 
Informed Consent, sites are required to update and submit for approval a r evised Informed 
Consent that takes into account the changes described in this amended protocol.  

[COMPANY_001]  Confidential  Page 24 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Amendment [ADDRESS_928818] been enrolled in the Phase I part (dose -escalation) of the 
study from [ADDRESS_928819] showed an overall response rate (ORR) of 59.5% by 
[CONTACT_685374] 25 (11 confirmed and 14 awaiting confirmation) out of 42 evaluable 
patients.  (Note: evaluable patients include those who were ongoing and had at least one post -
baseline tumor assessment or who discontinued study treatment as of the data cut -off date.) 
Based on these response data, changes have been made to the existing groups and two additional 
groups have been added to the Phase II part in Amendment 4.  
The primary purpose of Amendment 4 is to revise the patient populations and/or the number of 
patients to be enrolled in each group in the Phase II part.  
In addition, the number of groups in the Phase II part is revised from 4 groups (as per 
Amendment 3) to 6 groups (Amendment 4). Each group has a distinctive patient population, 
determined by [CONTACT_685375], including prior EGFR TKIs.  
Throughout Amendment 4, advanced NSCLC refers to patients with either locally advanced or 
metastatic NSCLC. Locally advanced NSCLC is defined as stage IIIB NSCLC not amenable to 
definitive multi -modality therapy including surgery. Metastatic NSCLC refers to stage IV 
NSCLC . 
The table below presents the summary of changes in the groups between Amendment 3 and 
Amendment 4 and the rationale for those changes.  
[COMPANY_001]  Confidential  Page 25 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Summary of the changes in the groups between Amendment 3 and Amendment 4 and the rationale for the changes:  
Group  Amendment 3  Amendment 4  
Rationale for the changes  Patient population  N Patient population  N 
Group 1  Advanced NSCLC EGFR 
mutant (L858R and/or 
ex19del, not T790M)  
Who are intolerant to an 
approved EGFR TKI (e.g., 
erlotinib, gefitinib, afatinib) 
and/or for whom these drugs 
are not appropriate  ~ 20 Locally advanced or metastatic NSCLC 
with EGFR activating mutation (e.g., 
L858R and/or ex19del)  
Who have not received any systemic 
antineoplastic therapy, including EGFR 
TKI treatment, for advanced NSCLC  
Note: patients who have received no 
more than [ADDRESS_928820]-generation irreversible EGFR TKI that 
selectively inhibits activating and acquired resistance 
mutants (L858R, ex19del and T790M), while sparing WT 
EGFR.  
In preclinical study using tumor model with EGFR ex19del, 
EGF816 treatment was more efficacious compared to 
treatment with erlotinib. Other 3rd-generation EGFR TKIs, 
such as AZD9291, have shown promising preliminary data 
in this patient population (ESMO 2014); both AZD9291 and 
CO-[ADDRESS_928821] line 
setting.  
Based on the mechanism of action (MoA), EGF816 will likely 
have similar clinical activity in this patient population.  
The sample size is increased to approximately [ADDRESS_928822] about 81% probability to observe an overall response 
rate ≥ 60%  given the true response rate of this population is 
65%.  
Group [ADDRESS_928823] progressed on 
EGFR TKI (no more than 1 
previously approved EGFR 
TKI) ~ 80 Locally advanced or metastatic NSCLC 
with EGFR activating mutation (e.g., 
L858R and/or ex19del) and an acquired 
EGFR T790M mutation  
Who have progressed on [ADDRESS_928824]-generation 
EGFR TKI (e.g., erlotinib, gefitinib or 
icotinib) or 2nd-generation EGFR TKI 
(e.g., afatinib or dacomitinib)  
No more than 3 prior lines of systemic 
antineoplastic therapi[INVESTIGATOR_014] (including EGFR 
TKI) in the advanced setting  
EGFR TKI treatment must be the last 
prior treatment before study entry.  [ADDRESS_928825]-generation irreversible EGFR TKI that 
selectively inhibits activating and acquired resistance 
mutants (L858R, ex19del and T790M), while sparing WT 
EGFR.  
Preliminary efficacy results from the Phase I part in 
advanced NSCLC patients with both EGFR activati ng 
mutation (L858R and/or ex19del) and T790M mutation 
showed significant antitumor activity of EGF816 that is in 
line with other 3rd-generation EGFR TKIs, and a tolerable 
safety profile  
The increase in sample size will permit a more accurate  
assessment of overall response rate and a better 
understanding of the frequency and types of adverse events 
reported during treatment with EGF816.  
EGFR TKI treatment is required to be the last prior treatment 
before study entry to avoid potential “re -challenge” effect.  
[COMPANY_001]  Confidential  Page 26 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Group  Amendment 3  Amendment 4  
Rationale for the changes  Patient population  N Patient population  N 
Group 3  Advanced NSCLC with a “de 
novo” EGFR T790M mutation  
Who have not received prior 
treatment with an EGFR TKI  ~ 80 Locally advanced or metastatic NSCLC 
with a “de novo” EGFR T790M mutation  
For purposes of this protocol, “de novo” 
T790M will be defined as the presence 
of EGFR T790M mutation in NSCLC 
patients who have NOT been previously 
treated with any therapy known to  inhibit 
EGFR.  
No more than [ADDRESS_928826] antitumor activity in 
this patient population. Of note, one NSCLC patient with a 
“de novo” T790M mutation has been enrolled in the Phase I 
part (dose -escalation) of thi s study. This patient has been 
treated with 225 mg of EGF816 and showed a tumor 
reduction of 41.54% from baseline and continued the study 
treatment for at least 5 months.  
The estimated incidence of “de novo” T790M mutation is low 
(~1%). Thus, the sampl e size is decreased to 40 patients to 
allow completion of enrollment within a reasonable 
timeframe. With a sample size of approximately 40 patients, 
there is about ≥ 78% probability to observe an overall 
response rate ≥ 55% given the true response rate of this 
population is 60%.  
Group 4  Advanced solid tumor 
harboring any EGFR mutation 
and NOT be otherwise eligible 
for groups 1 -3 
No limitation of previous anti -
neoplastic therapi[INVESTIGATOR_685327]  >10 Locally advanced or metastatic NSCLC 
whose tumor harbors EGFR exon 20 
insertion or deletion  
No more than 3 prior lines of systemic 
antineoplastic therapi[INVESTIGATOR_014], including EGFR 
TKI, in the advanced setting  ~ 
10 The patient population in Group 4 was not well defined 
under Amendment 3.  
EGFR exon 20 insertion/deletions are resistant to clinically 
achievable doses of marketed or investigational EGFR 
inhibitors, such as gefitinib, erlotinib, neratinib, afatinib, and 
PF00299804. This group of patients currently represents a 
high unmet medical need.  
In a preclinical study, treatment with EGF816 demonstrated 
promising efficacy and tolerability in an exon [ADDRESS_928827] the potential to provid e 
clinical benefit to this patient population.  
Group 5  New group (added under 
Amendment 4)  - Locally advanced or metastatic NSCLC 
with EGFR activating mutation (e.g., 
L858R and/or ex19del) AND without  an 
acquired EGFR T790M mutation  
Who have progressed on [ADDRESS_928828]-generation 
EGFR TKI (e.g., erlotinib, gefitinib or 
icotinib), or 2nd-generation EGFR TKI 
(e.g., afatinib or dacomitinib)  
No more than [ADDRESS_928829]-generation EGFR 
TKIs, such as AZD9291 and CO -1686, with the overall 
response rates ranging from 21% -36%.  
Given similar MoA between EGF816 and other 3rd-
generation EGFR TKIs, EGF816 may exhibit similar clinical 
activity in this patient population.  
[COMPANY_001]  Confidential  Page 27 
Amended Protocol Version  07 (Track Changes)   Protocol No. CEGF816X2101  
 
 Group  Amendment [ADDRESS_928830] 
prior treatment before study entry.  
Group 6  New group (added under 
Amendment 4)  - Locally advanced or metastatic NSCLC 
with EGFR activating mutations (e.g., 
L858R or ex19del) and an acquired 
T790M mutation  
Who have had treatment with a 1st/2nd-
generation EGFR TKI  
Who have progressed on or are 
intolerant to a 3rd-generation EGFR TKI 
(e.g., AZD9291, CO -1686, or ASP8273)  
No more than [ADDRESS_928831]-generation 
EGFR TKIs; therefore, patients who are intolerant to 
treatment with those agents may be able to tolerate EGF816 
treatment.  
Patients who have progressed on or are intolerant to a 3rd-
generation EGFR TKI represent a population with a 
significant unmet medical need.  
Data may provide further understanding of the mechanism 
of resistance to 3rd-generation EGFR TKIs.  
[COMPANY_001]  Confidential  Page 28 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Furthermore, Amendment 4 implements other important changes affecting the Phase II part  
of this trial as follows:  
• Implements Interactive Response Technology (IRT) to track patient enrollment, document 
key eligibility criteria, allocate patients into 6 different groups based on their disease 
characteristics at study entry, and track EGF816 drug dispensing.  
• Implements a Blinded Independent Review Committee ( BIRC ) for tumor assessment to 
allow an independent and unbiased evaluation of tumor response for the Phase I part and 
Phase II part.  
• Implements the central laboratories to evaluate the safety of EGF816 (e.g., hematology, 
chemistry, urinalysis, coagulation and pregnancy test) for all 6 groups. The use of a central 
laboratory will allow a consistent laboratory assessment and interpretatio n of the results 
across a multitude of countries participating in this study.  
• Implements the central laboratory to determine the EGFR mutation status for Groups [ADDRESS_928832] does not meet the protocol specified 
criteria . The use of a central laboratory will allow a consistent determination of the EGFR 
mutation status across a multitude of countries participating in this study.  
• Implements a requirement of ECOG performance status of [ADDRESS_928833] important 
prognostic factors for survival of patients with NSCLC.  
• Added overall survival (OS) as a secondary objective to assess clinical benefit and to obtain 
additional information for the future trial planning.  
•  
 
 
 
 
 
 
 
 
 
 
  
 
 
. 
In addition, for the Phase I part, BIRC will be implemented retroactively to one of the secondary 
objectives to  evaluate ORR, duration of response (DOR), disease control rate (DCR), 
progression -free survival (PFS), and time to response (TTR) . 
Changes to the protocol include:  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  

[COMPANY_001]  Confidential  Page 29 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Section 1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_013]  
• Added a sentence to provide the rationale for Group 5.  
• Section [IP_ADDRESS].1  Non-clinical pharmacokinetics and metabolism  
• Removed the restriction on use of concomitant medications which are sensitive 
substrates of CYP2C8 and CYP2D6.  
• Section [IP_ADDRESS] Clinical experience  
• Added the efficacy  and safety summaries of EGF816 based on the data from 2 -Feb-
2015 (data cut -off date) . 
• Added Figure 1 -1 to provide EGF816 clinical activity observed at all dose levels 
tested. 
• Added the description to define the purpose of the Phase II.  
• Section 2.2 Rationale for the study design  
• Added descriptions to define the 6 groups of the Phase II part and corresponding 
rationales.  
• Section 2.3 Rationale for dose and regimen selection  
• Deleted the rationale for once daily dosing.  
• Added a sentence to describe that the recommended phase II dose (RP2D) will be 
based on the efficacy and safety data of the Phase I part.  
• Section 3 Objectives and endpoints   
• Separated the Phase I objectives and related endpoints (Table 3 -1) from the Phase II 
objectives and related endpoints  (Table 3 -2). 
• Added BIRC to one of the secondary objectives for the Phase I part  
• Revised the primary endpoint of Phase II to add overall  response rate (ORR) by [CONTACT_14988]  
• Added the secondary objectives and related endpoints for the Phase II part.  
•  
 
 
•  
• Added a sentence to state that patients enrolled in the Phase I part will follow the visit 
schedule noted in Table 7 -1. 
• Moved up the paragraph “Pati ents may have tumor tissues… once approved and open” 
and stated it is for the Phase I part.  
• Added the descriptions for the six distinctive groups, corresponding sample size for 
each respective group and key changes in Amendment 4.  
• Figure [ADDRESS_928834] the current study design of the Phase II part under  
Amendment 4.  
• Table 4 -1 was added to provide key features of patient population in each of the 6 
groups.  
• In Figure 4 -2, the sequence of the study visit flow was revised so that the 30 days 
follow -up period is now before the disease progression follow -up period and the 

[COMPANY_001]  Confidential  Page 30 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 survival follow -up period was added following the disease progression follow -up 
period.  
• Created Figure 4 -3 for the Phase II part  
• Section 4.2 Timing of interim analyses and design adaptations  
• New description was added to describe the updated information for the interim futility 
analyses. The previous description of the interim analyses for Phase II was deleted.  
• Section 4.4 Early study termination  
• Added “discontinued or” and deleted “prematurely” per the guidelines for 
discontinuation of clinical trial protocol (CTP) elements . 
• Section 5 Population  
• Deleted the previous language for describing the different groups in Phase II and 
added new descriptions for these groups.  
• Added a sentence to define treatment failure.  
• Added “Patients enrolled in the study are not permitted to participate in additional 
parallel investigational drug or device studies.”  
• Section 5.1 Patient population  
• Added clarification that exceptions to the inclusion/exclusion criteria in the Phase II 
part are not allowed.  
• Section 5.2 Inclusion criteria  
• Added the corresponding inclusion criteria for each of the 6 groups in Phase II.  
• Added clarification that an ECOG performance status of 0, 1 or 2 will be required for 
Phase I and an ECOG performance status of 0 or 1 will be required for Phase II.  
• Section 5.3 Exclusion criteria  
• Added the corresponding exclusion criteria for each of the 6 groups in Phase II.  
• In Prior therapi[INVESTIGATOR_685328], remove “phototoxicity” as EGF816 may have 
photosensitivity.  
• The renal function exclusion criterion was changed to measured or calculated 
creatin ine clearance <45 m L/min.  
• For exclusion criteria, highly effective methods of contraception or condom must be 
used while taking the study drug and for 3 months after stoppi[INVESTIGATOR_056].  
• Section 6.1.1 Dosing regimen  
• Added clarification that the 25 mg tablet will be available at the start of Phase II. The 
50 mg tablet will be available at a later time during the study.  
• Table 6 -4 of Amendment 3 was moved up to this section to better align with the 
heading. A footnote was added to clarify that the 50 mg tablet will be available at a 
later time.  
• Section 6.1.2 Treatment duration  
• Added new criteria or definitions for treatment discontinuation.  
• Section 6.2.1 Starting dose rationale  
[COMPANY_001]  Confidential  Page 31 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Deleted “The highest provisional dose planned (1000 mg, qd) can be dissolved in less 
than [ADDRESS_928835] volume of water required for the administration of the drug.”  
• Table 6 -2 Provision dose levels : added a row for 100 mg dose.  
• Section [IP_ADDRESS] Change of drug formulation  
• Added clarification that the EGF816 tablet will be used in Phase II.  
• Section 6.3.1 Dose modification and dose delay  
• Added the guidelines for the management and dose modification of skin -related 
toxicities.  
• Added the guidelines for the management and dose modification of non -infectious 
pneumonitis/interstitial lung disease.  
• Section 6.4.1 Permitted concomitant therapy  
• Added clarification that radiotherapy is permitted for patients who develop 
progressive disease limited to bone in addition to CNS involvement.  
• Section 6.5.1 Patient numbering  
• Added a new description about implementation of IRT for Phase II.  
• Section 6.5.2 Treatment assignment  
• Revised the description about IRT for the Phase II  part. 
• Section 6.6 Study drug preparation and dispensation  
• As described above  under Section 6.1.1 , Table 6 -4 was deleted and moved up to 
Section 6.1.1.  
• Section 7.1 Study flow and visit schedule  
• Added the description that written informed consent must be obtained before any 
study specific assessments are performed.  
• Added clarifications for visit  and schedule windows for Phase I and Phase II.  
• Added a separate visit evaluation schedule (Table 7 -2) for Phase II.  
• Added clarification that Phase I and Phase II will follow visit evaluation schedule 
outlined in Table 7 -1 and Table 7 -2, respectively.  
• Deleted any assessments that are applicable to Phase II from  Table 7 -1. 
• The Japan only requirement regarding hospi[INVESTIGATOR_316671] C1 was removed.  
• Section 7.1.1 Molecular pre -screening  
• Modified the descriptions for the requirements of the local/central laboratory testing 
of the EGFR mutation status for the Phase I part and Phase II part.  
• Section 7.1.2 Screening  
• Modified the descriptions for the screening period.  
• Section [IP_ADDRESS] Eligibility screening  
• A new section titled “Eligibility screening” was added.  
• Section [IP_ADDRESS] Information to be collected on screening failures  
[COMPANY_001]  Confidential  Page 32 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Section [IP_ADDRESS] titled “Information to be collected on screening failures” was revised 
and is now number ed as Section [IP_ADDRESS]. The eCRF pages to be completed for 
screening failure patients are listed.  
• Section [IP_ADDRESS] Patient demographics and other baseline characteristics  
• Section [IP_ADDRESS] titled “Patient demographics and other baseline characteristics” was 
revised and is now numbered as Section [IP_ADDRESS]. The types of data to be collected are 
outlined.  
• Section 7.1.4 End of treatment visit including study completion and premature withdrawal  
• Section 7.1.4 in Amendment 3 was deleted to better align with the guidelines for 
discontinuation of CTP elements . 
• Section [IP_ADDRESS] Criteria for premature patient withdrawal  
• Section 7.1.4 in Amendment 3 was deleted to better align with the guidelines for 
discontinuation of CTP elements . 
• Section 7.1.4 Discontinuation of study treatment  
• Section 7.1.[ADDRESS_928836] Section 7.1.4 
Criteria for premature patient withdrawal per the guidelines for discontinuation of 
CTP elements . 
• Section [IP_ADDRESS] Replacement policy  
• Section [IP_ADDRESS] Replacement policy in Amendment 3 was moved to a later part of the 
amendment and is now numbered as Section [IP_ADDRESS].  
• Section 7.1.5 Follow up period  
• Section Disease progression follow -up and Section 30 day safety follow -up were 
deleted and replaced with Section [IP_ADDRESS] Follow -up for safety evaluations, Section 
[IP_ADDRESS] Post -treatment follow -up, Section [IP_ADDRESS] Study phase completion and Section 
[IP_ADDRESS] Survival follow -up. 
• Section 7.1.6 Withdrawal of consent  
• Section 7.1.6 was added per the guidelines for discontinuation of CTP elements . 
• Section 7.1.[ADDRESS_928837] to follow -up 
• Section 7.1.7 was added per the guidelines for discontinuation of CTP elements . 
• Section 7.2.1 Efficacy assessment  
• Imaging collection plans were separated for Phase I and Phase II.  
• Table 7 -4 was added to introduce the imaging collection plan for the Phase II part.  
• Section [IP_ADDRESS] Baseline imaging assessment  
• Additional descriptions were added to this section for imaging requirement at baseline 
and tumor assessments required at baseline.  
• Section [IP_ADDRESS] Subsequent imaging for response assessment  was added.  
• Section [IP_ADDRESS] Transmission of efficacy data to BIRC was added per BIRC 
implementation.  
• Section [IP_ADDRESS] BIRC confirmation of disease progression was added per BIRC 
implementation.  
• Section [IP_ADDRESS] Laboratory evaluations  
[COMPANY_001]  Confidential  Page 33 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Descriptions were added per implementation of central laboratory for safety 
evaluations.  
• Table 7 -6 was relabeled as “Central/local clinical laboratory parameters collection 
plan.”  
• Section [IP_ADDRESS].1 Electrocardiogram (ECG)  
• Table 7 -7 was revised with the following changes: 1) Central ECG co llection plan for 
all patients; 2) Triplicates are  added for pre -dose timepoints; 3) The requirement for 
Japan only was removed.  
• Table 7 -8 was added for implementation of extensive ECG collection plan at pre -
selected sites.  
• Section [IP_ADDRESS] Pharmacokinetic blood sample collection and handling  
• Table 7 -10 was revised with the following changes: 1) “scheme 1” wa s removed from 
the table title; 2) “first 10 patients in each group” wa s removed from the table title; 3) 
the 12 hr timepoint was removed from the table and the dose reference IDs and 
footnotes were updated accordingly.  
• Table 7 -11 was removed as Phase II part PK scheme 2 was not needed.  
•  
  
  
  
  
•  
  
•  
 
 . 
• Section 8.7 Blinded Independent Review Committee (BIRC) was added per BIRC 
implementation.  
• Section [IP_ADDRESS]  
• Modified the statistical success criterial for Group s 1, 2, and 3, and added statistical 
analysis and success criterial for Group s 5 and 6.  
• Section 10.5.2  
• Clarified the definition of all the efficacy objectives.  
  
  
 
• Section 10.7  
• The interim futility analysis for Group 2 (per Amendment 3) was removed due to 
encouraging preliminary clinical activity observed with EGF816 treatment which is in 
line with other 3rd-generation EGFR TKIs and better than the current standard -of-care 

[COMPANY_001]  Confidential  Page 34 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 chemotherapy (ORR of 34% observed for platinum doublet [IMPRESS trial, ESMO 
2014 ]). 
• Modified the interim analysis method for Group s 1 and 3, and added the interim 
analysis method for Group s 5 and 6 . 
• Section 10.8  
• Modified the sample size rationale for Group s 1, 2, and 3, and added the sample size 
rationale for Group s 5 and 6. 
IRB/IEC/REB Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into  account 
the changes described in this amended protocol.  
Amendment 0 3 
Amendment rationale  
In order to create a commercially viable format, tablet is going to be introduced  to the study.  
The main purpose of this amendment is to allow for the possibility of a formulation change 
during dose escalation from capsule to tablet , and the determination of a  MTD and/or RP2D  
with either formulation .  
Additional changes to the protocol:  
• Clarification of appropriate methodologies regarding patient selection strategy. Protocol is 
amended  to mandate that T790M positivity be defined by [CONTACT_685376] (Qiagen) for Group 2 and Group 3 in phase II part. This change is 
necessary to minimize the variance in testing methodologies and to meet health authorities 
standards. The addition of this requirement  necessitated several modifications to other 
specific parts including statistical part in protocol.  
• Clarification and modification of inclusion/exclusion criteria regarding previous number of 
treatments allowable for Groups [ADDRESS_928838] received multiple standards of care.  
• Clarification and modification of inclusion/exclusion criteria regarding washout time from 
previous treatments to be aligned with the current standard approach to treat patients with 
EGFR TKI s and to minimize tumor flare following EGFR TKI withdrawal.  
•  
 
 
• Minor changes to address consistencies within protocol  

[COMPANY_001]  Confidential  Page 35 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Changes to the protocol include:  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
Table 3 -1 Objectives and related endpoints  
  
Section 4.1 Description of study design  
• Added requirement that for patients to be recruited to Group [ADDRESS_928839] be defined by [CONTACT_685377] (Qiagen) at a [COMPANY_001] - 
designated  central laboratory.  
Section 5.2 Inclusion criteria  
• Group 1: added “Patients who were found to also have a T790M mutation  by [CONTACT_685378] T790M (for purposes of this protocol) and will be eligible for 
this group.”  
• Group 2 and Group 3: changed the documentation of EGFR mutational status to be 
compliant with description of study design . 
• Group 2 and Group 3: clarified that only adenocarcinoma patients will be included. 
Modifications were made in other parts of protocol to be consistent with this change.  
• Group 2: removed “according to RECIST v1.1” when defining “acquired T790M mutation 
following progression on EGFR TKI.  
Section 5.3 Exclusion criteria  
• Excluded in phase I part patients “previously treated with any investigational EGFR -TKI 
targeting EGFRmut -T790M” . 
• Revised to allow “no limitation of previous antineoplastic therapi[INVESTIGATOR_685329] ” for Group 1 and Group 4 in phase II part.  
• Modified washout time frame for previous treatment. In particular, “patients who have 
been treated with chemotherapy or biologic therapy or other investigational agent ≤ [ADDRESS_928840] dose of study treatment. ” 
• Modified washout time frame for radiation therapy and/or surgery for brain metastases to 
be consistent with exclusion number 5. And clarified that patients with controlled brain 
metastases may participate in this trial.  
Table 6 -1 Dose and treatment schedule  
• Added the dose and frequency of tablet and moved the table to Section 6.6 . 
• Clarified that the administration instruction will be the same as for tablet . 
Section 6.2.1 Starting dose rationale  
• Added starting dose rationale for tablet . 
Section [IP_ADDRESS] Definition and estimation of MTD/RP2D  
• Added “MTD/RP2D for each drug formulation or dosing schedule may be established  
when appropriate ”. 
Section [IP_ADDRESS] Dose cohort modification  

[COMPANY_001]  Confidential  Page 36 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Revised wording from “for the purposes of dose escalation decisions, each cohort will 
consist of 1 to 3 newly enrolled evaluable patients who will be treated at the specified 
dose level”  to “for the purposes of dose escalation decisions, each cohort will consist of 1 
to 6 newly enrolled evaluable patients who will be treated at the specified dose level.”  
• Added wording to “if significant activity is seen early in the dose escalation, then a 
recommended dose may be identified and the phase II groups may be initiated without 
determination of the MTD; therefore fewer than 21 patients may be required. ” 
• Added wording to allow cohort modification in case of “change of formulation ”. 
Section [IP_ADDRESS] Intra -patient dose escalation  
• Added “patients still on capsule treatment may switch to tablets at same dose level or 
following the same intra -patient dose procedure as for capsule ”. 
Section 6.2.4 Definitions of dose -limiting toxicities (DLTs)  
• Clarified that the definition of DLT is for phase I part only . 
Table 6 -2 Criteria for defining dose -limiting toxicities  
• Clarified that definition of grade 3 serum creatinine according to CTCAE .  
• Deleted criteria for “pancreas ”. 
Table 6 -3 Criteria for interruption and re -initiation of EGF816 treatment  
• Changed guidance for Grade 3 serum creatinine increase and Grade 2 Bilirubin increase . 
 
  
Section 7.1.1 Molecular pre -screening  
• Changed the documentation of EGFR mutational status to be compliant with description 
of study design . 
Section 7.2.1 Efficacy assessments  
• Clarified that imagining data will be centrally collected and checked for quality for Group 
2 and Group 3 only in Phase II part.  
 
  
 
  
Table 7 -6, Table 7 -7 and Table 7 -8: Schedule of blood sample collections for pharmacokinetics  
• Clarified in footnote that “If biopsy is collected on cycle 1 day 15, no unscheduled blood 
PK sample need s to be collected”.  
 
  
Section 10.4.2 Statistical hypothesis, model and method of analysis  
• Added wording for “change in drug formulation ”. 

[COMPANY_001]  Confidential  Page 37 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Section 14.2 Operational characteristics of the Bayesian logistic regression mode and 
hypothetical  dose escalation scenarios  
• Added specification of the  statistical model for tablet  and the corresponding hypothetical 
scenarios.  
Added or revised wording regarding optional companion sample collection protocol in Section 
4, Table 7 -1, Table 7 -9, Section 7.2.4, Section 8.2 and Section 9 . 
Replaced “RDE ” with “RP2D ” throughout the protocol . 
IRB/IEC/REB Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into  account 
the changes described in this amended protocol.  
Amendment 02  
Amendment 02 rationale  
The rational for the amendment is to address changes requested by [CONTACT_591122] (i.e. Japan 
PMDA) and includes the following:  
• Clarify  the definition of “women of childbearing potential”  
• Add “glucose” into chemistry panel in laboratory parameters  
  
[For Japan only]  
• Add a d escription in the protocol that in Japan, written consent is necessary both from the 
patient and his/her legal representative if he/she is under the age of 20 years.  
• Specify that Japanese patients will be hospi[INVESTIGATOR_217907] 1, vital signs will be 
obtained during the first week of hospi[INVESTIGATOR_059], chest X -ray will be obtained per cycle 
with an additional ECG on C1D1 per Japanese standards/concerns regarding EGFR TKI 
development.  
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.  
Section 5.3 exclusion criteria  
• Added definition of “women of childbearing potential”  
Table 7 -4 local clinical laboratory parameters collection plan  
• Added “glucose” into chemistry panel  
Section 7.2.4 biomarker  

[COMPANY_001]  Confidential  Page 38 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Added “Results of biomarker analysis whose clinical reliability has been validated will be 
communicated back to the investigator, who may discuss them with the patient.”  
[For Japan only]  
Section 5.2 inclusion criteria  
• Added “[For Japan only, written consent is necessary both from the patient and his/her 
legal representative if he/she is under the age of 20 years. ]” 
Section 5.3 exclusion criteria  
• Added “[For Japan only: Patients with a current or past history of interstitial lung 
disease.]”  
Table 7 -1 visit evaluation schedule, footnote  
• Added “[For Japan only, patients are required to be hospi[INVESTIGATOR_685330] 1” and 
“percutaneous oxygen saturation (SpO2) will be measured every time physical 
examination is performed. In addition, SpO2 and vital signs will be measured on Days 2 -7 
in Cycle 1] ”.  
Table [ADDRESS_928841] X -ray:  
• Added “ [For Japan only: A 2-view chest X -ray will be performed at screening, Day [ADDRESS_928842] X -
ray can be skipped except for at screening. ]” 
Table 7 -5 central ECG collection plan  
• Added “[For Japan only: triplicate [ADDRESS_928843] dose (±30 minutes) on 
C1D1]”  
Changes to specific sections of the protocol are shown in the track changes version of the  
protocol using strike through red font for deletions  and red underlined for insertions.  
IRB/IEC/REB Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into  account 
the changes described in this amended protocol.  
Amendment 0 1 
Amendment rationale  
The rationale for the amendment is to comply with health authority’s request to add a generic 
statement to this first -in-man trial: “ that all patients participating in this clinical trial must have 
recurred or progressed following standard therapy, unless no standard therapy exists, is 
tolerated or appropriate ”. The addition of this generic statement however necessitated several 
modifications to specific inclusion criteria as outlined : 
[COMPANY_001]  Confidential  Page 39 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 1. Specified  that all patients participating in this clinical trial must have recurred or 
progressed following standard therapy, unless no standard therapy exists, is tolerated or 
appropriate  
2. Revise d that Phase I part will recruit NSCLC patients harboring a documented EGFR 
T790M  mutation  
3. Revise d that the group [ADDRESS_928844] advanced NSCLC with 
EGFR mutation (L858R or ex19del, not T790M) and are intolerant to an approved EGFR 
TKI (e.g., erlotinib, gefitinib, afatinib); and/or for whom these drugs are not appropriate.  
Furthermore , times of blood pressure and time interval of 3 sequential ECGs were deleted to 
allow sites perform the assessments only to comply with institutional  standards.  
In addition, this amendment was used to make a few other changes for clarification (please see 
below Changes to the protocol for details ). 
Changes to the protocol  
Section 2.1 Study rational and purpose  
Section 2.2 Rational for study design  
Section 4.1 Description of study design  
• Revised wording in these 3 sections to be consistent with changes in inclusion criteria  
Section 5.2 – Inclusion criteria  
• Added one inclusion criteria to specify patient population  as stated above  
• Revised inclusion criteria for Phase I part  as stated above  
• Revised inclusion criteria for group 1 in Phase II part  as stated above  
Section 5.3 – Exclusion criteria  
• Revised wording of prior treatment to be consistent with changes  in inclusion criteria  
Table 6 -4 Criteria for interruption  and re -initiation of EGF816 treatment  
• Deleted “[ADDRESS_928845] conditions ” for 
hypertension  
Section [IP_ADDRESS].1 Electrocardiogram (ECG)  
• Time internal requirement (“separated  by 10 -15 minutes ”) was deleted for 3-sequential 
ECG s 
Section 8.7 Warnings and precautions  
• Deleted due to duplication with Section 8.4  
Section 10.8 Sample size calculation  
• Revised wording to be consistent with changes in inclusion criteria  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions  and red underlined for insertions.  
[COMPANY_001]  Confidential  Page 40 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 IRB/IEC/REB Approval  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein  affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.  
[COMPANY_001]  Confidential  Page 41 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Protocol summary  
Protocol number  CEGF816X2101  
Title A phase I/II, multicenter, open -label study of EGFRmut –TKI EGF816, administered orally 
in adult patients with EGFRmut solid malignancies  
Brief title  n/a 
Sponsor and  
Clinical Phase  [COMPANY_001]  
Phase I/II  
Investigation type  Drug  
Study type  Interventional  
Purpose and 
rationale  The purpose of the Phase I part (dose -escalation) of this study is to determine the 
maximum tolerated dose (MTD) or recommended phase II dose (RP2D) and to evaluate 
the preliminary antitumor activity of single -agent EGF816 in adult patients with locally 
advanced (stage IIIB) or metastatic (stage IV) NSCLC harboring a documented EGFR 
mutation. Based on preclinical data for EGF816 and the known clinical activity of other 3rd-
generation epi[INVESTIGATOR_3506] (EGFR) inhibitors, it is expected that EG F816 
would exhibit to significant antitumor activity in non -small cell lung cancer (NSCLC) 
patients harboring the activating EGFR mutations (e.g., L858R and ex19del) and/or the 
acquired/resistant “gatekeeper” T790M mutation while sparing wild -type (WT) EGF R. 
The purpose of the Phase II part is to evaluate the efficacy and safety of single -agent 
EGF816 in adult patients with locally advanced (stage IIIB) or metastatic (stage IV) 
NSCLC whose tumors harbor specific EGFR mutations. The Phase II part will consist i n 
enrolling treatment naïve patients (i.e. have not received any systemic antineoplastic 
therapy for advanced NSCLC. Patients who have failed  no more than 1 cycle of 
antineoplastic therapy in the advanced setting are allowed. Treatment failure is defined a s 
documented disease progression or intolerance to treatment. Neo -adjuvant and adjuvant 
systemic therapi[INVESTIGATOR_685331] 1 prior line of treatment if relapse occurred within 12 
months from the end of the neo -adjuvant/adjuvant systemic therapy.  
Note: throughout this protocol, advanced NSCLC refers to patients with either locally 
advanced or metastatic NSCLC. Locally advanced NSCLC is defined as stage IIIB NSCLC 
not amenable to definitive multi -modality therapy including surgery. Metastatic NSCLC 
refers to stage IV NSCLC.  
Primary 
Objective(s)  Phase I part (dose -escalation)  
• To estimate the MTD or RP2D  of EGF816 as assessed by [CONTACT_685379] -limiting 
toxicities (DLTs) during the first 28 days of dosing.  
Phase II part  
• To evaluate the antitumor activity of EGF816 as measured by [CONTACT_193924] 
(ORR) determined by [CONTACT_565281] (BIRC) assessment in 
accordance to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)  
Secondary 
Objectives  Phase I part (dose -escalation)  
• To characterize the safety and tolerability of EGF816  
• To evaluate ORR, duration of response (DOR), disease control rate (DCR), 
progression -free survival (PFS), and time to response (TTR) by [CONTACT_685380] 1.1  
• To characterize the pharmacokinetics (PK) properties of EGF816 and metabolite 
LMI258  
• To assess the tumor EGFR signaling inhibition by [CONTACT_32574]816 (prior to protocol 
amendment 05)  
Phase II part   
• To further characterize the safety and tolerability of EGF816  
[COMPANY_001]  Confidential  Page 42 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • To evaluate ORR by [CONTACT_685381] 1.1  
• To evaluate DOR, DCR, PFS and TTR by [CONTACT_685382] 1.1  
• To evaluate overall survival (OS)  
• To characterize the pharmacokinetics (PK) properties of EGF816 and metabolite 
LMI258  
Note: ORR is defined as the proportion of patients with best overall response of PR+CR 
per RECIST 1.1; DOR is defined as the time from first documented response (PR or CR) 
to the date of first documented disease progression or death due to any cause; DCR i s 
defined as the proportion of patients with best overall response of CR, PR, or SD; PFS is 
defined as time from date of first dose of study treatment to date of first documented 
disease progression; TTR is defined as the time from the date of first dose o f study 
treatment to the date of first documented response (CR or PR). OS is defined as the time 
from the date of first dose of study treatment to the date of death due to any cause.  
Study design  This is a Phase  I/II, multi -center, open -label study starting with a Phase  I part (dose -
escalation ) followed by a Phase  II part. Oral EGF816 will be administered once daily on a 
continuous schedule until patient experiences unacceptable toxicity, progressive disease 
(PD),  and/or treatment is discontinued at the discretion of the investigator , patient  
withdrawal of consent , or due to any other reasons.  
Treatment with EGF816 may be continued beyond RECIST 1.[ADDRESS_928846] locally advanced or metastatic NSCLC 
harboring specific EGFR mutations. For the Phase II part, treatment naïve adult patients 
with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be 
enrolled. Note: Patients who have failed no more than 1 cycle of systemic antineoplastic 
therapy in the advanced setting are allowed. Treatment failure is defined as documented 
disease progression or intolerance to treatment. Neo -adjuvant and adjuvant system ic 
therapi[INVESTIGATOR_685331] 1 prior line of treatment if relapse occurred within 12 months 
from the end of the neo -adjuvant/adjuvant systemic therapy.  
Inclusion criteria  For all patients (unless otherwise specified):  
1. Written informed consent obtained prior to any screening procedures  
2. Patient (male or female) ≥ 18 years of age  
[For Japan only: written consent is necessary both from the patient and his/her legal 
representative if he/she is under the age of 20 years. ] 
3. Patients must have histologically or cytologically confirmed locally advanced (stage 
IIIB not amendable to definitive multi -modality therapy including surgery) or metastatic 
(stage IV) EGFR mutant NSCLC  
4. Patients with controlled brain metastases may participate in the trial. If applicable, 
they must complete any planned radiation therapy and/or surgery > [ADDRESS_928847] be neurologically stable, having no new neurologic deficits on clinical 
examination, and no new findings on central nervous system imaging.  
5. ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: [ADDRESS_928848] 1.1 per Investigator 
assessment. A previously irradiated site lesion may be counted as a target lesion only 
if there is clear sign of progression since the irradiation (see Section 14.1 Appendix 1 ) 
7. Patients must be screened for HBV. Patients who are either HBsAq positive or HBV -
[COMPANY_001]  Confidential  Page 43 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 DNA positive must be willing to take antiviral therapy [ADDRESS_928849] negative hepatitis C antibody 
(HCV -Ab) or positive HCV -Ab but undetectable level of HCV -RNA. Note patients with 
detectable HCV -RNA are not eligible to enroll into the study.  
9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory 
tests and other study procedures  
10. Requirements of EGFR mutation status and prior lines of treatment for Phase I 
patients  
Patients must meet one of the following criteria:  
• Locally advanced or metastatic NSCLC with EGFR activating mutation (e.g., L858R 
and/or ex19del); Who have not received any systemic antineoplastic therapy, 
including EGFR TKI treatment, for advanced NSCLC; Note: patients who have 
received no more than 1 cycle of chemotherapy in the advanced setting are allowed.  
• Locally advanced or metastatic NSCLC with EGFR activating mutation (e.g., L858R 
and/or ex19del) AND an acquired EGFR T790M mutation following progression on 
prior treatment with a 1st-generation EGFR TKI (e.g., erlotinib, gefitinib or icotinib) or 
2nd-generation EGFR TKI (e.g., afatinib or dacomitinib); No more than [ADDRESS_928850] received 
any agent targeting EGFR T790M mutation (e.g.,. 3rd generation  EGFR TKI)  
• Locally advanced or metastatic NSCLC with a “de novo” EGFR T790M mutation; For 
purposes of this protocol,  “de novo” T790M will be defined as the presence of EGFR 
T790M mutation in NSCLC patients who have NOT been previously treated with any 
therapy known to inhibit EGFR; No more than 3 prior lines of systemic antineoplastic 
therapi[INVESTIGATOR_014]; No prior treatment with any therapy known to inhibit EGFR, including EGFR 
TKI 
• Locally advanced or metastatic NSCLC whose tumor harbors EGFR exon 20 insertion 
or deletion; No more than 3 prior lines of systemic antineoplastic therapi[INVESTIGATOR_014], including 
EGFR TKI  
• Locally advanced or metastatic NSCLC with EGFR activating mutation (e.g., L858R 
and/or ex19del) AND without an acquired EGFR T790M mutation; Who have 
progressed on prior treatment with a 1st-generation EGFR TKI (e.g., erlotinib, gefitinib 
or icotinib), or 2nd-generation EGFR TKI (e.g. afatinib or dacomitinib); No more than 3 
prior lines of systemic antineoplastic therapi[INVESTIGATOR_014], including EGFR TKI  
• Locally advanced or metastatic NSCLC with EGFR activating mutations (e.g., L858R 
or ex19del) and an acquired T790M mutation; Who have had treatment with a 1st/2nd-
generation EGFR TKI; Who have progressed on or are intolerant to a 3rd-generation 
EGFR TKI (e.g., AZD9291, CO -1686, or ASP8273); No more than 3 prior lines of 
systemic antineoplastic therapi[INVESTIGATOR_014], including EGFR TKIs  
11. Requirements of EGFR mutation status and prior lines of treatment for Phase II 
patients : 
• Locally advanced or metastatic NSCLC with EGFR activating mutation (e.g., L858R 
and/or ex19del); Who have not received any systemic antineoplastic therapy, 
including EGFR TKI treatment, for advanced NSCLC; Note: patients who have failed 
no more than 1 cycl e of systemic antineoplastic therapy in the advanced setting are 
allowed. Treatment failure is defined as documented disease progression or 
intolerance to treatment. Note: Neo -adjuvant and adjuvant systemic therapi[INVESTIGATOR_685332] 1 prior line of trea tment if relapse occurred within 12 months from the end 
of the neo -adjuvant/adjuvant systemic therapy.  
Exclusion criteria  For All patients (unless otherwise specified):  
1. Patients with a history or presence of interstitial lung disease or interstitial 
pneumonitis, including clinically significant radiation pneumonitis (i.e. affecting 
[COMPANY_001]  Confidential  Page 44 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 activities of daily living or requiring therapeutic intervention)  
2. Patients with unstable brain metastases.  
3. Presence or History of another malignancy  
Exception: Patients who have been disease -free for 3 years, or patients with a history 
of adequately treated in -situ carcinoma of the uterine cervix, basal or squamous cell 
carcinoma, non -melanomatous cancer of skin, history of stage IA melanoma that has 
been cured, are eligible.  
4. Undergone a bone marrow or solid organ transplant  
5. Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is 
not mandatory)  
6. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids 
use at the time of study entry except for control of brain metastases, topi[INVESTIGATOR_14911], inhaled sprays, eye drops or local injections  
7. Any medical condition that would, in the investigator’s judgment, prevent the patient’s 
participation in the clinical study due to safety concerns or compliance with clinical 
study procedures  
8. Patients with out of range laboratory values defined as:  
• Absolute Neutrophil Count (ANC) < 1.5 x 109/L (1.5 x 103/µL) 
• Hemoglobin (Hgb) < 9 g/dL (90 g/L)  
• Platelets < 75 x 109/L (75 x 103/µL) 
• Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert’s 
syndrome total bilirubin >3.[ADDRESS_928851])  
• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >[ADDRESS_928852] for patients without hepatic metastasis  
• AST and/or ALT >[ADDRESS_928853] for patients with hepatic metastasis  
• Alkaline phosphatase (ALP) > [ADDRESS_928854]  
• Measured or calculated creatinine clearance < 45 mL/min (0.75 mL/sec)  
9. Patients with electrolytes outside the laboratory normal limits that cannot be corrected 
with supplements during screening:  
• Potassium  
• Magnesium  
• Phosphorus  
• Total calcium (corrected for serum albumin)  
10. Patients receiving treatment with medications that are known to be strong inhibitors or 
inducers of CYP3A4/5  and cannot be discontinued 1 week prior to the start of 
EGF816 treatment and for the duration of the study  
Additional exclusion criteria are listed in Section 5.3 . 
Investigational 
and reference 
therapy  EGF816 (Nazartinib)  
Efficacy 
assessments  Tumor assessment per RECIST 1.1 
Safety 
assessments  Incidence and severity of AEs and SAEs, including changes in laboratory values, vital 
signs and ECGs  
Other Plasma concentration vs. time profiles, plasma PK parameters  
[COMPANY_001]  Confidential  Page 45 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 assessments    
 
Data analysis  Phase I part (dose -escalation)  
Patients treated during the Phase I part (dose -escalation) with the same dose level, 
formulation (capsule vs. tablet) and schedule of EGF816 will be pooled into a single 
treatment group. All summaries, listings, figures and analyses will be performed by 
[CONTACT_685383] (unless otherwise specified). Subgroup analyses by 
[CONTACT_685384](s) may be performed as 
appropriate.  
An adaptive, 2 parameter Bayesian logistic regression model (BLRM) guided by [CONTACT_685385]/RP2D during the Phase I part study.  
Phase II part  
The primary analysis will be performed when patients have completed at least [ADDRESS_928855] 4 cycles of treatment or discontinued treatment prior to that time.  
Primary endpoint: ORR by [CONTACT_685386] 95% 
confidence interval.  
Key words  NSCLC, EGF816, Nazartinib, EGFR, TKI, T790M +, T790M -, acquired, de novo  

[COMPANY_001]  Confidential  Page 46 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 List of abbreviations  
Ab Antibody  
ADME  Absorption, Distribution, Metabolism and Excretion  
AE Adverse Event  
Ag Antigen  
AKT Also known as Protein Kinase B  
ALT Alanine aminotransferase/glutamic pyruvic transaminase/GPT  
ANC  Absolute Neutrophil Count  
ANOVA  Analysis of Variance  
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT  
ATC Anatomy Therapeutic Chemical  
AUC  Area Under the Curve  
BAL Bronchoalveolar Lavage  
BCRP  Breast Cancer Resistance Protein  
BCS Biopharmaceutics Classification System  
BIRC  Blinded Independent Review Committee  
BLRM  Bayesian Logistic Regression Model  
BOR  Best Overall Response  
BSA Body Surface Area  
BUN  Blood Urea Nitrogen  
CFR Code of Federal Regulations  
CI Confidence Interval  
CL Clearance  
Cmax  Maximum plasma concentration after a single dose  
CNS  Central Nervous System  
CR Complete Response  
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper  
CRO  Contract Research Organization  
CSR  Clinical study report  
CSR 
addendum  An addendum to Clinical Study Report (CSR) that captures all the additional 
information that is not included in the CSR  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTP Clinical trial protocol  
  
CYP Cytochrome  
DCR  Disease Control Rate  

[COMPANY_001]  Confidential  Page 47 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 DDS  Dose Determining Set  
DLT Dose -Limiting Toxicity  
DMC  Data Monitoring Committee  
DOR  Duration Of Response  
DS&E  Drug Safety and Epi[INVESTIGATOR_685333]6  Dual Specificity Phosphatase 6  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic Data Capture  
EGF Epi[INVESTIGATOR_685334]; also known as ErbB1  
EOT End of Treatment  
ERKs  Extracellular signal -Regulated Kinases  
EWOC  Escalation With Overdose Control  
FAS Full Analysis Set  
FDA Food and Drug Administration  
FFPE  Formalin -fixed, paraffin embedded  
FMI Formulated Market Image  
GGT  Gamma -glutamyltransferase  
GLP Good Laboratory Practice  
HBcAb  Hepatitis B core antibody  
HBsAb  Hepatitis B surface antibody  
HBsAg  Hepatitis B surface antigen  
HBV Hepatitis B virus  
HBV-DNA  Hepatitis B virus -DNA  
HCVAb  Hepatitis C antibody  
HCV  Hepatitis C virus  
HCV -RNA  Hepatitis C virus -RNA  
hCG Human Chorionic Gonadotropin  
HDL High-Density Lipoprotein  
Hgb Hemoglobin  
HIV Human immunodeficiency virus  
HNSTD  Highest Non -Severely Toxic Dose  
HR Hazard Ratio  
i.v. Intravenous(ly)  
ICF Informed Consent Form  
ICH International Council  for Harmonization  
[COMPANY_001]  Confidential  Page 48 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 IEC Independent Ethics Committee  
ILD Interstitial Lung Disease  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ITK interleukin -2-inducible T -cell kinase  
IUD Intrauterine Device  
IUS Intrauterine System  
KLH Keyhole Limpet Hemocyanin  
LC-MS Liquid Chromatography -Mass Spectrometry  
LDL Low-Density Lipoprotein  
LFT Liver Function Test  
LLN Lower Limit of Normal  
LLOQ  Lower Limit of Quantification  
LPLV  Last patient last visit  
LPS Lipopolysaccharide  
MAPKs  Mitogen -Activated Protein Kinases  
MATE  Multidrug and toxin extrusion transporter  
mPFS  Median Progression -Free Survival  
MRI Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NGS  Next Generation Sequencing  
NSCLC  Non-Small Cell Lung Cancer  
ORR  Overall Response Rate  
OS Overall survival  
p.o. Oral  
PAS Pharmacokinetic Analysis Set  
PD Pharmacodynamics or Progressive disease  
PET Positron Emission Tomography  
PFS Progression -free survival  
P-gp p-glycoprotein  
PHA Phytohemagglutinin  
PHI Protected Health Information  
PI3K  Phosphoinositide 3-Kinase  
PK Pharmacokinetics  
PLT Platelet  
[COMPANY_001]  Confidential  Page 49 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 PPOS  Predictive Probability of Success  
PR Partial Response  
PT Prothrombin Time  
q.d. quaque die /every day  
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides 
evidence of preplanned analyses  
RP2D  Recommended Phase II Dose  
REB Research Ethics Board  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE Serious Adverse Event  
SD Stable Disease or Standard Deviation  
SEC Safety Event Categories  
SGOT  Serum glutamic oxaloacetic transaminase  
SGPT  Serum glutamic pyruvic transaminase  
SOP  Standard Operating Procedure  
STD10  Severely Toxic Dose in 10% of animal  
T1/[ADDRESS_928856] Upper Limit of Normal  
VATS  Video -assisted thoracic surgery  
WCLC  World Conference on Lung Cancer  
WT Wild Type  
[COMPANY_001]  Confidential  Page 50 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Glossary of terms  
Assessment  A procedure used to generate data required by [CONTACT_90166]  A group of newly enrolled patients treated at a specific dose and regimen (i.e. 
treatment group) at the same time  
Cycles  Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g., q28 days)  
Dose level  The dose of drug given to the patient (total daily dose)  
CMO&PS  Chief Medical Office and Patient Safety  
Enrollment  Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)  
Investigational drug  The study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational 
new drug.”  
Investigational 
treatment  Drug whose properties are being tested in the study as well as their associated 
placebo and active treatment controls (when applicable). This also includes approved 
drugs used outside of their indication/approved dosage, or that are tested in a fixed 
combination. Investigational treatment generally does not include other study 
treatments administered as concomitant background therapy required or allo wed by 
[CONTACT_230753]/dosage  
Locally advanced  Stage IIIB not amenable to definitive multi -modality therapy including surgery  
Medication number  A unique identifier on the label of each study treatment package which is linked to 
one of the treatment groups of a study  
Metastatic NSCLC  Stage IV NSCLC  
Patient Number 
(Patient No.)  A unique identifying number assigned to each patient/subject/healthy volunteer who 
enrolls in the study  
Period  A subdivision of the study timeline; divides stages into smaller functional segments 
such as molecular pre -screening, screening, treatment, end of treatment, etc  
Stage in cancer  The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether the cancer has spread from the original site to other parts of the body  
Study treatment  Includes any drug or combination of drugs in any study arm administered to the 
patient (subject) as part of the required study procedures, including placebo and 
active drug run-ins. In specific examples, it is important to judge investigational 
treatment component relationship relative to a study treatment combination; study 
treatment in this case refers to the investigational and non -investigational treatments 
in combination . 
Study treatment 
discontinuation  Point/time when patient permanently stops taking study treatment for any reason  
Supportive treatment  Refers to any treatment required by [CONTACT_140946] a study treatment e.g. 
premedication of vitamin supplementation and corticosteroid for pemetrexed disodium  
Treatment group  A treatment group defines the dose and regimen and may consist of 1 or more 
cohorts. Cohorts are not expanded, new cohorts are enrolled  
Variable  Identifier used in the data analysis; derived directly or indirectly from data collected 
using specified assessments at specified time points  
Withdrawal of 
Consent  Withdrawal of consent occurs only when a patient does not want to participate in the 
study any longer, and does not want any further visits or assessments, and does not 
want any further study related contact  
[CONTACT_76644] 51 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 1 Background  
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_685335], lung cancer accounts for 13% (1.6 million) of all total cancer cases and 18% (1.4 
million) of cancer deaths. In the US, lung cancer accounts for over 160000 deaths per year 
(Sangodkar et al 2010 ; Brawley et al 2011 ). In Western countries, 10 -15% non -small cell lung 
cancer (NSCLC) patients express epi[INVESTIGATOR_3506]  (EGFR ) mutations in their 
tumors (accounting for [ZIP_CODE] to [ZIP_CODE] new patients per year in the US), and Asian countries 
have reported rates as high as 30 -40%. The predominant oncogenic EGFR mutations (L858R 
and ex19del) account for about 90% of EGFR NSCLC. This re sults in the activation of multiple 
pathways that promote survival, proliferation, angiogenesis and metastasis. Tumor dependence 
on EGFR signaling has been shown to correlate to tumors with high gene copy number and/o r 
with activating mutations in EGFR  (Mendelsohn et al 2000 ; Hirsch et al 2003 ; Lynch et al 2004 ; 
Paez et al 2004 ; Pao et al 2004 ). 
EGFR is an established  critical therapeutic target for lung cancer. Numerous trials with 1st-
generation (i.e. reversible) EGFR tyrosine kinase inhibitors (TKIs) (e.g., erlotinib and gefitinib)  
and more recently with the 2nd-generation (i.e. irreversible agents that covalently bind to 
cysteine 797 at the EGFR ATP site; potent on both activating [L858R, ex19del ] and acquired 
T790M mutations in pre -clinical models, but also equally potent on wild-type ( WT)) EGFR 
TKIs (e.g., afatinib and dacomitinib) have been conducted in the EGFR mutant NSCLC 
population. These trials have consistently demonstrated superior efficacy of EGFR TKIs over 
chemotherapy in this population ( Table 1 -1). EGFR  TKIs’ response rates in EGFR mutant 
NSCLC patients range from approximately 60  to 80% versus 20  to 30% for the chemotherapy 
control arms. Similarly, median progression -free survival (mPFS) is prolonged via EGFR TKI 
treatment on average by 50%; ranging from [ADDRESS_928857] 
not been shown to definitively translate into prolonged overall survival.  
Table 1-1 Superiority of EGFR TKIs over chemotherapy in EGFRmut NSCLC  
Trial  Compound  RR (%)  Median PFS (mo)  Median OS (mo)  
TKI Chemo  TKI Chemo  TKI Chemo  
IPASS (mut+)  
(Mok et al 2009 ) gefitinib  71.[ADDRESS_928858]-SIGNAL (mut+)  
(Han et al 2012 ) gefitinib  84.6 37.5 8.4 6.7 30.6 26.5 
WJTOG  
(Mitsudomi et al 2010 ) gefitinib  62.1 32.2 9.2 6.3 30.9 NR 
NEJ002  
(Inoue et al 2009 ) gefitinib  73.7 30.7 10.8 5.4 27.7 26.6 
OPTIMAL  
(Zhou et al 2011 ) erlotinib  83 36 13.7 4.6 22.6 28.8 
EURTAC  
(Rosell et al 2012 ) erlotinib  58 15 9.7 5.2 19.3 19.5 
Afatinib (LUX -Lung 3)  
(Sequist et al 2013 ) afatinib  56.1 23 13.6 6.9 28.1 28.2 
Afatinib (LUX -Lung 6)  
(Wu et al 2014 ) afatinib  66.9 23 11 5.6 22.1 22.2 
[COMPANY_001]  Confidential  Page 52 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 In up to 50% of NSCLC patients harboring a primary EGFR mutation treated with first 
generation EGFR TKIs, a secondary “gatekeeper” T790M mutation develops.  Although T790M 
is also in the tyrosine kinase domain of EGFR, it likely  results in steric hindrance to EGFR 
TKIs, and restores the affinity for ATP to comparable levels observed for WT EGFR  (Yu et al 
2013 ; Kobayashi et al 2005 ). In addition to being the predominant mechanism of resistance, 
multiple groups have reported various rates of T790M mutation in pre -treatment specimens, 
although this could be dependent on the sensitivity of the method of testing and may reflect 
underlying tumor heterogeneity (Rosell et al 2011 ; Su et al 2012 ; Kobayashi et al 2005 ; 
Takezawa et al 2012 ; Bean et al 2007 ; Engelman et al 2007 ; Yu et al 2013 ; Sequist et al 2011 ). 
Third -generation (i.e. irreversible; WT EGFR sparing; re lative equal potenc y for activating 
EGFR mutations [ L858R, ex19del ] and acquired T790M) EGFR TKIs  are beginning to enter 
clinical development and showing significant initial promise (e.g., CO -1686: ORR of 67% in  
28 evaluable T790M+ NSCLC patients  treated at the clinical doses  (EORTC -NCI-AACR 2014 ); 
AZD9291: ORR of 7 0% ( 30/43 ) in T790M+ NSCLC patients treated at the RP2D (ESMO 
2014 )). In addition, encouraging antitumor activity has been observed for 3rd-generation EGFR 
TKIs (AZD9291 and CO -1686) in advanced NSCLC patients without  an acquired EGFR 
T790M mutation, who have become resistant to a 1st/2nd-generation EGFR TKI, with the ORRs 
ranging from 21% to 36% ( ESMO 2014 , EORTC -NCI-AACR 2014 ).  
Despi[INVESTIGATOR_685336], a definitive improvement in overall survival 
has not been demonstrated and there  is still a need for better treatment options for patients with 
EGFR mutant NSCLC.  Novel 3rd-generation EGFR therapi[INVESTIGATOR_014] , that can target not only th e 
primary activating mutations but also the acquired gatekeeper T790M mutation  while sparing 
WT EGFR inhibition  and thus reducing toxicity,  are therefore urgently needed.  
1.2 Introduction to investigational treatment(s) and other study 
treatment(s)  
1.2.1  Overview of  EGF816  
EGF816 is a targeted covalent irreversible EGFR inhibitor that selectively inhibits activating 
and acquired resistance mutants (L858R, ex19del and T790M), while sparing WT EGFR. 
EGF816 has shown significant efficacy in EGFR mutant (L858R, ex19del and T790M ) cancer 
models ( in vitro  and in vivo ) with no indication of WT EGFR inhibition at clinically relevant 
efficacious concentrations.  
[IP_ADDRESS]  Non-clinical experience  
[IP_ADDRESS].1  Non-clinical pharmacokinetics and metabolism  
The pharmacokinetics ( PK) of EGF816 was investigated in the mouse, rat and dog. Following  
intravenous  administration, EGF816 exhibited: moderate plasma clearance, a large volume of 
distribution and a short terminal half -life (~3 h) in rodents; a high clearance, a high volume of 
distribution and a relatively long terminal half -life (~13 h) in the dog.  
Following single dose oral administration, EGF816 showed good oral bioavailability (>55%) 
in mouse, rat and dog, with Tmax reached at [ADDRESS_928859] -dose. EGF816 is highly permeable 
across the intestinal membrane as determined in the Caco2 monolayer system. Gi ven the high 
solubility of EGF816 observed across the pH range and in simulated intestinal fluid for both 
[COMPANY_001]  Confidential  Page 53 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 fasted and fed state, it is considered a biopharmaceutics classification system (BCS) class I 
compound with low food effect risk.  
EGF816 plasma protein binding is high and averaged 96.4%, 91.9%, 89.9% and 93.8% in 
mouse, rat, dog and human plasma, respectively. Following administration of 14C-EGF816 in 
rat, retention of radioactivity in blood was observed with a half -life of 80 -90 hours compared 
to the half -life of 3 hours in plasma. More than 75% of the EGF816 derived radioactivity in 
blood was covalently bound to red blood cells.  
Tissue distribution showed that 14C-EGF816 derived radioactivity was high in limited numbers 
of tissues. At 24h, colon wall, esophagus, harderian gland, kidney medulla, liver, uveal tract 
and skin showed higher radioactivity concentration than blood. At 168h, only pi[INVESTIGATOR_304], 
pi[INVESTIGATOR_350469] d skin and uveal tract showed higher concentration than blood, indicating affinity of 
EGF816 -derived radioactivity to melanin -rich tissues, and the amount of radioactivity 
associated with blood was 0.04% of the dose . The p enetration to brain was minimal with brain 
to blood ratio of 0.[ADDRESS_928860] complete (>97%) with 
only ~1% of the dose remaining in the carcass. The predominant route of elimination was via 
fecal excretion with renal excretion a minor pathway. The predominant circulating component 
in rat plasma was the parent compound. The cross -species metabolism comparison in 
hepatocytes showed that no human specific metabolite was observed, and that the N -
demethylation pathway was more predominant in human than that in dog and  rat. The N -
demethylated metabolite (LMI258) showed similar pharmacological activity to EGF816 in vitro . 
The exposure of LMI258 was 3 -9% and 20 -40% of the parent exposure in rat and dog  4-week 
toxicology studies, respectively.  
EGF816 is primarily metabolized by [CONTACT_097]3A4. CYP3A inhibitors ketoconazole and 
azamulin  completely inhibited the metabolism of EGF816 in human liver microsomes. EGF816 
showed weak to moderate inhibition of CYP2D6 (Ki 3.3 µM, unbound) and CYP2C8 (IC 50 ~11 
µM, unbound) whereas metabolite LMI258 showed relatively strong inhibition of CYP2D6 (Ki 
0.41 µM) and weak inhibition of CYP3A4 (IC 50 12 µM) in vitro .  Physiology -based 
pharmacokinetic (PBPK) predictions performed using SimCYP to further evaluate the DDI 
potential between EGF816  and a CYP2D6 substrate (dextromethorphan) or CYP2C8 substrate 
(repaglinide) did not suggest clinically relevant interactions. The predicted change in AUC ratio 
of dextromethorphan or repaglinide was less than 1.25 and hence a drug -drug interaction is 
unlikely in the presence of EGF816. EGF816 is a p -glycoprotein (P -gp) substrate with a Km 
value of 5.[ADDRESS_928861] cancer resistance protein (BCRP) with  an 
estimated IC 50 value of 4.0 µM.  
[IP_ADDRESS].[ADDRESS_928862] generation, irreversible E GFR mutant -selective inhibitor. It covalently 
links to Cys797 at ATP site of EGFR. In cell -based target modulation assays, EGF816 inhibits 
both oncogenic (L858R, ex19del) and TKI -resistance (L858R/T790M) lines with single digit 
nM potency and demonstrates good selectivity (~[ADDRESS_928863] active mutant line) 
over WT -EGFR cell lines. The potency and WT -selectivity of EGF816 was further confirmed 
in a receptor o ccupancy study using 14C-labeled EGF81 6. Profiling against several large panels 
[COMPANY_001]  Confidential  Page 54 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 of kinases indicates that EGF816 is highly selective. The confirmed off -target activities are 
mostly on kinases containing a similarly located cysteine as Cys797 in EGFR.  
As evidenced from in vivo  metabolism studies (see Section [IP_ADDRESS].1 ), several  metabolic 
pathways have been identified.  The major metabolite, LMI258, has a very similar overall profile 
as EGF816.  It is slightly more active than the parent compound across all cellular assays, while 
retaining comparable WT -EGFR selectivity.  
EGF816 demonstrated strong tumor regressions in several EGFR activating and resistant tumor 
models in vivo. These  include HCC827 (ex19del), H3255 (L858R) and H1975 (L858R; T790M) 
that are representative of the relevant clinical settings. In all of the models EGF816 inhibited 
tumor growth in a dose -dependent manner and achieved regressions of established tumors at 
well tolerated doses.  
The HCC827 (ex19del activating mutation) mouse xenograft model was very sensitive to 
EGF816. Even at the lowest tested daily dose of 3 mg/kg, significant tumor regression was 
achieved. The effect was comparable to erlotinib at 60 mg/kg, a clinically releva nt dose, which 
gave free plasma exposure similar to that observed at clinical efficacious dose. At doses of 10 
mg/kg q.d. or above, EGF816 showed maximum regression similar to erlotinib at its maximum 
tolerated dose (MTD) of 120 mg/kg.  EGF816 was very well  tolerated, with no body weight loss 
observed up to 100 mg/kg, while erlotinib at 120 mg/kg showed significant body weight loss 
(~10%).  
In the H3255 (L858R) mouse xenograft model, EGF816 was te sted at 30 mg/kg and 
demonstrated strong tumor regression with no effect on body weight compared to vehicle.  
In the H1975 (L858R/T790M) mouse and rat xenograft models, significant tumor regression 
was achieved at doses ≥ 30 mg/kg. Importantly, EGF816 demonstrated much improved 
tolerability with superior efficacy as compared to second -generation irreversible pan -EGFR 
inhibitor afatinib.  
Dose -dependent inhibition of pEGFR and its down -stream pharmacodynamics (PD) markers 
were observed following single oral dose of EGF816 at several dose levels. Sustained inhibition 
of pEGFR relative to plasma PK was evident in either model, and is consistent with the 
irreversible binding mechanism of action.  
Targeted inhibition of WT EGFR in cells also inhibits dual specificity phosphatase 6 ( DUSP6) 
(Vecchione et al 2011 ). In an effort to compare the in vivo  WT EGFR selectivity of EGF816 
and afatinib, the DUSP6 gene expression was measured in the skin of treated animals. While 
afatinib caused significant DUSP6 inhibition, EGF816 had no effect at the efficacious doses.  
Together with the in vitro  data, this indicates EGF816 exhibits antitumor activity in the relevant 
patient -derived tumor cell lines at well tolerated doses and is predicted to have antitumor 
activity in humans with known EGFR -driven cancers.  
Toxicology  
In the 4 -week GLP study in rats clinical signs associated with EGF816 were noted at a dose of 
75 mg/kg/day in both  sexes and included chromorhinorrhea (red secretion from noses ), 
salivation, pi[INVESTIGATOR_2657], staining of the fur, discolored skin and/or an increased incidence of 
scab(s)/scratches/abrasions and hair loss. Chromorhinorrhea and scab(s)/scratches/abrasions 
were also noted in 3 females, as well as an increased incidence o f hair loss at a dose of 50 
[COMPANY_001]  Confidential  Page 55 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 mg/kg/day. The scab(s)/scratches/abrasions were generally noted during the latter part of the 
dosing period and abated in the majority of animals during the recovery period. Discolored skin 
was noted during the last week of the dosing period and/or up to r ecovery day 9. There were no 
test article -related clinical signs noted at doses ≤ 50 mg/kg/day in males or at 30 mg/kg/day in 
females.  
Hematologic changes reflected the presence of mild, dose -dependent inflammation, 
characterized by [CONTACT_685387], monocyte and/or platelet counts, decreased 
hemoglobin concentrations and mean corpuscular hemoglobin and increased plasma fi brinogen 
concentrations.  Following compound withdrawal, neutrophil and monocyte counts remained 
mildly increased in both male and female rats dosed at 75 mg/kg/day, correlating with the skin 
changes described histologically . In clinical chemistry, mild, re versible decreases in serum 
triglyceride concentrations were noted in male rats dosed at 75 mg/kg/day and female rats dosed 
at ≥ 50 mg/kg/day, consistent with mildly decreased food consumption . No changes in 
urinalysis parameters were noted.  
Target organs in the rat included skin/eyelids (inflammation around hair follicles and in 
epi[INVESTIGATOR_49196]), lungs (foamy macrophages -phospholipi[INVESTIGATOR_16215]), lymphoid organs (cell depletion), 
vagina (atrophy of epi[INVESTIGATOR_2130]), uterus (atrophy of endometrium), anal (sebac eous) glands 
(inflammation).  
In conclusion the severely toxic dose to 10% of animals (STD10) in rodents was 75 mg/kg/day.  
In the 4 -week GLP study in beagle dogs, clinical signs associated with EGF816 were noted at 
a dose of 20 mg/kg/day and included emesis and salivation during the first week of dosing.  
Clinical signs of fecal changes including decreased/soft feces and diarrhea, absent feces, and 
feces with apparent blood were noted on 1 or 2 occasions during the dosing period.  Discolored 
urine was noted in one animal on study day 7 and in another animal on 4 occasions between 
study days 7 and 16; subsequently, this animal was  noted to have decreased motor activity 
intermittently on study days 23 through 30 and was recumbent on study day 23.  One male dog 
had reddened conjunctiva, excessive blinking and/or ptosis intermittently on study day 6 
through recovery day 1. During the recovery period at the 20 mg/kg/day dose level, soft feces 
and diarrhea were noted.  Discolored skin, reddened skin and hair loss were noted during the 
non-dosing period and generally persisted through the end of the recovery period.  Skin swelling, 
scab(s)/s cratches/abrasions and reddened ears were also noted. In males at a dose of 8 
mg/kg/day, emesis was noted on study day 3 and salivation on 2  occasions in one dog. In 
females at a dose of 8 mg/kg/day, emesis with apparent compound was noted on one occasion 
in a single animal. There were no test article -related clinical signs noted in either sex at a dose 
of 4 mg/kg/day.  Test article -related effects on body weight parameters were noted at doses ≥ 8 
mg/kg/day in males and females. In all males (5/5) at a dose of 20 mg/kg/day, body weight loss 
of 0.5 to 0.8 kg (5.3 to 12.8%) was noted between  day 1 to 29.  During the non -dosing period, 
body weights rebounded resulting in 6.3 to 7.2% body weight increases from recovery days 1 
to 29. In females at a dose of 20 mg/kg/day, body weight loss of 0.6 kg (9.6 to 10.3%) was 
noted in 2 out of 5 animals.  During the recovery period, body weight gains rebounded (0.5 to 
0.8 kg) in animals given 20 mg/kg/day resulting in 10.9 to 15.4% body weight increases 
between  recovery days 1  to 29. Mild effects on body weight in males and no effects on body 
weights in females were observed at a dose of 8 mg/kg/day; no effects were seen for either sex 
at a dose of 4 mg/kg/day.  
[COMPANY_001]  Confidential  Page 56 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Hematology and coagulation changes were noted in male and female dogs dosed at ≥ 8 
mg/kg/day when results were compared to those from the pretest period, and included increased 
neutrophil and monocyte counts (≥ +100%), decreased RBC counts, hemoglobin concentration 
and hematocrit (≥ -25%), and decreased albumin (≥ -20%) and increased globulins (≥ +25%).  
Target organs in the dog included cornea (epi[INVESTIGATOR_427864]), and various glands throughout 
the organ system (atrophy). The highest non -severely toxic dose (HNSTD) was determined to 
be 20 mg/kg/day.  
EGF816 showed a potential for phototoxicity in the 3T3 NRU in vitro  assay.  
The Ames assay for EGF816 indicated that it was not a potential mutagen and the chromosomal 
aberration assay in human peripheral blood lymphocytes did not indicate the potential to cause 
chromosomal aberrations. An  in vivo  evaluation of the bone marrow for the presence of 
micronuclei was negative in rats. The IC50 for the hERG potassium channel is 6 µM.  
The confirmed off -target activities of EGF816 in cellular assays are mostly on Cys -kinases (i.e., 
kinases containing an analogous cysteine as Cys797 in EGFR). These kinases include Tec 
family kinases (TEC, ITK, TXK) with IC 50=31 nM. EGF816 showed >[ADDRESS_928864] to H3255 ( L858R ) activity (IC 50=5 nM). Because Tec kinases 
are involved in T cell function, T cell proliferation  induced by [CONTACT_685388] (TT) as antigen, 
lipopolysaccharide  (LPS ) and phytohemagglutinin  (PHA) as mitogens  were measured in the 
absence or presence of EGF816. All stimuli increased T cell proliferation compared to DMSO 
controls.  EGF816 suppressed this T cell proliferation at concentrations of 0.[ADDRESS_928865] of EGF816 was also 
conducted. Rats were immunized subcutaneously on Days 11 and 21 with keyhole limpet 
hemocyanin (KLH) antigen during 28 continuous days of oral exposure to EGF816 at 30 or 50 
mg/kg or to Prograf at 3 mg/kg as a positive control (an immunosuppressive compound used in 
transplantation). Serum was collected from all animals and KLH -specific IgM and IgG antibody 
concentrations were measured by [CONTACT_6428]. Dose -related immunomodulat ory responses in 
EGF816 -treated animals following sensitization with KLH immunization  were noted when 
values were compared to concurrent vehicle controls. Recovery following withdrawal of 
EGF816 treatment was noted, indicating that the EGF816 -related decrease of anti - KLH 
antibody production was reversible. This included both the primary re sponse (anti -KLH IgM), 
and the isotype switch as measured by [CONTACT_685389] -KLH IgG production.  
In conclusion, EGF816 dampened the antibody response to a neoantigen (KLH) in rats as 
measured by [CONTACT_14181] -KLH IgM and IgG antibody titers. This effect was reversed after withdrawal 
of EGF816. The clinical translation of this effect is not known.  
[IP_ADDRESS]  Clinical experience  
CEGF816X2101 is the first -in-human Phase I/II study of single -agent oral EGF816.  
As of the cut -off date of 18 -Dec-2015 (cut -off date of the Investigator ’s Brochure ed. 5) [ADDRESS_928866] been treated with EGF816 capsules or tablets at seven dose levels: 75 mg QD 
(N=7), 100 mg q.d. (N=29), 150 mg QD. (N=64), 200 mg QD  (N=8), 225 mg QD  (N=24), 300 
mg QD (N=5) and 350 mg QD (N=11). Eighty -four patients (56.8%) were still receiving 
treatment and 64 patients (43.2%) had discontinued treatment. Of these 64 patients, reasons for 
discontinuation were: progressive disease (53 patients), adverse events (3 patient s), death (3 
patients), subject guardian decision (3 patients), physician decision (2 patients). Of the three 
[COMPANY_001]  Confidential  Page 57 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 patients who discontinued treatment due to AE, one patient at the 350 mg QD reported Grade 
3 maculopapular rash, one patient at the 150 mg daily dose reported Grade 3 interstitial lung 
disease, and one patient at the 300 mg daily dose reported Grade 3 pulm onary edema. Of the 
three patients who discontinued treatment due to death, one patient died due to sepsis 
(considered not related to study treatment), one patient died due to hepatitis B virus (HBV) 
reactivation (considered related to study treatment), an d one patient died due to pneumonia 
(considered not related to study treatment).  
As of 18 -Dec-2015, dose -limiting toxicities (DLT) were reported in five patients: one patient 
at the dose level of 150 mg capsule reported Grade 3 maculopapular rash that resulted in 
temporary treatment interruption, one patient at the dose level of 225 mg  capsule reported Grade 
3 maculopapular rash that resulted in temporary treatment interruption, one patient at the dose 
level of 350 mg capsule reported Grade 3 acute kidney failure and Grade 3 maculopapular rash 
that resulted in temporary treatment interr uption, one patient at the dose level of 350 mg capsule 
reported Grade 3 maculopapular rash that resulted in permanent discontinuation of treatment, 
and one patient at the dose level of 350 mg capsule reported Grade 3 enteritis and Grade 3 
dehydration that  resulted in temporary treatment interruption. The maximum tolerated dose 
(MTD) has not been determined for EGF816 as a single agent.  
As of the data cut -off date of 18 -Dec-2015, 142 patients (95.9%) who were treated with EGF816 
capsules or tablets experienced at least one AE of any grade, regardless of relationship to the 
study drug. The most frequent AEs (all CTCAE grades, >10% of patie nts) regardless of study 
drug relationship at the seven dose levels were rash (group term) (56.1%), diarrhea (41.9%), 
maculopapular rash, pruritus (36.5%), fatigue (27.0%), stomatitis (27.0%), dry skin (24.3%), 
nausea (23.6%), cough (20.9%), decreased appe tite (20.3%), vomiting (14.9%), constipation 
(14.2%), headache (12.8%), anemia (12.2%), paronychia (11.5%), pyrexia (11.5%), dyspnea 
(10.8%), edema peripheral (10.8%), back pain (10.1%), and upper respi[INVESTIGATOR_1092] 
(10.1%).Seventy (47.3%) patient s who were treated with EGF816 capsules or tablets at any 
dose experienced Grade 3 or Grade 4 AEs regardless of relationship to the study drug. Grade 
3/4 AEs occurring in ≥ 2% of patients were rash (grouped term) (15.5%), anemia (5.4%), 
pneumonia (5.4%), d iarrhea (4.7%), fatigue (2.7%), dyspnea (2.7%), urticaria (2.7%), 
hypertension (2.7%), stomatitis (2.0%), decreased appetite (2.0%), hyperuricemia (2.0%), and 
seizure (2.0%).As of the data cut -off date (18 -Dec-2015) SAEs, regardless of study drug 
relations hip, were reported in 48 patients (32.4%) who received at least one dose of single agent 
EGF816 capsules or tablets.  
Of these 48 patients, 15 experienced SAEs that were suspec ted to be related to study drug, 
please refer to Investigator’s Brochure ed. [ADDRESS_928867] been reported in 2 patients participating 
in the CEGF816X2101 study. One case had a fatal outcome, and the second case was considered 
medically significant. The fatal case involved a patient who received E GF816 at 225 mg QD, 
had a history of HBV infection and was not on antiviral treatment at study entry. The patient 
developed HBV reactivation during the study and died due to hepatic failure despi[INVESTIGATOR_685337] h ad been confirmed. The second patient also 
received EGF816 at 225 mg QD, had a history of HBV and was not on antiviral treatment at 
[COMPANY_001]  Confidential  Page 58 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 the time of joining the study, HBV reactivation was detected after the patient had been on study 
for approximately 10 weeks. Antiviral treatment was immediately initiated, EGF816 was 
interrupted and the HBV infection was brought under control. The patient later resumed 
EGF816 at the same dose of 225 mg q.d. while continuing on antiviral medication. The viral 
reactivation in these two patients was likely due to immunosuppression related to EGF816. 
Reactivation of HBV and hepatitis C virus (HCV) has been repo rted with anticancer therapi[INVESTIGATOR_685338].  
It should be noted that the maculopapular rash associated with EGF816 treatment appear s to be 
different from the typi[INVESTIGATOR_685339] -related rash (e.g., acneiform rash). Its onset was generally 
in the first 2 -3 weeks of study treatment however it could be sporadic. The rash typi[INVESTIGATOR_685340], spread s out to the extremities, and in general spare s the palms and soles. EGF816 -
associated rash was well managed with dose interruption and/or steroid and antihistamine 
treatments. In most cases, the rash r esolved completely or almost completely within 1 week 
after drug interruption, and patients were able to restart study treatment, at the same dose or a 
reduced dose, without recurrence of the maculopapular rash.  
As of the data cut off of  29-Jan-2016, preliminary efficacy results showed a n overall response 
rate (ORR) of 46.9 % by [CONTACT_685374] 69 out of  147  evaluable patients treated at 
all dose levels. Note: evaluable patients include those who were ongoing and had at least one 
post-baseline tumor  assessment or who discontinued study treatment as of the data cut -off date. 
The antitumor activity of EGF816 is presented in Figure 1 -1. 
Please refer to the current Investigator’s Brochure for more details.  
Figure 1-[ADDRESS_928868] percentage change from baseline in sum of diameters of target 
lesions as per investigator by [CONTACT_3148] (Capsule) – Full analysis set  
 
*Patient discontinued. † Patient’s NSCLC was negative for EGFR T790M.  
n: number of evaluable patients responders, N: number of patients enrolled  
(Evaluable patients include those who are ongoing with study treatment and have ≥ [ADDRESS_928869] -baseline 
response assessment  

[COMPANY_001]  Confidential  Page 59 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 or who have discontinued study treatment. This total is used for percentage calculation)  (Tan S -W D, 
Yang C -H J (2016 ) 
As of 14 -Sep-2015, data on EGF816 PK parameters are available following treatment with 
capsules or tablets at 75, 100, 150, 200, 225, 300, and 350 mg/day in patients. For a similar 
dose, similar exposure was observed with capsules and tablets. Systemic exp osure to EGF816 
generally increased with the dose, with a median Tmax of 3 -6 hr. The steady state was reached 
by [CONTACT_5265] 1 day 15. The terminal half -life T1/2 ranged from 13 to 18 hr. Accumulation of 
EGF816 following repeated administration is low with an ac cumulation ratio of up to 2 -fold.  
2 Rationale  
2.1 Study rationale and purpose  
Note: throughout this protocol, advanced NSCLC refers to patients with either locally advanced 
or metastatic NSCLC. Locally advanced NSCLC is defined as stage IIIB NSCLC not amenable 
to definitive multi -modality therapy including surgery. Metastatic NSCLC refers to stage IV 
NSCLC.  
Inhibitors of EGFR -mutant L858R and ex19del have been well validated as therapeutic age nts 
for advanced NSCLC patients. However, the narrow therapeutic window of currently available 
EGFR inhibitors limits the potential of this class of drugs.  In spi[INVESTIGATOR_685341] 1st- and 2nd-generation of EGFR TKIs, the overall survival has not improved and the dose -
limiting toxicities, particularly affecting the skin and gastrointestinal (GI) due to cross -activity 
with WT EGFR , are frequently reported.  Novel EGFR therapi[INVESTIGATOR_3066] 3rd-generation EGFR 
TKIs that can target not only the primary activating mutations, but also the acquired T790M  
mutation while sparing WT EGFR , are urgently needed.  The sparing of WT EGFR appears to 
improve the most common toxicities (rash and diarrhea) associated with EGFR TKIs. T he 3rd-
generation of i rreversible EGFR TKI s (e.g., CO-1686 and AZD9291) is entering clinical 
development and has show n significant initial promise. EGF816 is a 3rd-generation irreversible 
EGFR TKI  that selectively inhibits activating and acquired resistance mutants (L858R, ex19del 
and T790M +), while sparin g WT EGFR.  
The purpose of the Phase I part (dose -escalation) of this study is to determine the maximum 
tolerated dose (MTD) or recommended phase II dose (RP2D) and to evaluate the preliminary 
antitumor activity of single -agent EGF816 in adult patients with locally advanced (stage IIIB)  
or metastatic (stage IV) NSCLC. The Phase I part will include patients with tumors harboring 
specific EGFR mutations (refer to Section 2.2 ). The purpose of the Phase II part of this study is 
to evaluate  the efficacy and safety of single -agent EGF816 in adult patients with locally 
advanced (stage IIIB) or metastatic (stage IV) NSCLC whose tumors harbor specific EGFR 
activating mutations (e.g., L858R and ex19del)  in first line setting (EGFR TKI and 
chemotherapy naïve) . 
Based on the preclinical data of EGF816 and the known clinical activity  of other 3rd-generation 
EGFR inhibitors in advanced NSCLC patients harboring EGFR mutations, it is expect ed that 
EGF816 would have significant antitumor activity  in NSCLC patients harboring the activating 
EGFR mutations ( e.g., L858R and ex19del) and/or the acquired/resistant “gatekeeper” T790M  
mutation. W hile sparing WT EGFR, EGF816 is also expected to be better tolerated than 
current ly available treatment  options. Taking into consideration of effic acy and safety,  EGF816 
[COMPANY_001]  Confidential  Page 60 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 treatment should translate into longer sustained responses and improvement in patient s’ quality 
of life.  
The p reliminary results from this study in adva nced NSCLC patients  with EGFR  mutations  
(L858R and/or ex19del, T790M+ ) have shown  a tolerable safety profile and significant 
antitumor activity of EGF816 at different dose levels  (75 mg, 150 mg, 225 mg and 350 mg ) 
including the lowest dose  tested , that is in line with other 3rd-generation EGFR TKIs such as  
AZD9291 and CO -1686  (see Section [IP_ADDRESS] ). 
2.2 Rationale for the study design  
Phase I part   
This open -label , Phase I part  (dose-escalation ) of the first-in-human study is designed to 
determine  the MTD  or RP2D  of EGF816 in  adult patients with locally advanced (stage IIIB)  or 
metastatic (stage IV) NSCLC harboring specific EGFR mutations, The acceptable safety profile 
observed in the patients treated in the Phase I part to date supports the expansion of the eligible 
Phase I population.  The Phase I part will consist of the following:  
• Treatment naive patients , who have locally advanced or metastatic NSCLC with EGFR  
activating mutation (e.g., L858R and/or ex19del), have not received any systemic 
antineoplastic therapy for advanced NSCLC and are eligible to receive EGFR TKI 
treatment. Note: patients who have received only one cycle of chemotherapy in the 
advanced setting  are allowed . 
• Patients who have locally advanced or metastatic NSCLC with EGFR activating mutation 
AND an acquired T790M mutation (e.g., L858R and/or ex19del, T790M+) follo wing 
progression on  prior treatment with a 1st-generation EGFR TKI (e.g., erlotinib, gefitinib or 
icotinib) or 2nd-generation EGFR TKI (e.g., afatinib or dacomitinib). These patients may 
not have received more than [ADDRESS_928870] received any agent targeting EGFR T790M mutation (i.e. 3rd-generation 
EGFR TKI).  
• Patients who have locally advanced or metastatic NSCLC with a “de novo” T790M 
mutation (i.e. no prior treatment with any agent known to inhibit EGFR including EGFR 
TKI). These patients may not have received more than [ADDRESS_928871] received any prior agent known to inhibit EGFR, including 
EGFR TKIs.  
• Patients who have locally advanced or metastatic NSCLC harboring EGFR exon [ADDRESS_928872] received more than 3 prior lines of 
antineoplastic therapy, including EGFR TKIs.  
• Patients who have locally advanced or metastatic NSCLC with EGFR activating mutation 
AND without  an acquired T790M mutation (e.g., L858R and/or ex19del, T790M -) 
following progression on a 1st-generation EGFR TKI (e.g., erlotinib, gefitinib or icotinib) 
or 2nd-generation EGFR TKI (e.g., afatinib or dacomitinib). These patients may not have 
received more than [ADDRESS_928873] received any agent targeting EGFR T790M (i.e. 3rd-generation EGFR TKI).  
• Patients who have locally advanced or metastatic NSCLC with EGFR activating mutation 
and an acquired T790M mutation (e.g., L858R or ex19del, T790M+) following 
progression on a prior treatment with a 1st/2nd-generation EGFR TKI, and have progressed 
[COMPANY_001]  Confidential  Page 61 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 on or are intolerant to a 3rd-generation EGFR TKI (e.g., AZD9291, CO -1686, or 
ASP8273).  These patients may not have received more than 3 prior lines of antineoplastic 
therapy, including EGFR TKIs.  
This study will utilize a Bayesian logistic regression model (BLRM) to guide dose escalation 
and predict the MTD  or determine the RP2D for EGF816 . The BLRM with escalation with 
overdose control (EWOC) enables incorporation of available prior information and updates the 
model parameters based upon new information about observed dose -limiting toxicities seen in 
the clinical study. The dose recommende d by [CONTACT_685390]. The updated model then provides 
information on the probabilities of DLTs from the current dose to the next predicted dose level. 
The use of Bayesian response adaptive models for small datasets has been accepted by [CONTACT_111829] 
(“Guideline on clinical trials in small populations”, February 1, 2007) and endorsed by 
[CONTACT_111830] ( Babb et al 1998 , Neuenschwander et al 2008 , Neuenschwander et al 
2010 ), and its development and appropriate use is one aspect of the FDA’s Critical Path 
Initiative.  The decision to dose escalate is made by [CONTACT_685391], patient tolerability 
and safety, PK, PD and efficacy information available to date.  
Phase II part  
The Phase II part  will open at the MTD or RP2D  using the tablet formulation . The purpose of 
the Phase II part  is to characterize the antitumor activity , safety, tolerability, PK and PD of 
EGF816  at the selected dose  level . The primary objective is to evaluate the antitumor activity 
of EGF816  in the described patient population. The primary endpoint  of antitumor activity is 
the overall response rate (ORR) per  RECIST 1.1 as determined by [CONTACT_685392] (BIRC) to ensure unbiased assessment. A supportive analysis of ORR will 
be performed based on the Investigators’ assessment.  
The Phase II part will enroll a minimum of [ADDRESS_928874] locally 
advanced or metastatic NSCLC with locally documented EGFR activating mutation (L858R, 
ex19del). The patients will have not received any systemic antineoplastic therapy for advanced 
NSCLC and will be eligible to receive EGFR TKI treatment.  Note: patients who have failed no 
more than 1 cycle of systemic antineoplastic therapy in the advanced setting are allowed. 
Treatment failure is defined as documented disease progressi on or intolerance to treatment.  
Neo-adjuvant and adjuvant systemic therapi[INVESTIGATOR_685331] 1 prior line of treatment if 
relapse occurred within 12 months from the end of the neo -adjuvant/adjuvant systemic therapy . 
EGF816 is a 3rd generation irreversible EGFR TKI that selectively inhibits activating and 
acquired resistance mutants (L858R, ex19del and T790M), while sparing WT EGFR. Inhibitors 
of EGFR -mutant L858R and ex19del, such as 1st and 2nd generation EGFR TKIs, have been 
well validated as therapeut ic agents for advanced NSCLC patients who are treatment naïve . 
Novel EGFR therapi[INVESTIGATOR_3066] 3rd generation EGFR TKIs can also target the primary activating 
mutations. In a preclinical study using tumor model with EGFR ex19del, EGF816 treatment 
was more efficacious compared to treatment with erlotinib. Other 3rd generation EGFR TKIs, 
such as AZD9291, have shown promising preliminary data in this patient population ( Jänne et 
al. 2015 ). AZD9291 has an ongoing Phase III clinical trial in the first line setting. Based on the 
mechanism of action, EGF816 will likely have similar clinical activity in this patient population.  
[COMPANY_001]  Confidential  Page 62 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 In the Phase II part, the patients will enter the study in the 1st line setting, i.e. will not have 
received any prior systemic antineoplastic therap y for advanced disease. Note: patients who 
have failed no more than 1 cycle of systemic antineoplastic therapy in the advanced setting are 
allowed. Treatment failure is defined as documented disease progression or intolerance to 
treatment. Neo -adjuvant and adjuvant systemic thera pi[INVESTIGATOR_685331] 1 prior line of 
treatment if relapse occurred within 12 mon ths from the end of the neo -adjuvant/adjuvant 
systemic therapy  
Details of the statistical hypothesis, model and analysis are provided in Section 10.4.2  and 
sample size is provided in  Section 10.8   
2.3 Rationale for dose and regimen selection  
The human starting dose for EGF816 is 75 mg administered orally on a continuous, once daily 
dosing schedule. The starting dose was determined based on GLP -toxicology studies  using rat 
as the toxicology species according the regulatory guidance (see Section 6.2.1 ). 
2.4 The recommended phase II dose (RP2D) was determined based 
on the safety and efficacy data obtained from the Phase I part 
(dose -escalation) at 150 mg/day  on capsules and tablets. 
Rationale for choice of combination drugs  
Not applicable  
2.5 Rationale for choice of comparators drugs  
Not applicable  
2.6 Risks and benefits  
Appropriate eligibility criteria and specific DLT definitions, as well as specific dose 
modification and stoppi[INVESTIGATOR_004], are included in Section 5  and Section 6  of this protocol. 
Recommended guidelines for prophylactic or supportive management of study -drug induced 
adverse events are provided in Section 6.3 . The risks to subjects in this trial may be minimized 
by [CONTACT_685393].  
The preliminary results from this study in advanced NSCLC patients with EGFR mutations 
(L858R and/or ex19del, T790M) have shown a tolerable safety profile and significant antitumor 
activity of EGF816 at different dose levels (75 mg, 150 mg, 225 mg and 350 mg) including the 
lowest dose tested, that is in line with other 3rd -generation EGFR TKIs such as AZD9291 . All 
available safety and pharmacokinetic data have been  reviewed by [CONTACT_685394] e Phase I  after the completion of each 
cohort. In these dose escalation meetings, all participants have  reach ed a consensus to declare 
RP2D at [ADDRESS_928875] been 2 reported SAEs of viral hepatitis B reactivation related to 
EGF816 reported in 2 patients participating in the EGF816 single agent study 
(CEGF816X2101). One case had a fatal outcome, and the second case was medically signi ficant. 
The viral hepatitis reactivation is likely related to immunosuppression caused by [CONTACT_32574]816 
although the exact mechanism of the reactivation is unknown. Reactivation of HBV and HCV 
has been reported with other anticancer therapi[INVESTIGATOR_685342]. To minimize 
[COMPANY_001]  Confidential  Page 63 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 the risk to all trial subjects and to manage the potential risk of severe liver toxicity associated 
with hepatitis reactivation, [COMPANY_001] has amended the protocols for all clinical trials involving 
EGF816 to provide guidance for patients with evidence of c urrent or prior HBV/HCV infection . 
However, there may be unforeseen risks with the study treatment which could be serious. Refer 
to the  EGF816 Investigator’s Brochure for further information regarding clinical toxicity.  
Based on the available pre -clinical and clinical data for EGF816 and the known clinical activity 
of other 3rd -generation EGFR inhibitors in advanced NSCLC patients harboring EGFR 
mutations, it is foreseeable that EGF816 will continue to demonstrate signifi cant antitumor 
activity in NSCLC patients harboring the activating EGFR mutations (i.e. L858R and ex19del) 
and/or the acquired/resistant “gatekeeper” T790M mutation with better tolerability than the 
currently available treatment options due to sparing of t he WT EGFR. The improved efficacy 
and tolerability reported with EGF816 treatment should translate into prolonged and sustained 
responses with improved quality of life.  
Therefore evidence and current clinical experience, the overall risk/benefit assessment of 
EGF816 is predicted to be favorable in treatment naïve patients with advanced NSCLC tumors 
harboring EGFR activating mutations.  
3 Objectives and endpoints  
Objectives and related endpoints are described in Table 3 -1 and Table 3 -2 below.  
Table 3-1 Objectives and related endpoints (Phase I part)  
Objective  Endpoint  Analysis  
Primary  Refer to Section 10.4  
To estimate the maximum tolerated 
dose (MTD) or recommended phase 2 
dose ( RP2D ) of EGF816  Incidence of dose -limiting toxicity (DLT) 
during the first 28 days of dosing  Refer to Section 10.4  
Secondary  Refer to Section 10. 5 
To characterize the safety and 
tolerability of EGF816  Safety: Incidence and severity of AEs and 
SAEs, including changes in laboratory 
values, vital signs and ECGs  
Tolerability: Dose interruptions and 
reductions  Refer to Section 
10.5.1  
To evaluate overall response rate 
(ORR), duration of response (DOR), 
disease control rate (DCR), 
progression -free survival (PFS), and 
time to response (TTR) determined by 
[CONTACT_685395] (RECIST 1.1): 
ORR, DOR, DCR, PFS and TTR*  Refer to Section 
10.5.2  
To characterize the pharmacokinetics 
(PK) properties of EGF816 and 
metabolite LMI258  Plasma concentration vs. time profiles, 
plasma PK parameters  Refer to Section 
10.5.3  
To assess the tumor EGFR signaling 
inhibition by [CONTACT_32574]816 (prior to Protocol 
amendment 05)  Pre- and on - treatment 
immunohistochemistry of EGFR pathway 
molecules (e.g., p -EGFR, p -AKT, p -ERK) 
in newly obtained tumor samples  Refer to Section 
10.6.2  

[COMPANY_001]  Confidential  Page 64 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Objective  Endpoint  Analysis  
*ORR is defined as proportion of patients with best overall response of PR+CR per RECIST 1.1; DOR is 
defined as the time from first documented response (PR or CR) to the date of first documented disease 
progression or death due to any cause ; DCR is defined as the proportion of patients with best overall response 
of CR, PR, or SD; PFS is defined as the time from the date of first dose of study treatment to the date of first 
documented disease progression (per RECIST 1.1) or death due to any cause ; TTR is defined as the time 
between date of start of treatment until first documented response (CR or PR) . 
Table 3-2 Objectives and related endpoints (Phase II part)  
Objective  Endpoint  Analysis  
Primary  Refer to Section 10.4  
To investigate the  antitumor activity of 
EGF81  6 Overall response rate (ORR) by [CONTACT_685396] (BIRC) 
assessment in accordance to Response 
Evaluation Criteria in Solid Tumors  
(RECIST 1.1)  Refer to Section 10.4  
Secondary  Refer to Section 10.5  
To further characterize the safety and 
tolerability of EGF816  Safety: Incidence and severity of AEs and 
SAEs, including changes in laboratory 
values, vital signs  and ECG s 
Tolerability: Dose interruptions  and 
reductions  Refer to Section 
10.5.[ADDRESS_928876] 1.1  Refer to Section 
10.5.2  
To evaluate duration of response 
(DOR), disease control rate (DCR), 
progression -free survival (PFS) and 
time to response (TTR)  The following endpoints will be evaluated 
by [CONTACT_685397] 1.1: DOR, DCR, PFS and TTR*   Refer to Section 
10.5.[ADDRESS_928877] 1.1: DOR, DCR, PFS and 
TTR*   Refer to Section 
10.5.2  
To evaluate overall survival (OS)  OS  

[COMPANY_001]  Confidential  Page 65 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Objective  Endpoint  Analysis  
To characterize the pharmacokinetics 
(PK) properties of EGF816  and 
metabolite LMI258  for all groups  Plasma concentration vs. time profiles, 
and plasma PK parameters as 
appropriate  Refer to Section 
10.5.3  
*ORR is defined as proportion of patients with best overall response of PR+CR per RECIST 1.1; DOR is 
defined as the time from first documented response (PR or CR) to the date of first documented disease 
progression or death due to any cause ; DCR is defined as the proportion of patients with best overall response 
of CR, PR, or SD; PFS is defined as the time from the date of first dose of study treatment to the date of first 
documented disease progression (per RECIST 1.1) or death due to any cause ; TTR is def ined as the time 
between date of start of treatment until first documented response (CR or PR) ; OS is defined as the time from 
first dose of study treatment to the date of death due to any cause.  
4 Study design  
4.1 Description of study design  
This is a Phase I /II, multi -center, open -label study starting with a Phase I part (dose -escalation) 
followed by a Phase II part . Oral EGF816  will be administered once daily on a continuous 
schedule  until patient experiences unacceptable toxicity, progressi ve disease  (PD) and/or 
treatment is discontinued at the  discretion of the investigator, patient withdraw s consent  or due 
to any other reasons . Treatment with EGF816  may be contin ued beyond RECIST 1.1 defined 
PD, if, in the judgment of the investigator, there is evidence of clinical benefit and the patient 
wishes to continue with the study treatme nt (see Section 6.1.2  for details).  
A treatment cycle is defined as 28 days.  

[COMPANY_001]  Confidential  Page 66 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Per protocol definition, advanced NSCLC refers to patients with either locally advanced or  
metastatic NSCLC. Locally advanced NSCLC is defined as stage IIIB NSCLC not amenable  to 
definitive multi -modality therapy including surgery. Metastatic NSCLC refers to stage IV  
NSCLC.  
Phase I  part 
In the Phase I part, patients must have locally advanced (stage IIIB) or metastatic (stage IV) 
NSCLC harboring specific EGFR mutations as described in Section 2.[ADDRESS_928878] six patients treated at the MTD or RP2D (Refer to Section [IP_ADDRESS] ). 
Patients enrolled in the Phase I part  must continue to be evaluated according to the evaluation 
schedule noted in Table 7 -1. 
Phase I I part 
The Phase II part will start when the RP2D in tablet formulation has been identified. A 
minimum of 40 patients with advanced (stage IIIB) or metastatic (stage IV) NSCLC and 
documented EGFR activating mutation, who have never received any systemic antineoplastic 
therapy will be enrolled  (Figure 4 -1). Note: patients who have received no more than 1 cycle of 
systemic antineoplastic therapy  in the advanced setting are allowed.  
The EGFR mutation status is determined by a local laboratory (pre -screening phase). The 
mutations L858R and exon 19 deletion account for approximately 90% of the EGFR activating 
mutations and confer sensitivity to the EGFR TKIs. Additionally the other rare mutations such 
as L861Q, G719S/A/C, and S768I also confer sensitivity to the EGFR TKIs and will also satisfy 
eligibility criteria.  
The EGFR mutation status may be determined from any available tumor tissue. A laboratory 
report showing evidence of EGFR activating mutation must be available in the source 
documents.  
Details of the sample size calculations leading to the patient number s are provided in  Section 
10.8. Patients enrolled in the Phase II part will follow the evaluation schedule noted in Table 7 -
2.  
[COMPANY_001]  Confidential  Page 67 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Figure 4-1 Study design, Phase II part  
 
The study includes different periods as illustrated in  Figure 4 -2 and Figure 4 -3. Refer to Table 
7-1 and Table 7 -2 for detailed information . 
Figure 4-2 Study visit flow (Phase I part)  
 
Figure 4-3 Study visit flow (Phase II part)  
 
In the Phase I part, patients may have tumor tissue and blood samples collected at screening 
and at disease progression to study the mechanisms of drug treatment resistance. For sites that 
are participating in a [COMPANY_001] optional companion sample collectio n protocol to study treatment 
resistance, the collection of these samples is guided by [CONTACT_685398].  
4.2 Timing of interim analyses and design adaptations  
For the Phase I part, no formal interim analyses are planned. However, the dose -escalation 
design foresees that decisions based on the current data are taken before the end of the study. 
More precisely, after each cohort in the dose -escalation part, the ne xt dose will be chosen 
depending on the observed data. Details of this procedure and the process for communication 
with investigators are provided in Section 6.2.3 . 

[COMPANY_001]  Confidential  Page 68 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 During the Phase II part  there will be one interim futility analysis when approximately [ADDRESS_928879] 4 cycles of treatment or discontinued treatment prior to that 
time.  
Assessment of futility will be based on the calculated Bayesian probability of success (PoS). 
The Phase II will be stopped for futility if the PoS is less than 10% at the interim analysis.  
If applicable, enrollment of patients into the Phase II  part will continue between the time the 
required data for patients in the interim analysis are observed and the time the results of the 
interim analysis are available.  
Detailed information on the statistical considerations for the interim analysis is provided in 
Section 10.7  and Section 10.8 . 
In addition, data from patients in the Phase II part will be reviewed on an ongoing basis to 
monitor the safety and tolerability of the MTD/RP2D  (Section 8.5 ). 
4.[ADDRESS_928880] 6 
cycles of treatment or discontinued treatment prior to that time  (if not sopped for futility at 
interim analysis).  The primary analysis data will be summarized in the primary clinical study 
report (CSR)  including Phase I and II data .  
Following the cut -off date for the analysis reported in the primary CSR, the study will remain 
open. , Ongoing patients will continue to receive study treatment and be followed as per the 
schedule of assessments, as long as patients derive benefit from EGF816 or until the end of 
study  defined as the earliest occurrence of the following:   
• All patients have died or discontinued from the study   
• Another clinical study becomes available that can continue to provide EGF816   in this 
patient population of this study and all patients ongoing are eligible to be transferred to 
that clinical study  
At the end of the study, every effort will be made to continue provision of study treatment 
outside this study through an alternative setting to patients who in the opi[INVESTIGATOR_685343].  
Last patient last visit (LPLV) is defined as the date when the last visit is performed by [CONTACT_685399]. The final analysis will occur at the end of the study.  All available data 
from all patients up to LPLV will be summarized in a final CSR.  
4.4 Early study termination  
The study can be terminated at any time for any reason by [CONTACT_5343]. Should this be necessary, 
the patient should be seen as soon as possible for an EOT visit, and the assessments for EOT as 
described in Section 7  should be performed for a discontinued or withdrawn patient . The 
investigator may be informed of additional procedures to be followed in order to ensure that 
adequate consideration is given to the protection of the patient’s interests. The investigator will 
be responsible for informing IRBs and/or ECs of the early t ermination of the trial.   
[COMPANY_001]  Confidential  Page 69 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 [ADDRESS_928881] received any prior systemic antineoplastic therapy in the advanced 
setting (NSCLC stage IIIB or IV). However,  patients who have failed no more than 1 cycle of 
systemic antineoplastic therapy in the advanced setting are allowed. Note: Neo -adjuvant and 
adjuvant systemic therapi[INVESTIGATOR_685331] 1 prior line of treatment if relapse occurred 
within 12 months from  the end of the neo -adjuvant/adjuvant systemic therapy.  
The EGFR mutation status for the Phase II part will be determined by [CONTACT_685400].  
Treatment failure is defined as documented disease progression or intolerance to treatment.  
Patients enrolled in the study are not permitted to participate in additional parallel 
investigational drug or device studies.  
The investigator or designee must ensure that only patients who meet all the following inclusion 
and none of the exclusion criteria are offered treatment in the study.  
5.[ADDRESS_928882] to meet all of the following criteria:  
For all patients (unless otherwise specified):  
1. Written informed consent must be obtained prior to any screening procedures  
2. Patient (male or female) ≥ 18 years of age  
[For Japan only: written consent is necessary both from the patient and his/her legal 
representative if he/she is under the age of 20 years. ] 
3. Patients must have histologically or cytologically confirmed locally advanced (stage IIIB 
not amenable to definitive multi -modality therapy including surgery) or metastatic (stage 
IV) EGFR mutant NSCLC.  
4. Patients with controlled brain metastases may participate in the trial. If applicable, t hey must 
complete any planned radiation therapy and/or surgery >[ADDRESS_928883] be neurologically 
stable, having no new neurologic deficits on clinical examination, and no new findings on 
central nervous system imaging.  
5. ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or 1  
[COMPANY_001]  Confidential  Page 70 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 6. Presence of at least one measurable lesion according to RECIST 1.1 per Investigator 
assessment. A previously irradiated site lesion may be counted as a target lesion only if 
there is clear sign of progression since the irradiation. (see Section 14.1 Appendix 1 ) 
7. Patients must be screened for HBV. Patients who are either HBsAg positive or HBV -DNA 
positive must be willing and able to take antiviral therapy [ADDRESS_928884] negative hepatitis C antibody (HCV -
Ab) or positive HCV -Ab but undetectable level of HCV -RNA. Note: patients with 
detectable HCV -RNA are not eligible for the study.  
9. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests 
and other study procedures  
10. Requirements of EGFR mutation status and prior lines of treatment for Phase I  
patients:  
Patients must have locally advanced or metastatic NSCLC  and meet one of the following 
criteria:  
• Treatment naive patients , who have locally advanced or metastatic NSCLC with EGFR  
activating mutation (e.g., L858R and/or ex19del), have not received any systemic 
antineoplastic therapy for advanced NSCLC and are eligible to receive EGFR TKI 
treatment. Note: patients who have received only one cycle of chemotherapy in the 
advanced setting  are allowed . 
• Patients who have locally advanced or metastatic NSCLC with EGFR activating 
mutation AND an acquired T790M mutation (e.g., L858R and/or ex19del, T790M+) 
follo wing progression on  prior treatment with a 1st-generation EGFR TKI (e.g., 
erlotinib, gefitinib or icotinib) or 2nd-generation EGFR TKI (e.g., afatinib or 
dacomitinib). These patients may not have received more than [ADDRESS_928885] received any agent 
targeting EGFR T790M mutation (i.e. 3rd-generation EGFR TKI). EGFR mutation 
testing must be performed after progression on EGFR TKI.  
• Patients who have locally advanced or metastatic NSCLC with a “de novo” T790M 
mutation (i.e. no prior treatment with any agent known to inhibit EGFR including 
EGFR TKI). These patients may not have received more than [ADDRESS_928886] received any prior agent known to inhibit 
EGFR, including EGFR TKIs.  
• Patients who have locally advanced or metastatic NSCLC harboring EGFR exon [ADDRESS_928887] received more than 3 prior lines of 
antineoplastic therapy, including EGFR TKIs.  
• Patients who have locally advanced or metastatic NSCLC with EGFR activating 
mutation AND without  an acquired T790M mutation (e.g., L858R and/or ex19del, 
T790M -) following progression on a 1st-generation EGFR TKI (e.g., erlotinib, gefitinib 
or icotinib) or 2nd-generation EGFR TKI (e.g., afatinib or dacomitinib). These patients 
may not have received more than [ADDRESS_928888] received any agent targeting EGFR T790M (i.e. 3rd-
[COMPANY_001]  Confidential  Page 71 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 generation EGFR TKI). EGFR mutation testing must be performed after progression 
on EGFR TKI.  
• Patients who have locally advanced or metastatic NSCLC with EGFR activating 
mutation and an acquired T790M mutation (e.g., L858R or ex19del, T790M+) 
following progression on a prior treatment with a 1 st/2nd-generation EGFR TKI, and 
have progressed on or are intolerant to a 3 rd-generation EGFR TKI (e.g., AZD9291, 
CO-1686, or ASP8273).  These patients may not have received more than [ADDRESS_928889] be available in the source documents.  
11. Requirements of EGFR mutation status and prior lines of treatment for Phase II 
patients:  
Patients must have advanced NSCLC with locally documented EGFR mutation L858R 
and/or ex19del (or other rare activating mutations that confer sensitivity to first and second 
generation EGFR inhibitors (e.g. L861Q, G719A/S/C, S768I)) , and must be naïve from any 
systemic antineoplastic therapy in the advanced setting . Patients who have failed no more 
than 1 cycle of systemic antineoplastic therapy in the advanced setting are allowed. 
Treatment failure is defined as documented disease progression or intolerance  to treatment. 
Note: Neo -adjuvant and adjuvant systemic therapi[INVESTIGATOR_685331] 1 prior line of 
treatment if relapse occurred within 12 months from the end of the neo -adjuvant/adjuvant 
systemic therapy.  
5.[ADDRESS_928890] not meet any of the following criteria:  
For All patients (unless otherwise specified):  
1. Patients with a history or presence of interstitial lung disease or interstitial pneumonitis, 
including clinically significant radiation pneumonitis (i.e. affecting activities of daily living 
or requiring therapeutic intervention)  
2. Patients with unstable brain metastases  
3. Presence or h istory of another malignancy  
Exception: Patients who have been disease -free for 3 years, or patients with a history of 
adequately treated in -situ carcinoma of the uterine cervix, basal or squamous cell carcinoma, 
non-melanomatous cancer of skin, history of stage IA melanoma that has been cured, are 
eligible.  
4. Undergone a bone marrow or solid organ transplant  
5. Known history of human immunodeficiency virus (HIV) seropositivity (HIV testing is not 
mandatory)  
6. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use at 
the time of study entry except for control of brain metastases, topi[INVESTIGATOR_14929], inhaled 
sprays, eye drops or local injections  
7. Patients with clinically significant, uncontrolled heart disease, such as:  
• Unstable angina within 6 months prior to screening  
• Myocardial infarction within 6 months prior to screening  
[COMPANY_001]  Confidential  Page 72 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Patients with a history of documented congestive heart failure ([LOCATION_001] Heart 
Association functional classification III -IV) 
• Patients with uncontrolled hypertension defined as a Systolic Blood Pressure (SBP) ≥ 
160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without anti -
hypertensive medication. Initiation or adjustment  of antihypertensive medication (s) is 
allowed prior to screening  
• Ventricular arrhythmias  
• Supraventricular and nodal arrhythmias not controlled with medication  
• Other cardiac arrhythmia not controlled with medication  
• Patients with a history of congenital long QT syndrome, history of Torsade de Pointes or 
patients with corrected QT (QTc) > 470 msec using  Fridericia correction (QTcF) on the 
screening ECG (using the mean QTcF value from  triplicate ECGs)  according to 
Investigator assessment  
8. Patients who have received thoracic radiotherapy to lung fields ≤ [ADDRESS_928891] not recovered from radiotherapy -related toxicities. 
For all other anatomic sites (including radiotherapy to thoracic verteb rae and ribs), 
radiotherapy ≤ [ADDRESS_928892] not 
recovered from radiotherapy -related toxicities. Palliative radiotherapy for bone lesions ≤ [ADDRESS_928893] had major surgery (e.g., intra -thoracic, intra -abdominal or intra -pelvic) 
within 4 weeks prior (2 weeks for resection of brain metastases) to starting study drug or 
who have not recovered from side effects of such procedure. Video -assiste d thoracic surgery 
(VATS) and mediastinoscopy will not be counted as major surgery and patients can be 
enrolled in the study ≥1 week after the procedure . 
10. Any medical condition that would, in the investigator’s judgment, prevent the patient’s 
participation in the clinical study due to safety concerns or compliance with clinical study 
procedures. Any severe, acute, or chronic medical or psychiatric condition or laboratory 
abnormality that may increase the risk associated with study participation or study treatment 
administration or that may interfere with the interpretation of study results and, in the 
judgment of the investigator, would make the patient inapp ropriate for the study  
11. Prior therap ies 
• Patients who have been treated with chemotherapy or biologic therapy or other 
investigational agent ≤ [ADDRESS_928894] dose of study treatment  
• Unresolved toxicity greater than CTCAE grade 1 from prior anticancer therapy or 
radiotherapy (excluding neurotoxicity, alopecia, lymphopenia)  
• Note: exceptions to the above are possible, on a case by [CONTACT_413], following discussion 
and mutual agreement between investigator and [COMPANY_001] ( applicable to the Phase I 
part only ). 
12. Patient s who have out of range laboratory  values  defined as  
• Absolute Neutrophil Count (ANC) <1.5 x 109/L (1.5 x 103/µL) 
• Hemoglobin (Hgb) <9 g/dL  (90 g/L)  
• Platelets < 75 x 109/L (75 x 103/µL) 
[COMPANY_001]  Confidential  Page 73 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Total bilirubin >1.5 x upper limit of normal (ULN). For patients with Gilbert’s 
syndrome total bilirubin >3.[ADDRESS_928895]  
• Aspartate aminotransferase (AST) and /or alanine aminotransferase (ALT ) >[ADDRESS_928896]  
for patients without hepatic metastasis  
• AST and /or ALT >[ADDRESS_928897]  for patients with hepatic metastasis  
• Alkaline phosphatase (ALP) >[ADDRESS_928898]  
• Measured or calculated creatinine clearance < 45 ml/min  (0.75 mL/sec) using 
Cockcroft -Gault formula  
13. Patients who have the following laboratory values outside of the laboratory normal limits 
or cannot be corrected to within normal limits with supplements during screening:  
• Potassium  
• Magnesium  
• Phosphorus  
• Total calcium (corrected for serum albumin)  
14. Patients who are receiving treatment with medications that are known to be strong inhibitors 
or inducers of CYP3A4/[ADDRESS_928899] dose of study treatment  
Note: exceptions to the above are possible, on a case by [CONTACT_413], following discussion 
and mutual agreement between investigator and [COMPANY_001] ( applicable to the Phase I part 
only). 
16. Patients who have impairment of GI function or GI disease that may significantly alter the 
absorption of EGF816 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or 
malabsorption syndrome)  
17. Patients who are receiving treatment with any enzyme -inducing anticonvulsant that cannot 
be discontinued at least [ADDRESS_928900] dose of study treatment, and for the duration of 
the study. Patients on non -enzyme -inducing anticonvulsants are eligible  
18. Pregnant or nursing (lactating) women  
19. Women of child -bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless  they are using highly effective methods of contraception during 
the study and for 3 months after stoppi[INVESTIGATOR_217909] . Highly effective  
contraception methods include:  
• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. 
Periodic abstinence (e.g., calendar, ovulation, symptom thermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception  
• Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case 
of oophorectomy alone, only when the reproductive status of the woman has been 
confirme d by [CONTACT_104]  
• Male Partner: m ale sterilization (at least 6 months prior to screening). For female 
subjects on the study the vasectomized male partner should be the sole partner for that 
subject.  
[COMPANY_001]  Confidential  Page 74 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal 
contraception that have comparable efficacy (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.  
• In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_5311] a minimum of [ADDRESS_928901] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical 
bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal 
ligation at least six weeks ago. In the case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by [CONTACT_685401].  
20. Sexually active males unless they use a condom during intercourse while taking drug and 
for 3 months after stoppi[INVESTIGATOR_056]; men  should not father a child in this period. A condom 
is required to be used also by [CONTACT_64064] a male 
partner in order to prevent delivery of the drug via seminal fluid.  
[ADDRESS_928902] cohort of patients will be 75 mg  QD capsule .  
For the Phase II part, patients will be treated at the RP2D (150 mg QD) declared on 30-Aug-
2016 during Phase I part of the study.  
From protocol amendment # 03 dated 21 Aug 2014 , an immediate release film -coated tablet 
was introduced during the dose -escalation phase I and patients were  switch ed from capsules to 
tablets based on tablets stock availability . As of 07 -Mar-2017, 44 patients from Phase I part 
were ongoing and were receiving capsule or tablet formulations .  
 
Upon the implementation of  protocol amendment # 07  dated 11-March -2020 , all patients 
receiving  tablets will begin to receive capsules, once the capsule formulation is released and 
available for dispensation, and will no longer receive tablets . 
The dose strength of both capsule s and tablet s can be found in  Table 6 -1. 
Table 6-1 Dose and treatment schedule  
Study  treatment  Pharmaceutical form and 
route of administration  Strength  Frequency and/or 
Regimen  
EGF816  Capsule  for oral use  25 mg, 5 0 mg , 100 mg   Daily  
EGF816  Tablet  for oral use  25 mg, 50 mg , 200 mg * Daily  
[COMPANY_001]  Confidential  Page 75 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Study  treatment  Pharmaceutical form and 
route of administration  Strength  Frequency and/or 
Regimen  
*200 mg Tablet formulation will be supplied to patients from Phase I and cannot be provided to 
patients in Phase II (RP2D is 150 mg QD)  
EGF816  (either as capsule or tablet)  should be taken as follows:  
• Patients should be instructed to take their dose at approximately the same time of day.  
• On days when blood for PK samples need to be collected, the patient should take the dose 
during  the clinic  visit after the pre -dose PK samples and prior to the post -dose PK samples, 
when instructed by [CONTACT_7893] . 
• Each dose should be taken with a glass of water and swallowed  over a short period of time.  
• Patients should be instructed to swallow capsules or tablets whole and not to chew or open 
them . 
• Since EGF816 is preliminary BCS class 1 (Section [IP_ADDRESS].1 ), EGF816 can be taken with or 
without food. On days when blood PK samples are collected, the time of the meal before 
and after the dose need to be recorded on the eCRF.  
• Grapefruit or grapefruit juice , seville orange (and juice), pummelos, pomegranate (and juice)  
star citrus fruits  and hybrids of these mentioned fruits must  be avoided during the treatment 
period of the study.  
• If vomiting occurs , no attempt should be made to replace the vomited dose befor e the next 
scheduled dose . 
• On days of PK/PD sampling, every effort must be made to capture the time of any vomiting 
within 4 hours of drug administration . 
• If the patient forgets to take his/her daily dose, then he/she should take EGF816  within [ADDRESS_928903] passed, then that day’s dose should 
be omitted and the patient should continue treatment with the next scheduled dose.  
• Patients should inform the investigational site staff of any missed or delayed doses . 
• During the whole duration of the treatment with EGF816, the patient is recommended to 
use precautionary measures against sunlight  exposure (refer to Section 6.3.3  and Table 6 -9) 
6.1.2  Treatment duration  
Treatment with EGF816 will continue until:  
• Adverse event (based on the recommendations in Table 6 -5) 
• Death  
• Progressive disease  
• Pregnancy  
• Protocol deviation  
• Study terminated by [CONTACT_3211]  
• Technical problems  
• Lost to follow -up 
• Physician decision  
• Subject/guardian decision  
[COMPANY_001]  Confidential  Page 76 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Patients who permanently discontinue the study treatment during the treatment phase will 
continue tumor assessments every 8 weeks until:  
• the patient has disease progression or  
• the study is terminated by [CONTACT_456], or  
• withdrawal of consent for further assessments, or  
• the patient is lost to follow -up or   
• the patient dies.  
Patient may continue treatment with the study treatment until patient experiences unacceptable 
toxicity, disease progression and/or treatment is discontinued at the discretion of the 
investigator or withdrawal of consent.  
[IP_ADDRESS]  Treatment beyond disease progression  
Patients may derive benefit from continuing study treatment despi[INVESTIGATOR_685344]816 will be permitted to continue study 
treatment beyond initial disease progression as per RECIST 1.1 criteria provided they meet the 
following criteria:  
• Benefit assessed by [CONTACT_093] (s)  
• No rapid disease progression  
• Tolerance of study treatment  
The judgment of the investigator should be documented in the Case Report Form as an 
Investigator comment and the continued evidence of clinical benefit should be updated on a 
regular basi s.In addition, treatment beyond disease progression should not jeopardize critical 
interventions to treat/prevent severe complications, or prevent patients from receiving adequate 
care.  
Patients who meet above criteria and continue treatment beyond initial disease progression will 
continue all study procedures as outlined in Section [ADDRESS_928904] criteria for an 
anticancer drug were applied. In the 4 -week GLP rat study, the 75 mg/kg dose was considered 
to approximate the severely toxic dose in 10% of animal  (STD 10). Expressing 75 mg/kg in the 
rat based on the body surface area is equivalent to 450 mg/m2. Applying a safety factor of 10, 
the starting dose in humans would be 1/10th  of the STD 10 in rats or 1/10th of 450 mg/m2 = 45.0 
[COMPANY_001]  Confidential  Page 77 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 mg/m2. Since 1/10th of the STD [ADDRESS_928905] non-severely toxic dose (HNSTD ) 
in the dog (20 mg/kg or 400 mg/m2), this dose is expected to be well -tolerated by [CONTACT_685402]. 
Therefore, the rat is considered an appropriate species for evaluating EGF816 toxicity and the 
rat STD 10 was used as the basis for the starting dose calculation. Thus, based on an average 
body surface area ( BSA ) of 1.73m2, the recommended safe starting dose of EGF816 is 77.8 
mg/patient (~75 mg/patient /day). 
Formulation change from capsule to tablet  (based on protocol amendment 03)  
An immediate release film -coated tablet will be introduced during the dose -escalation phase.  
EGF816 has a high solubility across the pH range of [ADDRESS_928906] completely absorbed as demonstrated in the 
rat radiolabel ADME study. The oral bioavai lability of 55% observed in rat was due to the first -
pass metabolism. Therefore, based on available data EGF816 is considered a preliminary BCS 
class 1 compound. The dissolution profile of the capsule formulation was categorized as very 
rapi[INVESTIGATOR_685345] >  85% of drug in solution within [ADDRESS_928907] 3 patients and shown to 
satisfy the EWOC principle . In the situation that MTD /RP2D  has been reached for capsule 
formulation, the EGF816 tablet will be introduced at the highest previously tested dose  that is 
lower than the capsule MTD /RP2D , and the MTD /RP2D  with the tablet formulation will be 
established separately.  Dose-escalation for the tablet formulation will continue following the 
procedure specified in Section 6.2.3 .  
EGF81 6 will be supplied by [CONTACT_5343].  EGF816  25 mg, 50 mg, 100 mg capsules and  25 mg , 50 
mg and 200 mg tablets  will be packaged in high -density polyethylene  (HDPE) bottles.   Similar 
exposures were observed in the phase I part between capsules and tablets at 150 mg QD  (refer 
to latest Investigator’s Brochure Edition ). 
6.2.2  Provisional dose levels  for Phase I part (dose -escalation)  
Table 6 -2 describes the starting dose and the dose levels that may be evaluated during this trial.  
Dose escalation will continue until MTD is reached and/or RP2D  is determined. At all decision 
time points, the adaptive BLRM permits alterations in the dose increments based on the 
observed DLTs . 
[COMPANY_001]  Confidential  Page 78 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Table 6-2 Provisional dose levels  for Phase I part (dose -escalation)  
Dose level  Proposed daily dose*  Increment from previous dose  
-1** 50 mg  - 
1 (starting dose)  75 mg  (starting dose)  
2 100 mg 33% 
3 150 mg  50% 
4 300 mg  100%  
5 450 mg  50% 
6 600 mg  33% 
7 800 mg  33% 
8 1000 mg  25% 
*It is possible for additional and/or intermediate dose levels to be added during the course of the 
study. Dose levels may also be skipped if the safety data and BLRM analyses support a higher 
increase limited to at most 100% increase in dose level (e.g. a move from 300 mg to 600 mg). 
Cohorts may be added at any time (either during Phase I and/or during Phase II part) and at any 
dose level below either the estimated MTD or the RP2D  for which safety data exists in order to 
better understand safety, PK or PD  
**Dose level −1 represents a treatment dose for patients requiring a dose reduction from the starting 
dose level.  
6.2.3  Guidance for dose escalation and determination of MTD/ RP2D  
[IP_ADDRESS]  Definition and estimation of MTD/ RP2D  
The MTD is the highest drug dosage that is unlikely (<25% posterior probability) to cause DLT 
in more than 33% of the treated patients in the first cycle of EGF816  treatment.  
A two -parameter BLRM employing the EWOC principle ( Neuenschwander 2008 ; Babb 1998 ) 
will be used during the dose escalation to guide dose level selection and to estimate the MTD. 
Dose escalation will continue until the MTD is reached or until [COMPANY_001] and Investigators reach 
consensus that, based on a review of the totality of the clini cal data (e.g., DLT, lower grade AE, 
PK, , preliminary antitumor activity etc.) there is no benefit to continue escalation and a 
lower RP2D  is identified (e.g., when  PK modeling predicts that further escalation will not result 
in higher drug exposures).  
Estimation of the MTD during the Phase I dose-escalation part of the study will be based upon 
the estimation of the probability of DLT in cycle 1 in patients in the Dose -Determining Set 
(DDS). The corresponding statistical methodology is described in Section 10.4.2 . 
MTD/ RP2D  for each drug formulation or dosing schedule may be established when appropriate.  
[IP_ADDRESS]  Dose cohort modification  for Phase I part (dose -escalation)  
For the purposes of dose -escalation decisions, each cohort will consist of [ADDRESS_928908] cohort will be treated 
with the starting dose of 75 mg  QD. When two patients (who may be in different cohorts) have 
experienced a toxicity of CTCAE grade 2 for which relationship to study drug cannot be ruled 
out; or when any single patient experiences a DLT or AE of CTCAE grade 3 or greater during 
Cycle 1, the cohort size will be chan ged to between 3 and 6 evaluable patients for the current 
and subsequent cohorts.   

[COMPANY_001]  Confidential  Page 79 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Patients must complete a minimum of [ADDRESS_928909] cycle of treatment to be considered 
evaluable for dose -escalation decisions. Dose -escalation decisions will occur when the cohort 
of patients has met these criteria.  
Dose -escalation decisions will be made by [CONTACT_217951]. 
Decisions will be based on a synthesis of all relevant data available from all dose levels 
evaluated in the ongoing study including safety information (DLTs, all CTCAE Grade ≥ 2 
toxicity data during Cycle 1 ), PK, and PD data from evaluable patients. The recommended dose 
for the next cohort of subjects will be guided by [CONTACT_632749] ( Section 2.2 ). 
The adaptive Bayesian methodology provides an estimate of all dose levels of EGF816 that do 
not exceed the MTD and incorporates all DLT information at all dose levels for this estimation. 
In general, the next dose will have the highest chance that the DLT rate will fall in the target 
interval [16 -33%) and will always satisfy the EWOC principle ( Section 10.4.2 ). In all cases, the 
dose for the next cohort will not exceed a 100% increase from the previous dose. Smaller 
increases in dose may be recommended by [CONTACT_685403]. If needed to bette r define the dose -toxicity relationship 
additional patients may be enrolled to the current dose level, to a preceding dose level, or to an 
intermediate dose level before proceeding with further dose escalation.  
If 2 patients in a previously untested dose level experience a DLT, enrollment to that cohort 
will stop, the BLRM will be updated and the next cohort will be opened at the next lower dose 
level or an intermediate dose level (see Section 14.2 Appendix 2 ) that satisfies the EWOC 
criteria. However, if 2 patients in a new cohort at a previously tested dose  level experience a 
DLT (e.g., a total of 8 patients are treated on this dose level with 2 DLT observed), further 
enrollment to that cohort will stop, the BLRM will be updated with this new information and 
re-evaluation of the available safety, PK, and PD data will occur. By [CONTACT_685404], additional patients may be enrolled into the current dose 
cohort only if the dose still meets the EWOC criteria and as agreed by [CONTACT_685405]. Alter natively, if recruitment to the same cohort may not resume, a new cohort of 
patients may be recruited to a lower dose as agreed by [CONTACT_685406] 25% 
(EWOC). Re -escalation may then occur if data in subsequent cohorts supports this (EWOC 
criteria are satisfied) and Investigators and [COMPANY_001] personnel agree.  
Dose escalation will continue until identification of the MTD or a suitable lower dose for Phase 
II part . This will occur when the following conditions are met:  
1. at least [ADDRESS_928910] been treated at this dose  
2. this dose satisfies one of the following conditions:  
a. the posterior probability of targeted toxicity at this dose exceeds 50% and is the highest 
among potential doses, or  
b. minimum of [ADDRESS_928911] already been treated on the trial.  
3. it is the dose recommended for patients, either per the model or by [CONTACT_685407] a dose -escalation teleconference . 
Note: if significant activity is seen early in the dose escalation, then a recommended dose may 
be identified and the phase II groups may be initiated without determination of the MTD; 
therefore fewer than 21 patients may be required.  
[COMPANY_001]  Confidential  Page 80 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 To better understand the safety, tolerability, PK, PD (paired tumor biopsy) or preliminary 
activity of EGF816 , additional cohorts of one to six patients may be enrolled at preceding dose 
levels, or to intermediate dose levels before or while proceeding with further dose escalation.  
If a decision is made to escalate to a higher dose level but one or more additional patient(s) 
treated at the preceding dose level experiences a DLT during the first cycle of treatment, then 
the BLRM will be updated with this new information before any add itional patients are enrolled 
at that higher dose level. Subjects ongoing will continue treatment at their assigned dose levels.  
Change of drug formulation : 
By [CONTACT_12548] 07, the dose escalation decisions were already made and no additional 
patients were included for BLRM, hence the  new change in formulation from tablet to capsule  
are not expected to impact this part of the study .  
Change of schedule:   
In the event of a change in dosing schedule, then a new BLRM would have  been set up.  This 
new BLRM would have  incorporate d down -weighted existing dose -escalation data in the prior 
distribution and a starting dose would have  been identified at that time. Subsequent dosing 
decisions for the new schedule would have  follow ed the same rules defined within the above 
paragraphs of this section.   
[IP_ADDRESS]  Implementation of dose-escalation decisions  
To implement dose -escalation decisions, the available toxicity information (including adverse 
events and laboratory abnormalities that are not DLTs), the recommendations from the BLRM, 
and the available PK and PD information will all be evaluated by [CONTACT_685408] (including the study physician and statistician) during a dose decision meeting 
by [CONTACT_577]. Drug administration at the next higher dose level may not proceed until the 
investigator receives written confirmati on from [COMPANY_001] indicating that the results of the 
previous dose level were evaluated and that it is permissible to proceed to a higher dose level.  
[IP_ADDRESS]  Intra -patient dose escalation  for Phase I part (dose -escalation)  
Intra -patient dose escalation is not permitted during the first [ADDRESS_928912] four cycles 
of therapy without a toxicity ≥ CTCAE grade [ADDRESS_928913] eCRF.  
. 
[COMPANY_001]  Confidential  Page 81 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 6.2.4  Definitions of dose -limiting toxicities (DLTs)  for Phase I part (dose -
escalation)  
A dose -limiting toxicity (DLT) is defined in the Phase I part  as an adverse event or abnormal 
laboratory value assessed as unrelated to disease, progressive disease, inter -current illness, or 
concomitant medications that occurs within the first 28 days of treatment with EGF816  and 
meets any of the criteria included in Table 6 -3. National  Cancer Institute Common Terminology 
Criteria for Adverse events (NCI CTCAE) version 4.[ADDRESS_928914] notify the Sponsor immediately of any unexpected CTCAE grade ≥ 3 
adverse events or laboratory abnormalities. Prior to enrolling patients into a higher dose level, 
CTCAE grade ≥ 2 adverse events will be reviewed for all patients at the  current dose level.  
Table 6-3 Criteria for defining dose -limiting toxicities in the Phase I part  
Toxicity  Any of the following criteria:  
Hematology  Any hematologic toxicity = grade 3, lasting for >7 consecutive days  
Any hematologic toxicity ≥ grade 4 (of any duration)  
Febrile neutropenia (ANC  1.0 x 109/L or 1000/mm3 with a single 
temperature of >38.3 °C (101 °F) or a sustained temperature of ≥38 °C 
(100.4 °F) for more than one hour.  
Renal  Serum creatinine ≥ grade 3  (> 3.[ADDRESS_928915] or >3.0 x baseline)  
Hepatic  total bilirubin ≥ grade 3 (> [ADDRESS_928916])  
AST or ALT = grade 3 (>5.[ADDRESS_928917]) for ≥ [ADDRESS_928918] or ALT = grade 4 (>20.[ADDRESS_928919])  
AST or ALT grade 3 and ≥ grade 2 bilirubin  
Neurologic  Any neurological abnormality or toxicity ≥ grade 2  
Diarrhea  ≥ grade 3 despi[INVESTIGATOR_685346]  ≥ grade 3 despi[INVESTIGATOR_040] 7 days optimal treatment  
Other adverse events  Any adverse event ≥ grade 3 . 
Single event or multiple occurrences of the same event that lead to a 
dosing delay of > 7 days in cycle 1, may be considered to be DLTs by [CONTACT_111854], even if not CTCAE grade 3 or higher  
CTCAE version 4.03 will be used for all grading.  
Patients may receive supportive care (e.g. transfusion of red blood cells) as per local institutional 
guidelines, as long as causality can clearly be established that supportive care is to treat disease 
related events and not related to investigational age nt 
6.3 Dose modifications  for toxicities  
6.3.1  Dose modification and dose delay  
If a patient requires a dose interruption of   >[ADDRESS_928920] be discontinued from the study 
treatment  unless described otherwise (see Table 6 -7 and Table 6 -8 for exception) .   
[COMPANY_001]  Confidential  Page 82 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 For patients who do not tolerate the protocol -specified dosing schedule due to drug related 
toxicities, dose interruptions and/or reductions  are recommended  in order to allow patient s to 
continue the study treatment.  
Table 6 -5 provides recommendations for dose modification and dose interruption  (i.e., 
interruption and re -initiation criteria for EGF816 treatment).  
Each patient is allowed a maximum of [ADDRESS_928921] discon tinue 
treatment with EGF816, if after treatment is resumed at a lower dose, the toxicity recurs with 
the same or worse severity. Exceptions can be made on a case by [CONTACT_685409]  (applicable to the Phase I part ). 
All dose interruptions or modifications must be recorded on the Dosage Ad ministration Record 
CRF.  
In case of study treatment interruption, visit schedule should still be followed and  assessments 
performed as per Table 7 -1 (Phase I part) and Table 7 -2 (Phase II part) . 
Refer to Table 6 -4 for recommended dose reduction steps for the Phase I and Phase II part of 
the study.  
Table 6-4 Recommended dose reduction steps for the Phase I and  II parts  
Dose level  Reduction from 
initial dose for 
phase I* Proposed daily dose for phase II  
0 0% (current dose)  RP2D = 150 mg  
-1 25%-33% reduction 
from current dose  100 mg  
-2 50% reduction from 
current dose  75 mg  
*Note: Since phase I part is exploring dose escalation, the dose reductions in phase I are given as 
percent of initial dose rather than an absolute number because individual patients may be started on 
different initial doses.  
Table 6-5 Criteria for dose reduction/ interruption and re -initiation of EGF816 
treatment  for adverse drug reactions  
Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
Investigations (Hematologic)  
Neutropenia (ANC)  
Grade 1 (ANC <LLN - 1500/mm3) Recommendation: m aintain dose level  
Grade 2 (ANC <1500 - 1000/mm3) Recommendation: m aintain dose level  
Grade 3 (ANC <1000 - 500/mm3) Recommendation: omit dose  until resolved ≤ Grade 2, then maintain 
dose level  
Grade 4 (ANC <500/mm3) Recommendation: omit dose until resolved to ≤ Grade 2, then ↓ 1 dose 
level 
[COMPANY_001]  Confidential  Page 83 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
Febrile neutropenia (ANC <1.0 x 
109/L, fever ≥ 38.5°C)  Recommendation: omit dose until resolved, then ↓ 1 dose level  
Thrombocytopenia  
Grade 1 (PLT <LLN - 75,000/mm3) May m aintain dose level  
Grade 2 (PLT <75,000 - 50,000/mm3) May m aintain dose level  
Grade 3 (PLT <50,000 - 25,000/mm3) Recommendation: omit dose until resolved to ≤ Grade 1, then:  
If resolved in ≤ 7 days, then maintain dose level  
If resolved i n >7 days, then ↓ 1 dose level  
Grade 4 (PLT <25,000/mm3) Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1 dose 
level 
Investigations (Renal)  
Serum creatinine  
Grade 1 (>ULN - 1.[ADDRESS_928922]) - May m aintain dose level  
Grade 2 (>1.5 – 3,.[ADDRESS_928923])  Recommendation: omit dose until resolved to ≤ Grade 1 or baseline, 
then maintain dose level  
Grade 3 (>3.0 – 6.[ADDRESS_928924]  Recommendation: omit dose and discontinue patient from study drug 
treatment  
Grade 4 (>6.[ADDRESS_928925])  Recommendation: omit dose and discontinue patient from study drug 
treatment  
Investigations (Hepatic)b 
Isolated Total Bilirubin  
(for patients with Gilbert Syndrome these dose modifications apply to changes in direct [conjugated] bilirubin 
only)  
>ULN -1.[ADDRESS_928926]  Recommendation: maintain dose level  
>1.[ADDRESS_928927]  
 Recommendation: omit dose. Monitor LFTsc weekly, or more frequently 
if clinically indicated until resolved to ≤ 1.[ADDRESS_928928]  ,then:  
If resolved in ≤14 days, then maintain dose level  
If resolved in >14 days, then  1 dose level  
>3.0 - 10.0 x ULNg  Recommendation: omit dose. Monitor LFTsc weekly, or more frequently 
if clinically indicated until resolved to ≤ 1.[ADDRESS_928929], then:  
If resolved in ≤14 days, then  1 dose level  
If resolved in 14 days, then discontinue patient from study drug 
treatment. The patient should be monitored weekly (including LFTsb), 
or more frequently if clinically indicated, until total bilirubin has resolved 
to baseline or stabilization over 4 weeks.   
>10.0 x ULNg Recommendation: Discontinue patient from study drug treatment  
The patient should be monitored weekly (including LFTsb), or more 
frequently if clinically indicated, until total bilirubin have resolved to 
baseline or stabilized over 4 weeks.  
[COMPANY_001]  Confidential  Page 84 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
Isolated AST or ALT  
>ULN - 3.[ADDRESS_928930]  Recommendation: maintain dose level  
>3.[ADDRESS_928931]  
For patients with baseline value ≤ 3.[ADDRESS_928932]  Recommendation: maintain dose level.  Repeat LFTsb as soon as 
possible, preferably within 48 - 72 hours from awareness of the 
abnormal results; if abnormal lab values are confirmed upon the repeat 
test, then monitor LFTsb weekly, or more frequently if clinically 
indicated, until resolved to ≤ 3.[ADDRESS_928933]  
For patients with baseline value > 3.[ADDRESS_928934]  Maintain dose level   
>5.[ADDRESS_928935]  
For patients with baseline value ≤ 3.[ADDRESS_928936]  Recommendation: omit dose. Repeat LFTsb as soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal results; 
monitor LFTsb weekly, or more frequently if clinically indicated, until 
resolved to ≤ 3.[ADDRESS_928937] Then  
If resolved in ≤ 14 days, maintain dose level  
If resolved in > 14 days, ↓ 1 dose level  
For patients with baseline value > 3.[ADDRESS_928938]  
 Maintain dose level. Repeat LFTsb as soon as possible, preferably 
within 48 -72 hours from awareness of the abnormal results; if abnormal 
lab values are confirmed upon the repeat test, then monitor LFTsb, 
weekly, or more frequently if clinically indicated, until resolved to ≤ 5.[ADDRESS_928939] or ALT > [ADDRESS_928940] or ALT ≤ [ADDRESS_928941] or ALT > [ADDRESS_928942] or ALT > [ADDRESS_928943] 
but ≤ [ADDRESS_928944] HBV -DNA or HCV -
RNA monitoring during the study should be re -tested immediately  
> 10.[ADDRESS_928945]  Recommendation: Omit dose. Repeat LFTsb as soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal results; 
monitor LFTsb weekly, or more frequently if clinically indicated, until 
resolved to ≤ Grade 1 (or to baseline), then ↓ 1 dose level.  
> 20.[ADDRESS_928946]  
For patients deriving clinical benefit 
upon investigator’s judgement  Recommendation: omit dose. Repeat LFTsb as soon as possible, 
preferably within 48 -72 hours from awareness of the abnormal results; 
monitor LFTsb weekly, or more frequently if clinically indicated, until 
resolved to ≤ [ADDRESS_928947] (or ≤ [ADDRESS_928948] for patients with baseline value > 
3.[ADDRESS_928949]), then resume treatment at ↓ 1 dose level. Only 1 dose 
reduction is allowed; if reoccurs at > [ADDRESS_928950], discontinue patient from 
study drug treatment  
For all other patients  
 Discontinue patient from study drug treatment  
Repeat LFTsb as soon as possible, preferably within 48 -72 hours from 
awareness of the abnormal results; monitor LFTsb weekly, or more 
frequently if clinically indicated, until resolved to baseline or stabilization 
[COMPANY_001]  Confidential  Page 85 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
over [ADDRESS_928951] or ALT>20.[ADDRESS_928952] or total bilirubin value:  
AST or ALT >3.0xULN combined  with 
total bilirubin >2.[ADDRESS_928953] or ALT or  total bilirubin value:  
[AST or ALT>2x baseline AND > 3.[ADDRESS_928954]] OR [AST or ALT > 8.[ADDRESS_928955]], 
whichever is lower, combined with 
[total bilirubin >2x baseline AND >2.[ADDRESS_928956]]  Mandatory: permanently discontinue study treatment Repeat  as soon 
as possible, preferably within 48 hours from awareness of the abnormal 
results, then with weekly monitoring of LFTsb), or more frequently if 
clinically indicated, until AST, ALT, or bilirubin have resolved to baseline 
or stabilization over 4 weeks. Testing for viral hepatitis infection or 
reactivation should be performed, see Section 6.3.4 .  
Investigation (metabolic)h 
Asymptomatic amylase and/or lipase elevation  
Grade 1 (>ULN - 1.[ADDRESS_928957])  May m aintain dose level  
Grade 2 (>1.[ADDRESS_928958])  May m aintain dose level  
Grade 3 (>2.[ADDRESS_928959])  Recommendation: omit dose until resolved to Grade ≤ 2, then:  
If resolved in ≤ 14 days, then maintain dose level  
If resolved in >14 days, then ↓ 1 dose level  
Grade 4 (>5.[ADDRESS_928960])  Recommendation: Omit dose and discontinue patient from study drug 
treatment  
Note: withhold EGF816 for acute onset of new or progressive unexplained abdominal symptoms, such as severe 
pain or vomiting; perform diagnostic procedures (e.g., abdominal CT scan or ultrasound) to exclude pancreatic 
pathology.  
HBV and HCV reactivation  
Refer to Table 6 -6, Table 6 -7 and Table 6 -8, and Section 6.3.4  for details.  
Cardiac Investigations  
Electrocardiogram QT corrected (QTc) interval prolonged  
Grade 1 (QTc 450 -480 ms)  May maintain dose level  
Grade 2 (QTc 481 -500 ms)  May maintain dose level  
Grade 3 (QTc ≥ [ADDRESS_928961] two 
separate ECGs)  Recommendation: omit dose until QTC is less than 481 ms and then  
[ADDRESS_928962] with supplements to within normal limits. - Repeat ECG 
[COMPANY_001]  Confidential  Page 86 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
in 24 hours, or less, as clinically indicated; continue monitoring as 
clinically indicated until QTc <481 ms  
- Repeat ECGs 7 days after dose resumption for all patients who had 
therapy  interrupted due to QTc ≥ 501 ms.  
Grade 4 (QTcF ≥ 501 or > 60 ms 
change from baseline and Torsades 
de pointes or polymorphic ventricular 
tachycardia or signs/symptoms of 
serious arrhythmia)  Recommendation : discontinue  patient from study treatment  
Bradycardia  
Grade 1 or 2  
 Recommendation: omit dose until recovery to asymptomatic 
bradycardia or to a heart rate ≥ [ADDRESS_928963] the dose of EGF816  
Grade 3  
Grade 4 (in patients taking a 
concomitant medication also known to 
cause bradycardia or a medicatio n 
known to cause hypotension)  Recommendation: omit dose until recovery to asymptomatic 
bradycardia or to a heart rate ≥ 60 bpm  
If the concomitant medication can be adjusted or discontinued, resume 
EGF816 at ↓ 1 dose  level with frequent monitoring  
Grade 4 (in patients who are not taking 
a concomitant medication also known 
to cause bradycardia or known to 
cause hypotension)  Recommendation: permanently discontinue EGF816  
Vascular disorders  
Hypertension  
CTCAE Grade 3  Recommendation: omit dose until resolved  ≤ Grade 1, then ↓ 1 dose 
level 
CTCAE Grade 4  Recommendation: omit dose and discontinue patient from study drug 
treatment  
Gastro intestinal  
Diarrheae 
Grade 1 (despi[INVESTIGATOR_76303] -
diarrheal medication)  Recommendation: maintain dose level but adjust anti -diarrhea 
treatment  
Grade 2 (despi[INVESTIGATOR_76303] -
diarrheal medication)  Recommendation: omit dose until resolved to ≤ Grade 1, then maintain 
dose level.  
If diarrhea returns as ≥ Grade 2, then omit dose until resolved to ≤ 
Grade 1, then ↓ 1 dose level  
Grade 3 (despi[INVESTIGATOR_76303] -
diarrheal medication)  Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1 dose 
level 
Grade 4 (despi[INVESTIGATOR_76303] -
diarrheal medication)  Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1  dose 
level 
Nausea  
Grade 1 or 2  Recommendation: maintain dose level b ut adjust anti -emetic treatment  
[COMPANY_001]  Confidential  Page 87 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
Grade 3 (despi[INVESTIGATOR_111763] -
emetics)  Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1 dose 
level 
Vomiting  
Grade 1 (despi[INVESTIGATOR_111763] -
emetics)  Recommendation: maintain dose level but adjust anti -emetic treat ment  
Grade 2 (despi[INVESTIGATOR_111763] -
emetics)  Recommendation: omit dose until resolved to ≤ Grade 1, then maintain 
dose level.  
If vomiting returns as ≥ Grade 2, then suspend dose until resolved to  ≤ 
Grade 1, then ↓ 1 dose level  
Grade 3 (despi[INVESTIGATOR_111763] -
emetics)  Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1 d ose 
level 
Grade 4 (despi[INVESTIGATOR_111763]-
emetics)  Recommendation: omit dose until resolved to ≤ Grade 1, then ↓ 1 dose 
level 
Dose modifications apply to patients who experience nausea and/or vomiting despi[INVESTIGATOR_685347]. This medication should be started at the first sign of nausea and/or vomiting.  
Skin and subcutaneous tissue disorders  
Rash/photosensitivity  
Refer to Table 6 -9, Table 6 -10 , and Table 6 -11 for management and dose modification for rash/skin toxicities  
Pneumonitis/Interstitial lung disease  
Refer to Table 6 -12 for management and dose modification for non -infectious pneumonitis/interstitial lung 
disease  
Fatigue/ Asthenia (General disorders and administration site conditions ) 
Grade 1 or 2  May maintain dose level  
Grade 3  Recommendation: omit dose until resolved to ≤ grade 1, then :  
If resolved in ≤ 7 days, then maintain dose level  
If resolved in > 7 days, then↓ 1 dose level  
Metabolic  
Any Grade hypophosphatemia  Treatment with phosphate supplements as clinically indicated and 
maintain dose level  
Persistent hyperglycemia  (glucose > 
250 mg/dL) despi[INVESTIGATOR_9025] -
hyperglycemic therapy  Omit dose until hyperglycemia is adequately controlled then resume 
EGF816 at ↓ 1 dose level  
If adequate hyperglycemic control cannot be achieved with optimal 
medical management permanently discontinue patient from EGF816  
Other adverse events  
Grade 1 or 2  May maintain dose level  
Grade 3  Recommendation: omit dose until resolved to ≤ grade 1, then↓ 1 dose 
level 
Grade 4  Recommendation: omit dose and then discontinue from study 
treatment.  
[COMPANY_001]  Confidential  Page 88 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Dose modifications for  EGF816  
Worst toxicity  
CTCAEa Grade (value) during a 
cycle of therapy   
Note:  
Recommendation: Omit dose for ≥ grade 3 vomiting or grade 3 nausea 
only if the vomiting or nausea cannot be controlled with optimal 
antiemetic (as per local practice)  
All dose modifications should be based on the worst preceding toxicity.  
a Common Terminology Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_928964] (non -conjugated) component only, and hemolysis as 
the etiology has been ruled out as per institutional guidelines (e.g., Review of peripheral blood smear and 
haptoglobin determination), then ↓ [ADDRESS_928965], total bilirubin (fractionated if total bilirubin >2.[ADDRESS_928966]), alkaline phosphatase 
(fractionated if alkaline phosphatase > 2.[ADDRESS_928967]) and GGT. For isolated elevations of any grade of alkaline 
phosphatase and/or gamma -glutamy l transpeptidase (GGT), maintain dose level.  
d “Combined” defined as: total bilirubin increase to the defined threshold concurrently with ALT/AST increase to 
the defined threshold  
e “Cholestasis” defined as: ALP elevation  (>2xULN and R value< 2) in patients without bone metastasis, or 
elevation of ALP liver fraction in patients with bone metastasis  
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. 
It  denotes the relative pattern of ALT and/or ALP elevation is due to cholestatic or hepatocellular liver injury  
f If combined elevations of AST or ALT and total bilirubin do not meet the defined thresholds, please follow the 
instructions for isolated elevation of total bilirubin and isolated elevation of AST/ALT, and take a conservative 
action based on the degree of the elevations (e.g. discontinue treatment at the situation when omit dose is 
needed for one parameter and discontinue treatment is required for another parameter).   After all elevations 
resolve to the defined thresholds that allow treatment re -initiation , re-start the treatment either at the same dose 
or at one dose lower if meeting a criterion for dose reduction  
g Note: If total bilirubin > 3.[ADDRESS_928968] (non -conjugated) component only, and hemolysis as the 
etiology has been ruled out as per institutional guidelines (e.g., review of peripheral blood smear and haptoglobin 
determination), then ↓ [ADDRESS_928969] occurrence of any ≥ Grade 3 of amylase and/or lipase. If asymptomatic Grade 2 elevations of 
lipase and/or amylase occur again at th e reduced dose, patients will be discontinued permanently from study 
treatment.  
iAntidiarrheal medication is recommended at the first sign of abdominal crampi[INVESTIGATOR_007], loose stools or overt diarrhea.  
6.3.2  Guidelines for screening, monitoring and management of HBV / HCV 
reactivation  
HBV screening tests, on study monitoring, and management of HBV reactivation  
1. All patients must be screened with HBV serologic mar kers: HBsAg, HBsAb, and HBcAb.  
2. If HBsAg and/or HBcAb are positive , test for HBV -DNA.  
3. Refer to Table 6 -6 for actions to be taken based on screening HBV results.  
4. If a patient is HBsAg positive or HBV -DNA positive BUT is not on antiviral therapy:  
a. Consult a physician with expertise in managing HBV   
[COMPANY_001]  Confidential  Page 89 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 b. Initiate antiviral therapy with entecavir 0.5mg QD 1-[ADDRESS_928970] dose of  
EGF816 treatment.  Note: ongoing patients prior to initiation of Amendment [ADDRESS_928971] an appropriate antiviral therapy .  
d. If antiviral therapy cannot be given, the patient is not eligible for EGF816  dosing .  
e. During the study, monitor HBV -DNA every 4 weeks (or more frequently if clinically 
indicated).  (Refer to Table 6 -7 if there is evidence of viral reactivation on study)  
f. Antiviral therapy should continue for at least [ADDRESS_928972] been 
receiving antiviral therapy are eligible provided the patient remains on antiviral treatment.   
a. Identify a consulting  physician with expertise in managing HBV  who can provide 
treatment guidance, if required, while the patient is on study.   
b. HBV -DNA should be monitored every 4 weeks (or more frequently if clinically 
indicated) . 
c. Antiviral therapy should continue for at least [ADDRESS_928973] Result  Result  Result  Result  Result  
HBV-DNA  + + or - - - - 
HBsAg  + or - + - - - 
HBsAb  + or - + or - + 
and no 
prior HBV 
vaccination  - 
or + with 
prior HBV 
vaccination  -  
or + with 
prior HBV 
vaccination  
HBcAb  + or - + or - + or - + - 
Required 
actions  * Consult a physician with expertise in managing 
HBV.  
After the consultation, antiviral therapy should be 
started [ADDRESS_928974] [COMPANY_001] if a patient cannot 
take entecavir or if entecavir is not available at 
your institution.  
Monitor HBV -DNA every 4 weeks (or more 
frequently if clinically indicated).  
Antiviral therapy should continue for at least [ADDRESS_928975] dose of EGF816.  No antiviral therapy.  
Monitor HBV -DNA every 4 
weeks . No antiviral 
therapy.  
HBV-DNA 
screening 
not 
required 
unless 
HBsAg 
and/or 
HBcAb are 
positive  
[COMPANY_001]  Confidential  Page 90 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Table 6-7 Guidelines for management of HBV reactivation  
HBV reactivation (with or without clinical signs and symptoms)*  
Screening 
test results  Monitoring test results 
that define HBV 
reactivation  Actions to be taken  
Positive 
HBV-DNA  
OR 
Positive 
HBsAg  Increase of 1 log in HBV -
DNA relative to screening 
HBV-DNA value  
OR 
new appearance of 
measurable HBV -DNA  Interrupt EGF816 treatment. Assess patient compliance with 
antiviral therapy. Consult a physician with expertise in managing 
HBV and consider changing antiviral therapy.  
While patient is on antiviral therapy, continue interruption of 
EGF816 administration until resolution to:  
• ≤ screening HBV -DNA levels and 
• ≤ grade 1 ALT (or baseline ALT, if > grade 1) if ALT elevation 
was observed  
If resolution occurs within ≤ 21 days EGF816 should be re -
started at the same dose level unless dose 
reduction/interruption is indicated due to any other reason. 
Antiviral therapy should continue for at least [ADDRESS_928976] dose of EGF816  and is to be further maintained under the 
surveillance of a physician with expertise in the management 
of hepatitis B in compliance with international ( Terrault NA et 
al 2018 ) and local guidelines . 
If resolution occurs > [ADDRESS_928977] [COMPANY_001] for approval of 
restarting of EGF816.  
• If restarting of EGF816 is approved: follow the same guidelines 
as above.  
• If restarting of EGF816 is NOT approved: discontinue EGF816 
treatment. Continue antiviral therapy for at least [ADDRESS_928978] dose of EGF816 , antiviral treatment is to be further 
maintained under the surveillance of a physician with expertise 
in the management of hepatitis B in compliance with 
international ( Terrault NA et al 2018 ) and local guidelines . 
Monitor HBV -DNA every 4 weeks (or more frequently if 
clinically indicated).  
[COMPANY_001]  Confidential  Page 91 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 HBV reactivation (with or without clinical signs and symptoms)*  
Screening 
test results  Monitoring test results 
that define HBV 
reactivation  Actions to be taken  
Negative 
HBV-DNA  
AND  
Negative 
HBsAg  New appearance of 
measurable HBV -DNA  Interrupt EGF816 treatment. Consult a physician with expertise in 
managing HBV. After the consultation, start antiviral therapy.  
While patient is on antiviral therapy, continue interruption of 
EGF816 administration until resolution to:  
• ≤ baseline HBV -DNA levels and 
• ≤ grade 1 ALT (or baseline ALT, if > grade 1) if ALT elevation 
was observed . 
If resolution occurs within ≤ 21 days EGF816 should be re -
started at the same dose level unless dose 
reduction/interruption is indicated due to any other reason. 
Antiviral therapy should continue for at least [ADDRESS_928979] dose of EGF816  and is to be further maintained under the 
surveillance of a physician with expertise in the management 
of hepatitis B in compliance with international ( Terrault NA et 
al 2018 ) and local guidelines . 
If resolution occurs > [ADDRESS_928980] [COMPANY_001] for approval of 
restarting of EGF816.  
• If restarting of EGF816 is approved: follow the same guidelines 
as above.  
• If restarting of EGF816 is NOT approved: discontinue EGF816 
treatment. Continue antiviral therapy for at least [ADDRESS_928981] dose of EGF816.  
Monitor HBV -DNA every 4 weeks (or more frequently if 
clinically indicated).  
* All reactivations of HBV are to be recorded as serious adverse event (SAE). Date of viral reactivation is the 
date on which the defined lab results for reactivation were met (e.g. for a patient who was HBV -DNA positive on 
01-Jan-2015 and whose ALT reached > 5 × ULN on 01 -Apr-2015, the date of viral reactivation is 01 -Jan-2015). 
HCV screening tests, on study monitoring, and management of HCV 
reactivation  
1. Screen all new patients for HC V-Ab. If HC V-Ab is detected then check HCV -RNA.    
2. Only patients with negative HC V-Ab or with positive HC V-Ab but undetectable level of 
HCV -RNA are eligible to be dosed with EGF816  (assuming all other eligibility criteria are 
met).  Patients with detectable HCV -RNA are not eligible to be enrolled in the study.  
3. The following two categories of patients should be monitored every 4 weeks (or more 
frequently if clinically indicated) with HCV RNA -PCR for HCV reactivation:   
a. Patients with detectable HCV -RNA at screening and were treated until HCV -RNA 
becomes undetectable ( only applicable to patients  enrolled prior to amendment 5 ) 
b. Patients with known history of HCV infection and undetectable HCV -RNA at 
screening  
4. Refer to Table 6 -8 for definition of HCV reactivation and the management guidelines.  
[COMPANY_001]  Confidential  Page 92 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Table 6-8 Guidelines for management of HCV reactivation  
HCV reactivation (with or without clinical signs and symptoms)[ADDRESS_928982] 
hepatitis C infection with 
no detectable HCV -RNA  
OR  
Detectable HCV -RNA at 
screening and was 
treated until HCV -RNA 
becomes undetectable 2 New appearance of 
detectable HCV -RNA  Interrupt EGF816 treatment. Consult a physician with 
expertise in managing HCV. After the consultation, start 
antiviral therapy.  
While patient is on antiviral therapy, continue interruption 
of EGF816 administration until resolution to:  
• no detectable HCV -RNA and 
• ≤ grade 1 ALT (or baseline ALT, if > grade 1) if ALT 
elevation was observed.  
If resolution occurs within ≤ 21 days EGF816 should 
be re -started at the same dose level unless dose 
reduction/interruption is indicated due to any other 
reason.  
If resolution occurs > [ADDRESS_928983] [COMPANY_001] for 
approval of restarting of EGF816.  
• If restarting of EGF816 is approved: follow the same 
guidelines as above.  
• If restarting of EGF816 is NOT approved: 
permanently discontinue the patient from EGF816 
treatment  
Monitor HCV -RNA every 4 weeks (or more 
frequently if clinically indicated)  
1. All reactivations of HCV are to be recorded as serious adverse event (SAE). Date of viral reactivation is the 
date on which the defined lab results for reactivation were met (e.g., for a patient whose HCV -RNA was 
detectable on 01 -Jan-2015 and ALT reached > [ADDRESS_928984] on 22 -Jan-2015, the date of viral reactivation is 01 -
Jan-2015). 
2. Applicable to ongoing patients only  
On study monitoring of liver function test (LFT) for all patients  
LFTs should be monitored for all patients as per protocol, or more frequently if clinically 
indicated.  
At any time during the study, if ALT > [ADDRESS_928985] in patients with baseline ALT ≤ [ADDRESS_928986], or 
if ALT > [ADDRESS_928987] in patients with baseline ALT > [ADDRESS_928988] but ≤ [ADDRESS_928989]: immediately  
1. Perform test(s) for viral hepatitis infection or reactivation: all patients should be screened 
with viral hepatitis panel (HA V-Ab-IgM, HBsAg, HBcAb -IgM, and HC V-Ab).  In addition  
a. Patients who have HBV -DNA monitoring during the study should be re -tested for 
HBV -DNA immediately; refer to Table [ADDRESS_928990] HCV -RNA monitoring during the study should be re -tested for 
HCV -RNA immediately; refer to Table 6 -8 for definition and management of HCV 
reactivation.  
2. If any of the above tests indicate : 
a. HBV reactivation: refer to Table 6 -7 for management guidelines.  
[COMPANY_001]  Confidential  Page 93 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 b. HCV reactivation: refer to Table 6 -8 for management guidelines.  
c. New viral infection : immediately  interrupt dosing, consult a physician with expertise 
in managing viral hepatitis and contact [CONTACT_685410].  
3. Perform other relevant tests/procedures as clinically indicated.  
4. Follow the dosing modification for ALT elevation according to guidelines in Table [ADDRESS_928991] be closely monitored for any signs/symptoms 
related to rash/skin toxicities. Recommended guidelines for management  and dose modification 
of rash/ skin toxicities are provided in Table 6 -9 , Table 6 -10 , and Table 6 -11. 
Table 6-9 Guidelines for prevention and symptomatic care of rash/skin toxicities  
Type of care  Action  
Prevention/Prophylaxis  
Starting from Day 1 for all 
patients  • Avoid unnecessary exposure to sunlight/ ultraviolet  
• Apply broad -spectrum sunscreen with SPF≥[ADDRESS_928992] twice daily  
• Use thick, alcohol -free emollient cream (e.g. glycerine and cetomacrogol 
cream) on dry areas of the body at least twice daily  
Symptomatic care* • Pruritic lesions: cool compresses , topi[INVESTIGATOR_27560] s and oral antihistamine 
therapi[INVESTIGATOR_014]  
• Desquamation: thick, alcohol -free emollient cream and mild soap  
• Paronychia: antiseptic bath and topi[INVESTIGATOR_8163]; if no improvement, 
consult dermatologist  
• Infected lesions: appropriate topi[INVESTIGATOR_11981]  
• Avoid exposure to sunlight/ultraviolet  
*Patients who develop rash/skin toxicities should be evaluated by a qualified physician and receive symptomatic 
and supportive care management.  
Table 6-10 Management and dose modification for maculopapular rash1, 2 
CTCAE Grade  Adverse Event Management  Action and Dose Modification  
Grade 1  
Macules/papules 
covering <10% 
BSA • Initiate appropriate symptomatic care (Refer 
to Table 6 -9) 
• Initiate oral antihistamine treatment (e.g. 
levocetirizine 5mg qd, desloratadine 5mg 
qd, or fexofenadine 180 mg qd) maintained 
for 1 week after resolution of Grade 1 rash  
• Consider steroid use:  
• Low-dose oral steroid (e.g. 
prednisolone 5mg -10mg po qd for 3 -5 
days)  
• If pruritus with inflammation signs like 
scaling, erythema and infiltration: 
Moderate potency topi[INVESTIGATOR_27560] (e.g. 
0.1% momentasone or 0.1% 
betamethasone valerate cream) on 
affected areas  
•  
• Re-assess after 1 week  until resolution  Continue study drug at same dose level  
[COMPANY_001]  Confidential  Page 94 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 CTCAE Grade  Adverse Event Management  Action and Dose Modification  
Grade 2  
Macules/papules 
covering 10 -30% 
BSA • Initiate appropriate symptomatic care (Refer 
to Table 6 -9) 
• Consult a dermatologist.  
• Initiate oral antihistamine treatment (e.g. 
levocetirizine 5mg qd, desloratadine 5mg 
qd, or fexofenadine 180 mg qd) maintained 
for 4 weeks after resolution  
• Steroid use:  
• consider initiating oral steroids  (e.g. 
20mg -40mg po qd for 1 -2 weeks) with 
taper  
• If pruritus with inflammation signs like 
scaling, erythema and infiltration: Potent or 
ultrapotent topi[INVESTIGATOR_27560] (e.g. 0.025% 
desoximetasone ointment or 0.05% 
clobetasol propi[INVESTIGATOR_229756]) on affected 
areas  
• Re-assess after 1 week  Continue study drug at same dose level  
If no recovery to Grade ≤ 1 within 2 
weeks, despi[INVESTIGATOR_685348], interrupt 
EGF816 for 1 week.  
• If recovers to Grade ≤ 1, within 1 
week of dose interruption restart at 
same dose  
• If rash does not recover to Grade ≤ 
1 within 1 week of dose interruption, 
restart EGF816 at reduced dose -1 
only after rash has recovered to ≤ 
Grade 13 
Grade ≥3  
Macules/papules 
covering >30% 
BSA • Initiate appropriate symptomatic care (Refer 
to Table 6 -9) 
• Consult dermatologist  
• Initiate oral antihistamine treatment (e.g. 
levocetirizine 5mg qd, desloratadine 5mg 
qd, or fexofenadine 180 mg qd) maintained 
for 4 weeks after resolution  
• Steroid Use:  
• Mid-dose oral steroid (e.g. 20 -40mg po 
qd for 1 -2 weeks) with taper  
• If pruritus with inflammation signs, (scaling, 
erythema and infiltration), potent or 
ultrapotent topi[INVESTIGATOR_27560] (e.g. 0.025% 
desoximetasone ointment or 0.05% 
clobetasol propi[INVESTIGATOR_229756]) on affected 
areas  
• Re-assess every week  until resolution  Continue EGF816 at same dose level  
If no recovery to Grade ≤ 1 within 1 week, 
despi[INVESTIGATOR_685349], interrupt for 1 week  
• *If recovers to Grade ≤ 1 within 1 
week of dose interruption, restart at 
same dose   
• *If rash does not recover to Grade ≤ 
1 within 1 week, restart EGF816 
reduced by 1 dose level only after 
rash has recovered to ≤ Grade 1  
1 Maculopapular rash (group term) includes the following preferred terms: rash erythematous, rash morbilliform, 
rash papular, rash maculo -papular, rash rubelliform, rash scarlatiniform, rash macular .  
2 For all grade  2 and 3  of maculopapular rash, consider skin biopsy for pathologic evaluation. Study drug may be 
resumed although steroids are still ongoing or being tapered.  
3 A maximum of 2 dose reductions is allowed. Patients, who require further dose decrease after 2 dose 
reductions, should be discontinued from study drug. Escalation by [CONTACT_685411] 4 weeks of uninterrupted study drug at the reduced dose level. Re -escalation 
can only be done once.  
* Guidelines to be followed even if EGF816 interrupted earlier  
Table 6-11 Management and dose modification for other rashes including 
acneiform rash  
CTCAE 
Grade  Adverse Event Management  Action and Dose Modification  
Grade 1  • Monitor for change in severity and consider 
symptomatic and/or topi[INVESTIGATOR_35786] (Refer 
to Table 6 -9) Continue study drug at same dose level  
[COMPANY_001]  Confidential  Page 95 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 CTCAE 
Grade  Adverse Event Management  Action and Dose Modification  
• Re-assess every 2 weeks  
Grade 2  • Initiate appropriate symptomatic care (Refer 
to Table 6 -9)  
• Depending on the type of rash, a variety of 
agents can be used including mild to 
moderate strength steroid creams, , topi[INVESTIGATOR_685350], topi[INVESTIGATOR_685351].  
• Re-assess every 2 weeks  Continue study drug at same dose level  
• If no recovery or worsened within 2 weeks, 
interrupt study drug until rash recovers to ≤ 
Grade 1  
• Once rash recovers to ≤ Grade 1, then 
restart study drug at one reduced dose level  
Grade ≥3  • Initiate appropriate symptomatic care (Refer 
to Table 6 -9) 
• Depending on the type of rash, a variety of 
agents can be used including mild to 
moderate strength steroid creams, low -dose 
oral steroids, etopi[INVESTIGATOR_11981], 
topi[INVESTIGATOR_471062].  
• Consult dermatologist  
• Re-assess every 2 weeks  Interrupt study drug until rash recovers  
to ≤ Grade 1.  
Once rash recovers to ≤ Grade 1, restart study 
drug at one reduced dose level  
• If no recovery to ≤ Grade 2 within 3  
weeks, permanently discontinue study  
drug 
• Patients who develop more than 1  
epi[INVESTIGATOR_119988] ≥3 rash will be  
permanently discontinued from study  
treatment  
*A maximum of 2 dose reductions is allowed. Patients, who require further dose decrease after 2 dose reductions, 
should be discontinued from study drug. Escalation by [CONTACT_685412] 4 weeks of uninterrupted study drug at the reduced dose. Re -escalation can only be done 
once.  
6.3.4  Guidelines for the management and dose modification of non-
infectious pneumonitis/interstitial lung disease  
Monitor patients for pulmonary symptoms indicative of pneumonitis/ILD. In addition, withhold 
study treatment for acute onset of new or progressive unexplained pulmonary symptoms, such 
as dyspnea, cough and fever and during diagnostic workup for pneumonitis /ILD to exclude 
alternative causes such as, but not limited to infections, lymphangitic carcinomatosis, 
cardiogenic edema, or pulmonary hemorrhage. Permanently discontinue study treatment if the 
diagnosis of ILD is confirmed and initiate appropriate treatm ent as necessary.  
Recommended guidelines for management of non-infectious pneumonitis/interstitial lung 
disease are provided in Table 6 -12 . These general guidelines constitute guidance to the 
Investigator and may be supplemented by  [CONTACT_685413].  
[COMPANY_001]  Confidential  Page 96 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 Table 6-12 Management of non -infectious pneumonitis / interstitial lung disease  
CTCAE Grade  Required investigations  Management of 
pneumonitis  Action and dose modification  
Grade 1 
Asymptomatic, 
radiographic 
findings only  • Exclude infectious 
etiology. CT scan (high -
resolution with lung 
windows) recommended, 
with serial imaging to 
monitor for resolution or 
progression - re-image at 
least every 3 weeks  
• Monitor for symptoms 
every 2 -3 days - Clinical 
evaluation and laboratory 
work -up for infection  
• Monitoring of oxygenation 
via pulse oximetry 
recommended  
• Consultation of 
pulmonologist 
recommended  
 No specific therapy 
is required.  Interrupt study treatment during 
diagnostic workup for 
pneumonitis/ILD. Exclude infections 
and other etiologies.  
If diagnosis of pneumonitis/ILD is 
confirmed, permanently discontinue 
study treatment . In absence of 
diagnosis of pneumonitis/ILD: 
restart study treatment at the same 
dose. If symptoms recur after 
resumption of study treatment, 
permanently discontinue study 
treatment  
Grade 2 
Symptomatic, not 
interfering with 
activity daily 
living (ADL)  Exclude infectious etiology.  
CT scan (high resolution with 
lung windows ). 
• Monitor symptoms 
daily, consider 
hospi[INVESTIGATOR_059]  
• Clinical evaluation 
and laboratory work 
up for infection  
• Consult 
pulmonologist  
Consider pulmonary function 
testinga. 
. Consider a bronchoscopy 
with biopsy and /or 
bronchoalveolar lavage 
(BAL)c. 
Symptomatic therapy 
including corticosteroids if 
clinically indicated (1 to 2 
mg/kg/day prednisone or 
equivalent as clinically 
indicated)b  Symptomatic only.  
Consider 
corticosteroidsb if 
symptoms are 
troublesome.  Interrupt study treatment during 
diagnostic workup for 
pneumonitis/ILD and until 
improvement to ≤ Grade 1. Exclude 
infections and other etiologies.  
If diagnosis of pneumonitis/ILD is 
confirmed, permanently discontinue 
study treatment . In absence of 
diagnosis of pneumonitis/ILD: if 
symptoms resolve to ≤ Grade 1 in ≤ 
7 days restart the study treatment  
at one reduced dose level  *. 
If symptoms fail to resolve within 7 
days or recur after resumption of 
study treatment at decreased dose, 
permanently discontinue study 
treatment.  
[COMPANY_001]  Confidential  Page 97 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 CTCAE Grade  Required investigations  Management of 
pneumonitis  Action and dose modification  
Grade 3 
Symptomatic, 
interfering with 
ADL; O 2 
indicated  
 
AND  
 
Grade 4 Life -
threatening; 
ventilatory 
support indicated  CT scan (high resolution with 
lung windows ) 
Clinical evaluation and 
laboratory work -up for 
infection  
Consult pulmonologist  
Pulmonary function testinga. 
If < normal, repeat every 8 
weeks until ≥ normal  
Bronchoscopy with biopsy 
and/or BALc if possible  
 
Repeat every cycle until 
return to within normal limits.  
 Treat with IV 
steroids 
(methylprednisolone 
125 mg) as 
indicated. When 
symptoms improve 
to ≤ Grade 1, a high 
dose oral steroid 
(prednisone 1 to 2 
mg/kg once per day 
or dexamethasone 
4 mg every 4 
hours)b. 
If IV steroids 
followed by [CONTACT_685414] 48 to 72 
hours, consider 
non-corticosteroid 
immunosuppressive 
medication.  
Oxygen therapy as 
indicated . Mandatory: p ermanently 
discontinue study drug.  
    
a PFT (Pulmonary function tests) to include: diffusing capacity corrected for hemoglobin (DLCO); spi[INVESTIGATOR_038]; 
resting oxygen saturation  
Guideline for significant deterioration in lung function: Decrease in spi[INVESTIGATOR_10230]/or DLCO of 30% and/or O 2 
saturation ≤ 88% at rest on room air.  
b Duration and dose of course of corticosteroids will vary according to circumstances but should be as limited 
as possible. Consider tapering dosage at end.  
c If bronchoscopy is performed, bronchoalveolar lavage (BAL) should be done where possible to exclude 
alveolar hemorrhage, opportunistic infections, cell count + determination lymphocyte CD4/[ADDRESS_928993] once a week (or more 
frequently if required by [CONTACT_15931], or if clinically indic ated) for [ADDRESS_928994] doses of  EGF816  as part of the study requirements . 
[IP_ADDRESS]  Follow -up on potential QTcF prolongation  
In case of QTcF >500 ms, (or QTcF prolongation >60 ms from baseline)  
• Assess the quality of the ECG recording and the QT value and repeat if needed  
• Interrupt st udy treatment  
• Determine the serum electrolyte levels (in particular hypokalemia, hypomagnesemia). If  
abnormal, correct abnormalities before resuming study drug treatment . 
[COMPANY_001]  Confidential  Page 98 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 • Review concomitant medication use for other causes for  QT prolongation, and for drugs 
with the potential to increase the risk of drug e xposure related QT prolongation  
• Check study drug dosing schedule  and study treatment compliance  
• Consider collecting a time -matched PK samp le, and rec ord time and date of last study 
drugs intake.  
After confirming ECG reading at site, if QTcF > 500 ms  
• Interrupt study treatment  
• Repeat ECG and confirm ECG diagnosis by a cardiologist or central ECG lab  
• If QTcF confirmed > 500 ms:  
• Correct electrolytes, eliminate culprit concomitant treatments, and identify clinical  
conditions that could potentially prolong the QT  
• Consult with a cardiologist (or qualified specialist)  
• Increase cardiac monitoring as clinically indicated, until the QTcF returns to ≤ 480 
ms. 
• After resolution to ≤480 ms, consider re -introducing study treatment at reduced dose, and 
increase ECG monitoring:  
• If QTcF remains ≤500 ms after dose reduction, continue planned ECG monitoring  
during subsequent study treatment  
• If QTcF recurs > 500 ms after dose reduction, recommendation: discontinue patient 
from  trial 
[IP_ADDRESS]  Follow up on potential drug -induced liver injury (DILI) cases  
Patients with transaminase increase combined with TBIL increase may be indicative of 
potential DILI, and should be considered as clinically important events.  
The threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:  
• For patients with normal ALT and AST and TBIL value at baseline: AST or ALT > 3.[ADDRESS_928995] combined with TBIL > 2.[ADDRESS_928996]  
• For patients with elevated AST or ALT or TBIL value at baseline: (AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_928997]) OR (AST or ALT > 8.[ADDRESS_928998]), combined with (TBIL > 2 x 
baseline AND > 2.[ADDRESS_928999])  
Medical review needs to ensure that liver test elevations are not caused by [CONTACT_15014], defined 
as ALP elevation > 2.[ADDRESS_929000] with R value < 2 in patients without bone metastasis, or elevation 
of ALP liver fraction in patients with bone metastasis.  
Note: (The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury).  
In the absence of cholestasis, these patients should be immediately discontinued from study 
drug treatment, and repeat LFT testing as soon as possible, preferably within 48 hours from the  
awareness of the abnormal results. The evaluation should include laboratory tests, detailed 
[COMPANY_001]  Confidential  Page 99 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 history, physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.  
1. Laboratory tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, GGT, prothrombin time (PT)/INR and alkaline phosphatase.  
2. A detailed history, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consumption, history of any pre -existing liver 
conditions or risk factors, should be collected.  
3. Further t esting for acute hepatitis A, B, C or E infection and liver imaging (e.g. biliary tract) 
may be warranted.  
4. Obtain PK sample, as close as possible to last dose of study drug, if PK analysis is performed 
in the study.  
5. Additional testing for other hepatotropic viral infection (CMV, EBV or HSV), autoimmune 
hepatitis or liver biopsy may be considered as clinically indicated or after consultation with 
specialist/hepatologist.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medically 
significant”, thus, met the definition of SAE ( Section 8.2.1 ) and reported as SAE using the term 
“potential drug -induced liver injury”. All events should be followed up with the outcome clearly 
documented.  
6.3.6  Anticipated risks and safety concerns of the study drug  
For the Phase I part, a ppropriate eligibility criteria and specific DLT definitions, as well as 
specific dose modification and stoppi[INVESTIGATOR_49315]. Prophylactic or 
supportive treatment for other expected toxicities, including management of other study -drug 
induced adverse events  will be as per institutional  guidelines.  Refer to preclinical toxicity 
(Section [IP_ADDRESS].2 ) and or clinical data found in the [Investigator’s Brochure].  
6.4 Concomitant medications  
6.4.1  Permitted concomitant therapy  
In general, concomitant medications and therapi[INVESTIGATOR_217905]  
(e.g., such as anti -emetics, anti -diarrhea) and safety of the patient are allowed.  Anticoagulation 
treatment is also allowed if INR has been established within the therapeutic range prior to study 
entry.  PT and PTT ≥ 1.5x ULN are permitted in these cases . 
The patient must be told to notify the investigational site about any new medications he/she 
takes after the start of the study treatment. All medications (other than study treatment) and 
significant non -drug therapi[INVESTIGATOR_014] (including physical therapy, herbal/n atural medications and 
blood transfusions) administered within [ADDRESS_929001] be listed on the Prior and Concomitant Medications or the Surgical 
and Medical procedures  eCRF.  
After discussion with [COMPANY_001], p atients who develop progressive disease limited to the bone or 
central nervous system ( CNS ) may undergo radiotherapy to the bone or CNS and surgical 
resection of CNS metastases, and remain on study.  EGF816 should be he ld for at least 5 days 
prior to radiotherapy or surgery.  EGF816 may be resumed >[ADDRESS_929002] resolved to ≤ Grade 1.  
[COMPANY_001]  Confidential  Page 100 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 The exception to this is palliative bone radiation, which is permitted throughout the study. 
However, study treatment should be interrupted on the day of radiotherapy.  
The use of bisphosphonates is allowed regardless of indication provided patients have been on 
stable doses optimally for at least [ADDRESS_929003] udy should be assessed by 
[CONTACT_685415]; if disease progression is 
documented, the patient should discontinue study treatment.  
No drug -drug interaction is expected between EGF816 and bisphosphonates as the drugs are 
eliminated through different elimination pathways. Bisphosphonates are not inhibitors of 
human CYP450 enzymes involved in the metabolism of EGF816 and do not undergo 
metabolism in vivo.  
6.4.2  Permitted concomitant therapy requiring caution and/or action  
Based on the in vitro  studies, EGF816 is primarily metabolized by [CONTACT_097]3A4. Moderate 
inhibitors and inducers of CYP3A4 should be used with caution.   
EGF816 is a P -gp substrate. Co -administration of EGF816 with P -gp inhibitors may increase 
systemic exposure and/or alter tissue uptake of EGF816. EGF816 is a moderate inhibitor of 
BCRP with IC50 value of 4 µM. The exposure of BCRP substrate may increase wh en co -
administered with EGF816. EGF816 is an inhibitor of the human multidrug and toxin extrusion 
transporter 1 and 2 -K (MATE1 and MATE2 -K) with an IC50 of 0.70 and 4.6 µM respectively. 
As a result EGF816 has potential to increase the exposure of co -medica tions whose clearance 
is significantly mediated by [CONTACT_286808]. In the absence of data confirming whether such an 
interaction occurs in patients, caution should be exercised when potent P -gp inhibitors and 
MATE or BCRP substrates are concurrently used.  
The patient and the Investigator should be aware of potential signs of overdose of the 
concomitant medication. In the event of suspected toxicity, administration of either EGF816 or 
concomitant drugs should be discontinued according to Investigator judgmen t. 
Refer to Section 14.3 Appendix 3  for permitted medications that require caution  when 
concomitantly used with EGF816 . 
6.4.3  Prohibited concomitant therapy  
Concomitant antineoplastic therapy (including radiotherapy and surgery) or other 
investigational treatment is prohibited except as described in  Section 6.4.1 . 
EGF816 is primarily metabolized by [CONTACT_097]3A4, therefore strong inhibitors and strong inducers 
of CYP3A4 should not be used concomitantly with EGF816.  
Live vaccines (e.g., intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow 
fever, varicella, and TY21a typhoid vaccines) should not be administered while a patient is 
dosed with EGF816 and for [ADDRESS_929004] be discontinued from the study . 
[COMPANY_001]  Confidential  Page 101 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 6.5 Patient numbering, treatment assignment or randomization  
This is a non -randomized  trial and Integrated Response Technology (IRT) will only be used for 
patient registration and study medication  management  in the Phase II part.  
6.5.[ADDRESS_929005] Number (Subject No.), that is assigned when 
the patient is first enrolled for molecular pre -screening or screening, as applicable and is 
retained as the primary identifier for the patient throughout his/her entire participation in the 
trial. The Subject No. consists of the Center Number (Center No.) (as assigned by [CONTACT_685416]) with a sequential patient number suffixed to it, so that each subject is 
numbered uniquely across the enti re database. Upon signing the molecular pre -screening or 
screening informed consent form, as applicable, the patient is assigned to the next sequential 
Subject No. available to the investigator through the Oracle Clinical RDC interface.  
For the Phase II part, a t the molecular pre -screening visit , the investigator or designated staff 
will contact [CONTACT_15017] ( IRT) to provide the requested information 
for patient  regist ration.  Once assigned, the Subject No. must not be reused for any other subject 
and the Subject No. for that individual must not be changed, even if the patient is re -screened.  
If the patient fails to  start treatment for any reason, the reason will be entered into the  Screening 
Disposition page.  IRT must be notified within 2 days that the patient was not enrolled.  
6.5.2  Treatment assignment  
This is a non -randomized trial . For the Phase I part, t he assignment of a patient to a particular 
group  will be  coordinated by [CONTACT_456].  
For the Phase II part, a n IRT will be used to track pat ient enrollment, document key eligibility 
criteria, and track individual assignment of EGF816 drug supplies.  The IRT will dispense the 
selected EGF816 dose to each patient participating in this trial.  
For each allocated patient, and prior to dosing, all patients who fulfill all inclusion/exclusion  
criteria will be assigned via IRT an inclusion number . The IRT will also specify medication 
number of   the first bottles of EGF816  study drug to be dispensed to the patient.  IRT must be 
notified within [ADDRESS_929006] CRF. Study treatment including instructions for administration is 
dispensed by [CONTACT_3462]. Patients will be provided with adequate supply of EGF816 . 
6.6.1  Study drug packaging and labeling  
The study medication packaging has a 2 -part label  (base plus tear -off label). Immediately before 
dispensing the package to the patient, site personnel will detach the outer part of the label from 
the package and affix it to the source document (Drug Label Form) for that patient’s unique 
patient number.  
[COMPANY_001]  Confidential  Page 102 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 In Phase I , responsible site personnel will add the patient number on the label.  
For the Phase II part, a  unique medication number will also be  printed on each part of this label. 
Responsible site personnel will identify the study treatment package(s) to dispense to the patient 
by [CONTACT_15020](s)  for the Phase II part . Site personnel 
will add the patient number on the label.  
Medication labels will be in the local language and comply with the legal requirements of each 
country. They will include storage conditions for the drug and the medication number  but no 
information about the patient.  
6.6.[ADDRESS_929007] access. Upon receipt, the study treatment s hould be stored according to the 
instructions specified on the drug labels and in the [Investigator’s Brochure].  
Table 6-13 Supply and storage of study treatment  
Study treatments  Supply  Storage  
EGF816  Centrally supplied by [CONTACT_685417]  
6.6.3  Study drug compliance and accountability  
[IP_ADDRESS]  Study drug compliance  
Compliance will be assessed by [CONTACT_1755]/or study personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability Form. This information must be captured in the source document at each patient 
visit.  
[IP_ADDRESS]  Study drug accountability  
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study treatment in a drug accountability log. Drug accountability will be noted by [CONTACT_5364]. Pati ents will be asked to return all 
unused study treatment and packaging on a regular basis, at the end of the study or at the time 
of study treatment discontinuation.  
At study close -out, and, as appropriate during the course of the study, the investigator will return 
all used and unused study treatment, packaging, drug labels, and a copy of the completed drug 
accountability log  to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the investigator 
folder at each site.  
6.6.[ADDRESS_929008] party, as appropriate  
Study treatment destruction at the investigational site will only be permitted if authorized by 
[CONTACT_15024] a prior agreement and if permitted by [CONTACT_427].  
[COMPANY_001]  Confidential  Page 103 
Amended Protocol Version 07 (Track Changes )  Protocol No. CEGF816X2101  
 
 [ADDRESS_929009] all of the assessments for the Phase I part  and Phase II part, 
respectively, and indicate with an “X”, the visits when they are performed. All data obtained 
from these assessments must be supported in the patient’s source documentation. The tables 
indicate which assessments produce data to be entered into database (D) or remain in source 
documents only (S) (“Category” column).  
No CRF will be used as a source document.  
Visit  and schedule windows  
Written informed consent must be obtained before any study specific assessments are 
performed, including those at molecular screening and screening. Screening/baseline 
evaluations (including baseline radiological assessment/s) must be performed ≤ [ADDRESS_929010] 
dosing day.   
For the Phase II part, l aboratory assessments and height/weight performed as part of the 
screening evaluations and within [ADDRESS_929011] and/or procedures should occur on schedule whenever 
possible. All safety assessments (e.g., hematology, chemistry, vitals, etc.) have a +/- 3 day s 
window  of the due date of the safety assessment . HBV/HCV results should be available prior 
to the first dose of EGF816 treatment. On days when  PK is collected the window is only +/ - 1 
day. PK sample of C1D1  (Cycle 1, Day 1)  must be collected at the same day of first dose.   
Radiological assessments must be performed +/ -[ADDRESS_929012] dose of the study 
treatment unless otherwise specified. The investigator should check the pre -dose laboratory 
results prior to starting treatment.  
Note: Phase I patients will follow the visit schedule outlined in Table 7 -1 while Phase II patients 
will follow the visit schedule outlined in Table 7 -2. 
[COMPANY_001]  Confidential  Page 104 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 7-1 Visit evaluation schedule  (Phase I Part)  
Visit Name  
[CONTACT_685462] -Up Molecular Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent cycles  
End of study 
treatment (EoT)  
30-day Safety  
F/U 
Disease 
progression F/U  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16  
Day 22  
Day 1  
Day 2  
Day 8  
Day 15  
Day 22  
Day 1  
Day 15  
  
 
Obtain Molecular 
Pre-screening 
Informed Consent 
(if applicable)  D 7.1.1   X                  
Obtain Main 
Informed Consent  D 7.1.2    X                 
Patient history                      
Demography  D [IP_ADDRESS]   X X                 
Inclusion/exclusio
n criteria  D 5  X X                 
Current medical 
conditions at entry  D [IP_ADDRESS]    X                 
Diagnosis and 
extent of cancer  D [IP_ADDRESS]    X                 
Prior 
antineoplastic 
therapi[INVESTIGATOR_014]  D [IP_ADDRESS]    X                 
Prior/concomitant 
medications  D [IP_ADDRESS]    X Continuously for concomitant medications  
[COMPANY_001]  Confidential  Page 105 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685462] -Up Molecular Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent cycles  
End of study 
treatment (EoT)  
30-day Safety  
F/U 
Disease 
progression F/U  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16  
Day 22  
Day 1  
Day 2  
Day 8  
Day 15  
Day 22  
Day 1  
Day 15  
  
 
Antineoplastic 
therapi[INVESTIGATOR_545084]  D [IP_ADDRESS]                  X X X 
Tumor 
progression status  D [IP_ADDRESS]    X                 
Physical 
examination  S [IP_ADDRESS]    X X  X X  X X  X X X X  X   
Vital signs  D [IP_ADDRESS]    X X  X X  X X  X X X X  X   
Height  D [IP_ADDRESS]    X                 
Weight  D [IP_ADDRESS]    X X      X     X  X   
Performance 
status  D [IP_ADDRESS]    X X      X     X  X   
Laboratory 
assessments  D [IP_ADDRESS]                     
Hematology  D [IP_ADDRESS].1    X X  X X  X X  X X X X  X   
Chemistry  D [IP_ADDRESS].2    X X  X X  X X  X X X X  X   
Coagulation  D [IP_ADDRESS].3    X                 
Urinalysis  D [IP_ADDRESS].4    X X             X   
HBV testing  D 6.3.3   
[IP_ADDRESS].5   X In cases of positive HBV testing, monitor HBV -DNA every 4 weeks, per Table 6 -6 and Table 6 -7 (or 
more frequently if clinically indicated).   
[COMPANY_001]  Confidential  Page 106 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685462] -Up Molecular Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent cycles  
End of study 
treatment (EoT)  
30-day Safety  
F/U 
Disease 
progression F/U  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16  
Day 22  
Day 1  
Day 2  
Day 8  
Day 15  
Day 22  
Day 1  
Day 15  
  
 
HCV testing  D 6.3.3   
[IP_ADDRESS].5    X In cases of positive HCV -Ab, monitor HCV -RNA every 4 weeks, per Table 6 -8 (or more frequently if 
clinically indicated).   
Pregnancy test  D [IP_ADDRESS].[ADDRESS_929013] X -raye D [IP_ADDRESS]    X    X   X     X     
ECG  D [IP_ADDRESS].1    X X      X     X  X   
Safety                      
Adverse events  D 8  SA
E 
only Continuously  X   
Biomarkers                      
Collection of 
archival tumor 
sample  D 7.1.1   
7.2.4   Xb Xb                 
Collection of 
newly obtained 
tumor from 
biopsy/resection  D 7.1.1  
7.2.4  Xb Xb            Xb  Xb    
[COMPANY_001]  Confidential  Page 107 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685462] -Up Molecular Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent cycles  
End of study 
treatment (EoT)  
30-day Safety  
F/U 
Disease 
progression F/U  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16  
Day 22  
Day 1  
Day 2  
Day 8  
Day 15  
Day 22  
Day 1  
Day 15  
  
 

[COMPANY_001]  Confidential  Page 108 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685462] -Up Molecular Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent cycles  
End of study 
treatment (EoT)  
30-day Safety  
F/U 
Disease 
progression F/U  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16  
Day 22  
Day 1  
Day 2  
Day 8  
Day 15  
Day 22  
Day 1  
Day 15  
  
 
End of Phase 
Disposition  D   X              X  X 
Safety follow -up S [IP_ADDRESS]                  X  
Study Drug 
administration  D 6.1.1     Continuously     
PK sampling   D [IP_ADDRESS]     X X X X X  X X    Xd     
a.Tumor assessment every 8 weeks from the start of cycle 3 until progression of disease as per Table 7 -3; EOT scan not required if previous scan was done ≤ 28 days  
b Refer to Section 7.1.1  and Section 7.2.4 . For subsequent cycles, newly obtained samples will be collected at C4D1, C6D1  (optional) and C8D1 (optional)  and EOT 
(optional) . 
d Cycle 3 and cycle 4 only  
e [For Japan only, refer to Section 7.2.5 ] [For Japan only, percutaneous oxygen saturation (SpO 2) will be measured every time physical examination is performed. In 
addition, SpO 2 and vital signs will be measured on Days 2 -7 in Cycle 1. ] 
* Collect at screening or anytime thereafter  
**Sample will not be collected if a newly obtained tumor sample has already been collected at screening for the purpose of DN A sequencing  
***Mandatory if participating in the Companion Sample Collection Protocol. Refer to Companion Sample Collection Protocol for further information  

[COMPANY_001]  Confidential  Page 109 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 7-2 Visit evaluation schedule  (Phase II part)  
Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
Pre-Screening  
Obtain 
Molecular Pre -
screening ICF  D 7.1.1  X                    
IRT 
Registration  D 6.5.1  X X                   
Confirmation of 
EGFR mutation 
status by [CONTACT_197243]  D 7.1.1  X                    
Main Screening  
Obtain Main 
ICF D 7.1.2   X                   
Patient history  
Demography  D [IP_ADDRESS]   X                   
Inclusion/exclus
ion criteria  D 5.2, 5.3   X                   
Eligibility check  S [IP_ADDRESS]   X                   
Relevant 
medical 
history/c urrent D [IP_ADDRESS]   X                   
[COMPANY_001]  Confidential  Page 110 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
medical 
conditions at 
entry  
Diagnosis and 
extent of cancer  D [IP_ADDRESS]   X                   
Smoking history  D [IP_ADDRESS]   X                   
Prior 
antineoplastic 
therapi[INVESTIGATOR_014] 
(meds, surgery, 
radiation)  D [IP_ADDRESS]   X                   
Prior/concomita
nt medications 
(including OTC 
meds), 
procedures and 
significant non -
drug therapi[INVESTIGATOR_014]  D [IP_ADDRESS]   X Continuously for concomitant medications   
Tumor 
progression 
status  D [IP_ADDRESS]   X                   
[COMPANY_001]  Confidential  Page 111 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
Physical examination  
Complete 
physical 
examination, 
including 
neurological 
exams  S [IP_ADDRESS]   X Clinically indicated      
Targeted 
physical 
examination  S [IP_ADDRESS]    X      X     X  X     
Vital signs  D [IP_ADDRESS]   X X      X     X  X     
Height  D [IP_ADDRESS]   X                   
Weight  D [IP_ADDRESS]   X X      X     X  X     
ECOG 
Performance 
status  D [IP_ADDRESS]   X X      X     X  X     
Chest X -rayc D [IP_ADDRESS]   X    X   X     X       
Laboratory 
assessments  D [IP_ADDRESS]                      
Hematology  D [IP_ADDRESS].1   X X      X     X  X    
Chemistry  D [IP_ADDRESS].2   X X      X     X  X    
Coagulation  D [IP_ADDRESS].3    X As clinically indicated      
[COMPANY_001]  Confidential  Page 112 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
Urinalysis  D [IP_ADDRESS].4    X As clinically indicated      
HBV testing  D 6.3.3   
[IP_ADDRESS].5    X In cases of positive HBV testing, monitor HBV -DNA every 4 weeks, per Table 6 -66 
and Table 6 -7 (or more frequently if clinically indicated).     
HCV testing  D 6.3.3   
[IP_ADDRESS].5    X In cases of positive HCV -Ab, monitor HCV -RNA every 4 weeks, per Table 6 -8 (or 
more frequently if clinically indicated).     
Serum 
pregnancy test  D [IP_ADDRESS].6 
6   X 
(within  
72 hr)  Xj  X     
Urine 
pregnancy test  D [IP_ADDRESS].[ADDRESS_929014]/MRI of 
chest, 
abdomen, 
pelvis  D 7.2.1   X Treatment period : 
C3D1 and every 8 weeks (±7 days)  
End of treatment (EOT):  
Scans not required if previous CAP scans were performed within ≤28 days)  
Disease Progression Follow Up : 
Every 8 weeks (±7 days)   
Whole body 
bone scan  D 7.2.[ADDRESS_929015]/MRI of brain  D 7.2.1   X C3D1 and every 8 wks (if positive at baseline) or if clinically indicated   
[COMPANY_001]  Confidential  Page 113 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -[ADDRESS_929016]/MRI of other  
metastatic sites 
(e.g., neck, 
etc.) D 7.2.1   Xf C3D1 and every 8 wks (if positive at baseline) or if clinically indicated   
Localized bone 
CT scan, MRI 
or X-ray (for 
any lesions 
identified on the 
whole body 
bone scan that 
are not visible 
on the 
chest/abdomen/
pelvis CT scan 
or MRI)  D 7.2.1   Xg C3D1 and every 8 wks (if positive at baseline) or if clinically indicated   
Photography 
(for skin 
lesions)  D 7.2.1   Xh C3D1 and every 8 wks (if positive at baseline) or if clinically indicated   
Safety assessments  
Adverse events  D 8  SA
E 
only Continuously    X 
[COMPANY_001]  Confidential  Page 114 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
Study drug administration  
EGF816 dosing  D 6.1    Continuously      
Biomarkers assessments  
Collection of 
archival tumor 
sample  D 7.2.4   X X                  

[COMPANY_001]  Confidential  Page 115 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
Pharmacokinetics and ECG assessments  
Extensive ECG 
collection  D [IP_ADDRESS].1   X X X  X   X X    Xb  X     
PK sampling   D [IP_ADDRESS]    X X X X   X X    Xb       
Post -treatment follow -up 
Antineoplastic 
therapi[INVESTIGATOR_014] 
(medications, 
surgeries, 
radiotherapi[INVESTIGATOR_014]) 
since 
discontinuation 
of study drug  D [IP_ADDRESS]                 X (continuous until the last follow -up visit)  
End of Phase 
Disposition  D   X              X   X  
Safety follow -up S [IP_ADDRESS]                  X    
Survival  D [IP_ADDRESS]                     X 

[COMPANY_001]  Confidential  Page 116 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Visit Name  
[CONTACT_685463] -treatment 
Follow -up Phase  Survival 
Follow -
up 
Phase  Molecular  
Pre-screening  
Screening  
Cycle 1  Cycle 2  
Subsequent 
cycles  
End of study treatment 
(EOT) Visit (within 7d of 
last dose)  
30-day Safety  
F/U 
Disease progression 
F/U (every 8 wks)  
Study Phase 
Completion  
Survival (every 3 
months)  Day -28 
to 1 
Day 1  
Day 2  
Day 8  
Day 15  
Day 16K 
Day 22 K 
Day 1  
Day 2  
Day 8 K 
Day 15 K 
Day 22 K 
Day 1  
Day 15 K 
a Tumor assessment every 8 weeks from the start of cycle 3 until progression of disease  
b Cycle 3 and cycle 4 only  
c [For Japan only, refer to Section 7.2.5 ][For Japan only, percutaneous oxygen saturation (SpO2) will be measured every time physical examination is performed. In 
addition, SpO2 and vital signs will be measured on Days 2 -7 in Cycle 1 ] 
d Patients who permanently discontinue the study treatment without having disease progression will continue tumor assessments e very 8 weeks until disease 
progression.  
e Refer to Section [IP_ADDRESS].[ADDRESS_929017] cycle thereafter  
J Serum pregnancy should be done at screening and/or at C1D1 before the start of EGF816  
K Visits not applicable for Phase II  
Abbreviations: ICF, informed consent form; C, cycle; CAP, chest/abdomen/pelvis; CT, computed tomography; D, entered into database; d, day; ECG, 
electrocardiogram; EOT, end of treatment; EOS, end of study; F/U, follow -up; MRI, magnetic resonance imaging; NSCLC, non -small cell lung cancer; PD, progressive 
disease; PK, pharmacokinetics; S, remains in source document only; Tx, t reatment; wks, weeks;  
*Collect at baseline or anytime thereafter  
**Sample will not be collected if a fresh tumor sample has already been collected at baseline fo r the purpose of DNA sequencing  
[COMPANY_001]  Confidential  Page 117 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 7.1.[ADDRESS_929018] sign the molecular pre -screening informed  
consent form (ICF).  
In order to be considered eligible for the study, the  following sample and testing requirements 
apply : 
For Enrollment in the  Phase I part:  
Evidence of previously documented EGFR mutation status is acceptable. Alternatively, patients 
can participate in molecular pre -screening to assess whether or not their tumor harbors specific 
documented EGFR mutations by [CONTACT_65087]. Refer to  Section 5.2  for 
specifics regarding the eligible EGFR mutations and required timing (if any) relative to prior 
treatment of the tumor sample tested.  
For enrollment in the Phase II part : 
NSCLC  patients with EGFR activating mutation (e.g., L858R and/or ex19del), as determined  
by a local test.  
Existing local data and the results of local testing must be captured on the appropriate eCRF 
upon enrollment onto the study after the patient has signed the study’s Informed Consent.  
Patients in Phase II will be able to proceed with main informed consent form  signature [CONTACT_685464] s (e.g. L858R and/or  ex19del ) 
analysis results are documented .  
During the molecular pre -screening period, the Investigator or designee should start gathering 
all available supportive screening evaluations (e.g., demography, relevant medical 
history/current medical conditions, prior antineoplastic therapi[INVESTIGATOR_685352].) in or der to prepare for  a 
potential patient enrollment.  
Upon local confirmation of the presence of EGFR  activat ing mutations , patients may advance 
to the screening period to complete the required  study eligibility assessments.  
7.1.[ADDRESS_929019] sign and date the  
study IRB/IEC approved main ICF prior to performing any screening procedures  based on the 
study inclusion and exclusion criteria.   
 
 
 
 
. 
Screening assessments must be completed  within [ADDRESS_929020] 1.1 ( Section 14.1 

[COMPANY_001]  Confidential  Page 118 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Appendix 1 ) should be conducted preferably within 1 week (7 days) prior to the first dose of 
the study treatment; however tumor assessments up to 4 weeks (28 days) prior to the first dose 
will be acceptable. The tumor assessment made during the screening phase will provide the 
baseline tumor measurements, which will be used to determine future responses and/or 
progression. A complete list of screening evaluations is provided in the visit schedule evaluation 
table s (Table 7 -1 and Table 7 -2).  
Screening for hepatitis B  
Prior to study entry , all patients must be screened with HBV serologic markers: HBsAg, 
HBsAb, and HBcAb.  Check HBV -DNA if HBsAg and/or HBcAb are positive. Refer to Table 
6-6 for actions to be taken based on screening HBV results.  
Screening for hepatitis C  
Screen all patients for HCV -Ab. If HCV -Ab is detected then check HCV -RNA. Only patients 
who are HCV -Ab negative or HCV - Ab positive with undetectable level of RNA are eligible to 
be enrolled.  Note: patients with detectable HCV -RNA will not be eligible for  the study. Patients 
with HCV -Ab positive or history of hepatitis C infection  should be monitored every 8 weeks  
(or more frequently if clinically indicated) with HCV -RNA . 
All screening evaluations will be performed within 28 days prior to Treatment Day 1.  
HBV/HCV tests will be performed by a local laboratory for the Phase I part and the Phase II 
part. HBV/HCV test results should be available prior to the first dose of EGF816 treatment.  
[IP_ADDRESS]  Eligibility screening  
The main screening period commences as soon as the patient signs the main ICF and ends when 
the patient fails screening or starts treatment. Evaluations will be performed within 4 weeks (i.e. 
within 28 calendar days) prior to the first dose of study drug, unless otherwise noted. All 
screening assessments, including laboratory assessments, must be performed as described in the 
protocol ( Table 7 -1 and Table 7 -2). Any imaging assessments already completed as patient’s 
standard of care within [ADDRESS_929021](s) repeated. These test(s) may be repeated as soon as the  investigator 
believes the re -test result(s) is/are likely to be within the acceptable range to  satisfy the entrance 

[COMPANY_001]  Confidential  Page 119 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 criteria. If re -tests are performed during the [ADDRESS_929022](s) cannot be performed  during the original 
screening period of [ADDRESS_929023](s) do not meet the entrance  criteria, or other eligibility 
criteria have changed and are not met anymore, the patient is  considered a screen failure, and 
must be discontinued from the study. Patients who met all  eligibility criteria but fail to be started 
on treatment as scheduled may also be re -screened,  provided the patient was not registered 
previously in the CRF as having entered the Treatment  Period.  
A new ICF will need to be signed if the investigator chooses to re -screen the patient after a  
patient has screen failed.  
All required screening activities must be performed when the patient is re -screened for  
participation in the study. An individual patient may only be re -screened once for the study.  
Once the number of patients screened and enrolled is likely to ensure target enrollment, the  
Sponsor may close the study to further screening. In this case, the patients who screen failed  
will not be permitted to re -screen.  
If a subject fails screening but is rescreened, the subject must be rescreened using the same  
subject number.  
All eligibility criteria must be re -checked, based on the most recent data available, and met  prior 
to enrollment of the patient into the study.  
If the rescreening is successful, the following information should be collected in the CRF:  
• Date the study informed consent was first signed.  
• All assessments done during the first screening period.  
• All assessments repeated during the re -screening period (e.g. ECG, lab).  
• Updated information as per latest status during the re -screening period e.g. Medical  history, 
diagnosis and extent of cancer.  
• Adverse events based on the date of re -consent.  
[IP_ADDRESS]  Information to be collected on screening failures  
Patients who signed an ICF but failed to be started on treatment for any reason will be 
considered a screen failure. Both patients who signed a molecular pre -screening ICF but are 
considered ineligible after molecular pre -screening, as well as patients who are found not 
eligible af ter signing the main study consent will be considered as screening failures, and data 
will be handled in the same manner. The reason for not satisfying eligibility criteria and not 
being enrolled will be entered on the Sc reening P hase Disposition eCRF p age. The following 
eCRF pages must be completed for screening failure patients:  
• Screening Phase Disposition  
• Demography  
• Informed consent  
• Inclusion/Exclusion Criteria  
• Withdrawal of consent (if applicable)  
• Death (if applicable)  
[COMPANY_001]  Confidential  Page 120 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 No other data will be entered into the clinical database for patients who are screen failures, 
unless the patient experienced a Serious Adverse Event during the Screening Phase (see Section 
8 for SAE reporting details). For molecular pre -screening failures, only SAEs possibly related 
to a study procedure will be reported.  
If the patient fails to be enrolled, the IRT (for patients in Phase II only) must be notified within 
2 days of the screen fail that the patient was not enrolled.  
[IP_ADDRESS]  Patient demographics and other baseline characteristics  
Data to be collected include:  
• EGFR mutation  status  
• Demography (including: date of birth, age, patient initials  if permitted , gender, 
childbearing potential, race and ethnicity, or as allowed by [CONTACT_427])  
• Relevant medical history  
• Phase  assignment  
• Smoking history  
• NSCLC diagnosis and extent of disease, including:  
• Date of diagnosis and stage of NSCLC  
• Site of  metastatic  disease  
• Characteristics of disease  
• Prior antineoplastic therapi[INVESTIGATOR_014] (medications, radiation, surgeries)  
• Prior and current concomitant medications, surgical and medical procedures  
• HBV and HCV status  
Note: all other medications taken within [ADDRESS_929024] be recorded on the Prior and current concomitant medication eCRF page and 
updated on an ongoing basis if there is new change to the medication.  
7.1.3  Treatment period  
Following completion of screening procedures and confirmation of patient eligibility, the 
patient will be enrolled via the IRT (for patients in Phase II only) .   
The study treatment will begin on Cycle 1, Day [ADDRESS_929025] eCRF.  
A treatment cycle is defined as 28 days (4 calendar weeks) for the purposes of scheduling 
procedures and evaluations. Please refer to Table 7 -1 and Table 7 -2 for details of the timing of 
required assessments  and Section 7.1  for visit windows.  
7.1.4  Discontinuation of Study Treatment  
Patients may voluntarily discontinue the study treatment for any reason at any time. If a patient 
decides to discontinue the study treatment, the investigator should  make every effort (e.g. 
telephone, e -mail, letter) to determine the primary reason for this decision and record this 
information in the patient’s chart and on the appropriate CRF pages. Patients  may be considered 
[COMPANY_001]  Confidential  Page 121 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 withdrawn if they state an intention to withdraw  consent , fail to return for visits, or become lost 
to follow -up for any other reason.  
The investigator must  discontinue study treatment for a given patient if, he/she believes that 
continuation would be detrimental to the patient’s well -being such as the emergence of the 
severe adverse events, significant laboratory abnormalities or pregnancy . Treatment may also be 
discontinued due to protocol deviations that result in a significant risk to the patient’s safety, 
deviations from the prescribed dose regimen such as missed doses or prolonged drug interruptions, 
or use of prohibited medications which are summarized in Appendix [ADDRESS_929026]-treatment follow -up phase.  Patients who discontinue study treatment should not  be 
considered withdrawn from the study. They should return for the assessments indicated in 
Section 7.2.1 . In addition, before a new anti -neoplastic therapy is initiated for a patient, it is 
strongly recommended to perform a tumor assessment. If they fail to return for these 
assessments for unknown reasons, every effort (e.g. telephone, email, letter) should b e made to 
contact [CONTACT_15026] 7.1.[ADDRESS_929027] the IRT (for patients in Phase II only) to register the patient’s 
discontinuation from study treatment.  
In some circumstances patients may be allowed to continue to receive study treatment beyond 
disease progression as per RECIST criteria ( Section [IP_ADDRESS] ). These patients will continue 
assessments as outlined in Section 7, and will complete the EOT visit only after permanent 
discontinuation of study treatment.  
7.1.5  Follow -up period  
[IP_ADDRESS]  Follow -up for safety evaluations  
30-day follow -up 
All patients must have safety evaluations for [ADDRESS_929028] dose of study treatment.  
At the end of this period, the investigator should assess and discuss with the patient any AE 
observed/concomitant medication taken since discontinuation of study treatment. This can be 
done via a phone contact.  
Data collected should be added to the Adverse Events eCRF and the Concomitant Medications 
eCRF. Antineoplastic therapi[INVESTIGATOR_565267] 'Antineoplastic therapi[INVESTIGATOR_685353]' eCRF page.  
Patients whose treatment is permanently discontinued due to an AE (clinical or based on 
abnormal laboratory value) must be followed until resolution or stabilization of the event, 
whichever comes first. In case of an abnormal laboratory value, blood tests should be repeated 
until resolution or stabilization.  
Post-treatment follow -up 
Patients who discontinue the study treatment (i.e. EGF816) without a radiological confirmation 
of disease progression  (i.e. patients who discontinue  due to clinical disease progression, or 
unaccep table toxicity, or physician  or patient ’s decision  or patient ’s withdraw al of consent ) will 
continue to have follow -up tumor assessment s according to the current tumor assessment 
schedule or as clinically indicated until  radiological confirmation  of disease progression by 
[CONTACT_76644] 122 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Investigator assessment (both Phase I and II parts), or withdrawal of consent for further tumor 
assessments, or loss to follow -up or death. The results of follow -up tumor assessments should 
be documented in patient’s source documents. Scans performed during the tumor follow -up 
period must be sent promptly to BIRC for an independent tumor assessment.  Antineoplastic 
therapi[INVESTIGATOR_685354].  
Survival follow -up 
As of amendment 4, a ll patients  enrolled in the Phase II part  will be followed for survival every 
[ADDRESS_929029] to follow -up or withdrawal of consent for survival  follow -up. Patient’s 
survival status may be collected via a phone call. Antineoplastic therapi[INVESTIGATOR_685355] 'Antineoplastic therapi[INVESTIGATOR_236005]' eCRF page following the  
last dose of the study treatment.  
[IP_ADDRESS]  Replacement policy  
Phase I part  
Patients will not be replaced on study. However, if a patient is considered as non -evaluable for 
the DDS, enrollment of a new patient to the current cohort will be considered if there is less 
than the required number of evaluable patients. Enrollment of ne w patients may be considered 
until at least the minimum number (1 or 3) or at most the maximum number (3 or 6) of evaluable 
patients is achieved within the cohort. Minimum and maximum numbers of evaluable patients 
per cohort are defined in Section 6.2.[ADDRESS_929030] already been collected may be retained and 
analyzed at a later date (or as required by [CONTACT_198245]). 
If a patient withdraws consent, the investigator should  make every effort (e.g. , telephone, e -mail, 
letter) to determine the primary reason for this decision and record this information.  
Study treatment  must be discontinued and no further assessments should be conducted.  
Further attempts to contact [CONTACT_685418].  
7.1.[ADDRESS_929031] to follow -up 
For patients whose status is unclear because they fail to appear for study visits without stating 
an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_685419] 123 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 the patient, family or family physician as agreed in the informed consent and by [CONTACT_15028], e.g ., dates of telephone calls, 
registered letters, etc. A patient should not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.  
7.2 Assessment types  
7.2.1  Efficacy assessments  
Tumor response will be assessed locally and centrally according to the [COMPANY_001] guideline 
version 3. 2 (Appendix 1 ) based on RECIST 1.1 ( Eisenhauer et al 2009 ). Details of the central 
review process will be described in the independent review charter.  
Imaging data will be centrally collected and checked for quality by [CONTACT_447311] (CRO) designated by [CONTACT_5343].    
Information regarding prior interventions (e.g. radiotherapy), pre -existing radiographic findings 
that mimic metastatic disease at baseline/screening and prior interventions should be 
transmitted to the imaging CRO via the Baseline Clinical Form along with  the baseline imag ing 
data for review by [CONTACT_286780]. Sites must ensure the data entered on the form 
is consistent with the data entered in the clinical database.  
Information regarding cytology results should be transmitted to the imaging CRO via the 
Cytology Form for all visits, when applicable, for review by [CONTACT_286780]. Sites 
must ensure the data entered on the form is consistent with the data ent ered in the clinical 
database.  
The imaging assessment collection plans are presented in Table 7 -3 and Table 7 -4 for the Phase 
I part a nd Phase II part, respectively.  
Table 7-3 Imaging collection plan  (Phase I part)  
Procedure  Screening/Baseline  During Treatment/Follow -up 
CT or MRI  
with contrast 
enhancement  
(Chest and Abdomen)  Mandated  Mandated, every 8 weeks  
(±7 days)  
Whole body bone scan  If clinically indicated  Not applicable  
Brain CT or MRI  Mandated  If brain lesions at screening  
every 8 weeks (±7 days)  
Bone X -ray, CT or MRI  
(bone lesions only)  If lesions on bone scan that are not 
visible on the chest and abdomen 
CT/MRI  If bone lesions at screening  
every 8 weeks (±7 days)  
Skin color photography 
(skin lesions only)  Mandated if skin lesions at screening  If skin lesions at screening  
every 8 weeks (±7 days)  
CT or MRI of other tumor 
sites (e.g., pelvis)  If clinically indicated  If lesions identified at 
screening every 8 weeks (±7 
days)  
For the Phase I part, the imaging data will be retrospectively collected and stored for possible 
independent review by [CONTACT_685420] ; tumor response will be 
[COMPANY_001]  Confidential  Page 124 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 determined locally according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 
(Section 14.1 Appendix 1 ). The local investigator’s assessment will be used for efficacy  
analysis and for treatment decision making .  
Table 7-4 Imaging collection plan  (Phase II part)  
Procedure  Screening/Baseline  During Treatment/Follow -up 
Computed tomography (CT) or 
magnetic resonance imaging 
(MRI) of CAP (Chest, Abdomen, 
Pelvis) with contrast 
enhancement  Mandated  Every 8 weeks (±7 days) until PD 
determined by [CONTACT_685421] , End of treatment (EOT) 
scan not required if previous CAP 
scan was performed within ≤28 days)  
CT or MRI of other metastatic 
sites (e.g., neck, etc.), if 
applicable  Only if other metastatic sites are 
suspected  Mandated if patient has other 
metastatic sites at baseline (following 
the same schedule as CT/MRI of 
chest/abdomen/pelvis) or otherwise, 
only if clinically indicated  
Whole Body Bone Scan [e.g. Tc -
99 bone scan, whole body bone 
MRI, Fluorodeoxyglucose 
positron emission tomography 
(FDG -PET) or sodium fluoride 
positron emission tomography 
(NaF PET)]  Mandated  If clinically indicated” (Refer to Section 
[IP_ADDRESS] ).  
Brain CT or MRI  Mandated  If brain lesions at screening  
every 8 weeks (±7 days)  
Bone X -ray, CT or MRI (bone 
lesions only)  If lesions on bone scan that are 
not visible on the chest and 
abdomen CT/MRI  Every 8 weeks (±7 days)  
Skin color photography (skin 
lesions only)  Mandated if skin lesion(s) is/are 
selected as target lesion(s) at 
baseline  Every 8 weeks (±7 days)  
For the Phase II part, imaging data will be centrally collected, checked for quality, and read by 
[CONTACT_685422] ( Section 14.1 - Appendix 1 ) based on RECIST 1. 1. 
[IP_ADDRESS]  Baseline imaging assessment  
Baseline i maging assessments will be performed within [ADDRESS_929032] dose of study 
treatment (prior to Cycle 1 Day 1).  
Any imaging assessments already completed during the regular work -up of the patient within 
[ADDRESS_929033] 
dose cannot be considered baseline images.   
Imaging requirements at baseline  
• Patients must have measurable disease as RECIST 1.1 ( Section 14.1 - Appendix 1 ). 
Measurable (“target”) lesions include lytic or mixed (lytic + blastic) bone lesions with an 
identifiable soft tissue component that meets the measurability criteria per RECIST 1.1 
(Appendix 1).  
• Patients with only non -measurable lesions are not eligible.  
[COMPANY_001]  Confidential  Page 125 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be 
confirmed by [CONTACT_3973]/histology.  
• Any potentially measurable lesion that has been previously treated with radiotherapy should 
be considered as a non -measurable (“non -target”) lesion. However, if a lesion previously 
treated with radiotherapy has clearly progressed since the radiotherapy, it  can be considered 
as a measurable lesion.  
All measurable lesions up to a maximum of 5 nodal and/or non -nodal lesions in total (and a 
maximum of 2 lesions per organ), representative of all involved organs, should be identified as 
target lesions and recorded and measured at baseline.  
Tumor assessments required at baseline  
The following assessments will be performed : 
• Computed Tomography (CT) with IV contrast or Magnetic Resonance Imaging (MRI) of 
chest, abdomen and pelvis.  
• The preferred radiologic technique is CT with intravenous (IV) contrast. If a patient is 
known to have a contraindication to CT contrast media or develops a contraindication 
during the trial, a non -contrast CT of the chest (MRI is not recommended due to 
respi[INVESTIGATOR_217919]) plus a contrast -enhanced MRI (if possible) of the abdomen and 
pelvis should be performed.  
• Brain CT or MRI with IV contrast , if clinically indicated   
• If brain lesions are documented at screening , scans need to be continued following the 
same schedule as CT/MRI of chest, abdomen and pelvis. The same methodology as at 
screening should be used. Contrast enhanced brain MRI is preferred, however, if MRI 
contrast is contraindicated, then MRI without contrast or CT with/without contrast is 
acceptable.  
• A whole body bone scan according to institutional guidelines [e.g. Tc -99 bone scan, whole 
body bone MRI, Fluorodeoxyglucose positron emission tomography (FDG -PET) or sodium 
fluoride positron emission tomography (NaF PET)]  required at screening and if clinically 
indicated on study.  
• Whole body bone scans is needed for Phase I if clinically indicated at screening and not 
required on study.  
• Whole body bone scans is required for the Phase II if clinically indicated on study. If 
indicated, the same methodology as at s creening should be used.  
• Localized bone CT, MRI or X -rays for any  lesions identified on the  whole body bone scan, 
that are not visible on the chest, pelvis and abdomen CT  or MRI.  
• If skeletal lesions are documented at baseline, scans need to be continued following the 
same schedule as CT/MRI of chest  and abdomen. The same methodology as at screening 
should be used.  
• CT or MRI of other metastatic sites not captured by [CONTACT_487712] (e.g., 
neck)  if clinically indicated . 
• If additional sites of disease are documented at screening , scans need to be continued 
following the same schedule as CT/MRI of chest, abdomen and pelvis. The same 
methodology as at screening should be used.  
• Color photography for any skin lesions present, if clinically indicated.  
[COMPANY_001]  Confidential  Page 126 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • Color photograph y should be continued following the same schedule as CT/MR I of 
chest, abdomen and pelvis acquired  using a digital camera in clear focus, including a 
scale/ruler, in such a way that the size of the lesion(s) can be determined from the 
photograph.  
Note: c hest X-ray and ultrasound must not be used to measure tumor lesions.  
[IP_ADDRESS]  Post -baseline imaging assessments  
Imaging assessments as described in Table 7 -3 (Phase I)  and Table 7 -4 (Phase II)  should be 
performed at the timepoints specified using the same imaging modality used at baseline, 
irrespective of study treatment interruption or actual dosing (see Table 7 -1 and Table 7 -2). 
Imaging assessments for response evaluation will be performed every 8 weeks ( ±7 days ) until 
disease progression, death, lost to follow -up or withdrawal of consent . Imaging assessments 
should be scheduled using the first dose date as the reference date (not the date of the previous 
tumor assessment), and should be respected regardless of whether treatment with study 
treatment is temporarily withheld or unscheduled assessments  performed .  
Additional imaging assessments may be performed at any time during the study at the 
investigator’s discretion to support the efficacy evaluations for a patient, if necessary. Clinical 
suspi[INVESTIGATOR_436650] a physical examination and imaging 
assessments to be performed promptly rather than waiting for the next scheduled imaging 
assessment.  
Each lesion that is measured at baseline must be measured by [CONTACT_286802] (either same 
imaging method or by [CONTACT_249985], including a metric ruler) and when possible, the same local 
radiologist/physician throughout the study so that the comparison is con sistent. If an off -
schedule imaging assessment is performed because progression is suspected, subsequent 
imaging assessments should be performed in accordance with the original imaging schedule.  
Combined PET/CT may be used only if the CT is of similar diagnostic quality as a CT 
performed without PET, including the utilization of IV contrast media. At the discretion of the 
Investigators, FDG -PET scans may be performed to document PD per RECIST 1.1 (Appendix 
14.1). 
All Phase I retrospective and Phase II prospective study imaging (including any off -schedule 
imaging studies) performed to evaluate progression or response should be submitted to the 
designated imaging CRO  for quality control and review by [CONTACT_115365], promptly after acquisition  
(as applicable) . 
[IP_ADDRESS]  Transmission of efficacy data to BIRC  
All radiological assessments will be read locally and by [CONTACT_14988]. The imaging assessments should 
be submitted promptly after acquisition to the imaging vendor designated by [CONTACT_5343] . Rapid 
image transmission to the central imaging vendor will be accomplished by [CONTACT_685423] a secured website (e.g. , via the internet)  or 
by a courier. In all instances, the process at the imaging vendor will ensure that the central 
reviewers remain blinded to the results o f the local assessment and the expedited nature of the 
review.  
[COMPANY_001]  Confidential  Page 127 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 7.2.2  Safety and tolerability assessments  
Safety will be monitored by [CONTACT_685424]. 
For details on AE collection and reporting, refer to Section 8 . 
[IP_ADDRESS]  Physical examination  
A complete physical examination must be performed as indicated in Table 7 -1 and Table 7 -2 
and will include the examination of general appearance, skin, neck (including thyroid), eyes, 
ears, nose, throat, lungs, heart, abdomen, back, lymph nodes, extremities, vascular, and 
neurological assessments . 
Physical examination will be performed on the scheduled day, even if study treatment is being 
withheld. More frequent examinations may be performed at the discretion of the Investigator 
and if medically indicated.  
A targeted (short) p hysical examination will be performed according to the standards at each 
institution.  
Information about the physical examination must be present in source documentation at the 
study site. Significant findings that are present prior to signing of informed consent form for 
the study must be included in the Medical History page on the patient’ s eCRF. Significant new 
findings that begin or worsen after informed consent for the study must be recorded on the 
Adverse Events  eCRF.  
[IP_ADDRESS]  Vital signs  
Vital signs (body temperature, pulse rate, blood pressure) must be performed as per institutional 
standards before dosing and as indicated in Table 7 -1 and Table 7 -2. 
Vital signs should be assessed on the scheduled day, even if study treatment is being withheld. 
More frequent examinations may be performed at the discretion of the Investigator and if 
medically indicated.  
[IP_ADDRESS]  Height and weight  
Height  (screening only)  and body weight (in indoor clothing, but without shoes) will be 
measured  at screening and at subsequent time points as specified in Table 7 -1 and Table 7 -2. 
[IP_ADDRESS]  Performance status  
ECOG performance status will be assessed according to Table 7 -1 and Table 7 -2. 
Table 7-5 ECOG performance status  
Grade  ECOG Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature (e.g., light house work, office work)  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and about 
more than 50% of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
[COMPANY_001]  Confidential  Page 128 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 [IP_ADDRESS]  Laboratory evaluations  
For the phase I  and phase II , all laboratory parameters assessed for safety purposes will be 
evaluated locally, at the site. Refer to Table 7 -6 for a summary of the parameters to be evaluated 
and the frequency of the assessments  according to Table 7 -1 and Table 7 -2 respectively.  
Local laboratory assessments may also be performed when an immediate clinical decision needs 
to be made. In those cases locally unscheduled testing may be performed.  
Each time local laboratory results (including unscheduled laboratory assessments) are reported 
on the eCRF page, the study monitor will collect and submit promptly the local laboratory 
normal ranges and local laboratory certification.Details on the collect ion, shipment of samples 
and reporting of results by [CONTACT_131356] a separate 
[Laboratory Manual] . 
Table 7-[ADDRESS_929034] Name  
[CONTACT_6675], Hemoglobin, Platelets, Red blood cells, White blood cells, RBC Morphology 
with, Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Bands, 
other)  
Chemistry  Albumin, Alkaline phosphatase, ALT (SGPT), AST (SGOT), Gamma -glutamyl 
transpeptidase (GGT) Calcium, Chloride, Magnesium, Phosphorus (screening in Phase II 
part only), Potassium, Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Total 
Prote in, Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose (fasting at 
baseline),  
Urinalysis  Dipstick measurements for specific gravity, pH, protein, glucose, bilirubin, ketones, 
leukocytes, and blood will be performed. Any clinically significant findings on dipstick will be 
followed up with a microscopic evaluation. (Red Blood Cells, White Blood Cells, Casts, 
Crystals, Bacteria, Epi[INVESTIGATOR_1663])  
Coagulation  Prothrombin time (PT) or International normalized ratio (INR),  
HBV and HCV  HBsAg, HBsAb, HBcAb, HBV -DNA, HCV -Ab, HCV -RNA  
[IP_ADDRESS].1  Hematology  
Hematology panel outlined in Table 7 -6 will be performed as per the assessment schedule in  
Table 7 -1 and Table 7 -2. 
[IP_ADDRESS].2  Clinical chemistry  
Clinical chemistry  panel outlined in Table 7 -6 will be performed as per the assessment schedule 
in Table 7 -1 and Table 7 -2. 
[IP_ADDRESS].3  Coagulation  
Coagulation panel outlined in Table 7 -6 will be performed as per the assessment schedule in 
Table 7 -1 and Table 7 -2. 
[IP_ADDRESS].4  Urinalysis  
Urinalysis  panel outlined in Table 7 -6 will be performed as per the assessment schedule in Table 
7-1 and Table 7 -2. 
[COMPANY_001]  Confidential  Page 129 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 [IP_ADDRESS].5  HBV and HCV testing  
HBV tests outlined in Table 7 -6 will be performed as per the assessment schedule in Table 7 -1 
and Table 7 -2. 
HCV tests outlined in Table 7 -6 will be performed as per the assessment schedule in Table 7 -1 
and Table 7 -2. 
[IP_ADDRESS].[ADDRESS_929035] is required for women of 
childbearing potential at screening (within 72 hours) and/or at Cycle 1 Day 1 (prior to dosing) 
and at the end of the study treatment. During subsequent cycles , for women of childbearing 
potential urine pregnancy tests will be performed at day 1 of each cycle in the Phase I part, and 
as clinically indicated in the Phase II part.  
[IP_ADDRESS]  Cardiac assessments  
[IP_ADDRESS].1   Electrocardiogram (ECG)  
Standard [ADDRESS_929036] dose (estimated Tmax) on Cycle 1 Day 1 and Cycle 2 Day 1 , at pre -
dose on Cycle 3 Day 1 and at EOT . Triplicate ECG s will be performed at all time-points during 
the trial.  
Table 7-7 Central  ECG collection plan  for all patients (for Phase I)  
Cycle  Day Time   
Screening  -[ADDRESS_929037] an extensive ECG collection as shown in Table 7 -
8. 
Table 7-8 Extensive ECG collection plan (for Phase II)  
Cycle  Day Time   
Screening  -[ADDRESS_929038] -dose  Triplicate 12 Lead  
[COMPANY_001]  Confidential  Page 130 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Cycle  Day Time   
2 1 Pre-dose  Triplicate 12 Lead  
2 1 0.5, 2, 4, 8 and 24 hr  Triplicate 12 Lead  
3-4 1 Pre-dose  Triplicate 12 Lead  
EOT   Triplicate12 Lead  
Unscheduled   Anytime  Triplicate12 Lead  
Interpretation of the tracing will be made by a central ECG lab. Each ECG tracing should be 
labeled with the study number, patient initials  (where regulations permit) , patient number, date, 
and kept in the source documents at the study site. New or worsened  clinically significant 
abnormalities occurring after informed consent will be recorded in the AE eCRF page. 
Clinically significant abnormalities present when the patient signed informed consent at 
screening should be recorded on the Medical history eCRF page  and discussed with [COMPANY_001] 
prior to enrolling the patient in the study.  
Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at 
any time during the study as clinically indicated. Unscheduled ECGs with clinically significant 
findings should be collected in triplicate. Local ECG assessment m ay also be performed at any 
time during the study at the discretion of the investigator  by a qualified physician and 
documented on the ECG CRF page .  
All ECGs, including unscheduled triplicate safety ECGs with clinically relevant findings, 
collected during the study should be transmitted to the central c ore ECG laboratory for review.  
7.2.3  Pharmacokinetics  
Serial blood samples will be collected from all patients for the analysis of EGF816 and LMI258 
plasma PK. The PK analysis will be performed according to  Section 10.5.3 . 
 
 
 
[IP_ADDRESS]  Pharmacokinetic blood sample collection and handling  
PK blood samples will be collected in both Phase I  and Phase II parts . 
For patients treated in the Phase I part , three PK profiles will be collected on Day 1, Day 15 of 
Cycle 1, and Day 1 of Cycle 2. In addition, trough samples will be taken on Day 8 of Cycle 1, 
and Day 1 of Cycle 3 and Cycle 4 ( Table 7 -9). 
For patients treated in the Phase II part, two PK profiles will be collected on Cycle 1 Day 1 and 
Cycle 2 Day 1 in addition to several trough samples as shown in Table 7 -10. 
Table 7-9 Phase I part : schedule of blood sample collections for 
pharmacokinetics  
Dose 
reference ID 
following PK 
sampling  Dose 
reference ID 
prior to PK 
sampling  Sample 
number  Cycle  Day Scheduled time (hours)  
1  1 1 1 Pre-dose/0 hra 
1  2 1 1 0.5 hr (±10 minutes)  

[COMPANY_001]  Confidential  Page 131 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Dose 
reference ID 
following PK 
sampling  Dose 
reference ID 
prior to PK 
sampling  Sample 
number  Cycle  Day Scheduled time (hours)  
1  3 1 1 1 hr (±10 minutes)  
1  4 1 1 2 hr (±10 minutes)  
1  5 1 1 3 hr (±15 minutes)  
1  6 1 1 4 hr (±15 minutes)  
1  7 1 1 6 hr (±30 minutes)  
1  8 1 1 8 hr (±1 hr)  
1  9 1 1 12 hr (± 1 hr) b 
2 1 10 1 2 24 hr/pre -C1D2 dose a 
3 102 11 1 8 Pre-C1D8 dose  
4 103 12 1 15 Pre- C1D15 dose/0 hr a 
4  13 1 15 0.5 hr (±10 minutes)  
4  14 1 15 1 hr (±10 minutes)  
4  15 1 15 2 hr (±10 minutes)  
4  16 1 15 3 hr (±15 minutes)  
4  17 1 15 4 hr (±15 minutes)  
4  18 1 15 6 hr (±30 minutes)  
4  19 1 15 8 hr (±1 hr)  
4  20 1 15 12 hr (± 1 hr) b 
5 4 21 1 16 24 hr/pre -C1D16 dose a 
6 105 22 2 1 Pre-C2D1 dose/0 hr a 
6  23 2 1 0.5 hr (±10 minutes)  
6  24 2 1 1 hr (±10 minutes)  
6  25 2 1 2 hr (±10 minutes)  
6  26 2 1 3 hr (±15 minutes)  
6  27 2 1 4 hr (±15 minutes)  
6  28 2 1 6 hr (±30 minutes)  
6  29 2 1 8 hr (±1 hr)  
6  30 2 1 12 hr (± 1 hr) b 
7 6 31 2 2 24 hr/pre -C2D2 dose a 
8 107 32 3 1 pre-C3D1 dose a 
9 108 33 4 1 pre-C4D1 dose a 
  1001+    At the time of newly obtained biopsy on 
C4D1 (±3 days) and time of progression d 
--  2001+c NA NA Unscheduled  
a Take samples immediately prior to the administration of EGF816 
b Optional 
c Unscheduled blood samples will be uniquely, sequentially numbered 2001, 2002, 
d Time of the dose taken prior to biopsy  
If biopsy is collected on Cycle 4 Day 1, no unscheduled blood PK sample needs to be collected  
[COMPANY_001]  Confidential  Page 132 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 7-10 Phase II part : schedule of blood sample collections for 
pharmacokinetics  
Dose 
reference ID 
following PK 
sampling  Dose 
reference ID 
prior to PK 
sampling  Sample 
number  Cycle  Day Scheduled time (hours)  
11  101 1 1 Pre-dose/0 hr a 
11  102 1 1 0.5 hr (±10 minutes)  
11  103 1 1 1 hr (±10 minutes)  
11  104 1 1 2 hr (±10 minutes)  
11  105 1 1 3 hr (±15 minutes)  
11  106 1 1 4 hr (±15 minutes)  
11  107 1 1 6 hr (±30 minutes)  
11  108 1 1 8 hr (±1 hr)  
12 11 109 1 2 24 hr/pre -C1D2 dose a 
13 120 110 1 8 Pre-C1D8 dose  
14 130 111 1 15 Pre-C1D15 dose a 
15 140 112 2 1 Pre-C2D1 dose/0 hr a 
15  113 2 1 0.5 hr (±10 minutes)  
15  114 2 1 1 hr (±10 minutes)  
15  115 2 1 2 hr (±10 minutes)  
15  116 2 1 3 hr (±15 minutes)  
15  117 2 1 4 hr (±15 minutes)  
15  118 2 1 6 hr (±30 minutes)  
15  119 2 1 8 hr (±1 hr)  
16 15 120 2 2 24 hr/pre -C2D2 dose a 
17 160 121 3 1 pre-C3D1 dose a 
18 170 122 4 1 pre-C4D1 dose a 
--  3001+b NA NA Unscheduled  
a Take samples immediately prior to the administration of EGF816 
b Unscheduled blood samples will be uniquely, sequentially numbered 3001, 3002, …  
The exact date and clock times of drug administration and PK blood draw will be recorded on 
the appropriate eCRF. The timing of meals, before and after the dose on days when PK samples 
are drawn, should be recorded in the source documents. If vomiting occu rs within [ADDRESS_929039] venipuncture or an indwelling cannula inserted in 
a forearm vein. At specified time points, 2 mL blood will be collected into tubes containing K2 
EDTA. Refer to the  [EGF816X2101 Laboratory Manua l] for detailed instructions for the 
collection, handling, and shipment of PK samples.  
[IP_ADDRESS]  Analytical method  
EGF816 and LMI258 concentrations in human plasma will be determined with a validated 
liquid chromatography -tandem mass spectrometry (LC -MS/MS) assay. Any results below the 
lower limit of quantification (LLOQ) of 1.0 ng/mL and any missing samples will be la beled 
accordingly.  
[COMPANY_001]  Confidential  Page 133 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 7.2.[ADDRESS_929040] of the EGF816 at the 
molecular and cellular level  
 The sample collection information as required should be 
recorded on the eCRF page(s) and central laboratory requisition form(s). Detailed instructions 
for the collection, handling, and shippi[INVESTIGATOR_685356] 
[EGF816X2101 Laboratory Manual] . 
[IP_ADDRESS]  Biomarker  assessments  for Phase I part  
[IP_ADDRESS].1  Pharmacodynamic assessments in newly obtained tumor specimens  (For 
patients enrolled before protocol amendment 5 only  (For Phase I part only)  
Collection of paired tumor specimens is critical to assess the pharmacodynamic effect of 
EGF816 on the EGFR pathway. Tumor specimens will be used to assess the phosphorylation 
state of pathway molecules (e.g. EG FR, AKT, ERK) by [CONTACT_685425], other pathways that may interact with the EGFR 
pathway, or are thought to be important in cancer. Additional markers or methods maybe 
utilized if indicated by [CONTACT_685426].  
[IP_ADDRESS].2  Assessment of tumor immune infiltrates in newly obtained tumor specimens 
(For Phase I part only)  
To assess whether treatment with EGF816 results in a change in tumor immune infiltrates, 
immunohistochemical analyses of immune cell markers will be performed on newly obtained 
tumor samples collected at screening/baseline, C4D1, C6D1 (optional) ,C8D1(opti onal) and 
EOT (optional). Additional markers or methods maybe utilized if indicated by [CONTACT_685427].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

[COMPANY_001]  Confidential  Page 134 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 7-11 Biomarker sample collection plan  – Phase I part  
Sample type  Analysis  Collection visit schedule  
Newly obtained tumor 
samples  Immune infiltrate 
assessment  Screening/baseline, Cycle 4 Day 1, Cycle 6 Day 1 
(optional), Cycle 8 Day 1 (optional) and at EOT 
(optional)(+/ - 28 days for each time point or 
otherwise as agreed between investigators and 
[COMPANY_001])  
[IP_ADDRESS]  Biomarker Assessments  for Phase II part  
[IP_ADDRESS].1   Biomarker Assessments in Tumor  
Archival or newly acquired biopsy are required w hen a patient enters the screening phase ; 
archival tumor material is requested to assess markers associated with EGFR signaling, EGF816 
and cancer with methods including but not limited to Next Generation Sequencing (NGS), 
immunohistochemistry and fluorescence in -situ hybridization.  
 
  
 
 
  

[COMPANY_001]  Confidential  Page 135 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 Table 7-12 Biomarker sample collection plan -Phase II part  
Sample Type  Volume  Visit  Time point  
Tumor samples  
Mandatory  
Newly obtained formalin -fixed biopsy or archival 
tumor block or slides from a formalin -fixed paraffin 
embedded (FFPE).  Block or  
minimum of 11 
slides (5 microns)  Screening   Screening  
Mandatory  (if available)  
Either the remaining archival tumor block or 
additional 5 slides from same archival biopsy that 
was provided at molecular screening or the same 
block used to determine EGFR status locally  
 
 
Additional slides not required if a suitable block 
(newly acquired or archival) was submitted for 
molecular screening  Block or  
additional 5 
slides   Cycle 1 Day 1  1Upon 
enrollment  

[COMPANY_001]  Confidential  Page 136 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Sample Type  Volume  Visit  Time point  
Optional  
Newly obtained tumor biopsy or archival material if 
fresh not available at C1D1  
 
 
 
 
 
 
Requires separate consent within the main ICF.  Newly acquired 
biopsy or archival 
material, block or 
3-10 slides  Cycle 1 Day 1  Pre-dose  
If a newly 
obtained tumor 
biopsy was 
submitted for 
screening, this 
biopsy is not 
required  
Newly acquired  
biopsy  EOT Anytime  
Newly acquired  
biopsy  On treatment  Any time  
Sample Type  Volume  Visit Time point  
Blood samples  

[COMPANY_001]  Confidential  Page 137 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 7.2.5  [For Japan only] Radiological examinations  
[IP_ADDRESS]  Chest X -ray 
A 2-view chest X -ray will be performed  at screening, Day [ADDRESS_929041] X -ray can be skipped  except for at 
screening .  
8 Safety monitoring and reporting  
8.1 Adverse events  
8.1.1  Definitions and reporting  
An adverse event is defined as the appearance of (or worsening of any pre -existing) undesirable 
sign(s), symptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.  
For patients whose EGFR mutation status is unknown and who sign the molecular pre -screening 
ICF, AEs which occur after signature [CONTACT_111936] 8.2  and are reported to be causally related with study 
procedures (e.g. an invasive procedure such as biopsy). Once the main study ICF is signed, all 
AEs per the descriptions below will be captured in the Adverse Event eCRF.  
Patients whose EGFR mutation  status is known will sign the main study ICF.  
Abnormal laboratory values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically significant, 
require therapy (e.g., hematologic abnormality that requires transf usion or hematological stem 
cell support), or require changes in study medication(s).  
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events eCRF. Conditions that were already present at the time of informed consent should be 
recorded in the Medical History page of the patient’s eCRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half -lives, whichever is longer) following the last dose 
of study treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis  whenever possib le, rather than individual underlying signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.  
Adverse events will be assessed and graded according to the Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.03. 
If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, 
and life -threatening, corresponding respectively to Grades 1 - 4, will be used. CTCAE Grade 5 
(death) will not be used in this study; rather information about any deaths (related to an Adverse 
Event or not) will also be collected th rough a Death form . 
The occurrence of adverse events should be sought by [CONTACT_105] -directive questioning of the patient 
(subject) during the screening process after signing informed consent and at each visit during 
the study. Adverse events also may be detected when they are volunt eered by [CONTACT_685428] 138 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 (subject) during the screening process or between visits, or through physical examination, 
laboratory test, or other assessments. As far as possible, each adverse event should be evaluated 
to determine:  
1. The severity grade (CTCAE Grade s 1-4) 
2. Its duration (Start and end dates)  
3. Its relationship to the study treatment (Reasonable possibility that AE is related: No, Yes)  
or 
Its relationship to the study treatment (Reasonable possibility that AE is related: No,  
Yes, investigational treatment, Yes, the study treatment (non -investigat ional), Yes, both 
and/or indistinguishable)  
4. Action taken with respect to study or investigational treatment (none, dose adjusted, 
temporarily interrupted, permanently discontinued, unknown, not applicable)  
5. Whether medication or therapy was given (no concomitant medication/non -drug therapy, 
concomitant medication/non -drug therapy)  
6. Outcome (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown) Delete for NOVDD Trials as outcome 
is not collected  
7. Whether it is serious, where a serious adverse event (SAE) is defined as in Section 8.2.1  
If the event worsens the event should be reported a second time in the CRF noting the start date 
when the event worsens in toxicity. For Grade 3 and 4 adverse events only, if improvement to 
a lower grade is determined a new entry for this event should be reported in the CRF noting the 
start date when the event improved from having been Grade 3 or Grade 4.  
All adverse events should be treated appropriately. If a concomitant medication or non -drug 
therapy is given, this action should be recorded on the Adverse Event eCRF.  
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently, if necessary) 
of any changes in severity, the suspected relationship to th e study treatment, the interventions 
required to treat it, and the outcome.  
Progression of malignancy (including fatal outcomes), if documented by [CONTACT_5371] (for example, as per RECIST criteria for solid tumors or as per Cheson's guidelines for 
hematological malignancies), should not be reported as a serious advers e event.  
Adverse events separate from the progression of malignancy (example, deep vein thrombosis 
at the time of progression or hemoptysis concurrent with finding of disease progression) will 
be reported as per usual guidelines used for such events with proper att ribution regarding 
relatedness to the drug.  
8.1.[ADDRESS_929042] abnormalities  
[IP_ADDRESS]  Definitions and reporting  
Laboratory abnormalities that constitute an Adverse event in their own right (are considered 
clinically significant, induce clinical signs or symptoms, require concomitant therapy or require 
changes in study treatment), should be recorded on the Adverse Ev ents eCRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for Adverse Events should be 
[COMPANY_001]  Confidential  Page 139 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 followed until they have returned to normal or an adequate explanation of the abnormality is 
found. When an abnormal laboratory or test result corresponds to a sign/symptom of an already 
reported adverse event, it is not necessary to separately record the lab/test result as an additional 
event.  
Laboratory abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined b elow and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality may be required by 
[CONTACT_217974], by [CONTACT_108], be an adverse event 
and must be reported as such.  
8.1.[ADDRESS_929043] (AESI) are defined as events (serious or non -serious) which 
are ones of scientific and medical concern specific to the sponsor’s product or program . 
Adverse events of special interest are defined on the basis of an ongoing review of the safety 
data. AESIs are discussed in detail in the Investigator ’s Brochure.  
The adverse events of special interest to be monitored for EGF816 are diarrhea and 
gastrointestinal toxicities; pneumonitis/ interstitial lung disease; hepatitis B reactivation;   skin 
adverse events including   rash and mucocutaneous dryness; and dry eye disorders.  
8.2 Serious adverse events  
8.2.1  Definitions  
Serious adverse event (SAE) is defined as one of the following:  
• Is fatal or life -threatening  
• Results in persistent or significant disability/incapacity  
• Constitutes a congenital anomaly/birth defect  
• Is medically significant, i.e. defined as an event that jeopardizes the patient or may require 
medical or surgical intervention to prevent one of the outcomes listed above  
• Requires inpatient hospi[INVESTIGATOR_1081],  
• Note that hospi[INVESTIGATOR_14944]:  
• Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition  
• Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent  
• Social reasons and respi[INVESTIGATOR_064]’s 
general condition  
• Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_286743] a SAE given above 
is not a serious adverse event  
[COMPANY_001]  Confidential  Page 140 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • Serious adverse events considered by [CONTACT_685429] a biopsy 
procedure will be indicated as such in the AE eCRF.  
8.2.2  Reporting  
For patients with unknown EGFR mutation  status and who sign the molecular pre -screening 
ICF, SAE collection will start upon signing the molecular pre -screening ICF. SAEs will only 
be reported if the event is suspected to be causally related to a study procedure as assessed by 
[CONTACT_093] ( e.g., an invasive procedure such as biopsy). SAEs will be followed until 
resolution or until clinically relevant improvement or stabilization. If the main ICF is not signed 
(molecular screen failure), SAE collection e nds [ADDRESS_929044] be reported to [COMPANY_001] within 24 hours of learning of its occurrence.  
Any SAEs experienced after this 30 days period (or 5 half -lives,  whichever is longer) should 
only be reported to [COMPANY_001] if the investigator suspects a causal relationship to the study 
treatment. Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported 
as follow -up to the original epi[INVESTIGATOR_1865] w ithin 24 hours of the investigator receiving the follow -up 
information. An SAE occurring at a different time interval or otherwise considered completely 
unrelated to a previously reported one  should be reported separately as a new event.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study treatment (if there is more than one study treatment), complete the SAE Report 
Form in English  and submit the completed form within [ADDRESS_929045] as each re -occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study participation.  
If the SAE is not previously documented in the [Investigator’s Brochure] or Package Insert 
(new occurrence) and is thought to be related to the [COMPANY_001] study treatment, an oncology 
[COMPANY_001] Chief Medical  Office and Patient Safety ( CMO&PS) department associate may 
urgently require further information from the investigator for Health Authority reporting. 
[COMPANY_001] may need to issue an Investigator Notification (IN), to inform all investigators 
involved in any study with the same drug that this  SAE has been re ported. Suspected 
Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to the 
competent authorities and relevant ethics committees in accordance with Directive 2001/20/EC 
or as per national regulatory requirements in participating c ountries.  
[COMPANY_001]  Confidential  Page 141 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 8.[ADDRESS_929046] 
be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or volunt ary termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.  
Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported by [CONTACT_685430] (CMO&PS) . 
Pregnancy follow -up should be recorded on the same form and should include an assessment 
of the possible relationship to the study treatment any pregnancy outcome. Any SAE 
experienced during pregnancy must be reported on the SAE Report Form.  
Pregnancy outcomes should  be collected for the female partners of any males who took study 
treatment  in this study. Consent to report information regarding these pregnancy outcomes 
should be obtained from the mother.  
8.4 Warnings and precautions  
No evidence available at the time of the approval of this study protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided [Investigator 
Brochure]. Additional safety information collected between IB upd ates will be communicated 
in the form of Investigator Notifications. This information will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.  
8.[ADDRESS_929047] investigator teleconferences on 
a regular basis during the study. Further, [COMPANY_001] and the investigators will meet at the end of 
each treatment cohort to discu ss and evaluate all of the gathered safety data. At the dose -
escalation teleconference the clinical course (safety information including both DLTs and all 
CTCAE Grade [ADDRESS_929048] cycle of treatment, and PK data) for 
each patient in the current dose cohort will be described in detail. Updated safety data on other 
ongoing patients, including data in later cycles, will be discussed as well.  
Dose -escalation decisions will be based on a clinical synthesis of all relevant available data and 
not solely on DLT information. Selection of the actual dose for the next cohort of patients will 
be guided by [CONTACT_111848]’s (with EWOC)  recommendation, and a 
medical review of relevant clinical, PK and laboratory data. [COMPANY_001] and the investigator parties 
must reach a consensus on whether to declare MTD, escalate the dose any further, or whether 
to de -escalate and/or recruit an addi tional cohort of patients at the current dose level (see Section 
10.4.2 ). 
[COMPANY_001]  Confidential  Page 142 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Phase II part  
This is a single arm trial (i.e. no comparator arm) and there is no apriori information as per the 
FDA Guidance of “situations in which safety concerns may be unusually high” or the patient 
population being studied are “potentially fragile population such as children, pregnant women  
or the very elderly, or other vulnerable populations, such as those who are terminally ill or of 
diminished mental capacity.”  Thus, an independent data monitoring committee  will not be 
constituted for the Phase II  part of this study.  
The [COMPANY_001] clinical team will review the safety data on a regular basis. A review of the safet y 
data and  assessment of futility based on the calculated Bayesian  probability of success (POS) 
will be performed at the interim analysis by [CONTACT_685431] a data review meeting.  
At the time of the interim analysis, the best overall response for each patient will be derived 
from the overall lesion response assessments performed by [CONTACT_115365]  . These will be used to 
calculate the overall response rate for the respective group and a Bayesian analysis will be 
performed to estimate the POS of the trial given the current data (see Section 10.7  for details).  
It is envisioned that the team may make t hree types of recommendations at the respective 
interim analysi s, namely:  
• No safety or efficacy issues, ethical to continue the study group  as planned  
• POS is too small and the study  group is terminated due to lack of significant activity  
• Serious safety concerns precluding further treatment in study group , regardless of efficacy.  
8.6 Steering Committee  
Not applicable.  
8.7 Blinded Independent Review Committee  (BIRC)  
A Blinded Independent Review Committee (BIRC) will review the Phase I and Phase II part 
radiographic and photographic data to determine tumor response and progression. The 
designated imaging CRO will be responsible for assembling and managing the BIRC. Thi s and 
all other imaging procedures will be documented in an independent review charter agreed upon 
between [COMPANY_001] and the imaging vendor before initiation of any BIRC reviews.  
[ADDRESS_929049] of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
[COMPANY_001]  Confidential  Page 143 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to  collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safety information (e.g. has the subject 
experienced any new or worsened AEs) at the end of their scheduled study period.  
The data collection system for this study uses built -in security features to encrypt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence  of individually assigned 
user identification codes and passwords, made available only to authorized personnel who have 
completed prerequisite training.  
Prior to entering key sensitive personally identifiable information (Subject Initials and exact 
Date of Birth), the system will prompt site to verify that this data is allowed to be collected. If 
the site indicates that country rules or ethics committee st andards do not permit collection of 
these items, the system will not solicit Subject Initials. Year of birth will be solicited (in the 
place of exact date of birth) to establish that the subject satisfies protocol age requirements and 
to enable appropriate  age-related normal ranges to be used in assessing laboratory test results.  
9.2 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study, the field monitor will visit the site re gularly to check the 
completeness of patient records, the accuracy of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for  according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.  
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of a ny other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed copy is given to the patient).  
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the CRF entries. [COMPANY_001] monitoring standards require full verification for the 
presence of informed consent, adherence to the inclusion/exclu sion criteria and documentation 
of SAEs. Additional checks of the consistency of the source data with the CRFs are performed 
according to the study -specific monitoring plan.  
9.3 Data collection  
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_5374] (eCRF). The eCRFs 
have been built using fully validated secure web -enabled software that c onforms to [ADDRESS_929050] been trained. Automatic validation programs check for data discrepancies in the eCRFs 
and, allow modification or verification of the entered data by [CONTACT_6649].  
[COMPANY_001]  Confidential  Page 144 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 The Principal Investigator [INVESTIGATOR_20115], 
accurate, and that entry and updates are performed in a timely manner.  
Blood and tumor samples for PK and biomarkers will be collected by [CONTACT_685432] a Central 
laboratory for processing. The Laboratory results will be sent  electronically to [COMPANY_001]  
database as third party data . Radiological and photography data will be acquired by [CONTACT_685433]. Additionally, radiological and photography data will be transmitted by 
[CONTACT_685434]. 
Details regarding all vendor  procedures inclu ding collection and shipment of data will be 
described in the manual provided by [CONTACT_685435] .  
PK and Biomarker (blood and tissue) samples drawn during the course of the study will be 
collected from the Investigator sites and analyzed by a [COMPANY_001] assigned laboratory or 
contracted central laboratories. The site staff designated by [CONTACT_685436], 
respectively, as well as the designated laboratory’s requisition forms that will be printed on 2 - 
part paper. One copy of the requisition form will be fo rwarded to the central laboratory along 
with the corresponding samples with required information (including study number, subject ID, 
etc.) and the other copy will be retained by [CONTACT_779]. The field monitor will review the relevant 
eCRFs for accuracy and c ompleteness and will work with the site staff to adjust any 
discrepancies as required. The field monitor will also review the requisition forms for 
completeness.  
Biomarker , ECG and central laboratory  data obtained by [CONTACT_685437].  
In addition, data entered into the IRT for drug  assignment and patient identifiers (i.e. date of 
birth, gender and Patient ID) will be transferred  electronically to [COMPANY_001] as described in the 
Data Transfer Specifications for the designated  IRT vendor.  
If a patient enrolls on a companion sample collection study to evaluate the mechanisms of 
resistance, data required for the companion sample collection study are collected in the clinical 
trial database for the treatment protocol.  A description of the dat a to be collected for the study 
of resistance is provided in the companion sample collection protocol.  
9.[ADDRESS_929051], which employs the Anatomical Therapeutic Chemical classification 
system. Medical history/current medical conditions and adverse events w ill be coded using the 
Medical dictionary for regulatory activities (MedDRA) terminology.  
PK, biomarker samples, ECG , imaging  and IRT data will be processed centrally and the results 
will be  sent electronically to [COMPANY_001] . 
[COMPANY_001]  Confidential  Page 145 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 For Phase II patients, data about all study treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using an Interactive Response Technology. The system 
will be supplied by a vendor(s), who will also manage the database. The  data will be sent 
electronically to [COMPANY_001] personnel . 
The occurrence of any protocol  violations will be determined.  
After these actions have been completed and the data have  been verified to be complete and 
accurate, the database will be declared locked and made available for data analysis. 
Authorization is required prior to making any database changes to the locked data  by [CONTACT_79608].  
For EDC studies, after database lock, the investigator will receive a CD -ROM of the patient 
data for archiving at the investigational site.  
[ADDRESS_929052] to demographic and baseline characteristics, 
efficacy observations and measurements, safety observations and measurements, and all 
relevant PK and PD measurements.  
Categorical data will be presented as contingency tables (frequencies and percentages). For 
continuous data summary statistics of mean, standard deviation, median, minimum, and 
maximum will be presented.  
The following rules will be followed for reporting results unless stated otherwise:  
• Phase I part : Patients treated during the Phase I part  (dose escalation) with the same dose 
level, formulation (capsule vs. tablet) and schedule of EGF816 will be pooled into a single 
treatment group. All summaries, listings, figures and analyses will be performed by 
[CONTACT_1570] (unless otherwise specified).  Subgroup analyses by [CONTACT_685438](s)  may be performed as appropriate.  
• Phase II part : The primary analysis will be performed  when patients enrolled have 
completed at least [ADDRESS_929053] the data cut -off date 
for the primary analysis will be reported in the final CSR at the end of the study.   
10.1 Analysis sets  
10.1.1  Phase I part  
[IP_ADDRESS]  Full analysis set  
The full analysis set (FAS) includes all patients who received at least one dose of EGF816. 
Patients will be analyzed according to the planned treatment (regimen). The FAS will be used 
for all listings of raw data. Unless otherwise specified, the FAS will be the default analysis set 
used for all analyses.  
[COMPANY_001]  Confidential  Page 146 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 [IP_ADDRESS]  Safety set  
The Safety Set includes all patients who received at least one dose of EGF816. Patients will be 
analyzed according to the study treatment (regimen) they actually received.  
A precise definition of “actually received” will be added in the Reporting and Analysis Plan 
(RAP).  
[IP_ADDRESS]  Dose -determining set  
The dose -determining set (DDS) consists of all patients from the safety set of phase I part who 
either meet the following minimum exposure criterion and have sufficient safety evaluations, 
during the first [ADDRESS_929054] met the minimum exposure criterion if he received at leas t 75% of the planned doses of 
EGF816 in the first 28 days of dosing  (e.g., 21 of the planned 28 doses on a q.d. schedule).  
Patients who do not experience DLT during the first cycle are considered to have sufficient 
safety evaluations if they have been observed for ≥ [ADDRESS_929055] enough safety  data to conclude that a 
DLT did not occur.  
Patients who do not meet these minimum safety evaluation requirements will be regarded as 
ineligible for the DDS and an additional patient may be recruited (see Section 7.1.4 ). 
[IP_ADDRESS]  Pharmacokinetic analysis set  
The pharmacokinetic analysis set (PAS) consists of all patients who received at least one dose 
of EGF816 and have at least one evaluable EGF816 PK sample. Details of PAS definition can 
be found in the statistical analysis plan.  
10.1.2  Phase II part  
[IP_ADDRESS]  Full analysis set  
The full analysis set (FAS) includes all patients who received at least one dose of EGF816. The 
FAS will be used for all listings of raw data. Unless otherwise specified, the FAS will be the 
default analysis set used for all analyses.  
[IP_ADDRESS]  Per protocol set  
The Per -Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with the requirements of the clinical study protocol. The protocol deviations or conditions 
leading to exclusion from the PPS will be detailed in the statistical analysis plan.  
[IP_ADDRESS]  Safety set  
The Safety Set includes all patients who received at least one dose of EGF816 . 
[IP_ADDRESS]  Pharmacokinetic analysis set  
The pharmacokinetic analysis set (PAS) consists of all patients who received at least one dose 
of EGF816 and have at least one evaluable EGF816 PK sample. Details of PAS definition can 
be found in the statistical analysis plan.  
[COMPANY_001]  Confidential  Page 147 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 10.2 Patient demographics/other baseline characteristics  
Demographic and other baseline data will be summarized descriptively by [CONTACT_6656] . 
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)  
10.3.1  Study treatment  
The actual dose and duration in days of EGF816 treatment as well as the dose intensity (dose 
received/duration) and relative dose intensity (the ratio of dose intensity to planned 
dose/planned duration) will be listed and summarized by [CONTACT_685439] . 
10.3.2  Concomitant therapi[INVESTIGATOR_685357] -drug therapi[INVESTIGATOR_685358] . 
10.3.3  Compliance  
Compliance to the protocol will be assessed by [CONTACT_632776]. These will be identified prior to database lock and will be listed and 
summarized by [CONTACT_685440] . 
10.4 Primary objective  
Phase I part : The primary objective is to determine the MTD and or RP2D  of single agent 
EGF816 when administered orally to adult patients with NSCLC  harboring EGFR  T790M 
mutations.  
The corresponding primary analysis method is an adaptive Bayesian logistic regression model 
(BLRM) guided by [CONTACT_111814] (EWOC) principle ( Neuenschwander 
et al 2008 ). 
Phase II part : The primary objective of the Phase II part  is to estimate antitumor activity of 
EGF816 as measured by [CONTACT_34426] (ORR) determined by [CONTACT_565291] (BIRC) assessment in accordance to RECIST 1.1:  
• At least [ADDRESS_929056] advanced NSCLC with EGFR  activating 
mutation (e.g., L858 R and/o r ex19del) 
10.4.1  Variable  
[IP_ADDRESS]  Phase I part  
The primary endpoint is the incidence of dose -limiting toxicities (DLTs) in Cycle 1. Estimation 
of the MTD of the treatment will be based upon the estimation of the probability of DLT in 
[COMPANY_001]  Confidential  Page 148 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Cycle 1 for patients in the DDS. This probability is estimated by [CONTACT_685441] 
10.4.2 . 
[IP_ADDRESS]  Phase II part  
The primary endpoint is the overall response rate, determined as the proportion of patients in 
FAS experiencing a best overall response of CR or PR per RECIST 1.[ADDRESS_929057] overall response are based on confirmed responses only.  
10.4.2  Statistical hypothesis, model and method of analysis  
[IP_ADDRESS]  Phase I part  
An adaptive, 2 parameter Bayesian logistic regression model (BLRM) guided by [CONTACT_685442]/  RP2D  during the dose -escalation part of the study.  
The dose -toxicity (DLT) relationship in each dose escalation will be described by [CONTACT_685443]:  
logit(π(d)) = log(α) + β log(d/d*),  α>0, β>0                               [1]  
where logit(π(d))= ln (π(d)/(1 - π(d))), π(d) is the probability of a DLT at dose d, where d 
represents the total daily dose  in capsule . Doses are rescaled as d/d* with reference dose d*= 
300 mg of EGF816 as total daily dose. As a consequence α is equal to the odds of toxicity at 
d*. Note that for a dose equal to zero, the probability of toxicity is zero.  
The Bayesian approach requires the specification of prior distributions for the model parameters. 
The prior distributions and the process for their derivation based on available pre -clinical data 
are provided in  Section 14.2 Appendix 2 , along with examples of hypothetical decisions that 
may be followed during the dose escalation.  
Change in drug formulation  
By [CONTACT_61504] 07, the dose escalation decisions were already made and no additional patients 
were included for BLRM, hence the change in formulation doesn’t impact this part of the study .  
Change in dosing schedule  
In the event of a change in dosing schedule, then a new BLRM will be set up. This new BLRM 
will have the same functional form as equation [1] and will incorporate down -weighted existing 
dose-escalation data in the prior distribution. For comparability, doses for the new and old 
models will be normalized to dose in mg per day. The process by [CONTACT_685444] 14.2 Appendix 2 . 
Dose recommendation  
After each cohort of patients, the posterior distributions for the probabilities of DLT rates at 
different dose levels are obtained. The results of this analysis are summarized in terms of the 
estimated probabilities that the true rate of DLT at each dose -level will lie within each of the 
following intervals:  
[COMPANY_001]  Confidential  Page 149 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • [0, 0.16) under -dosing  
• [0.16, 0.33) targeted toxicity  
• [0.33, 1.00] excessive toxicity  
The overdose control criterion mandates that any dose of EGF816 for which the DLT rate has 
more than a 25% chance of being excessively toxic, i.e. P(DLT) is 0.33 or higher, will not be 
considered for the next dose cohort. The final estimate of the MTD/  RP2D  will also satisfy this 
condition.  
Details of the criteria for dose escalation and the estimation of the MTD/  RP2D  are provided in 
Section 6.2.3 . 
Listing/ summary of DLTs  
DLTs will be listed and their incidence summarized by [CONTACT_92869], preferred 
term type of adverse event, and by [CONTACT_1570]. The dose -determining set will be used for 
these summaries.  
[IP_ADDRESS]  Phase II part  
The primary analysis will be performed when patients enrolled have completed at least [ADDRESS_929058] 6 cycles of treatment or discontinued prior to that time for any reason.  
The preliminary anti -tumor activity of  the study treatment will be assessed using dual criteria:  
• The posterior median ORR is equal to or greater than 55%  
• The posterior risk of being in the unacceptable anti -tumor activity is lower than 5%.  
An observed ORR ≥ 55% based on BIRC assessments will be considered clinically meaningful 
as this similar with the reported ORRs for 1st -generation EGFR TKI (gefitinib, erlotinib) and 
2nd-generation EGFR TKI (afatinib) in similar setting, (Refer to Table 1 -1). 
The ORR < 40% will be considered as unacceptable anti -tumor activity. This is based on the 
ORR for carboplatin/paclitaxel -treated patients with metastatic adenocarcinoma histology 
NSCLC receiving first -line treatment. ( [COMPANY_008] Pharmaceuticals LP (2015) ). 
A Bayesian design will be used in order to estimate the ORR and to provide inferential 
summaries (e.g., mean, median, standard deviation, 90% credible intervals) based on the 
posterior distribution of ORR in the Phase II part. A minimally informative unimo dal Beta 
distribution ( Neuenschwander et al. 2008 ) will be used as a prior distribu tion. This prior 
distribution reflects the current uncertainty about the efficacy of EGF816. For the primary 
analysis, the posterior distributions of the ORR will be computed using the available data.  
Additionally , the ORR and 95% exact CI will be provided . 
[COMPANY_001]  Confidential  Page 150 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 An interim analysis for futility will be performed when approximately [ADDRESS_929059] 4 cycles of treatment or discontinued treatment prior to that time. More 
details on the interim analysis are presented in Section 10.7.  
The sample size calculation and rationale are provided in Section 10.8 . 
10.4.3  Handling of missing values/censoring/discontinuations  
For continuing events (e.g., AEs, concomitant medication, etc.), there will be an indication 
within listings that the event is continuing.  
The reason for discontinuation from study will be summarized and listed, along with dates of 
first and last study drug treatment, duration of exposure to study drug treatment and date of 
discontinuation for each patient.  
Patients who have missing BOR will be considered as a treatment failure within the interim and 
final analyses of ORR.  
Patients who have disease progression and continue to receive study drug after progression will 
qualify for PD at the time of progression and will be counted as PD in the derivation of efficacy 
endpoints.  
Other missing data will simply be noted as missing on appropriate tables/listings.  
10.4.4  Supportive analyses  
Additional supportive  analyses will be conducted to support the primary 
objective if appropriate and details of the analysis will be defined in the RAP.  
10.5 Secondary objectives  
10.5.1  Safety objectives  
[IP_ADDRESS]  Analysis set and groupi[INVESTIGATOR_685359]; these will be based on the FAS. For all safety 
analyses, the safety set will be used. The overall observation period will be divided into three 
mutually exclusive periods:  
1. Pre-treatment period: From the day of informed consent until the day before first dose of 
study medication  
2. On-treatment period: From the day of first dose of study medication until [ADDRESS_929060]-treatment period: Starting [ADDRESS_929061] dose of study medication  
All safety data will be listed. Where applicable, a flag indicating into which period observations 
fall will be provided. Safety summaries will contain only data collected in the On -treatment 
period, unless otherwise specified.  For the phase I part subgroup analyses by [CONTACT_685445](s)  may be performed as appropriate.  
[IP_ADDRESS]  Adverse events (AEs)  
Summary tables for adverse events (AEs) have to include only AEs that started or worsened 
during the on -treatment period, the treatment -emergent  AEs. However, all safety data 

[COMPANY_001]  Confidential  Page 151 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 (including those from the pre and post -treatment periods) will be listed and those collected 
during the pre -treatment and post -treatment period are to be flagged.  
The incidence of treatment -emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_30826], severity (based on CTCAE grades), 
type of adverse event, relation to study treatment by [CONTACT_1570].  
Deaths reportable as SAEs and non -fatal serious adverse events will be listed by [CONTACT_685446], non -serious adverse events and adverse events of special interest during 
the on -treatment period will be tabulated . 
[IP_ADDRESS]  Laboratory abnormalities  
For laboratory tests covered by [CONTACT_140069] 
(CTCAE) version 4.03, laboratory data will be graded accordingly.  The calculation of CTCAE 
grades will be based on the observed laboratory values only, clinical assessments will not be 
taken into account.  For laboratory tests covered by [CONTACT_3989], a  Grade 0 will be assigned for all 
non-missing values not graded as 1 or higher. Grade 5 will not be used.  
For laboratory tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory normal ranges . 
The following by -treatment summaries will be generated separately for hematology, 
biochemistry and urinary laboratory tests:  
• frequency table for newly occurring on -treatment grades 3 or 4  
• shift tables using CTCAE grades to compare baseline to the worst on -treatment value  
• for laboratory tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the worst on-
treatment  value.  
• listing of all  laboratory data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory normal ranges.  
 
 
 
[IP_ADDRESS]  Other safety data  
ECG  
The following analysis will be performed for ECG:  
• shift table baseline to worst on -treatment result for overall assessments  
• listing of ECG evaluations for all patients with at least one abnormality.  
Vital signs  
The following analysis will be performed for vital signs:  
• shift table baseline to worst on -treatment result  

[COMPANY_001]  Confidential  Page 152 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.  
[IP_ADDRESS]  Tolerability  
Tolerability of study drug will be assessed by [CONTACT_111894]. Reasons for dose interruption and dose reductions will be listed by [CONTACT_685447].  
10.5.[ADDRESS_929062]/MRI assessments will be used for all efficacy assessments of antitumor activity on study. 
Best overall response (BOR), o verall  response rate (ORR), progression -free survival (PFS), 
disease control rate (DCR), duration of response (DOR) and time to response (TTR) will be 
defined as per RECIST v1.1 (see  Section 14.1 ). Analyses will performed separately for data 
based on Investigator assessment for the Phase I part and both BIRC assessment and 
Investigator assessment  for the Phase II part . 
The analyses will be based on the FAS . 
[IP_ADDRESS]  Analysis set and the groupi[INVESTIGATOR_685360].  
Phase I part:  All secondary efficacy analyses will be summarized by [CONTACT_1570].  
Subgroup analyses by [CONTACT_685384](s) m ay 
be performed as appropriate.  
Phase II part:  All secondary efficacy analyses will be summarized for all patients . 
[IP_ADDRESS]  Secondary efficacy endpoints  
The secondary efficacy endpoints including:  
Phase I part : Overall response rate (ORR), duration of response (DOR), disease control rate 
(DCR), time to response (TTR), and progression -free survival (PFS) by [CONTACT_685380] 1.1  
Phase II part:  ORR by [CONTACT_3138], DOR, DCR, TTR, PFS by [CONTACT_685448] 1.1 and overall survival (OS).  
Phase I/II secondary efficacy endpoints  
Best overall response  
BOR is the best response recorded from the start of the treatment until documented radiological 
disease progression/recurrence. However, any assessments taken more than [ADDRESS_929063] overall  response derivation.  
The study requires that for a partial response (PR) or complete response (CR) changes in tumor 
measurements must be confirmed by [CONTACT_15030] [ADDRESS_929064] met.  
BOR will be summarized by [CONTACT_685373] . 
[COMPANY_001]  Confidential  Page 153 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Overall response rate (ORR)  
ORR is defined as the proportion of patients in FAS with a best overall response of complete 
response (CR) or partial response (PR) per  RECIST 1.1.  
ORR will be estimated together with 95% confidence intervals (CIs) based on the exact 
binomial distribution will be presented.  
Duration of response (DOR)  
Among patients with a confirmed PR or CR per RECIST 1.1, DOR is defined as the time from 
first documented response (PR or CR) to the date of first documented disease progression or 
death due to any cause. A patient who has not progressed or died at the dat e of the analysis or 
when he/she receives any further anticancer therapy in the absence of disease progression will 
be censored at the time of the last adequate tumor evaluation before the earlier of the cut -off 
date or the anticancer therapy date.  
DOR will be described using Kaplan -Meier methods and including estimated median (in 
months) with 95% CI, 25th and 75th percentiles.  Summary statistics of DOR for patients whose 
best response is CR or PR will be provided for groups with ≤ 5 responders.  
Disease control rate (DCR)  
DCR is defined as the proportion of patients in FAS with a best overall complete response (CR) 
or partial response (PR) or stable disease (SD) per RECIST 1.1.  
DCR will be estimated together with 95% confidence intervals (CIs) based on the exact 
binomial distribution will be presented.  
Time to response (TTR)  
TTR is defined as the time between date of start of treatment until first documented response 
(CR or PR). For patients who did not achieve a confirmed PR or CR, their TTR will be censored.  
TRR will be described using Kaplan -Meier methods and including estimated median (in months) 
with 95% CI, 25th and 75th percentiles. A summary statistics of TTR for patients whose best 
response is CR or PR will also be provided.  
Progression -free survival (PFS)  
PFS is defined as the time from the date of first dose of study treatment to the date of first 
documented disease progression per RECIST 1.[ADDRESS_929065] adequate 
tumor evaluation before the earlier of the cut -off date or the anticancer therapy date. By [CONTACT_15094], 
if disease progression or death is documented after one single missing tumor evaluation, the 
actual event date of disease pro gression/death will be used for the PFS event date. If disease 
progression or death is documented after two or more missing tumor evaluations, the PFS time 
of these patients will be censored at the date of the last adequate tumor evaluation without PD.  
PFS will be described using Kaplan -Meier methods and including estimated median (in months) 
with 95% CI, 25th and 75th percentiles.  
Phase II only efficacy endpoints  
Overall survival (OS)  
[COMPANY_001]  Confidential  Page 154 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 OS is defined as the time from the date of first dose of study drug to the date of death due to 
any cause. OS time for patients who are alive at the analysis cut -off date or are lost to follow -
up will be censored at the date of last contact. OS analysis wi ll only be performed for phase II 
part of patients.  
OS will be described using Kaplan -Meier methods and including estimated median (in months) 
with 95% CI, 25th and 75th percentiles.  
10.5.3  Pharmacokinetics  
The plasma samples from all patients will be assayed for EGF816 and LMI258 concentrations 
by [CONTACT_15035] a [COMPANY_001] -designated facility.  
Pharmacokinetic parameters will be determined by [CONTACT_105] -compartmental method(s) using the 
pharmacokinetic profile of EGF816 and LMI258. PK parameters such as listed in Table [ADDRESS_929066] measurable concentration sampling time (tlast) (mass x time x 
volume-1) 
AUCinf  The AUC from time zero to infinity (mass x time x volume-1) 
AUCtau  The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) 
Cmax  Maximum (peak) observed plasma drug concentration (mass x volume-1) 
Tmax  Time to reach maximum (peak) plasma drug concentration (time)  
CL/F  Apparent total body clearance of drug from plasma after oral administration (volume x time-1) 
Vz/F Apparent volume of distribution during terminal phase after oral administration (volume)  
T1/2, eff  Effective half -life calculated from Racc (time)  
T1/2 The elimination half -life associated with the terminal slope ( z) of a semi logarithmic 
concentration -time curve (time). Use qualifier for other half -lives 
Racc  Accumulation ratio calculated using AUCtau at steady state divided by [CONTACT_685449] C1D1  
[IP_ADDRESS]  Data handling principles  
All concentrations of EGF816  and LMI258  below their respective LLOQs (lower limits of 
quantification) or missing data will be labeled as such in the concentration data listings. 
Concentrations below the LLOQ will be treated as zero in summary statistics and for the 
calculation of pharmacokineti c parameters.  Any missing PK parameters will not be imputed.  
[IP_ADDRESS]  Data analysis principles  
[IP_ADDRESS].[ADDRESS_929067] dose date and time prior to the PK sample draw are non -missing will be included in the PK 
analysis. Unscheduled samples are not included in any analysis, but the se samples will be listed 
using FAS and flagged in the corresponding concentration listing.  

[COMPANY_001]  Confidential  Page 155 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
  
[IP_ADDRESS].2  Tables, figures and listings  
Descriptive statistics (n, mean, standard deviation, median, geometric mean, coefficient of 
variation CV (%), geometric CV (%), minimum, and maximum) will be presented for EGF816 
and LMI258 plasma concentrations by [CONTACT_2948]. Corresponding graphical presentation 
of the plasma concentration profiles will also be provided using the arithmetic mean (+/ - SD) 
and geometric mean values at each scheduled time point for full PK collections. The trough 
concentration -time profile  will also be plotted. PK parame ters will be summarized as well using 
descriptive statistics for EGF816 and LMI258. For Tmax, median values and ranges will be 
given.  
[IP_ADDRESS].3  Dose proportionality  and inter - and intra -individual variability  
An initial assessment of dose -proportionality and steady -state attainment will be conducted  
Inter - and intra -individual variability in systemic exposures will be assessed.  
  
 
 
 
 

[COMPANY_001]  Confidential  Page 156 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 10.7 Interim analysis  
Phase I part  
No formal interim analyses are planned. However, the dose -escalation design foresees that 
decisions based on the current data are taken before the end of the study. More precisely, after 
each cohort in the dose -escalation part, the next dose will be chosen  depending on the observed 
data. Details of this procedure and the process for communication with investigators are 
provided in Section 6.2.3 . 
Phase II part  
A futility  interim analysis  (IA) will be performed when approximately [ADDRESS_929068] 4 cycles or discontinued treatment prior to that time.  
The decision to stop enrollment  will be based on the predictive probability of success (PPS), 
which is the predictive probability that the observed ORR at the end of the study  will reach the 
target 55% (i.e., the probability of a positive conclusion of the study, should the trial be 
conducted to the maximum planned sample size). Given the interim observed data: x responders 
among n patients,   
PPS = Prob [Final Observed ORR All patients ≥ 55%| x, n]  
The enrollment and/or treatment will be stopped at the interim analysis if PPS < 0.10 (i.e., if 
less than [ADDRESS_929069] overall response of CR or PR). The criterion 
(number of responders) will be based on the actual number of patients in the FAS at the time  of 
the interim analysis.  
For the purpose of PPS computation, vague prior beliefs about the ORR distribution reflecting 
the current uncertainty about the efficacy of EGF816 in the study populationwill be summarized 
in prior distribution. A minimally informative Beta distribution prior ( Neuenschwander et al. 
2008 ) with prior m ean equal to a clinical threshold for futility on this population (5 5%) will be 
used (beta distribution with parameters a  = 1 and b  = (1 – 0.55)/0.55  = 0.818). At the time of 
interim analys is, the posterior parameters of the beta distribution of ORR will be computed 
using the available data. The number of responses in the potential future patients follows a beta -
binomial distribution with the same parameters. From this, the probability that the  final 
observed ORRs exceeds a given threshold can  be computed.  
Table 10-2 Probability of success at the primary analysis based on various numbers 
of responders observed at the IA  
Responders at IA out of 20 evaluable patients at IA  Probability of Success  
8/20 0.04 
9/20 0.14 
10/20  0.33 
11/20  0.57 
12/20  0.79 

[COMPANY_001]  Confidential  Page 157 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 10.[ADDRESS_929070] 
six patients at the MTD/  RP2D  level will be enrolled, as described in Section 6.2.3 . Multiple 
cohorts may be sequentially enrolled to the same dose level. Additional cohorts of 1 to 6 patients 
may be enrolled at any dose level below the estimated MTD/ RP2D  for further elaboration of 
safety and pharmacokinetic parameters as required. At least [ADDRESS_929071] reasonable operating characteristics 
relating to its MTD recommendation.  
10.8.2  Phase II part  
The operating characteristics of the statistical design are presented below with the probabilities 
to stop for futility at the interim analysis and to declare preliminary anti -tumor activity of the 
study treatment at the primary analysis (observing at leas t 22 responses in 40 patients) under 
different true ORR values (see also Table 10 -3). The actual total sample size may be greater 
than 40. The cut -off for the number of responders needed will be determined at the time of the 
interim analysis based on the a ctual number of patients who completed up to  4 cycles of study 
treatment.  
Table 10 -3 displays the probabilities to stop for futility at the interim analysis and to declare 
preliminary anti -tumor activity of the study treatment at the primary analysis (observing at least 
22 responses in 40 patients) under different true ORR values   
Table 10-3 Operating characteristics given sample size of 40 patients and interim 
analysis at 2 0 patients  
True ORR  Probability to stop for futility at IA  Success probability at primary analysis  
0.40 0.596  0.038  
0.45 0.414  0.129  
0.50 0.252  0.309  
0.55 0.131  0.553  
0.60 0.057  0.780  
0.65 0.020  0.923  
0.70 0.005  0.982  
0.75 0.001  0.998  
0.80 0.000  1.000  
With a sample size of 40 patients, the operating characteristics show reasonable characteristics  
of stoppi[INVESTIGATOR_685361] 55% and low 
probabilities of stoppi[INVESTIGATOR_685362] 55% or above. The probability of 
a positive conclusion at the primary analysis with 40 patients is greater th an 0.55 if the true 
ORR is greater or equal to 55%.  
10.9 Power for analysis of key secondary variables  
Not applicable.  
[COMPANY_001]  Confidential  Page 158 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 11 Ethical considerations and administrative procedures  
11.1 Regulatory and ethical compliance  
This clinical study was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical p rinciples laid down in the Declaration of Helsinki.  
11.2 Responsibilities of the investigator and IRB/IEC/REB  
The protocol and the proposed informed consent form must be reviewed and approved by a 
properly constituted Institutional Review Board/Independent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study start. Prior to study start, the investigator is required 
to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in 
accordance with these docum ents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs an d regulatory authorities as required.  
11.3 Informed consent procedures  
Eligible patients may only be included in the study after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent if applicable:, or, if 
incapable of doing so, after such consent has been provided by a legally acceptable 
representative of the patient. In cases where the patient’s representative gives consent, the 
patient should be informed about the study to the exten t possible given his/her understanding. 
If the patient is capable of doing so, he/she should  indicate assent by [CONTACT_685450] a separate assent form.  
Informed consent must be obtained before conducting any study -specific procedures (i.e. all of 
the procedures described in the protocol). The process of obtaining informed consent should be 
documented in the patient source documents. The date when a subjec t’s Informed Consent was 
actually obtained will be captured in their CRFs.  
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study and complies with the ICH GCP 
guideline and regulatory requirements. Any changes to this ICF suggested by t he investigator 
must be agreed to by [CONTACT_109060]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] monitor after IRB/IEC/REB approval.  
Women of childbearing potential should be informed that taking the study medication may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception  requirement for the 
duration of the study. If there is any question that the patient will not reliably comply, they 
should not be entered in the study.  
Additional consent form  
Companion study  will have a separate consent form covering this study . This form will be 
adapted for each Study based on a standard template used globally for all Studies. These 
[COMPANY_001]  Confidential  Page 159 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 informed consent forms will be submitted for ethical approval together with the Study Protocol 
and the main informed consent form of the Study. If a subject opts not to participate in the 
optional assessments, this in no way affects the subject’s ability t o participate in the main 
research study.  
11.4 Discontinuation of the study  
[COMPANY_001] reserves the right to discontinue this study under the conditions specified in the clinical 
study agreement. Specific conditions for terminating the study are outlined in  
Section 4.4 . 
11.5 Publication of study protocol and results  
[COMPANY_001] is committed to following high ethical standards for reporting study results for its 
innovative medicine, including the timely communication and publication of clinical trial 
results, whatever their outcome.  [COMPANY_001] assures that the key design elements of this protocol 
will be posted in a publicly accessible database e.g. such as ...clinicaltrials.gov, before study 
start. In addition, results of interventional clinical trials in adult patients are posted on 
www.novartisclinicaltrials.com, a public ly accessible database of clinical study results within 
1 year of upon study completion (i.e., LPLV), and finalization of the study report the results of 
this study will be either submitted for publication and/or posted in those for interventional 
clinical  trials involving pediatric patients within 6 months of study completion.  
[COMPANY_001] follows the ICMJE authorship guidelines (.. .icmje.org) and other specific guidelines 
of the journal or congress to which the publication will be submitted  
Authors will not receive remuneration for their writing of a publication, either directly from 
[COMPANY_001] or through the professional medical writing agency. Author(s) may be requested to 
present poster or oral presentation at scientific congress; however, t here will be no honorarium 
provided for such presentations.  
As part of its commitment to full transparency in publications, [COMPANY_001] supports the full 
disclosure of all funding sources for the study and publications, as well as any actual and 
potential conflicts of interest of financial and non -financial nature by [CONTACT_15064], including 
medical writing/editorial support, if applicable.  
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsor ed Research, 
please refer to .. .novartis.com.  
[COMPANY_001]  Confidential  Page 160 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 11.[ADDRESS_929072] keepi[INVESTIGATOR_540762], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional requirements 
for the protection of confidentiality of subjects. As part of par ticipating in a [COMPANY_001] -sponsored 
study, each site will permit authorized representatives of the sponsor(s) and regulatory agencies 
to examine (and when required by [CONTACT_1289], to copy) clinical records for the purposes of 
quality assurance reviews, a udits and evaluation of the study safety and progress.  
Source data are all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Examples 
of these original documents and data records include, but a re not limited to, hospi[INVESTIGATOR_1097], 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation 
checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_685363], microfiches, 
photographic negatives, microfilm or magnetic media, x -rays, and subject files and records kept 
at the pharmacy, at the laboratories, and medico -technical departments involved in the clinical 
trial. 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site Principal Investigator. The study case report form (CRF) is the primary data collection 
instrument for the study. The investigator should ensure  the accuracy, completeness, legibility, 
and timeliness of the data reported in the CRFs and all other required reports. Data reported on 
the CRF, that are derived from source documents, should be consistent with the source 
documents or the discrepancies s hould be explained. All data requested on the CRF must be 
recorded. Any missing data must be explained. Any change or correction to a paper CRF should 
be dated, initialed, and explained (if necessary) and should not obscure the original entry. For 
electron ic CRFs an audit trail will be maintained by [CONTACT_1190]. The investigator should retain 
records of the changes and corrections to paper CRFs.  
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by [CONTACT_5383]/or guidelines. The investigator/institution should tak e measures to prevent 
accidental or premature destruction of these documents.  
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an add itional period of time 
because of applicable laws, regulations and/or guidelines  
11.[ADDRESS_929073] ensure anonymity of the patients; patients must not be identified by [CONTACT_5384]. Signed informed consent forms and patient enrollment 
log must be kept strictly confidential to enable patient identification at the site.  
11.8 Audits and inspections  
Source data/documents must be available to inspections by [CONTACT_5385].  
[COMPANY_001]  Confidential  Page 161 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 11.[ADDRESS_929074] be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_5386]/IEC/REB it cannot be  implemented. All significant protocol 
deviations will be recorded and reported in the CSR.  
12.[ADDRESS_929075] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. Only 
amendments that are required for patient safety may be implemented prior  to IRB/IEC/REB 
approval. Notwithstanding the need for approval of formal protocol amendments, the 
investigator is expected to take any immediate action required for the safety of any patient 
included in this study, even if this action represents a deviati on from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed 
according to local regulations (e.g. [LOCATION_006] requires the notification of urgent safety measures 
within 3 days) but not later th an 10 working days.  
[COMPANY_001]  Confidential  Page 162 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 13 References (available upon request)  
[COMPANY_008] Pharmaceuticals LP (2015). IRESSA (gefitinib) [package insert]. Wilmington, 
DE: [COMPANY_008] Pharmaceuticals LP.  
Babb J,  Rogatko A and Zacks S. (1998)  Cancer Phase I clinical trials; efficient dose escalation 
with overdose control. Statist  Med 17, 1103 -1120 . 
Bean J, Brennan C, Shih JY, et al. (2007 ) MET amplification occurs with or without T790M 
mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc 
Natl Acad Sci U S A. 104(52):[ZIP_CODE] –7.  
Brawley OW  (2011) Avoidable cancer deaths globally . CA Cancer J Clin.  61(2):67 -8.  
ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004124/human_med_0
[ZIP_CODE].jsp&mid=WC0b01ac058001d124  
Engelman JA, Zejnullahu K, Mitsudomi T, et al. (2007 ) MET amplification leads to gefitinib 
resistance in lung cancer by [CONTACT_685451] g ERBB3 signaling. Science. 316(5827):1039 –43. 
fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm472565.htm  
Fowell DJ, Shinkai K, Liao XC, et al. (1999)  Impaired NFATc translocation and failure of Th2 
development in Itk -deficient CD4+ T cells. Immunity.  11(4):399 -409. 
Han J Y, Park K, Kim SW, et al (2012). First-SIGNAL: first -line single -agent iressa versus 
gemcitabine and cisplatin trial in never -smokers with adenocarcinoma of the lung. J Clin 
Oncol. 30 (10):1122 -28. 
Hirsch FR, Varella -Garcia M, Bunn Jr PA, et al.  (2003) Epi[INVESTIGATOR_621796]-small -cell lung carcinomas: correlation between gene copy number and protein 
expression and impact on prognosis. J Clin Oncol. 21(20):3798 –807. 
Inoue A, Kobayashi K, Usui K, et al. (2009) First-line gefitinib for patients with advanced 
non-small -cell lung cancer harboring epi[INVESTIGATOR_685364]. J Clin Oncol. 27(9):1394 –400. 
Jänne PA, Yang JC, Kim DW, et al (2015). AZD9291 in EGFR inhibitor -resistant non -small 
cell lung cancer. N Engl J Med; 372(18): 1689 -99. 
Kobayashi S, Boggon TJ, Dayaram T, et al. (2005) EGFR mutation and resistance of non -
small -cell lung cancer to gefitinib. N Engl J Med. 352(8):786 –92. 
Lynch TJ, Bell DW, Sordella R, et al. (2004) Activating mutations in the epi[INVESTIGATOR_626446] -small -cell lung cancer to gefitinib. N Engl J 
Med. 350(21):2129 –39. 
 
Mendelsohn J, Baselga J.  (2000)  The EGF receptor family as targets for cancer therapy. 
Oncogene. 19(56):6550 –65. 
Mitsudomi T, Morita S, Yatabe Y, et al. (2010) Gefitinib versus cisplatin plus docetaxel in 
patients with non -small -cell lung cancer harbouring mutations of the epi[INVESTIGATOR_13392] (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11(2):121 –8. 
[COMPANY_001]  Confidential  Page 163 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Mok TS, Wu YL, Thongprasert S, et al. (2009) Gefitinib or carboplatin -paclitaxel in 
pulmonary adenocarcinoma. N Engl J Med. 361(10):947 –57. 
Neuenschwander B, Branson M, Gsponer T . (2008) Critical aspects of the Bayesian approach 
to phase I cancer trials. Statist. Med . 27:2420 -2439 . 
Neuenschwander B, Capkun -Niggli G, Branson M, Spi[INVESTIGATOR_59898]. (2010) Summarizing 
historical information on controls in clinical trials. Clinical Trials. 7 , 5-18. 
Paez JG, Janne PA, Lee JC, et al. (2004) EGFR mutations in lung cancer: correlation with 
clinical response to gefitinib therapy. Science. 304(5676):1497 –500. 
Pao W, Miller V, Zakowski M, et al. (2004)  EGF receptor gene mutations are common in 
lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib 
and erlotinib. Proc Natl Acad Sci U S A. 101(36):[ZIP_CODE] –11. 
Rosell R, Carcereny E, Gervais R, et al. (2012) Erlotinib versus standard chemotherapy as 
first-line treatment for European patients with advanced EGFR mutation  positive non -small -
cell lung cancer (EURTAC): a multicentre, open -label, randomised phase 3 trial. Lancet 
Oncol. 13(3):239 –46. 
Rosell R, Molina MA, Costa C, et al. (2011)  Pretreatment EGFR T790M mutation and 
BRCA1 mRNA expression in erlotinib -treated advanced nonsmall -cell lung cancer patients 
with EGFR mutations. Clin Cancer Res. 17(5):1160 –8. 
Sagiv -Barfi I1, Kohrt HE1, Czerwinski DK1,  et al. (2015) . Therapeutic antitumor immunity 
by [CONTACT_685452], an inhibitor of both BTK and ITK. Proc Natl 
Acad Sci U S A. 112(9):E966 -72. doi: 10.1073/pnas.[PHONE_14269]. Epub 2015 Feb 17.  
Sangodkar J, Katz S, Melville H, et al. (2010) Lung adenocarcinoma: lessons in ranslation 
from bench to bedside. Mt Sinai J Med. 77(6):[ADDRESS_929076] LV, Yang JC, Yamamoto N, et al. (2013) Phase III study of afatinib or cisplatin plus 
pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin 
Oncol. 31(27):[ADDRESS_929077] LV, Waltman BA, Dias -Santagata D, et al. (2011)  Genotypic and histological 
evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 
3(75):75ra26.  
Soria J, Sequist LV, Goldman JW, et al. (2 -14) EORTC -NCI-AACR LATE BREAKING 
ABSTRACT Interim phase 2 results of study CO -1686 -008: A phase 1/2 study of the 
irreversible, mutant selective, EGFR inhibitor rociletinib . Presented at EORTC -NCI-AACR 
Annual Meeting.  
Su KY, Chen HY, Li KC, et al. (2012) Pretreatment epi[INVESTIGATOR_3506] (EGFR) 
T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients 
with non -small -cell lung cancer. J Clin Oncol. 30(4):433 –40. 
Takezawa K, Pi[INVESTIGATOR_657864] V, Arcila ME, et al.  (2012)  HER2 amplification: a potential 
mechanism of acquired resistance to EGFR inhibition in EGFR -mutant lung cancers that lack 
the second -site EGFR  T790M mutation. Cancer Discov. 2(10):922 –33.  
[COMPANY_001]  Confidential  Page 164 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Tan S-W D, Yang C-H J,(2016) Updated results of a phase [ADDRESS_929078] -
generation, mutant -selective EGFR tyrosine kinase inhibitor, in advanced non -small cell lung 
cancer harboring T790M , J Clin Oncol  34, (suppl; abstr 9044)  
Terrault NA, Lok AS F, McMahon BJ, et al (2018) Update on Prevention, Diagnosis , and 
Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology.  
67(4):  1560 -1599  
Wu YL, Zhou C, Hu CP, et al. (2014) Afatinib versus cisplatin plus gemcitabine for first -line 
treatment of Asian patients with advanced non -small -cell lung cancer harbouring EGFR 
mutations (LUX -Lung 6): an open -label, randomised phase 3 trial.  Lancet Oncol . S1470 -
2045(13)[ZIP_CODE] -1. 
Yang, J,et al. (2014) Updated safety andefficacy from a Phase 1 study of AZD9291 in patients (pts) 
withEGFR -TKI-resistant non -small cell lung cancer (NSCLC). Presented at European Society for 
Medical Oncology (ESMO) Annual Meeting,   
 Yu H, Arcila ME, Rekhtman N, et al. (2013)  Analysis of Mechanisms of Acquired 
Resistance to EGFR TKI therapy in 155 patients with EGFR -mutant Lung Cancers. Clin 
Cancer Res. 19(8): 2240 –2247 . 
Yu HA, Pao W. (2013) Afatinib -new therapy option for EGFR -mutant lung cancer.  Nat Rev 
Clin Oncol. 10(10):551 -2.  
Zhou C, Wu YL, Chen G, et al. (2011)  Erlotinib versus chemotherapy as first -line treatment 
for patients with advanced EGFR mutation -positive non -small -cell lung cancer Lancet Oncol . 
12:735 –42. 
[COMPANY_001]  Confidential  Page 165 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14 Appendices  
14.1 Appendix 1 – Guidelines for response, duration of overall 
response, TTF, TTP, progression -free survival and overall 
survival (based on RECIST 1.1)  
 
Document type:  TA Specific Guideline  
Document status:  Version 3.2: --> February 11, 2016  
Version 3.1:  29-Nov-2011  
Version 3:0:  19-Oct-2009  
Version 2:0:  18-Jan-2007  
Version 1:0:  13-Dec-2002  
Release date:  11-Feb-2016  
Authors (Version 3.2):   
 
Authors (Version 3.1):   
 
Authors (Version 3):   
 
Authors (Version 2):   
 
Authors (Version 1):   

[COMPANY_001]  Confidential  Page 166 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Glossary  
CR Complete response  
CRF Case Report Form  
CSR  Clinical Study Report  
CT Computed tomography  
DFS Disease -free survival  
eCRF  Electronic Case Report Form  
FPFV  First patient first visit  
GBM  Glioblastoma multiforme  
MRI Magnetic resonance imaging  
LPLV  Last patient last visit  
OS Overall survival  
PD Progressive disease  
PFS Progression -free survival  
PR Partial response  
RAP Reporting and Analysis Plan  
RECIST  Response Evaluation Criteria in Solid Tumors  
SD Stable disease  
SOD  Sum of Diameter  
TTF Time to treatment failure  
TTP Time to progression  
UNK  Unknown  
[COMPANY_001]  Confidential  Page 167 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.[ADDRESS_929079] criteria for tumor responses ( Therasse et al 2000 ) and the revised 
RECIST 1.1 guidelines ( Eisenhauer et al 2009 ). 
The efficacy assessments described in Section 14.1.[ADDRESS_929080] response. Section 14.1.18  is summarizing the “time to event” 
variables and rules which are mainly derived from internal discussions and regulatory 
consultations, as the RECIST criteria do not define these variables in detail. Section 14.1.29  of 
this guideline describes data handling and programming rules. This section is to be referred to 
in the SAP (Statistical Analysis Plan)  to provide further details needed for programming.  
14.1.[ADDRESS_929081] criteria ( Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; [ADDRESS_929082] guidelines (version 1.1) ( Eisenhauer et al 2009 ) European 
Journal of Cancer; 45:228 -247. 
14.1.3  Definitions  
14.1.4  Disease measurability  
In order to evaluate tumors throughout a study, definitions of measurability are required in order 
to classify lesions appropriately at baseline. In defining measurability, a distinction also needs 
to be made between nodal lesions (pathological lymph nodes ) and non -nodal lesions.  
• Measurable disease  - the presence of at least one measurable nodal or non -nodal lesion. If 
the measurable disease is restricted to a solitary lesion, its neoplastic nature should be 
confirmed by [CONTACT_3973]/histology.  
For patients without measurable disease see Section 14.1.27 . 
Measurable lesions  (both nodal and non -nodal)  
• Measurable non -nodal - As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should be no less than double the slice thickness or 10mm 
whichever is greater - e.g. the minimum non -nodal lesion size for CT/MRI with 5mm cuts  
will be 10 mm, for 8 mm contiguous cuts the minimum size  will be 16 mm. 
• Lytic bone lesions or mixed lytic -blastic lesions with identifiable soft tissue components, 
that can be evaluated by [CONTACT_4654]/MRI, can be considered as measurable lesions, if the soft tissue 
component meets the definition of measurability.  
• Measurable nodal lesions  (i.e. lymph nodes)  - Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non -measurable. Lymph nodes smaller than 10 mm in short axis at baseline, 
regardless of the slice thickness, are normal and not considered indicative of disease.  
• Cystic lesions : 
[COMPANY_001]  Confidential  Page 168 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • Lesions that meet the criteria for radiographically defined simple cysts (i.e. spherical 
structure with a thin, non -irregular, non -nodular and non-enhancing wall, no septations, 
and low CT density [water -like] content)  should not be considered as malignant lesions 
(neither measurable nor non -measurable) since they are, by [CONTACT_108], simple cysts.  
• ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable 
lesions, if they meet the definition of measurability described above. However, if 
noncystic lesions are present in the same patient, these are preferred for selection as 
target lesions.  
• Non-measurable lesions - all other lesions  are considered non -measurable, including small 
lesions (e.g. longest diameter <[ADDRESS_929083]/MRI or pathological lymph nodes with  10 
to < 15 mm short axis), as well as truly non -measurable lesions e.g., blastic bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory breast disease, 
lymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly  identified by 
[CONTACT_87415].  
14.1.5  Eligibility based on measurable disease  
If no measurable lesions are identified at baseline, the patient may be allowed to enter the study 
in some situations (e.g. in Phase III studies where PFS is the primary endpoint). However, it is 
recommended that patients be excluded from trials where the main focus is on the Overall 
Response Rate (ORR). Guidance on how patients with just non -measurable disease at baseline 
will be evaluated for response and also handled in the statistical analyses is given in Section 
14.1.27 . 
14.1.6  Methods of tumor measurement  - general guidelines  
In this document, the term “contrast” refers to intravenous (i.v) contrast.  
The following considerations are to be made when evaluating the tumor:  
• All measurements should be taken and recorded in metric notation  (mm) , using a ruler or 
calipers. All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than 4 weeks before the beginning of the treatment.  
• Imaging -based evaluation is preferred to evaluation by [CONTACT_111910] a treatment.  
• For optimal evaluation of patients, the same  methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow -up. 
Contrast -enhanced CT of chest, abdomen and pelvis should preferably be performed using 
a [ADDRESS_929084]/MRI scan slice 
thickness should not exceed [ADDRESS_929085] or develops 
a contraindication during the trial, the following change in imaging modality will be 
accepted for follow up: a non -contrast CT of chest (MRI not recommended due to 
respi[INVESTIGATOR_217919]) plus contrast -enhanced MRI of abdomen and pelvis.  
• A change in methodology can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_111796], like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a major change in technique (e .g. from CT 
to MRI, or vice -versa), or a change in any other imaging modality. A change from 
[COMPANY_001]  Confidential  Page 169 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 conventional to spi[INVESTIGATOR_14968] a major “change in method” for 
the purposes of response assessment. A change in methodology will r esult by [CONTACT_15074] a 
UNK overall lesion response assessment  as per [COMPANY_001] calculated response . However , 
another response assessment than the [COMPANY_001] calculated UNK response may be accepted 
from the investigator or the central blinded reviewer if a definitive response assessment can 
be justified, based on the available information.  
• FDG -PET : can complement CT scans in assessing progression (particularly possible for 
‘new’ disease). New lesions on the basis of FDG -PET imaging can be identified according 
to the following algorithm:  
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.  
• No FDG -PET at baseline with a positive FDG -PET at follow -up: 
• If new disease is indicated by a positive PET scan but is not confirmed by [CONTACT_4654] (or some other 
conventional technique such as MRI) at the same assessment, then follow -up assessments 
by [CONTACT_685453]. In all 
cases PD will be the date of confirmation of new disease by [CONTACT_4654] (or some other conventional 
technique such as MRI) rather than the date of the positive PET scan. If there is a positive 
PET scan without any confirmed progression at that si te by [CONTACT_4654], then a PD cannot be 
assigned.  
• If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.  
• Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they are 
clearly defined and surrounded by [CONTACT_6776]. However, CT is preferable.  
• Physical exams : Evaluation of lesions by [CONTACT_15076], with at least 10mm size, and can be assessed using calipers.  
• Ultrasound : When the primary endpoint of the study is overall  response rate, ultrasound 
(US) should not be used to measure tumor lesions , unless pre -specified by [CONTACT_760].  It 
is, however, a possible alternative to clinical measurements of superficial palpable lymph 
nodes, subcutaneous lesions and thyroid nodules. US might also be useful to confirm the 
complete disappearance of superficial lesions usually assessed by [CONTACT_198103] l examination.  
• Endoscopy and laparoscopy : The utilization of endoscopy and laparoscopy for objective 
tumor evaluation has not yet been fully and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological resp onse when biopsies are 
obtained.  
• Tumor markers : Tumor markers alone cannot be used to assess response. However, some 
disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, PSA 
for prostate cancer, alpha -FP, LDH and Beta -hCG for testicular cancer) can be integrated 
as non -target disease. If markers are initially above the upper no rmal limit they must 
normalize for a patient to be considered in complete clinical response when all lesions have 
disappeared.  
• Cytology and histology : Cytology and histology can be used to differentiate between PR 
and CR in rare cases (i.e. after treatment to differentiate between residual benign lesions and 
[COMPANY_001]  Confidential  Page 170 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 residual malignant lesions in tumor types such as germ cell tumors). Cytologic confirmation 
of neoplastic nature of any effusion that appears or worsens during treatment is required 
when the measurable tumor has met the criteria for response or stable dise ase. Under such 
circumstances, the cytologic examination of the fluid collected will permit differentiation 
between response and stable disease (an effusion may be a side effect of the treatment) or 
progressive disease (if the neoplastic origin of the flui d is confirmed).  
• Clinical examination : Clinical lesions will only be considered measurable when they are 
superficial (i.e. skin nodules and palpable lymph nodes). For the case of skin lesions, 
documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, is 
recomme nded.  
14.1.7  Baseline documentation of target and non-target  lesions  
For the evaluation of lesions at baseline and throughout the study, the lesions are classified at 
baseline as either target or non-target  lesions:  
• Target lesions : All measurable lesions (nodal and non -nodal) up to a maximum of five 
lesions in total (and a maximum of two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitability for accurate repeated measurements (either by [CONTACT_15078]). Each target lesion must be uniquely and sequentially  numbered on the CRF (even 
if it resides in the same organ).  
Minimum target lesion size at baseline  
• Non-nodal target : Non -nodal target lesions identified by [CONTACT_685454] (e.g. clinical examination, photography) should be at least [ADDRESS_929086] 
diameter. See Section 14.1.4 . 
• Nodal target : See Section 14.1.4 . 
A sum of diameters (long axis  for non -nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by [CONTACT_14218]. Each  
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF . 
• Non-target  lesions : All other lesions are considered  non-target  lesions , i.e. lesions not 
fulfilling the criteria for target lesions at baseline.  Presence or absence or worsening of non-
target lesions should be assessed throughout the study; measurements of these lesions  are 
not required.  Multiple non -target lesions involved in the same organ can be assessed as a 
group and recorded as a single item (i.e. multiple liver metastases). Each non -target lesion 
identified at baseline must be followed at each subse quent evaluation and documented on 
eCRF.  
14.1.8  Follow -up evaluation of target and non-target  lesions  
To assess tumor response, the sum of diameters for all target lesions will be calculated (at 
baseline and throughout the study). At each assessment response is evaluated first separately 
for the target ( Table 14 -1) and non -target lesions ( Table 14 -2) identified at baseline. These 
[COMPANY_001]  Confidential  Page 171 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 -3) as well as the presence or absence of new lesions.  
14.1.[ADDRESS_929087] to 
substantial “partial volume” effects (i.e. size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent examinations, when, in fact, they remain the same size).  
If the lesion has completely disappeared, the lesion size should be reported as [ADDRESS_929088] slice 
thickness (but should not be changed with varying CT slice thickness).  Actual measurement 
should be given for all lesions larger than [ADDRESS_929089] diameter irrespective of slice 
thickness/reconstruction interval.  
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated.  
14.1.11  Nodal lesions  
A nodal lesion less than 10 mm in size by [CONTACT_15082]. Lymph nodes are not 
expected to disappear completely, so a “non -zero size” will always persist.  
Measurements of nodal target lesions that become [ADDRESS_929090] slice thickness (but 
should not be changed with varying CT slice thickness). Actual measurement should be given 
for all lesions larger than 5 mm in short axis  irrespective of slice thickness/reconstruction 
interval.  
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of dia meters for target 
lesions, which may be required subsequently for response determination.  
[COMPANY_001]  Confidential  Page 172 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.12  Determination of target lesion response  
Table 14-1 Response criteria for target lesions  
Response Criteria  Evaluation of target lesions  
Complete Response (CR):  Disappearance of all non -nodal target lesions. In addition, any pathological lymph nodes 
assigned as target lesions must have a reduction in short axis to < 10 mm 1 
Partial Response (PR):  At least a 30% decrease in the sum of diameter of all target lesions, taking as reference 
the baseline sum of diameters.  
Progressive Disease (PD):  At least a 20% increase in the sum of diameter of all measured target lesions, taking as 
reference the smallest sum of diameter of all target lesions recorded at or after baseline. 
In addition to the relative increase of 20%, the sum must also demonstrate an absolute 
increase of at least 5 mm2. 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which 
would qualify for PD.  
Unknown (UNK)  Progression has not been documented and one or more target lesions have not been 
assessed or have been assessed using a different method than baseline.3 
1.SOD for CR may not be zero when nodal lesions are part of target lesions  
2. Following an initial CR, a PD cannot be assigned if all non -nodal target lesions are still not present and all  
nodal lesions are <10 mm in size. In this case, the target lesion response is CR  
3. In exceptional circumstances an UNK response due to change in method could be over -ruled by [CONTACT_685455] (see Notes on  
target lesion response and methodology change See Section 14.1.6 . 
Notes on target lesion response  
Reappearance of lesions : If the lesion appears at the same anatomical location where a target 
lesion had previously disappeared, it is advised that the time point of lesion disappearance (i.e. 
the “0 mm” recording) be re -evaluated to make sure that the lesion was not actually pre sent 
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following 
possibilities:  
• The lesion is a new lesion, in which case the overall tumor assessment will be considered as 
progressive disease  
• The lesion is clearly a reappearance of a previously disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
on the sum of tumor measurements as presented in Table 14 -1 above  (i.e. a PD will be 
determined if there is at least 20% increase in the sum of diameters of all measured target 
lesions, taking as reference the smallest sum of diameters of all target lesions recorded at or 
after baseline  with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision.  This applies to patients who have 
not achieved target response of CR. For patients who have achieved CR, please refer to last 
bullet in this section.  
• For those patients who have only one target lesion at baseline, the reappearance of the target 
lesion which disappeared previously, even if still small, is considered a PD.  
• Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for [ADDRESS_929091] -baseline visit is 140  
[COMPANY_001]  Confidential  Page 173 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 mm (with data for 2 other lesions missing) then a PD should be assigned. However, in other 
cases where a PD cannot definitely be attributed , the target lesion response would be UNK.  
• Nodal lesion decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they should still have a measurement 
recorded on scans. This measurement should be reported even when the nodes are normal in 
order not to overstate progr ession should it be based on increase in the size of nodes.  
• Lesions split : In some circumstances, disease that is measurable as a target lesion at baseline 
and appears to be one mass can split to become two or more smaller sub -lesions. When this 
occurs, the diameters (long axis - non-nodal lesion, short axis - nodal lesions) of the two split 
lesions should be added together and the sum recorded in the diameter field on the case report 
form under the original lesion number. This value will be included in the sum of diameters 
when deriving target lesion response.  The individual split lesions will not be considered as 
new lesions, and will not automatically trigger a PD designation.  
• Lesions coalesced : Conversely, it is also possible that two or more lesions which were 
distinctly separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may be maintained that would aid in obtaining diameter 
measur ements of each individual lesion. If the lesions have truly coalesced such that they are 
no longer separable, the maximal diameters (long axis - non-nodal lesion, short axis - nodal 
lesions) of the “merged lesion” should be used when calcu lating the sum of diameters for 
target lesions. On the case report form, the diameter of the “merged lesion” should b e 
recorded for the size of one of the original lesions while a size of “0”mm should be entered 
for the remaining lesion numbers which have coalesced.  
• The measurements for nodal lesions , even if less than [ADDRESS_929092] with slight modifications.  
• Since lesions less than [ADDRESS_929093] disappeared.  
• Once a CR target lesion response has been assigned a CR will continue to be appropriate 
(in the absence of missing data) until progression of target lesions.  
• Following a CR, a PD can subsequently only be assigned for target lesion response if 
either a non -nodal target lesion “reappears” or if any single nodal lesion is at least [ADDRESS_929094] 20% increase in sum of the diameters of all nodal target lesions 
relative to nadir with at least 5 mm increase in the absolute sum of the diameters.  
• A change in method for the evaluation of one or more lesions will usually lead to an UNK 
target lesion response unless there is progression indicated by [CONTACT_685456]. In exceptional circumstances an inv estigator or 
central reviewer might over -rule this assignment to put a non -UNK response using expert 
judgment based on the available information. E.g. a change to a more sensitive method 
might indicate some tumor shrinkage of target lesions and definitely rule out progression in 
which case the investigator might assign an SD target lesion response; however, this should 
be done with caution and conservatively as the response categories have well defined 
criteria.  
[COMPANY_001]  Confidential  Page 174 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.13  Determination of non -target lesion response  
Table 14-2 Response criteria for non-target  lesions  
Response Criteria  Evaluation of non -target lesions  
Complete Response (CR):  Disappearance of all non -target lesions. In addition, all lymph nodes assigned a non -
target lesions must be non-pathological in size (< 10 mm short axis)  
Progressive Disease (PD):  Unequivocal progression of existing non -target lesions.1 
Non-CR/Non -PD: Neither CR nor PD  
Unknown (UNK)  Progression has not been documented and one or more non -target lesions have not 
been assessed or have been assessed using a different method than baseline2. 
1 The assignment of PD solely based on change in non -target lesions in light of target lesion response of CR,  
PR or SD should be exceptional. In such circumstances, the opi[INVESTIGATOR_685365] (or study chair).  
2 It is recommended that the investigator and/or central reviewer should use expert judgment to assign  
a Non -UNK response wherever possible (see notes section for more details)  
Notes on non -target lesion response  
• The investigator and/or central reviewer can use expert judgment to assign a non -UNK 
response wherever possible, even where lesions have not been fully assessed or a different 
method has been used. In many of these situations it may still be possible to id entify 
equivocal progression (PD) or definitively rule this out (non -CR/Non -PD) based on the 
available information. In the specific case where a more sensitive method has been used 
indicating the absence of any non -target lesions, a CR response can also be  assigned  
• The response for non -target lesions is CR only if all non -target non -nodal lesions which 
were evaluated at baseline are now all absent and with all non -target nodal lesions returned 
to normal size (i.e. < 10  mm). If any of the non -target lesions are still present, or there are 
any abnormal nodal lesions (i.e.  10 mm) the response can only be ‘ Non-CR/Non -PD’ 
there is unequivocal progression of the non -target lesions (in which case response is PD) or 
it is not possible to determine whether there is unequivocal progression (in which case 
response is UNK) . 
• Unequivocal progression:  To achieve “unequivocal progression”  on the basis of non -target 
disease there must be an overall level of substantial worsening in non -target disease such 
that, even in presence of CR, PR or SD in target disease, the overall tumor burden has 
increased sufficiently to merit discontinuation of  therapy. A modest “increase” in the size 
of one or more non -target lesions is usually not sufficient to qualify for unequivocal 
progression status. The designation of overall progression solely on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. In order for a PD to be assigned on the basis of non -target lesions , the increase in the 
extent of the disease must be substantial  even in cases where there is no measurable disease 
at baseline. If there is unequivocal progression of non -target lesion (s), then at least one of 
the non -target lesions must be assigned a status of “Worsened”. Where possible, similar 
rules to those describ ed in Section 14.1.12  for assigning  PD following a CR for the non -
target lesion response in the presence of non -target lesions nodal lesions should be applied.  
[COMPANY_001]  Confidential  Page 175 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.14  New lesions  
The a ppearance of a new lesion is always associated with Progressive Disease (PD) and has to 
be recorded as a new lesion in the New Lesion CRF page.  
• If a new lesion  is equivocal , for example because of its small size, continued therapy and 
follow -up evaluation will clarify if it represents truly new disease. If repeat scans confirm 
there is definitely a new lesion, then progression should be declared using the date of the 
first observation of the lesion.  
• If new disease is observed in a region which was not scanned at baseline  or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for any of this patient's assessment 
(see Section 14.1.15 ). 
• A lymph node is considered as a “new lesion”  and, therefore, indicative of progressive 
disease if the short axis increases in size to  [ADDRESS_929095] time in the study plus 5 
mm absolute increase.  FDG -PET : can complement CT scans in assessing progression 
(particularly possible for ‘new’ disease). See Section 14.1.6 . 
14.1.15  Evaluation of overall lesion response  
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non -target lesion response and presence o f new lesions as shown below in  
Table 14-3. 
Table 14-3 Overall lesion response at each assessment  
Target lesions  Non-target lesions  New Lesions  Overall  
lesion response  
CR CR No CR1 
CR Non-CR/Non -PD3 No PR 
CR, PR, SD  UNK  No UNK  
PR Non-PD and not UNK  No PR1 
SD Non-PD and not UNK  No SD1, 2 
UNK  Non-PD or UNK  No UNK1 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.2. Once 
confirmed PR was achieved, all these assessments are considered PR.  
3. As defined in Section 14.1.8 . 
If there are no baseline scans available  at all , then the overall lesion response at each assessment 
should be considered Unknown (UNK).  
In some circumstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) t o confirm the CR.  
[COMPANY_001]  Confidential  Page 176 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.[ADDRESS_929096] response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). In general, the patient's best respons e assignment will depend on 
the achievement of both measurement and confirmation criteria.  
The best overall response will usually be determined from response assessments undertaken 
while on treatment. However, if any assessments occur after treatment withdrawal the protocol 
should specifically describe if these will be included in the determinat ion of best overall 
response and/or whether these additional assessments will be required for sensitivity or 
supportive analyses. As a default, any assessments taken more than [ADDRESS_929097] overall response determination. If response assessments taken after 
withdrawal from study treatment  and/or alternative therapy are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.  
Where a study requires confirmation of response  (PR or CR ), changes in tumor measurements 
must be confirmed by [CONTACT_15085] [ADDRESS_929098] be clearly stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasib le, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.  
• -For non -randomized trials where response is the primary endpoint, confirmation is needed.  
• -For trials intended to support accelerated approval, confirmation is needed  
• For all other trials, confirmation of response may be considered optional.  
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:  
• CR = at least two determinations of CR at least 4 weeks apart before progression  where 
confirmation required or one determination of CR prior to progression where confirmation 
not required  
• PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualifying for a CR)  where confirmation required or one determination of PR prior 
to progression where confirmation not required  
• SD = at least one SD assessment (or better) > 6 weeks after randomization/start of treatment 
(and not qualifying for CR or PR).  
• PD = progression  12 weeks after randomization/ start of treatment (and not qualifying for 
CR, PR or SD).  
[COMPANY_001]  Confidential  Page 177 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • UNK = all other cases (i.e. not qualifying for confirmed CR or PR and without SD after 
more than [ADDRESS_929099] 12 weeks)  
The time durations specified in the SD/PD/UNK definitions above are defaults based on a 6 
week tumor assessment frequency. However these may be modified for specific indications 
which are more or less aggressive. In addition, it is envisaged that the time duration may also 
take into account assessment windows. E.g. if the assessment occurs every 6 weeks with a time 
window of +/ - 7 days, a BOR of SD would require a SD or better response longer than 5 weeks 
after randomization/start of treatment.  
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot  subsequently have a lower status other than a 
PD, e.g. PR or SD, as this would imply a progression based on one or more lesions reappearing, 
in which case the status would become a PD.  
Once an overall lesion response of PR is observed (which may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where  
confirmation of response is required, if a patient has a single PR ( 30% reduction of tumor 
burden compared to baseline) at one assessment, followed by a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally 
disappear in w hich case a CR assignment is applicable. In studies where confirmation of 
response is not required after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is documented or the lesion totally disappears in whic h case a 
CR assignment is applicable.  
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 mm at baseline and then 14 0 mm - 150 mm - 140 mm - 160 mm - 160 mm at the subsequent 
visits. Assuming that non-target lesions did not progress, the overall lesion response would be 
PR - SD - PR - PR - PR. The second assessment with 14 0 mm confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (20 0 mm to 16 0 mm) at the following assessments.  
If the patient progressed but continues study treatment , further assessments are not considered 
for the determination of best overall response.  
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates. 
The best overall response for a patient is always calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may be provided 
from different sources:  
• Investigator overall lesion response  
• Central Blinded Review overall lesion response  
• [COMPANY_001] calculated overall lesion response (based on measurements from either 
Investigator or Central Review)  
[COMPANY_001]  Confidential  Page 178 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 The primary analysis of the best overall response will be based on the sequence of 
investigator/central blinded review/calculated (investigator)/calculated (central) overall lesion 
responses.  
Based on the patients’ best overall response during the study, the following rates are then 
calculated:  
Overall response rate (ORR)  is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.  
Disease control rate  (DCR)  is the proportion of patients with a best overall response of CR or 
PR or SD.  The objective of this endpoint is to summarize patients with signs of “activity” 
defined as either shrinkage of tumor (regardless of duration) or slowing down of tumor growth.  
Clinical benefit rate (CBR) is the proportion of patients with a best overall response of CR or 
PR , or an overall lesion response of SD or Non -CR/Non -PD which lasts for a minimum time 
duration (with a default of at least [ADDRESS_929100] cancer studies). This endpoint measures 
signs of activity taking into account duration of disease stabilization.  
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:  
Early progression rate (EPR)  is the proportion of patients with progressive disease within 
8 weeks of the start of treatment.  
The protocol should define populations for which these will be calculated. The timepoint for 
EPR is study specific. EPR is used for the multinomial designs of Dent and Zee (2001)  and 
counts all patients who at the specified assessment (in this example the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, wi ll not be counted as early 
progressors in the analysis but may be included in the denominator of the EPR rate, depending 
on the analysis population used. Similarly when examining overall response and disease control, 
patients with a best overall response a ssessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the analysis population (e.g. populations based on an ITT approach).  
14.1.18  Time to event variables  
The protocol should state which of the following variables is used in that study.  
14.1.19  Progression -free survival  
Usually in all Oncology studies, patients are followed for tumor progression after 
discontinuation of study medication for reasons other than progression or death. If this is not 
used, e.g. in Phase I or II studies, this should be clearly stated in the pro tocol. Note that 
randomized trials (preferably blinded) are recommended where PFS is to be the primary 
endpoint.  
Progression -free survival  (PFS)  is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event, progression -free survival is censored at the date of last adequate 
tumor assessment.  
[COMPANY_001]  Confidential  Page 179 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 PFS rate at x weeks is an additional measure used to quantify PFS endpoint. It is recommended 
that a Kaplan Meier estimate is used to assess this endpoint.  
14.1.[ADDRESS_929101] seen alive / last known date patient alive , the date of death and the reason of 
death (“Study indication” or “Other”).  
Overall survival (OS)  is defined as the time from date of randomization/start of treatment to 
date of death due to any cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive . 
14.1.21  Time to progression  
Some studies might consider only death related to underlying cancer as an event which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underlying cancer.  
Time to progression (TTP)  is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underlying cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate t umor 
assessment.  
14.1.22  PFS2  
A recent EMA guidance (EMA, 2012) recommends a substitute end point intermediate to PFS 
and OS called PFS2, a surrogate for OS when OS cannot be measured reliably, which assesses 
the impact of the experimental therapy on next -line treatment. The main purpo se of this 
endpoint is to assess long term maintenance strategies, particularly of resensitizing agents and 
where it is necessary to examine the overall “field of influence”.  
PFS2, which could be termed PFS deferred, PFS delayed, tandem PFS, or PFS version 2.0, is 
the time from date of randomization/start of treatment to the date of event defined as the first 
documented progression on next -line treatment or death from any cause . The censoring rules 
for this endpoint will incorporate the same principles as those considered for PFS in this 
document, and in addition may involve other considerations which will need to be detailed in 
the protocol.  
Please note that data collection for the PFS2 is limited to the date of progression and not specific 
read of the tumor assessments.  
It is strongly recommended that the teams consult regulatory agencies for scientific advice given 
the limited experience with the use of this endpoint in regulatory setting in light of 
methodological issues w.r.t. censoring foreseen.  
14.1.[ADDRESS_929102] of discontinuation 
[COMPANY_001]  Confidential  Page 180 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study or the disease.  
Time to treatment failure (TTF)  is the time from date of randomization/start of treatment to 
the earliest of date of progression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment  
failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.  
14.1.[ADDRESS_929103] been reports where 
a treatment with a significantly higher response rate had a significantly shorter duration of 
response but where this probably primarily reflected selection bias which is explained as 
follows: It is postulated that there are  two groups of patients: a good risk group and a poor risk 
group. Good risk patients tend to get into  response readily (and relatively quickly) and tend to 
remain in response after they have a response. Poor risk patients tend to be difficult to achieve  
a response, may have a longer time to respond, and tend to relapse quickly when they do respond. 
Potent agents induce a response in both good risk and poor risk patients. Less potent agents 
induce a response mainly in good risk patients only. This is de scribed in more detail by [CONTACT_15088] 
(1988) . 
It is recommended that an analysis of all patients (both responders and non -responders) be 
performed whether or not a “responders only” descriptive analysis is presented. An analysis of 
responders should only be performed to provide descriptive statistics and even then interpreted 
with caution by [CONTACT_15089]. If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” only) using appropriate statistical methods such as 
the techniques described in Ellis et al (2008) . It should  also be stated in the protocol if duration 
of response is to be calculated in addition for unconfirmed response.  
For summary statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all -patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study is usually taken into account in the analysis).  
Duration of overall response (CR or PR) : For patients with a CR or PR (which may have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.  
The following two durations might be calculated in addition for a large Phase III study in which 
a reasonable number of responders is seen.  
Duration of overall complete response (CR) : For patients with a CR (which may have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.  
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.  
[COMPANY_001]  Confidential  Page 181 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.25  Time to response  
Time to overall response (CR or PR)  is the time between date of randomization/start of 
treatment until first documented response (CR or PR). The response may need to be confirmed 
depending on the type of study and its importance. Where the response needs to be confirmed 
then time to respons e is the time to the first CR or PR observed.  
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “ responders ” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.1.24 . It is recommended that an 
analysis of all patients (both responders and non -responders) be  performed whether or not a 
“responders only” descriptive analysis is presented. Where an inferential statistical comparison 
is required, then all patients should definitely be included in the analysis to ensure the statistical 
test is valid. For analysis including all patients, patients who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.  
• at maximum follow -up (i.e. FPFV to LPLV used for the analysis)  for patients who had a 
PFS event (i.e. progressed or died due to any cause). In this case the PFS event is the worst 
possible outcome as it means the patient cannot subsequently respond. Since the statistical 
analysis usually makes use of the ranking of ti mes to response it is sufficient to assign the 
worst possible censoring time which could be observed in the study which is equal to the 
maximum follow -up time (i.e. time from FPFV to LPLV)  
• at last adequate tumor assessment date  otherwise . In this case patients have not yet 
progressed so they theoretically still have a chance of responding  
Time to overall complete response (CR)  is the time between dates of randomization/start of 
treatment until first documented CR. Similar analysis considerations including (if appropriate) 
censoring rules apply for this endpoint described for the time to overall response endpoint.  
14.1.26  Definition of start and end dates for time to event variables  
Assessment date  
For each assessment (i.e. evaluation number), the assessment date  is calculated as the latest of 
all measurement dates (e.g. X -ray, CT -scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise - if overall lesion response is progression - the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.  
In the calculation of the assessment date for time to event variables, any unscheduled 
assessment should be treated similarly to other evaluations.  
Start dates  
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start  will be used as the start date.  
For the calculation of duration of response the following start date should be used:  
• Date of first documented response is the assessment date of the first overall lesion response 
of CR (for duration of overall complete response) or CR / PR (for duration of overall 
response) respectively, when this status is later confirmed.  
[COMPANY_001]  Confidential  Page 182 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 End dates  
The end dates which are used to calculate ‘time to event’ variables are defined as follows:  
• Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study evaluation completion page or the survival follow -up 
page).  
• Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.  
• Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used.  If no post -
baseline assessments are available (before an event or a censoring reason occurred) the date 
of randomization/start of treatment is used.  
• Date of next scheduled assessment is the date of the last adequate tumor assessment plus the 
protocol specified time interval for assessments. This date may be used if back -dating is 
considered when the event occurred beyond the acceptable time window for the next tumor 
assessment as per protocol (see Section 14.1.26 ). 
Example  (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months - missing - missing - PD. Date of next scheduled assessment 
would then correspond to 9 months.  
• Date of discontinuation  is the date of the end of treatment visit.  
• Date of last contact [CONTACT_15090]. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive  from th e survival follow -up page is used. 
If no survival follow -up is available, the date of discontinuation is used as last contact [CONTACT_568].  
• Date of secondary anti -cancer therapy is defined as the start date of any additional 
(secondary) antineoplastic therapy or surgery.  
14.1.27  Handling of patients with non -measurable disease only at baseline  
It is possible that patients with only non -measurable disease present at baseline are entered into 
the study, either because of a protocol violation or by [CONTACT_8345] (e.g. in Phase III studies with PFS 
as the primary endpoint). In such cases the handling of th e response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.  
It is recommended that any patients with only non -measurable disease at baseline should be 
included in the main (ITT) analysis of each of these endpoints.  
Although the text of the definitions described in the previous sections primarily relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate manner. The overall response for pa tients with non -
measurable disease is derived slightly differently according to Table 14-4. 
Table 14-4 Overall lesion response at each assessment : patients with non -target 
disease only  
Non-target lesions  New Lesions  Overall lesion response  
[COMPANY_001]  Confidential  Page 183 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 CR No CR 
Non-CR/Non -PD1 No Non-CR/non -PD 
UNK  No UNK  
PD Yes or No  PD 
Any Yes PD 
1 As defined in Section 14.1.8 . 
In general, the non-CR/non -PD response  for these patients is considered equivalent to an SD 
response in endpoint determination. In summary tables for best overall response patients with 
only non -measurable disease may be highlighted in an appropriate fashion e.g. in particular by 
[CONTACT_685457] e specific numbers with the non -CR/non -PD category.  
In considering how to incorporate data from these patients into the analysis the importance to 
each endpoint of being able to identify a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.  
For ORR  it is recommended that the main (ITT) analysis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all othe r patients as “non -responders”.  
For PFS , it is again recommended that the main ITT analyses on these endpoints include all 
patients with only non-measurable disease at baseline, with possible sensitivity analyses which 
exclude these particular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients  with only non -measurable 
disease.  
14.1.28  Sensitivity analyses  
This section outlines the possible event and censoring dates for progression , as well as address es 
the issues of missing tumor assessments during the study. For instance, if one or more 
assessment visits are missed prior to the progression event, to what date should the progression 
event be assigned? And should progression event be ignored if it occurr ed after a long period 
of a patient being lost to follow -up? It is important that the protocol and SAP specify the primary 
analysis in detail with respect to the definition of event and censoring dates and also include a 
description of one or more sensitivity analyses to be performed.  
Based on definitions outlined in Section 14.1.26 , and using the draft FDA guideline on 
endpoints ( Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005 ) 
as a reference, the following analyses can be considered:  
Table 14-5 Options for event  dates used in PFS, TTP, duration of response  
Situation  Options for end -date (progression or 
censoring)1 
(1) = default unless specified differently in 
the protocol or RAP  Outcome  
A No baseline assessment  (1) Date of randomization/start of treatment3 Censored  
B Progression at or before next scheduled 
assessment  (1) Date of progression  
(2) Date of next scheduled assessment2 Progressed  
Progressed  
C1 Progression or death after exactly one 
missing assessment  (1) Date of progression (or death)  
(2) Date of next scheduled assessment2 Progressed  
Progressed  
[COMPANY_001]  Confidential  Page 184 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Situation  Options for end -date (progression or 
censoring)1 
(1) = default unless specified differently in 
the protocol or RAP  Outcome  
C2 Progression or death after two or more 
missing assessments  (1) Date of last adequate assessment2 
(2) Date of next scheduled assessment2 
(3) Date of progression (or death)  Censored  
Progressed  
Progressed  
D No progression  (1) Date of last adequate assessment  Censored  
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim  (1) Ignore clinical progression and follow 
situations above  
(2) Date of discontinuation (visit date at which 
clinical progression was determined)  As per above 
situations  
 Progressed  
F New anticancer therapy given  (1) Ignore the new anticancer therapy and 
follow situations above (ITT approach)  
(2) Date of last adequate assessment prior to 
new anticancer therapy  
(2) Date of secondary anti -cancer therapy  
(3) Date of secondary anti -cancer therapy  As per above 
situations  
Censored  
Censored  
Event  
G Deaths due to reason other than 
deterioration of ‘Study indication’  (1) Date of last adequate assessment  Censored 
(only TTP and 
duration of 
response)  
1.=Definitions can be found in Section 14.1.26  
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in Section 14.1.26 . 
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled assessment as 
defined in the protocol in which case this is a PFS event at the date of death.  
The primary analysis and the sensitivity analyses must be specified in the protocol. Clearly 
define if and why options (1) are not used for situations C, E and (if applicable) F.  
Situation s C (C1 and C2) : Progression or death after one or more missing assessments: The 
primary analysis is usually using option s (1) for situation s C1 and C2 , i.e. 
• (C1) taking the actual progression or death date, in the case of only one missing 
assessment . 
• (C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.  
In the case of two or missing assessments (situation C2), option (3)  may be considered jointly 
with option (1) in situation C1 as sensitivity analysis. A variant of this sensitivity analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.  
Situation E: Treatment discontinuation due to ‘Disease progression’ without documented 
progression : By [CONTACT_15094], option (1) is used for situation E  as patients without documented PD 
should be followed for progression after discontinuation of treatment . However, option (2) may 
be used as sensitivity analysis.  If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT -scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess th e tumor due to clinical deterioration.  
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), (ITT) is the recommended approach; events 
documented after the initiation of new cancer therapy will be considered for the primary 
analysis i.e. progressions and deaths documented after the initiation of new cancer therapy 
[COMPANY_001]  Confidential  Page 185 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 would be included as events. This will require continued follow -up for progression after the 
start of the new cancer therapy. In such cases, it is recommended that an additional sensitivity 
analysis be performed by [CONTACT_685458] . 
Option (2), i.e. censoring at last adequate assessment may be used as a sensitivity analysis. If a 
high censoring rate due to start of new cancer therapy is expected, a window of approximately 
8 weeks performed after the start of new cancer therapy can be used to calculate the date of the 
event or censoring. This should be clearly specified in the analysis plan.  
In some specific settings, local treatments (e.g. radiation/surgery) may not be considered as 
cancer therapi[INVESTIGATOR_14971]/censoring in PFS/TTP/DoR analysis. For example, 
palliative radiotherapy given in the trial for analgesic purposes or for lytic lesions at risk of 
fracture will not be considered as cancer therapy for the assessment of BOR and PFS analyses. 
The protocol should clearly state the local treatments which are not considered as antineoplastic 
therapi[INVESTIGATOR_14972]/TTP/DoR analysis.  
The protocol should state that tumor assessments will be performed every x weeks until 
radiological progression irrespective of initiation of new antineoplastic therapy. It is strongly 
recommended that a tumor assessment is performed before the patient is switched to a new 
cancer therapy.  
Additional suggestions for sensitivity analyses  
Other suggestions for additional sensitivity analyses may include analyses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by [CONTACT_15096]. The latter could be handled by [CONTACT_15097] 14 -5 the 
“Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled assessment (from 
baseline)”, with the following definition:  
• Date of previous scheduled assessment (from baseline)  is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly followed 
from baseline, immediately before or on  the date of the last adequate tumor assessment.  
In addition, analyses could be repeated using the Investigators’ assessments of response rather 
than the calculated response. The need for these types of sensitivity analyses will depend on the 
individual requirements for the specific study and disease are a and have to be specified in the 
protocol or SAP documentation.  
14.1.29  Data handling and programming rules  
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).  
14.1.30  Study/project specific decisions  
For each study (or project) various issues need to be addressed and specified in the protocol or 
SAP documentation. Any deviations from protocol must be discussed and defined at the latest 
in the SAP  documentation.  
The proposed primary analysis and potential sensitivity analyses should be discussed and 
agreed with the health authorities and documented in the protocol (or at the latest in the SAP 
documentation before database lock).  
[COMPANY_001]  Confidential  Page 186 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.[ADDRESS_929104] to follow -
up, the investigator or designee should show "due diligence" by [CONTACT_5367], e.g., dates of telephone calls, registered letters, etc.  
The end of treatment visit and its associated assessments should occur within [ADDRESS_929105] 
study treatment.  
Patients may discontinue study treatment for any of the following reasons:  
• Adverse event(s)  
• Lost to follow -up 
• Physician decision  
• Pregnancy  
• Protocol deviation  
• Technical problems  
• Subject/guardian decision  
• Progressi ve disease  
• Study terminated by [CONTACT_456]  
• Non-compliant with study treatment  
• No longer requires treatment  
• Treatment duration completed as per protocol (optional, to be used if only a fixed number 
of cycles is given)  
Death is a reason which “ must ” lead to discontinuation of patient from trial  
14.1.[ADDRESS_929106] -treatment follow -up (study phase completion)  
End of post -treatment follow -up visit will be completed after discontinuation of study treatment 
and post -treatment evaluations but prior to collecting survival follow -up. 
Patients may provide study phase completion information for one of the following reasons:  
• Adverse event  
• Lost to follow -up 
• Physician decision  
• Pregnancy  
• Protocol deviation  
• Technical problems  
• Subject/guardian decision  
• Death  
• Progressi ve disease  
• Study terminated by [CONTACT_685459] 187 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.[ADDRESS_929107] regarding measurement methods (i.e. any assessment with more or less sensitive 
method than the one used to assess the lesion at baseline is considered UNK) and not available 
evaluations (i.e. if any target or non-target  lesion was not evaluated the whole overall lesion 
response is UNK unless remaining lesions qualified for PD), This contrasts with the slightly 
more flexible guidance given to local inv estigators (and to the central reviewers) to use expert 
judgment in determining response in these type of situations, and therefore as a consequence 
discrepancies between the different sources of response assessment often arise. To ensure the 
quality of re sponse assessments from the local site and/or the central reviewer, the responses  
may be re -evaluated by [CONTACT_15098] (based on local investigator data recorded in eCRF or based 
on central reviewer data entered in the database)  at [COMPANY_001] or external exper ts. In addition, 
data review reports will be available to identify assessments for which the investigators’ or 
central reader’s opi[INVESTIGATOR_463739]. This may be queried for clarification. However, the investigator or central reader’s 
response assessment will never be overruled.  
If [COMPANY_001] elect to invalidate an overall lesion response as evaluated by [CONTACT_15099], the calculated overall lesion response 
at that specific assessment is to be kept in a dataset. This must be clearly documented in the 
SAP d ocumentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.  
Any discontinuation due to ‘Disease progression’ without documentation of progression by 
[CONTACT_218007]. Only patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or study evaluation.  
14.1.34  Programming rules  
The following should be used for programming of efficacy results:  
14.1.35  Calculation of ‘time to event’ variables  
Time to event = end date - start date + 1 (in days)  
When no post -baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as end date (duration = 1 day) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.  
14.1.36  Incomplete assessment dates  
All investigation dates (e.g. X -ray, CT scan) must be completed with day, month and year.  
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.1.26 ). If all measurement dates have no 
day recorded, the 1st of the month is used.  
If the month is not completed, for any of the investigations, the respective assessment will be 
considered to be at the date which is exactly between previous and following assessment. If a 
[COMPANY_001]  Confidential  Page 188 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 previous and following assessment is not available, this assessment will not be used for any 
calculation.  
14.1.[ADDRESS_929108].  
14.1.38  Non-target  lesion response  
If no non-target  lesions are identified at baseline (and therefore not followed throughout the 
study), the non-target  lesion response at each assessment will be considered ‘not applicable 
(NA)’.  
14.1.39  Study/project specific programming  
The standard analysis programs need to be adapted for each study/project . 
14.1.40  Censoring reason  
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.  
For survival the following censoring reasons are possible:  
• Alive  
• Lost to follow -up 
For PFS and TTP (and therefore duration of responses) the following censoring reasons are 
possible:  
• Ongoing without event  
• Lost to follow -up 
• Withdrew consent  
• Adequate assessment no longer available*  
• Event documented after two or more missing tumor assessments (optional, see Table 14 -5) 
• Death due to reason other than underlying cancer (only used for TTP and duration of 
response)  
• Initiation of new anti -cancer therapy  
*Adequate assessment is defined in Section 14.1.26 . This reason is  applicable when adequate 
evaluations are missing for a specified period prior to data cut -off (or prior to any other 
censoring reason) corresponding to the unavailability of two or more planned tumor 
assessments prior to the cut -off date. The following cl arifications concerning this reason should 
also be noted:  
• This may be when there has been a definite decision to stop evaluation (e.g. 
reason=“Sponsor decision” on study evaluation completion page), when patients are not 
followed for progression after treatment completion or when only UNK assessments are 
availabl e just prior to data cut -off). 
[COMPANY_001]  Confidential  Page 189 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 • The reason "Adequate assessment no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therapy) has occurred more than the specified period following the last  adequate 
assessment.  
• This reason will also be used to censor in case of no baseline assessment.  
[COMPANY_001]  Confidential  Page 190 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.1.41  References (available upon request)  
Dent S, Zee (2001) application of a new multinomial phase II stoppi[INVESTIGATOR_540788], J Clin Oncol; 19: 785 -791 
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECIST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47 
Ellis S, et al (2008) Analysis of duration of response in oncology trials. Contemp Clin Trials 
2008; 29: 456 -465 
EMA Guidance: 2012 Guideline on the evaluation of anticancer medicinal products in man  
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005  
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics,  May 2007  
Morgan TM (1988) Analysis of duration of response: a problem of oncology trials. Cont Clin 
Trials; 9: 11 -18 
Therasse P, Arbuck S, Eisenhauer E, et al (2000 ) New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16 
[COMPANY_001]  Confidential  Page 191 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.2 Appendix 2 – Operating characteristics of the Bayesian logistic 
regression mode and hypothetical dose -escalation scenarios  
14.2.1  Introduction  
An adaptive Bayesian logistic regression model (with 2 parameters) guided by [CONTACT_685442]/  RP2D  during the escalation part of the study. The use of Bayesian response adaptive 
models for Phase I studies has been advocated by [CONTACT_540895] 
(2006)  and by [CONTACT_540896] (2007)  and is one of the key elements of the FDA’s Critical Path 
Initiative.  
14.2.2  Model specifications  
[IP_ADDRESS]  Statistical model for capsule formulation in qd schedule  
The dose -toxicity (DLT) relationship in the escalation part of the study will be described by [CONTACT_685460]:  
logit(π (d)) = log(α) + β log(d/d*),  α>0, β>0  
where logit(π (d))= ln ( (d)/(1-(d))), and π (d) is the probability of a DLT at dose d  in capsule . 
Doses are rescaled as d/d* with reference dose d*=300 mg of EGF816. As a consequence α is 
equal to the odds of toxicity at d*. Note that for a dose equal to zero, the probability of toxicity 
is zero.  
This study uses a weakly informative bivariate normal prior for the model parameters 
(log( ),log( )) based on prior guesses (medians) from preclinical data and wide confidence 
intervals for the probabilities of DLT at each dose, and can be obtained as follows:  
• For the purposes of tuning the prior for the model, the median DLT rate at 75 mg qd is 
assumed to be at 0.1%, and the median DLT rate at 750 mg qd is assumed to be at 25%. For 
the remaining doses, median DLT rates a priori are assumed linear in the logit -scale as a 
function of log -dose.  
• Based on the above specified medians for the DLT rate at certain dose and wide prior 
confidence intervals, the optimal parameters of the bivariate normal distribution can be 
obtained following the procedure described by (Neuenschwander et al 2008 ). 
All the information to derive the prior distributions for the model parameters is provided in 
Table 14 -6. Table 14 -7 summarizes the associated  prior distribution of the DLT rates. The doses 
not meeting the overdose criteria are bold in the table, i.e. doses not eligible at the start of the 
study (under the prior).  
[COMPANY_001]  Confidential  Page 192 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 14-[ADDRESS_929109] deviations  Correlation  
log(α), log(β)  -3.068,0.564  2.706,0.728  -0.817 
Table 14-7 Summary of prior distribution of DLT rates  
EGF816 dose (mg 
qd) Prior probabilities that Pr(DLT) is 
in interval:  
Mean  SD Quantiles  
[0, 0.16)  [0.16, 0.33)  [0.33, 1]  2.50%  50.00%  97.50%  
50 0.871  0.047  0.082  0.075  0.186  0.000  0.002  0.772  
75 (starting dose)  0.849  0.055  0.096  0.088  0.199  0.000  0.004  0.808  
150 0.794  0.076  0.130  0.119  0.223  0.000  0.013  0.860  
300 0.700  0.110  0.190  0.170  0.251  0.000  0.044  0.903  
450 0.603  0.147  0.251  0.220  0.267  0.002  0.095  0.923  
600 0.485  0.185  0.330  0.280  0.277  0.006  0.170  0.938  
800 0.338  0.207  0.455  0.364  0.290  0.014  0.286  0.958  
1000  0.237  0.197  0.566  0.439  0.297  0.024  0.398  0.975  
Note: bold values indicate doses not meeting the overdose criterion (more than 25% chance of excessive toxicity) 
with the prior information only.  
To check the performance of the model, some hypothetical dose -escalation scenarios  were 
investigated and are summarized in Section [IP_ADDRESS]  below. Details regarding dose 
recommendation are described in Section 10.4.2  of the  protocol.  
[IP_ADDRESS]  Statistical model for tablet formulation in qd schedule  
A new BLRM will be set up  for tablet formulation . This new BLRM will have the same 
functional form as above:  
logit(π T(d)) = log(α T) + β T log(d/d*),  αT>0, β T>0 
where logit(π T(d))= ln ( T(d)/(1-T(d))), and π T(d) is the probability of a DLT at dose d  in tablet . 
Doses are rescaled as d/d* with reference dose d*=300 mg of EGF816. As a consequence α T is 
equal to the odds of toxicity at d*. Note that for a dose equal to zero, the probability of toxicity 
is zero.  
The prior distributions for the model parameters (log( T), log(T)) are the same as those  for 
(log( ), log()) in Table 14 -6.  
Prior to each dose -escalation meeting the available capsule dose -DLT data will be included in 
the likelihood with a discounted weight w:  
𝑤=1
1+2𝑛𝜏2/𝜎2 
In this formula n is the total number of evaluable patients in the DDS of capsule formulation, σ 
is the “outcome standard deviation” for one observation and set to 2, and τ is the between -
formulation standard deviation and set to 0.25 for moderate heterogeneity between capsule and 
[COMPANY_001]  Confidential  Page 193 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 tablet ( Neuenschwander et al. 2010 ). This choice of τ is based on the similar dissolution profiles 
of capsule and of tablet as described in Section 6.2.1 . 
14.2.3  Hypothetical dose -escalation scenarios  
In order to show how the Bayesian model reacts, different hypothetical dose -escalation 
scenarios were investigated. The design should make reasonable dose-recommendations during 
the clinical trial based on the observed DLTs. During the study, the decision to dose escalate 
after completion of a given cohort and the actual dose chosen for the subsequent cohort will 
depend on the recommendation of the BLRM  per EWOC principle and medical review of 
available clinical and laboratory data.  
[IP_ADDRESS]  Scenarios for capsule formulation in qd schedule  
Some scenarios to illustrate the dose escalation up to the fifth dose cohort are listed in Table 
14-8. The maximum dose increment allowed in the scenarios did not exceed 100% as per 
escalation rules defined in Section 6.2.3 . The recommended  next dose level satisfied the EWOC 
principle.  
Table 14-8 Hypothetical scenarios for capsule on-study decisions (cohort size: 1 -
6) 
Scenario  Current capsule status  For next capsule cohort  
EGF816 
dose 
(mg qd)  Npat  Ntox  EGF816 
dose 
(mg qd)  P(Target)  P(Over)  Median 
DLT rate  
1 75 1 0  
150  
0.074   
0.070   
0.009  
2 75 2 0  
150  
0.069   
0.042   
0.008  
3 75 3 1  
50  
0.255   
0.208   
0.143  
4 75 6 1  
150  
0.328   
0.228   
0.183  
5 75 
150 1 
2 0 
0  
 
300  
 
0.102   
 
0.057   
 
0.024  
6 75 
150 1 
3 0 
1  
 
150  
 
0.296   
 
0.225   
 
0.169  
7 75 
150 
300 1 
2 
4 0 
0 
0  
 
 
600  
 
 
0.186   
 
 
0.098   
 
 
0.078  
8 75 
150 
300 1 
2 
4 0 
0 
1  
 
 
300  
 
 
0.294   
 
 
0.110   
 
 
0.127  
9 75 
150 
300 1 
2 
4 0 
0 
2  
 
 
150  
 
 
0.314   
 
 
0.126   
 
 
0.140  
[COMPANY_001]  Confidential  Page 194 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Scenario  Current capsule status  For next capsule cohort  
EGF816 
dose 
(mg qd)  Npat  Ntox  EGF816 
dose 
(mg qd)  P(Target)  P(Over)  Median 
DLT rate  
10 75 
150 
300 1 
2 
6 0 
0 
1  
 
 
450  
 
 
0.353   
 
 
0.171   
 
 
0.169  
11 75 
150 
300 
600 
 1 
2 
4 
5 
 0 
0 
0 
0 
  
 
 
 
1000   
 
 
 
0.264   
 
 
 
0.216   
 
 
 
0.152  
12 75 
150 
300 
600 1 
2 
4 
5 0 
0 
0 
1  
 
 
 
600  
 
 
 
0.315   
 
 
 
0.082   
 
 
 
0.130  
13 75 
150 
300 
600 1 
2 
4 
5 0 
0 
0 
2  
 
 
 
450  
 
 
 
0.314   
 
 
 
0.081   
 
 
 
0.129  
14 75 
150 
300 
600 
800 1 
2 
4 
5 
4 0 
0 
0 
0 
0  
 
 
 
 
1000   
 
 
 
 
0.234   
 
 
 
 
0.082   
 
 
 
 
0.101  
15 75 
150 
300 
600 
800 1 
2 
4 
5 
4 0 
0 
0 
0 
1  
 
 
 
 
800  
 
 
 
 
0.345   
 
 
 
 
0.098   
 
 
 
 
0.144  
16 75 
150 
300 
600 
800 1 
2 
4 
5 
4 0 
0 
0 
0 
2  
 
 
 
 
600  
 
 
 
 
0.289   
 
 
 
 
0.037   
 
 
 
 
0.117  
17 75 
150 
300 
600 
800 1 
2 
4 
5 
4 0 
0 
0 
0 
3  
 
 
 
 
600  
 
 
 
 
0.421   
 
 
 
 
0.101   
 
 
 
 
0.165  
Within Table 14 -8, P(Target) represents the probability that the true DLT rate for the dose lies 
in the target interval (16%, 33%) while P(Over) represents the probability that the true DLT 
rate for the dose exceeds 33%. Note, the actual number of evaluable patients per co hort is 
variable (see Section 6.2.3 ) and the recommendations during the study will depend on the 
number of evaluable patients at each dose level and the observed number of DLT.  
[COMPANY_001]  Confidential  Page 195 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 For this FIH trial, in early cohort scenarios, the model is showing appropriate behaviors which 
are conservative but sensitive to data. Overall, the model is showing appropriate behaviors, in 
agreement with clinical sense and decision making process. The d ose levels investigated 
correspond to the provisional dose levels specified in Section 6.2.2 . 
Similarly, Table 14 -9 shows some scenarios with exactly  3 evaluable patients  in each cohort . 
Table 14-9 Hypothetical scenarios for capsule on-study decisions (cohort size: 3)  
Scenario  Current capsule status  For next  capsule cohort  
EGF816 
dose 
(mg qd)  Npat  Ntox  EGF816 
dose 
(mg qd)  P(Target)  P(Over)  Median 
DLT rate  
1 75 3 0  
150  
0.059   
0.032   
0.006  
2 75 3 1  
50  
0.255   
0.208   
0.143  
3 75 3 2  
STOP     
 
4 75 
150 3 
3 0 
0  
 
300  
 
0.085   
 
0.030   
 
0.050  
5 75 
150 3 
3 0 
1  
 
150  
 
0.280   
 
0.130   
 
0.128  
6 75 
150 3 
3 0 
2  
 
75  
 
0.358   
 
0.206   
 
0.184  
7 75 
150 
300 3 
3 
3 0 
0 
0  
 
 
600  
 
 
0.193   
 
 
0.103   
 
 
0.080  
8 75 
150 
300 3 
3 
3 0 
0 
1  
 
 
300  
 
 
0.287   
 
 
0.103   
 
 
0.124  
9 75 
150 
300 3 
3 
3 0 
0 
2  
 
 
150  
 
 
0.308   
 
 
0.085   
 
 
0.127  
10 75 
150 
150 3 
3 
3 0 
1 
0  
 
 
300  
 
 
0.352   
 
 
0.200   
 
 
0.182  
11 75 
150 
150 3 
3 
3 0 
1 
1  
 
 
150  
 
 
0.427   
 
 
0.199   
 
 
0.201  
12 75 
150 
150 3 
3 
3 0 
1 
2  
 
 
75  
 
 
0.424   
 
 
0.174   
 
 
0.191  
[COMPANY_001]  Confidential  Page 196 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Scenario  Current capsule status  For next  capsule cohort  
EGF816 
dose 
(mg qd)  Npat  Ntox  EGF816 
dose 
(mg qd)  P(Target)  P(Over)  Median 
DLT rate  
13 75 
150 
75 3 
3 
3 0 
2 
0  
 
 
75  
 
 
0.304   
 
 
0.071   
 
 
0.123  
14 75 
150 
75 3 
3 
3 0 
2 
1  
 
 
50  
 
 
0.400   
 
 
0.144   
 
 
0.173  
15 75 
150 
75 3 
3 
3 0 
2 
2  
 
 
STOP   
   
16 75 
50 3 
3 1 
0 
  
 
75  
 
0.265   
 
0.101   
 
0.111  
17 75 
50 3 
3 1 
1 
  
 
STOP     
18 75 
50 
75 3 
3 
3 1 
0 
0  
 
 
150  
 
 
0.327   
 
 
0.134   
 
 
0.147  
19 75 
50 
75 3 
3 
3 1 
0 
1  
 
 
75  
 
 
0.420   
 
 
0.166   
 
 
0.186  
20 75 
50 
75 3 
3 
3 1 
0 
2  
 
 
STOP   
 
 
  
 
 
  
 
 
 
21 75 
50 
75 
150 3 
3 
3 
3 1 
0 
0 
0 
  
 
 
 
300  
 
 
 
0.376   
 
 
 
0.223   
 
 
 
0.196  
22 75 
50 
75 
150 3 
3 
3 
3 1 
0 
0 
1 
  
 
 
 
150  
 
 
 
0.458   
 
 
 
0.188   
 
 
 
0.204  
23 75 
50 
75 
150 3 
3 
3 
3 1 
0 
0 
2 
  
 
 
 
75  
 
 
 
0.456   
 
 
 
0.125   
 
 
 
0.182  
[IP_ADDRESS]  Scenarios for tablet formulation in qd schedule  
The dose -escalation scenarios for tablet formulation will depend on the available capsule dose -
DLT data. Three hypothetical capsule datasets are considered ( Table 14 -10). 
[COMPANY_001]  Confidential  Page 197 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 14-[ADDRESS_929110] tablet dose -
escalation meeting  
Capsule  
dataset  75mg 150mg  300mg  Dose for next 
capsule cohort  Tablet  
starting dose  Npat Ntox Npat Ntox Npat Ntox 
1 3 0 3 0 3 0 600mg  300mg  
2 3 0 3 0 3 1 300mg  300mg  
3 3 0 3 0 3 2 150mg  150mg  
Assuming no further capsule data are available, s ome scenarios to illustrate the tablet dose 
escalation up to two cohorts based on specific hypothetical capsule datasets are listed in Table 
14-11 through Table 14 -13. The dose levels investigated correspond to the provisional dose 
levels specified in Section 6.2.2 . The maximum dose increments allowed in the scenarios do 
not exceed 100% as per escalation rules defined in Section 6.2.3 . The recommended next dose 
levels satisfy the EWOC principle and other rules specified in Section [IP_ADDRESS] . 
Table 14-11 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset 1  
Scenario  Current tablet status  For next tablet cohort  
EGF816 dose  
(mg qd)  Npat  Ntox  EGF816 dose  
(mg qd)  P(Target)  P(Over)  Median  
DLT rate  
1 300 3 0 600 0.181  0.080  0.075  
2 300 3 1 450 0.354  0.185  0.173  
3 300 3 2 150 0.232  0.040  0.096  
4 300 
600 3 
3 0 
0 800 0.232  0.121  0.105  
5 300 
600 3 
3 0 
1 600 0.341  0.145  0.156  
6 300 
600 3 
3 0 
2 450 0.350  0.120  0.151  
7 300 
450 3 
3 1 
0 600 0.381  0.184  0.182  
8 300 
450 3 
3 1 
1 450 0.460  0.232  0.224  
9 300 
450 3 
3 1 
2 300 0.479  0.170  0.202  
10 300 
150 3 
3 2 
0 300 0.428  0.142  0.181  
11 300 
150 3 
3 2 
1 150 0.382  0.072  0.148  
12 300 
150 3 
3 2 
2 75 0.320  0.054  0.128  
[COMPANY_001]  Confidential  Page 198 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 14-12 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset 2  
Scenario  Current tablet status  For next tablet cohort  
EGF816 dose  
(mg qd)  Npat  Ntox  EGF816 dose  
(mg qd)  P(Target)  P(Over)  Median  
DLT rate  
1 300 3 0 450 0.316  0.126  0.140  
2 300 3 1 300 0.412  0.176  0.187  
3 300 3 2 150 0.363  0.112  0.152  
4 300 
450 3 
3 0 
0 600 0.335  0.141  0.152  
5 300 
450 3 
3 0 
1 450 0.438  0.184  0.197  
6 300 
450 3 
3 0 
2 300 0.446  0.137  0.184  
7 300 
300 3 
3 1 
0 450 0.454  0.249  0.229  
8 300 
300 3 
3 1 
1 300 0.497  0.224  0.225  
9 300 
300 3 
3 1 
2 150 0.409  0.092  0.160  
10 300 
150 3 
3 2 
0 150 0.289  0.038  0.116  
11 300 
150 3 
3 2 
1 150 0.492  0.151  0.198  
12 300 
150 3 
3 2 
2 75 0.414  0.105  0.165  
[COMPANY_001]  Confidential  Page 199 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Table 14-13 Hypothetical scenarios for tablet on -study decisions (cohort size: 3) 
using hypothetical capsule dataset 3  
Scenario  Current tablet status  For next tablet cohort  
EGF816 dose  
(mg qd)  Npat  Ntox  EGF816 dose  
(mg qd)  P(Target)  P(Over)  Median  
DLT rate  
[ADDRESS_929111] cohort at 300mg.  
Using hypothetical capsule dataset 3 the model results in Table 14 -13 are more conservative 
and generally do not allow dose escalation even without observing DLTs, except for Scenario 
1. This is due to 2 DLTs at 300mg in the hypothetical capsule dataset.  
Overall, the model is showing appropriate behaviors, in agreement with clinical sense and 
decision making process. The dose levels investigated correspond to the provisional dose levels 
specified in Section 6.2.2 . 
14.2.4  References  
EMEA (2006) Guideline on small populations (Internet) Available from: emea.europa.eu/  
docs/en_GB/document_library/Scientific_guidiline/2009/09/WC500003615.pdf.  
Neuenschwander B, Capkun -Niggli G, Branson M, Spi[INVESTIGATOR_59898]. (2010) Summarizing 
historical information on controls in clinical trials. Clinical Trials; 7 (1):5 -18. 
[COMPANY_001]  Confidential  Page 200 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 Rogatko A, Schoeneck D, Jonas W, et al (2007) Translation of innovative designs into phase I 
trials. J Clin Oncol; 25(31): 4982 -6. 
[COMPANY_001]  Confidential  Page 201 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.3 Appendix 3 - Permitted Concomitant Medications requiring 
caution  
Table 14-14 Permitted concomitant medications requiring caution  
Mechanism of interaction  Drug name  
[CONTACT_15106]3A4 inhibitor  aprepi[INVESTIGATOR_053], amprenavir, atazanavir, cimetidine, ciprofloxacin, crizotinib, 
cyclosporine, darunavir, diltiazem, dronedarone, erythromycin, faldaprevir, 
fluconazole, imatinib, isavuconazole, netupi[INVESTIGATOR_053], nilotinib, tofisopam, Schisandra 
sphenanthera (nan wu w ei zi), asafoetida resin (Ferula asafoetida), verapamil  
Moderate CYP3A4 inducer  bosentan, dabrafenib , efavirenz, etravirine, genistein, lopi[INVESTIGATOR_054], modafinil, 
nafcillin, telotristat , thioridazine  
BCRP substrate  atorvastatin daunorubicin, dolutegravir , doxorubicin, hematoporphyrin, imatinib, 
methotrexate, mitoxantrone,  paritaprevir , pi[INVESTIGATOR_2830], rosuvastatin, irinotecan, 
ethinyl estradiol, simvastatin, sulfasalazine, sofosbuvir, topotecan, tenofovir, 
topotecan , venetoclax  
MATE substrate  acyclovir, cephalexin, cimetidine, ganciclovir, fexofenadine, glycopyrronium, 
metformin, pi[INVESTIGATOR_8405], pi[INVESTIGATOR_14959], procainamide, ranitidine, topotecan, 
varenicline , ,  
Potent P -gp inhibitor  alogliptin, amiodaron e, azithromycin , canaglifozin, captopril, carvedilol, 
clopi[INVESTIGATOR_63999], cremophor EL and RH40, curcumin, daclatasvir, diltiazem, 
dronedarone, eliglustat, erythromycin, felodipi[INVESTIGATOR_050], fluvoxamine, fostamatinib, 
ginkgo (Ginkgo biloba), green tea, isavuconazole, ivacaftor, lapatinib, lopi[INVESTIGATOR_054] , 
milk thistle (silymarin, silibinin), mirabegron, nifedipi[INVESTIGATOR_050], nitrendipi[INVESTIGATOR_050], paroxetine, 
propafenone, quercetin, quinidine, quinine, ranolazine, rolapi[INVESTIGATOR_053], saquinavir, 
Schisandra chinensis extract (wuweizi), simeprevir, survorexant, talinolol , 
telmisartan, ticagrelor, tipranavir, tolvaptan, valspodar, vandetanib, velpatasvir, 
verapamil, voclosporin, vorapaxar  
Source: Adapted Drug -Drug Interactions (DDI) and Co -medication Considerations for [COMPANY_001] Clinical Trials  
PK Sciences Internal Memorandum  (release date: Jan 2018 ) which was compi[INVESTIGATOR_583651]’s “Clinically Relevant” Table and supplemented with the FDA Draft Guidance for Industry, 
Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling (F ebruary 
2012), and the University of Washington’s Drug Interaction Database. Please note that this list may not be 
exhaustive. For the latest information, please refer to the above mentioned database.  
 
[COMPANY_001]  Confidential  Page 202 
Amended Protocol Version  07 (Clean)   Protocol No. CEGF816X2101  
 
 14.4 Appendix 4 - Prohibited Concomitant Medications  
Table 14-15 Prohibited concomitant medications  
Mechanism of interaction  Drug name  
[CONTACT_15105]3A4 inhibitor  ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak), indinavir/ritonavir, 
tipranavir/ritonavir, ritonavir, cobicistat, indinavir, ketoconazole, troleandomycin, 
telaprevir, danoprevir/ritonavir, elvitegravir/ritonavir, saquinavir/ritonavir, 
lopi[INVESTIGATOR_054]/ ritonavir, itraconazole, voriconazole, mibefradil, clarithromycin, 
posaconazole, telithromycin, grapefruit juice, conivaptan, nefazodone, nelfinavir, 
idelalisib, boceprevir, atazanavir/ritonavir, darunavir/ritonavir  
Strong CYP3A4 inducer  carbamazepi[INVESTIGATOR_050], enzalutamide, lumacaftor, phenobarbital, phenytoin, rifabutin, 
rifampi[INVESTIGATOR_2513], mitotane, St. John’s wort (Hypericum perforatum)  
Live vaccines  e.g., intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow 
fever, varicella, and TY21a typhoid vaccines  
NTI: narrow therapeutic index  
Source: Adapted from Drug -Drug Interactions (DDI) and Co -medication Considerations for [COMPANY_001] Clinical Trials  
PK Sciences Internal Memorandum  (release date: Jan 2018 ) which was compi[INVESTIGATOR_583651]’s “Clinically Relevant” Table and supplemented with the FDA Draft Guidance for Industry, 
Drug Interaction Studies – Study Design, Data Analysis, and Implications for Dosing and Labeling (F ebruary 
2012), and the University of Washington’s Drug Interaction Database. Please note that this list may not be 
exhaustive. For the latest information, please refer to the above mentioned database.  
 